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Preface to ”Therapy and Prevention of Atopic
Dermatitis and Psoriasis”
The skin is the outermost part of the body, where various external and internal stimuli interact. 
The complex interface reaction is necessary for maintaining the homeostasis of the epidermal and 
dermal compartments, but its imbalance results in numerous types of inflammatory disorders, 
such as psoriasis and atopic dermatitis. The excellent therapeutic success of biological treatments 
stresses the pathogenic importance of TNF-α/IL-23/IL-17 axis for psoriasis, and IL-4/IL-13 signals 
for atopic dermatitis. Common external stimuli include ultraviolet rays, chemicals, allergens, and 
environmental pollutants. Some of these agents modulate psoriatic and atopic inflammation by 
activating the oxidative aryl hydrocarbon receptor, as well as antioxidative NRF2 transcription 
factors. Various cytochemokines involved in Th17 and Th2 deviation are also operative in 
psoriatic and atopic inflammation, respectively, by facilitating the differentiation and recruitment of 
pathogenic dendritic cells, T-cells, and innate lymphoid cells. In this Special Issue, we will publish 
cutting-edge information regarding skin inflammation, therapy, and prevention, especially related to 
psoriatic and atopic inflammation.
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Abstract: The vicious itch–scratch cycle is a cardinal feature of atopic dermatitis (AD), in which
IL-13 signaling plays a dominant role. Keratinocytes express two receptors: The heterodimeric
IL-4Rα/IL-13Rα1 and IL-13Rα2. The former one transduces a functional IL-13 signal, whereas
the latter IL-13Rα2 works as a nonfunctional decoy receptor. To examine whether scratch injury
affects the expression of IL-4Rα, IL-13Rα1, and IL-13Rα2, we scratched confluent keratinocyte sheets
and examined the expression of three IL-13 receptors using quantitative real-time PCR (qRT-PCR)
and immunofluorescence techniques. Scratch injuries significantly upregulated the expression of
IL13RA2 in a scratch line number-dependent manner. Scratch-induced IL13RA2 upregulation was
synergistically enhanced in the simultaneous presence of IL-13. In contrast, scratch injuries did not
alter the expression of IL4R and IL13RA1, even in the presence of IL-13. Scratch-induced IL13RA2
expression was dependent on ERK1/2 and p38 MAPK signals. The expression of IL-13Rα2 protein
was indeed augmented in the scratch edge area and was also overexpressed in lichenified lesional AD
skin. IL-13 inhibited the expression of involucrin, an important epidermal terminal differentiation
molecule. IL-13-mediated downregulation of involucrin was attenuated in IL-13Rα2-overexpressed
keratinocytes, confirming the decoy function of IL-13Rα2. Our findings indicate that scratching
upregulates the expression of the IL-13 decoy receptor IL-13Rα2 and counteracts IL-13 signaling.
Keywords: scratch injury; IL-13Rα2; keratinocyte; IL-13; atopic dermatitis; IL-4Rα; IL-13Rα1;
involucrin
1. Introduction
Atopic dermatitis (AD) is a common, chronic or chronically relapsing, severely pruritic, eczematous
skin disease that markedly deteriorates the quality of life of afflicted patients [1–4]. Lifetime prevalence
of AD is estimated to be as high as 20% in the general population [5,6]. Clinical symptoms and signs of
AD are characterized by skin inflammation, barrier dysfunction (xerosis), and itching [1,7]. Severe and
chronic pruritus induces unavoidable scratching, and the vicious itch–scratch cycle exacerbates and
perpetuates atopic inflammation and skin barrier function [8,9].
Compounding evidence shows that acute AD lesions have a significantly greater number of T
helper 2 (TH2) cells expressing interleukin-4 (IL-4) and IL-13 than normal skin or uninvolved AD
skin [10]. The TH2-deviated immune response is demonstrated both in pediatric and adult AD [11,12]
and is greater in chronic than in acute lesions [11,13]. IL-4 and IL-13 inhibit filaggrin (FLG) and
Int. J. Mol. Sci. 2019, 20, 3324; doi:10.3390/ijms20133324 www.mdpi.com/journal/ijms1
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involucrin (IVL) expression in keratinocytes, leading to deteriorated barrier function [14,15]. IL-4
and IL-13 also potentiate the neuronal pruritic signal [16]. The pathogenic importance of IL-4/IL-13
signaling in AD has been recently highlighted because its blockage by dupilumab, a specific anti-IL-4
receptor α (IL-4Rα, IL4R) antibody, successfully improves skin inflammation in patients with AD [17].
Notably, a more recent large-scale transcriptomic analysis revealed a specific and dominant role of
IL-13 in lesional AD skin, but nearly undetectable IL-4 expression was found [18].
The IL-13 signal is regulated via a complex receptor system. In nonhematopoietic cells, IL-13
engages a heterodimeric receptor composed of IL-4Rα and IL-13Rα1 (IL13RA1) [19,20]. IL-13Rα1 binds
IL-13 with low affinity; however, when it forms a complex with IL-4α, it binds with much higher affinity,
inducing the effector functions of IL-13 [19,20]. A second receptor, IL-13Rα2 (IL13RA2), is closely
related to IL-13Rα1. IL-13Rα2 binds IL13 with high affinity, but it lacks any significant cytoplasmic
domain and does not function as a signal mediator [20]. Cells with high IL-13Rα2 expression can
rapidly and efficiently deplete extracellular IL-13 [21]. Likewise, IL-13 responses are enhanced in mice
lacking IL13RA2 [22]. These studies have highlighted that IL-13Rα2 can act as a scavenger or decoy
receptor of IL-13 and elicits antagonistic activity against IL-13 [20].
Epidermal keratinocytes express IL-4Rα, IL-13Rα1, and IL-13Rα2 [23,24]. However, it remains
unknown whether mechanical scratching affects the expression of these three IL-13 receptors.
In this study, confluent keratinocyte sheets were scratched and the expression of IL-4Rα, IL-13Rα1,
and IL-13Rα2 was assessed. Unexpectedly, this in vitro scratch model showed that scratch injuries
upregulated IL-13Rα2 expression in a scratch line number-dependent fashion. This is the first report
that scratch injuries may be able to produce an antagonistic signal against IL-13 by upregulating
IL-13Rα2 expression.
2. Results
2.1. Scratching Upregulates the Expression of IL13RA2, Which is Further Enhanced by IL-13
We first scratched confluent keratinocyte sheets in six-well culture plates with 14 scratch lines.
The expression of IL13RA2 was significantly enhanced in the scratched sheet, compared to that in
the non-scratched control (Figure 1A). Notably, the gene expression of IL4R (Figure 1B) and IL13RA1
(Figure 1C) was not affected by the scratch injury. The upregulation of IL13RA2 gene expression was
transient, peaking at 12 h and returning to a baseline level at 24 h (Figure 2A). The gene expression
of IL4R (Figure 2B) and IL13RA1 (Figure 2C) exhibited no differences over time. We next scratched
the keratinocyte sheets with 7, 14, or 18 scratch lines. IL13RA2 gene expression was significantly
upregulated in a scratch line number-dependent fashion (Figure 3A). Again, IL4R (Figure 3B) and
IL13RA1 (Figure 3C) gene expression levels were not altered, irrespective of scratch line numbers.
We next examined whether the simultaneous presence of exogenous IL-13 affected scratch-induced
IL13RA2 gene upregulation. Exogenous IL-13 itself significantly upregulated the baseline level of
IL13RA2 gene expression in non-scratched keratinocytes (Figure 4A). Notably, scratch-induced IL13RA2
gene upregulation was significantly augmented synergistically by IL-13 in a concentration-dependent
manner (Figure 4A). As shown in Figure 4B,C, graded concentrations of IL-13 did not alter the gene
expression of IL4R and IL13RA1 either alone or with a scratch injury.
2
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Figure 1. Scratching significantly upregulates the expression of IL13RA2 in NHEK cells. A confluent
keratinocyte culture was scratched with 14 lines, and the expression of IL13RA2, IL4R, and IL13RA1 was
analyzed by qRT-PCR and normalized to that of β-actin. Scratching significantly increased IL13RA2
expression in NHEK cells (A). IL4R (B) and IL13RA1 (C) expression was not altered. The cells were
incubated for 6 h after scratching. Data is shown as the mean ± SEM (n = 3). *** p < 0.001.
Figure 2. Time-course study for IL13RA2 (A), IL4R (B), and IL13RA1 (C) expression. The gene
expression of IL13RA2, IL4R, and IL13RA1 was measured with or without scratching at 0, 3, 6, 9, 12,
and 24 h (n = 3). Data is shown as the mean ± SEM. ns: not significant. *** p < 0.001.
Figure 3. Scratching upregulated IL13RA2 expression in a scratch line number-dependent manner.
The keratinocyte sheet was scratched with 7, 14, and 18 scratch lines, and the gene expression of
IL13RA2 (A), IL4R (B), and IL13RA1 (C) was measured (n = 3) 6 h after scratching. Data is shown as the
mean ± SEM. * p < 0.05, ** p < 0.01, *** p < 0.001.
3
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Figure 4. The effect of IL-13 on scratch-induced IL13RA2 (A), IL4R (B), and IL13RA1 (C) expression.
Confluent keratinocyte sheets were non-scratched or scratched with 18 lines in the presence or absence
of graded IL-13 concentrations (1, 5, 10 ng/mL). Cells were treated with IL-13 for 14 h before scratching
and then incubated for another 6 h. Data is shown as the mean ± SEM. * p < 0.05, *** p < 0.001.
2.2. Upregulation of IL-13Rα2 Protein in a Scratched Edge Area In Vitro as well as in Lesional AD Skin
In order to determine the spatial expression of IL-13Rα2 protein in the scratched sheet,
we conducted immunostaining. Immunostaining for IL-13Rα1 served as the unaffected control.
The immunofluorescence intensity for IL-13Rα2 protein was significantly upregulated in the scratch
edge area, compared to that in the non-scratched control (Figure 5A). The IL-13Rα2-positive signal
was also slightly enhanced in the peri-edge area, but it did not reach statistical significance, compared
to that in the non-scratched control (Figure 5A). In contrast, the immunofluorescence intensity for
IL-13Rα1 protein was comparable among the scratch edge area, peri-edge area, and non-scratched
control (Figure 5B). As a suitable anti-IL-13Rα2 antibody was unavailable, we were unable to detect
IL-13Rα2 protein with western blotting.
 
Figure 5. Immunofluorescence analysis for IL-13Rα2 (A) and IL-13Rα1 (B) proteins. Non-scratched
control or scratched confluent keratinocyte sheets were immunostained with anti-IL-13Rα2 or
anti-IL-13Rα1 antibodies. Data is shown as the mean ± SEM. * p < 0.05. Scale bar: 50 μm.
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We next immunostained IL-13Rα2 protein in lichenified lesional AD skin (n = 11) and normal
control skin (n = 11). In normal skin, IL-13Rα2 expression was immunodetectable, especially in
the epidermal basal layer (Figure 6A). Its expression was augmented in the lesional AD epidermis,
compared to that in the normal control epidermis (Figure 6A). The percentage of IL-13Rα2-positive
keratinocytes was significantly increased in the lichenified AD skin, compared to that in the normal
control skin (Figure 6B).
 
Figure 6. Immunohistochemical analysis for IL-13Rα2 expression. Control normal skin and lichenified
lesional AD skin were immunostained with control IgG and anti-IL-13Rα2 antibody (A). The percentage
of IL-13Rα2 positive keratinocytes was calculated in 11 normal skin and 11 AD skin samples (B). Data is
shown as the mean ± SEM. *** p < 0.001. Scale bar: 50 μm.
2.3. Contribution of ERK1/2 and P38MAPK Activation to Scratch-Induced IL13RA2 Upregulation
We next examined the MAPK signal transduction pathways leading to scratch-induced IL13RA2
upregulation. The scratch injury upregulated the phosphorylation of ERK1/2, JNK, and p38MAPK
(Supplementary Figure S1). Correspondingly, scratch-induced IL13RA2 upregulation was disrupted
in the presence of U0126 (MEK/ERK inhibitor) and SB203580 (p38MAPK inhibitor) (Figure 7A).
Interestingly, SP600125 (JNK inhibitor) did not affect scratch-induced IL13RA2 upregulation (Figure 7A).
Baseline IL4R expression was downregulated only by U0126 (Figure 7B). The gene expression of
IL13RA1 was stable, irrespective of these inhibitors (Figure 7C). These results suggested that ERK1/2
and p38MAPK were involved in scratch-induced IL13RA2 upregulation.
 
Figure 7. The effect of MAPK inhibitors on IL13RA2 (A), IL4R (B), and IL13RA1 (C) expression.
Non-scratched and scratched confluent keratinocytes were treated with or without U0126
(MEK 1/2-ERK1/2 inhibitor), SP600125 (JNK inhibitor), and SB203580 (p38MAPK inhibitor). Data is
shown as the mean ± SEM. * p < 0.05, ** p < 0.01, *** p < 0.001.
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2.4. IL-13-Mediated IVL Downregulation is Restored in IL-13Rα2-Overexpressed HaCaT Keratinocytes
It is known that IL-13Rα2 exhibits a decoy function for IL-13 [20]. In order to examine this
function, we established IL-13Rα2-Tg-HaCaT keratinocytes. The IL-13Rα2-Tg-HaCaT cells exhibited
significantly higher expression of IL-13Rα2 mRNA (Figure 8A) and protein than the mock-HaCaT
cells (Figure 8B and supplementary Figure S2). IL-13 is known to inhibit IVL and FLG expression
in normal keratinocytes [14,15]. Likewise, IL-13 inhibited IVL expression in HaCaT keratinocytes
(Figure 8C). However, IL-13-mediated IVL downregulation was partially, but significantly, attenuated
in the IL-13Rα2-Tg-HaCaT keratinocytes (Figure 8C), suggesting that the decoy function of IL-13Rα2
was operative in keratinocytes.
Figure 8. IL13RA2 expression was upregulated in the IL-13Rα2-Tg-HaCaT cells more than in
control Moc-HaCaT cells (A). Upregulated IL-13Rα2 protein expression was observed in the
IL-13Rα2-Tg-HaCaT cells, compared to that in Moc-HaCaT cells (B). IL-13-induced IVL downregulation
was partially restored in IL-13Rα2-Tg-HaCaT cells (C). ** p < 0.01, *** p < 0.001.
Intriguingly, IL-13 downregulated FLG expression in normal human keratinocytes, but it failed
to inhibit FLG expression in HaCaT keratinocytes (Supplementary Figure S3). Therefore, we did not
focus further on FLG expression.
3. Discussion
Itchiness is a specialized perception in the skin and an unpleasant sensation that elicits the desire
to scratch in order to remove harmful stimuli, leading to a scratching behavior [25]. Scratching
appears to exacerbate preexistent dermatitis in humans and mice [9,26], but it relieves the itching
sensation [27]. Among cutaneous inflammatory skin diseases, the vicious itch–scratch cycle is
particularly important in AD because it profoundly impairs the quality of life, treatment satisfaction
and adherence, and socioeconomic stability of patients [28–30]. However, the subcellular biological
effects caused by scratching keratinocytes remain elusive. As AD is a TH2-dominant, particularly
IL-13-dominant, skin disease [18], we focused on whether a scratch injury affects the expression of
three IL-13 receptors, IL-4R, IL-13Rα1, and IL-13Rα2, in keratinocytes.
In the present study, we demonstrated that the scratch injury enhanced the expression of an
IL-13 decoy receptor, IL-13Rα2. Scratch-induced IL-13Rα2 upregulation was selective because no
significant changes were recognized in the expression of the functional heterodimeric IL-13 receptor,
IL-4R, or IL-13Rα1. Scratch-induced IL-13Rα2 upregulation was highly dependent on scratch stress
because it was enhanced with more scratch lines. Moreover, immunofluorescence analysis revealed
that the upregulation of IL-13Rα2 was largely confined to the scratch edge area where scratch stress
was most observed. IL-13 itself enhanced IL-13Rα2 expression in keratinocytes, but this was less potent
6
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than with the scratch injury. However, strong and synergistic upregulation of IL-13Rα2 expression
was observed with co-treatment of IL-13 and a scratch injury.
Historically, the in vitro scratch injury of a keratinocyte sheet has been used as a good model
for wound closure in that it reflects the migratory and proliferative capacity of keratinocytes [31–33].
Therefore, no previous studies have sought to examine the scratch-mediated alteration of IL-13 receptors.
The selective upregulation of IL-13Rα2 was a novel and unexpected finding. We then investigated
signal transduction that led to scratch-induced IL-13Rα2 upregulation. In our experimental model, the
scratch injury augmented the phosphorylation of ERK1/2, JNK, and P38 MAPK. Likewise, inhibitors for
ERK1/2 and P38 MAPK, but not JNK, disrupted scratch-induced IL-13Rα2 upregulation. These results
suggest a crucial role of ERK1/2 and P38 MAPK in regulating scratch-induced IL-13Rα2 upregulation.
The vicious itch–scratch cycle is one of the cardinal features of AD [9,26]. Therefore, we
examined epidermal IL-13Rα2 expression in lichenified (scratched) AD lesions. IL-13Rα2 expression
was significantly increased in lesional AD skin, compared to that in the normal control epidermis.
To determine the functional implications of IL-13Rα2 overexpression, we finally examined whether
increased IL-13Rα2 expression suppresses an IL-13-mediated event, namely, IL-13-induced IVL
downregulation [14,15,34]. As expected, IL-13 inhibited IVL expression, which was significantly
restored in the IL-13Rα2 overexpressed keratinocytes. Based on these results, we deduced that
scratch-induced IL-13Rα2 overexpression is biologically functional and may diminish IL-13-mediated
hazardous events in the epidermal inflammatory microenvironment.
Scratching may induce various biological consequences. The scratch signal exacerbates skin
inflammation and conversely upregulates IL-13Rα2 expression, which may suppress excess IL-13
activity caused by the decoy function of IL-13Rα2 in keratinocytes. These fine-tuned mutually
counteracting molecular events may participate in the formation of scratch-induced lichenified
skin lesions.
4. Materials and Methods
4.1. Reagents and Antibodies
Recombinant human IL-13 (Peprotech, Rocky Hill, NJ, USA) was dissolved in distilled water
and added to the culture medium at a final concentration of 1, 5, or 10 ng/mL. The antibodies for
immunofluorescence and immunohistochemistry staining were used as follows: Anti-IL-13Rα2 mouse
monoclonal antibody (Abcam, Cambridge, UK), normal mouse IgG (Santa Cruz Biotechnology, Dallas,
TX, USA), and goat anti-mouse IgG conjugated with Alexa Fluor 488 dye (Thermo Fisher Scientific,
Waltham, MA, USA). The antibodies for western blotting were used as follows: Anti-ERK1/2, JNK, p38
MAPK, phospho-ERK1/2 (Thr202/Tyr204), phospho-JNK (Thr183/Tyr185), and phospho-p38 MAPK
(Thr180/Tyr182) rabbit monoclonal antibodies and β-actin mouse monoclonal antibody (Cell Signaling
Technology, Danvers, MA, USA) as primary antibodies, and anti-mouse IgG and anti-rabbit IgG
HRP-linked antibody (Cell Signaling Technology) as secondary antibodies. Signal transduction inhibitor
U0126 (ERK1/2 inhibitor) was purchased from Cell Signaling Technology. SP600125 (JNK inhibitor)
and SB203580 (p38 inhibitor) were obtained from Tocris Bioscience (Bristol, UK).
4.2. Cell Culture
Neonatal normal human epidermal keratinocytes (NHEKs) were purchased from Lonza
(Basel, Switzerland) and cultured in KGM-Gold (Lonza), supplemented with bovine pituitary extract,
recombinant human epidermal growth factor, insulin, hydrocortisone, gentamycin–amphotericin,
transferrin, and epinephrine (Lonza) at 37 ◦C in 5% CO2. The medium was changed every 2 days.
The cells reached 70–80% confluence and were passaged three times. The third passage of cells was
used in all experiments. HaCaT cells (human keratinocyte cell line) were maintained in DMEM,
supplemented with 10% fetal bovine serum (FBS) and antibiotics. Cells were passaged at 70–80%
confluence and used in the experiment of transfection of plasmids.
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4.3. In Vitro Scratched Keratinocyte Model
To establish the in vitro scratched keratinocyte model, NHEKs were seeded into 6-well plates
(Corning, NY, USA) (3.5 × 105 cells/well). Entire confluent keratinocyte sheets were scratched with 7,
14, and 18 lines, using 1000-μL tips (Greiner Bio-One, Kremsmünster, Austria), and incubated for 0, 3,
6, 9, 12, or 24 h at 37 ◦C in 5% CO2 after scratching. In several assays, the scratched cell sheets were
treated with IL-13 (1, 5, or 10 ng/mL, Peprotech).
4.4. Quantitative Real-Time PCR (qRT-PCR)
Total RNA was extracted from cells using RNeasy Mini Kit (Qiagen, Hilden, Germany), and
cDNA was synthesized using PrimeScript RT Reagent Kit (Takara Bio, Shiga, Japan).
qRT-PCR was performed on the CFX Connect Real-Time PCR Detection System (Bio-Rad, Hercules,
CA, USA), using TB Green Premix Ex Taq (Takara Bio). Denaturation was set at 95 ◦C for 30 s with
40 total cycles with a second step at 95 ◦C for 5 s. Annealing occurred at 63 ◦C for 30 s for IL4R and
IL13RA1, and at 60 ◦C for 30 s for IL13RA2 and IVL. The relative expression levels of IL4R, IL13RA1,
IL13RA2, IVL, and FLG were normalized to that of β-actin.
Gene-specific primers were as follows: IL4R forward, 5′-CTGCTCATGGATGACGTGGT-3′;
reverse, 5′-CTGGGTTTCACATGCTCGCT-3′; IL13RA1 forward, 5′-GTCCCAGTGTAGCACCAAT
GA-3′; reverse, 5′-GCTCAGGTTGTGCCAAATGC-3′; IL13RA2 forward, 5′-GCTGGGAAGGTGA
AGACCTA-3′; reverse, 5′-ACGCAAAAGCAGACCGGTTA-3′; IVL forward, 5′-TAACCACCCGC
AGTGTCCAG-3′; reverse, 5′-ACAGATGAGACGGGCCACCTA-3′; FLG forward, 5′-TAACCACC
CGCAGTGTCCAG-3′; reverse, 5′-ACAGATGAGACGGGCCACCTA-3′; β-actin forward, 5′-ATTGCC
GACAGGATGCAGA-3′; reverse, 5′-GAGTACTTGCGCTCAGGAGGA-3′.
4.5. Immunofluorescence Analysis
Immunofluorescent analysis was performed on cell sheets cultured in 4-well slide chambers
(Lab-Tek, Rochester, NY, USA) with KGM-Gold (Lonza) for 48 h, scratched using 1000-μL tips
(Greine Bio-One), and incubated for 6 h at 37 ◦C in 5% CO2. The cells were washed with
phosphate-buffered saline 3 times for 5 min each and fixed in cold acetone for 10 min at room
temperature. The cell sheets were blocked with 10% bovine serum albumin (Roche Diagnostics,
Basel, Switzerland) and incubated with mouse monoclonal anti-IL13Rα2 (Abcam) or control normal
mouse IgG (Santa Cruz Biotechnology). Goat anti-mouse IgG conjugated with Alexa Fluor 488 dye
(Thermo Fisher Scientific) was used for the secondary antibody. The nucleus was stained with
4′,6-diamino-2-phenylindole (DAPI). Slides were then mounted with Ultra Cruz mounting medium
(Santa Cruz Biotechnology) and were observed using a D-Eclipse confocal laser scanning microscope
(Nikon, Tokyo, Japan). The immunofluorescence intensity was measured using ImageJ software.
4.6. Immunohistochemistry
Eleven lichenified lesional AD skin and 11 normal skin samples were embedded in paraffin
by the conventional method and cut into 3-μm-thick sections. Antigen retrieval was performed
using Heat Processor Solution pH 6 (Nichirei Biosciences, Tokyo, Japan) at 100 ◦C for 40 min, and
endogenous peroxidase was blocked by incubating the sections with 3% H2O2 (Nichirei Biosciences).
The sections were then incubated with anti-IL-13Rα2 (Abcam, 750×) antibody or control normal mouse
IgG (Santa Cruz Biotechnology) for 30 min, followed by incubation with the secondary antibody,
N-Histofine Simple Stain MAX-PO MULTI (Nichirei Biosciences). Immunodetection was conducted
with 3,3-diaminobenzidine as the chromogen, followed by light counterstaining with hematoxylin.
The number of IL-13Rα2-positive keratinocytes was counted in three high-power view areas, and the
average percent positivity was calculated in each slide.
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4.7. Western Blotting
Scratched or non-scratched cells were solubilized in complete Lysis-M (Roche Diagnostics,
Rotkreuz, Switzerland). The cell lysates were prepared according to the standard protocol for western
blotting analysis. The cell lysates were centrifuged at 14,000 rpm for 25 min and the obtained
supernatants were used for analysis. The protein concentration was determined with a BCA protein
assay kit (Thermo Fisher Scientific). Equal 20 μg amounts of protein were mixed with 4× LDS sample
buffer (Invitrogen) and 10× sample reducing agent (Invitrogen), boiled at 70 ◦C for 10 min, loaded
onto Bolt 4–12% Bis-Tris Plus (Thermo Fisher Scientific), and electrophoresed using Power Station III
(Atto corporation, Tokyo, Japan) at 200 V and 180 mA for 25 min. The proteins were then transferred
to an Immobilon PVDF Transfer Membrane (Merck, Kenilworth, NJ, USA), using Power Station III
at 30 V for 1 h. Membranes were blocked with a blocking buffer, containing blocker diluent A and
B, (Invitrogen) for 30 min. Membranes were probed overnight at 4 ◦C with the following primary
antibodies: β-actin (Cell Signaling Technology), ERK1/2, JNK, p38, Phospho-ERK1/2, Phospho-JNK,
and Phospho-p38 (Cell Signaling Technology).
The secondary antibodies, anti-mouse IgG HRP-linked antibody (Cell Signaling Technology)
and anti-rabbit IgG HRP-linked antibody (Cell Signaling Technology), were applied at room
temperature for 30 min. Visualization of protein bands was accomplished with Super Signal West Pico
Chemiluminescent Substrate (Thermo Fisher Scientific), using the ChemiDoc Touch Imaging System
(Bio-Rad).
4.8. Plasmid DNA and Transfection of Plasmids
Plasmids pCMV6-Entry (Mock) and IL13RA2 (Myc-DDK-tagged), which contains a
cytomegalovirus promoter, and the IL13RA2 (NM_000640) human cDNA open reading frame clone
were obtained from Origene Technologies (Rockville, MD, USA). The plasmids (1 μg) were dissolved
in Amaxa P3 Primary Cell 4D-Nucleofector X Kit and were transfected into HaCaT cells using
4D-Nucleofector (Lonza, Basel, Switzerland), according to the manufacturer’s protocol. Transfected
cells were then selected in Dulbecco’s Modified Eagle’s Medium (DMEM, Sigma–Aldrich, St. Louis,
MO, USA) with 5% fetal bovine serum, Modified Eagle’s Medium Non-Essential Amino Acids, 10 mM
HEPES, 1 mM sodium pyruvate (Thermo Fisher Scientific), and G418 disulfate aqueous solution
(1500 μg/mL, Nacalai Tesque, Kyoto, Japan) for 3 weeks to obtain a stable cell line.
4.9. Statistical Analysis
All data are presented as mean ± standard error of the mean (SEM). The significance of differences
between groups was assessed using Student’s unpaired two-tailed t-test (two groups) or one-way
ANOVA, followed by Bonferroni’s multiple comparison test (multiple groups), using GraphPad PRISM
5 software Version 5.02 (GraphPad Software, La Jolla, CA). A p-value of less than 0.05 was considered
statistically significant.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/20/13/
3324/s1.
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Abbreviations
AD atopic dermatitis
ERK extracellular signal-regulated kinase
FLG filaggrin
IL interleukin
IL-4Rα IL-4 receptor α
IL-13Rα1 IL-13 receptor α1
IL-13Rα2 IL-13 receptor α2
IVL involucrin
JNK c-Jun N-terminal kinase
MAPK mitogen-activated protein kinase
MEK mitogen-activated protein kinase kinase
NHEK normal human epidermal keratinocyte
TH2 cell T helper 2 cells
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Abstract: Severe pruritus is a characteristic feature of atopic dermatitis (AD) and is closely related to
its activity. Recent studies have shown that IL-31 is a key determinant of pruritus in AD. Anti-IL-31
receptor alpha (IL-31RA) antibody treatment has also been reported to improve pruritus clinically,
subsequently contributing to the attenuation of AD disease activity. Therefore, IL-31 has been thought
to be an important cytokine for regulating pruritus and AD disease activity; however, how IL-31 is
involved in the immune response in AD has remained largely unknown. Epidermal Langerhans cells
(LCs) and dermal dendritic cells (DCs) derived from bone marrow cells have been reported to play a
critical role in AD pathogenesis. LCs and DCs produce Ccl 17 and Ccl 22, which chemoattract Th2 cells,
leading to AD development. Therefore, we aimed to clarify how IL-31/IL-31RA interaction affects
Ccl 17 and Ccl 22 production. To test this, we analyzed murine bone marrow-derived DCs (BMDCs)
stimulated with IL-4, an important cytokine in AD development. We found that IL-31RA expression
was upregulated by IL-4 stimulation in a dose-dependent manner in BMDCs. Furthermore, IL-31
upregulates Ccl 17 and Ccl 22 production in the presence of IL-4, whereas IL-31 stimulation alone
did not produce Ccl 17 and Ccl 22. These findings suggest that IL-4 mediates IL-31RA expression
and IL-31/IL-31RA interaction augments Ccl 17 and Ccl 22 production in BMDCs, which promotes
Th2-deviated immune response in AD. Since we previously reported that soybean tar Glyteer, an aryl
hydrocarbon receptor (AHR) ligand, impairs IL-4/Stat 6 signaling in BMDCs, we examined whether
Glyteer affects IL-31RA expression induced by IL-4 stimulation. Glyteer inhibited upregulation
of IL-31RA expression induced by IL-4 stimulation in a dose-dependent manner. Glyteer also
inhibited Ccl 17 and Ccl 22 production induced by IL-4 and IL-31 stimulation. Taken together, these
findings suggest that Glyteer treatment may improve AD disease activity by impairing IL-31/IL-31RA
interaction in DCs.
Keywords: IL-31; IL-31 receptor alpha; Ccl 17; Ccl 22; dendritic cell; atopic dermatitis
1. Introduction
Interleukin (IL)-31 is a four-helix bundle cytokine closely related to the IL-6 cytokine family [1]. It
is the only known ligand for IL-31 receptor alpha (IL-31RA), which belongs to the glycoprotein 130
receptor family [2]. IL-31/IL-31RA interaction initiates signal transduction resulting in the expression
of several pro-inflammatory cytokines and chemokines, which play a crucial role in inflammatory
diseases relating to Th2 cytokines including IL-4 and IL-13 [3,4].
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Atopic dermatitis (AD) is a chronic or chronically relapsing, eczematous, and severely pruritic
skin disorder. The lesional skin of AD exhibits Th2-deviated immune reactions such as those involving
IL-4, IL-5, and IL-13, which contribute to the development of this disease [5]. It has been shown that
the anti-IL-4 receptor alpha (IL-4RA) antibody dupilumab causes marked and rapid improvement
in AD patients [6], indicating that IL-4 plays a critical role in AD development. A recent study
has also shown that anti-IL-31 receptor alpha (IL-31RA) antibody treatment using nemolizumab
produced clinical improvement of pruritus, subsequently contributing to the attenuation of AD disease
activity [7]. The mechanism behind this is still not fully understood, but it has been shown that
IL-31RA is expressed on sensory neurons and IL-31 derived from activated T cells under Th2-skewed
conditions stimulates IL-31RA on sensory nerves, resulting in severe pruritus in AD [8]. Although
IL-31/IL-31RA interaction has been identified as one of the key determinants of pruritus in AD, there are
limited reports regarding the effect of IL-31/IL-31RA interaction on Th2-deviated immune conditions
in AD [4,9]. It has been reported that transgenic mice overexpressing IL-31 develop AD-like skin
lesions with severe pruritus [10]. In addition, the neutralization of IL-31 and genetic inhibition of
EPAS1, a regulator of IL-31 induction in CD4+ T cells, have been reported to ameliorate AD-like skin
lesions [11]. Therefore, IL-31/IL-31RA interaction is deeply involved in AD disease activity in addition
to pruritus.
Given that (1) CCL 17 and CCL 22 chemoattract Th2 cells and maintain the Th2 immune
response [12,13], (2) serum CCL 17 and CCL 22 levels are closely related to the disease activity of
AD [14], and (3) Langerhans cells and dermal dendritic cells (DCs) produce prominent CCL 17 and
CCL 22 in the skin of AD patients [12,15], we investigated whether IL-31/IL-31RA interaction affects
CCL 17 and CCL 22 production in DCs during the development of AD. To test this, we analyzed
murine bone marrow-derived DCs (BMDCs) treated with IL-4, which is thought to recapitulate the
conditions of skin myeloid DCs in AD.
2. Results
2.1. IL-4 Stimulation Upregulated IL-31RA Expression in BMDCs
We first examined whether IL-4 stimulation upregulated IL-31RA expression in BMDCs. We
analyzed BMDCs stimulated with IL-4 (0.1, 1, and 10 ng/mL) for 24 h. Quantitative reverse-transcription
(qRT-PCR) analysis revealed that IL-4 stimulation upregulated IL-31RA expression at the mRNA level
in a dose-dependent manner (Figure 1a). Flow cytometry analysis of BMDCs stimulated with IL-4
(10 ng/mL) for 24 h also showed that IL-4 stimulation upregulated IL-31RA expression at the protein
level (Figure 1b). We also examined expression of OSMRβ, the other subunit of IL-31 receptor; however,
it was not upregulated by IL-4 stimulation at the mRNA level (Figure 1c) in BMDCs stimulated with
IL-4 (0.1, 1 and 10 ng/mL) for 24 h (Figure 1c).
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Figure 1. IL-4 stimulation upregulated IL-31RA expression in bone marrow-derived dendritic cells
(BMDCs). (a,c) Data are expressed as mean ± standard error of the mean (S.E.M.); n = 3 for each group;
* p < 0.05. Expression of IL-31RA (a) and OSMRβ (c) mRNA in BMDCs stimulated with IL-4 (0.1, 1 and
10 ng/mL) for 24 h. mRNA levels normalized for ACTB are expressed as fold induction compared with
that in the control group. ACTB was utilized as a housekeeping gene. (b) BMDCs were treated with
or without IL-4 (10 ng/mL) for 24 h. IL-31RA expression was evaluated using anti-murine IL-31RA
antibody. Data are representative of experiments repeated three times with similar results.
2.2. IL-31 Stimulation Enhanced IL-4-Induced Ccl 17 and Ccl 22 Production in BMDCs
In addition to our previous report [15] describing that IL-4 stimulation induced Ccl 17 and Ccl 22
production in BMDCs, we next examined how IL-31 stimulation affects Ccl 17 and Ccl 22 production.
We analyzed Ccl 17 and Ccl 22 expression in BMDCs stimulated with or without IL-4 (10 ng/mL) and
IL-31 (50 and 100 ng/mL) for 24 h. qRT-PCR analysis showed that IL-31 stimulation alone (50 and
100 ng/mL) did not induce upregulation of Ccl 17 and Ccl 22 mRNA expression. Alternatively, IL-31
(50 and 100 ng/mL) with IL-4 (10 ng/mL) stimulation enhanced expression of Ccl 17 and Ccl 22 rather
than IL-4 alone at the mRNA level (Figure 2a,c). ELISA analysis of the culture medium of BMDCs
stimulated with IL-31 (50 and 100 ng/mL) with IL-4 (10 ng/mL) for 48 h also showed that IL-31 (50 and
100 ng/mL) with IL-4 (10 ng/mL) stimulation enhanced production of Ccl 17 and Ccl 22 rather than IL-4
alone at the protein level (Figure 2b,d). These results suggest that IL-4-induced IL-31RA upregulation
is functional through IL-31/IL-31RA interaction, which leads to the enhanced production of Ccl 17 and
Ccl 22 in BMDCs. Since another previous report stimulation with a high concentration (250 ng/mL) of
IL-31 led to CCL22 production in human monocyte-derived DCs [16], we examined whether IL-31
stimulation (250 ng/mL) affects Ccl 22 expression. In our study, IL-31 stimulation alone (250 ng/mL)
did not induce upregulation of Ccl 22 expression at the mRNA level (Figure S1a) and the protein level
(Figure S1b), in BMDCs.
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Figure 2. IL-31 stimulation enhanced IL-4-induced Ccl 17 and Ccl 22 production in BMDCs. (a–d) Data
are expressed as mean ± standard error of the mean (S.E.M.); n = 3 for each group; * p < 0.05. Expression
of Ccl 17 (a) and Ccl 22 (c) mRNA in BMDCs stimulated with or without IL-4 (10 ng/mL) and IL-31
(50 and 100 ng/mL) for 48 h and production of Ccl 17 (b) and Ccl 22 (d) in the culture supernatant
were measured.
2.3. Glyteer Treatment Inhibited IL-4-Induced IL-31RA Expression in BMDCs
Since we previously reported that Glyteer treatment impairs the IL-4/STAT6 signaling pathway
in BMDCs [15] and human keratinocytes [17], we examined whether Glyteer treatment also inhibits
IL-31RA expression induced by IL-4 stimulation in BMDCs. We analyzed BMDCs stimulated with
IL-4 (10 ng/mL) for 24 h in the presence or absence of Glyteer (10−5, 10−6, and 10−7%). qRT-PCR
analysis showed that Glyteer treatment inhibited IL-4-induced IL-31RA expression at the mRNA level
in a dose-dependent manner (Figure 3a). Flow cytometry analysis of BMDCs stimulated with IL-4
(10 ng/mL) for 24 h in the presence or absence of Glyteer (10−5%) also showed that IL-31RA-positive
cells increased upon stimulation with IL-4 (10 ng/mL), compared with that in the control group,
which was inhibited by Glyteer treatment (10−5%) (around the area indicated by a white arrow).
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Figure 3. Glyteer impaired IL-4-induced IL-31RA expression. (a) Data are expressed as mean ±
standard error of the mean (S.E.M.); n = 3 for each group; * p < 0.05. Expression of IL-31RA mRNA
in BMDCs stimulated with or without IL-4 (10 ng/mL) and Glyteer (10−7, 10−6 and 10−5%) for 24 h.
(b) BMDCs were treated with or without IL-4 (10 ng/mL) and Glyteer (10−5%) for 24 h. IL-31RA
expression was evaluated using anti-murine IL-31RA antibody. IL-31RA-positive cells increased upon
stimulation with IL-4 (10 ng/mL), compared with that in the control group, which was inhibited by
Glyteer treatment (10–5%) (around the area indicated by a white arrow). Data is representative of
experiments repeated three times with similar results.
2.4. Glyteer Treatment Inhibited IL-4- and IL-31-Induced Ccl 17 and Ccl 22 Production in BMDCs
To further confirm the inhibitory effects of Glyteer treatment, we examined whether the
enhancement of Ccl 17 and Ccl 22 production by IL-31 with IL-4 stimulation was inhibited in
BMDCs. We analyzed Ccl 17 and Ccl 22 expression in BMDCs stimulated with or without IL-4
(10 ng/mL) and IL-31 (50 and 100 ng/mL) for 24 h in the presence or absence of Glyteer (10−5, 10−6 and
10−7%). qRT-PCR analysis showed that Glyteer treatment inhibited the upregulation of Ccl 17 and Ccl
22 induced by IL-4 stimulation at the mRNA level (Figure 4a,c). ELISA analysis of the culture medium
of BMDCs stimulated with or without IL-4 (10 ng/mL) and IL-31 (50 and 100 ng/mL) for 48 h in the
presence or absence of Glyteer (10−5, 10−6 and 10−7%) also showed that Glyteer treatment inhibited the
upregulation of Ccl 17 and Ccl 22 induced by IL-4 stimulation at the protein level (Figure 4b,d). These
results are already proven in our previous report [15]. Furthermore, Glyteer treatment inhibited the
upregulation of Ccl 17 and Ccl 22 by IL-31 with IL-4 stimulation at the mRNA level (Figure 4a,c) and
the protein level (Figure 4b,d) in a dose-dependent manner.
17
Int. J. Mol. Sci. 2019, 20, 4053
Figure 4. Glyteer impaired IL-4 with IL-31-induced Ccl 17 and Ccl 22 production in BMDCs. (a–d)
Data are expressed as mean ± standard error of the mean (S.E.M.); n = 3 for each group; * p < 0.05.
Expression of Ccl 17 (a) and Ccl 22 (c) mRNA in BMDCs stimulated with or without IL-4 (10 ng/mL),
IL-31 (100 ng/mL), and Glyteer (10−7, 10−6 and 10−5%) for 48 h and production of Ccl 17 (b) and Ccl 22
(d) in the culture supernatant were measured.
3. Discussion
Although it has been reported that the IFN-γ/STAT1 signal mediates IL-31RA expression in
DCs [16], whether Th2 cytokines such as IL-4 and IL-13 can upregulate IL-31RA expression in DCs
has not been examined. Since recent studies have shown that IL-31 and its interaction with IL-31RA
play a crucial role in the development of AD [7,11], clarifying the regulatory mechanism of IL-31RA
expression under Th2-deviated conditions is very useful for treating AD. The present study has shown
for the first time that IL-4 stimulation is capable of upregulating IL-31RA in BMDCs, which is consistent
with a previous report describing that either IL-4 or IL-13 can upregulate IL-31RA via Stat6 in murine
macrophages [4].
To further determine whether the IL-4-induced IL-31RA is functional, we stimulated IL-4-treated
BMDCs with IL-31. This IL-31 stimulation without IL-4 treatment did not induce Ccl 17 and Ccl 22
production, indicating that the upregulation of IL-31RA expression is required for Ccl 17 and Ccl 22
production induced by IL-31, which is partially consistent with a previous report describing that CCL
17 is not produced by IL-31-stimulated human DCs [16]. Nevertheless, the IL-31 stimulation with
IL-4 treatment enhanced Ccl 17 and Ccl 22 production compared with IL-4 treatment alone. These
findings suggest that a Th2-prone immune condition including IL-4 treatment augments IL-31/IL-31RA
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interaction, which enhances Ccl 17 and Ccl 22 production and subsequently exacerbates the disease
activity of AD.
The mechanism by which IL-31 stimulation enhances IL-4-induced Ccl 17 and Ccl 22 production
remains incompletely understood. Several studies have reported that IL-31/IL-31RA interaction
mediates STAT1/3/5 and MAP kinase activation [18,19]. Based on the evidence (1) that STAT1 activation
induces CCL 17 and CCL 22 in HaCaT cells (human keratinocytes) [20], and (2) that the inhibition of
MAP kinase activation reduces CCL 17 and CCL 22 production in HaCaT cells [21], multiple pathway
signal transduction such as STAT1/3 and MAP kinase induced by the IL-31/IL-31RA interaction may be
involved in the enhancement of Ccl 17 and Ccl 22 production by IL-31 stimulation. However, further
studies are required to confirm this.
Since Glyteer inhibits IL-4-induced upregulation of IL-31 RA expression and IL-4-induced Ccl 17
and Ccl 22 production in BMDCs, the dual effects of Glyteer on IL-31RA expression and Ccl 17 and Ccl
22 production contribute to its inhibition of Ccl 17 and Ccl 22 production in AD. These findings suggest
that Glyteer treatment potentiates the efficiency of nemolizumab, an IL-31 receptor α-antagonist, and
dupilumab, an IL-4 receptor α-antagonist, in the treatment of AD. Nemolizumab has recently been used
for the treatment of AD patients and shown to significantly improve clinical outcomes [7]. Although
IL-31 is considered to be an important cytokine in the pruritus of AD, the present study revealed a new
role of IL-31 in Th2-deviated immune conditions such as the production of CCL 17 and CCL 22 in AD.
In conclusion, we have demonstrated (i) that IL-31/IL-31RA interaction in dendritic cells under
Th2-skewed conditions may increase the production of CCL17 and CCL22, contributing to the disease
activity of AD, and (ii) that Glyteer treatment could have potential to prevent the production of CCL17
and CCL22 in AD (Figure 5). These findings should also promote our understanding of the roles of
dendritic cell functions in AD.
Figure 5. IL-4 augments IL-31/IL-31 RA interaction leading to enhanced Ccl 17 and Ccl 22 production
in BMDCs. IL-4 induces upregulation of IL-31RA expression at the mRNA levels 1 and the protein
levels 2. IL-31RA expression initially upregulated by IL-4 stimulation can lead upregulation of Ccl
17 and Ccl 22 production at the mRNA levels 3 and the protein levels 4, whereas IL-31 stimulation
alone without IL-31RA upregulation did not upregulate Ccl 17 and Ccl 22 production 5. Impairment
of STAT6 signaling pathway activation by Glyteer 6 inhibits upregulation of IL-31RA expression and
Ccl 17 and Ccl 22 production induced by IL-4 in BMDCs.
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4. Materials and Methods
4.1. Reagents
DMSO was purchased from Sigma-Aldrich (St. Louis, MO, USA). Recombinant murine IL-31 and
IL-4 were purchased from PeproTech (Rocky Hill, NJ, USA). Glyteer was provided by Fujinaga Pharm
Co. Ltd. (Tokyo, Japan) as original sticky-liquid stock. Glyteer is generated from soybean as dry
distillated tar after delipidation, which contains wide-ranged organic compounds such as polycyclic
aromatic hydrocarbons. Since Glyteer is known to act as a potent AHR ligand, no farther investigations
have been conducted to clarify the detailed bioactive components.
4.2. Generation of Bone Marrow-Derived DCs (BMDCs) and Cell Culture
C57BL/6J mice were housed and bred in a clean breeding facility, and the trial was approved
by the animal facility of Kyushu University (A30-258-0, 20 Aug 2018–31 Mar 2020). Bone marrow
cells were collected freshly from femoral and tibial bones of mice and cultured in RPMI 1640 medium
(Sigma-Aldrich) containing 1 mmol/L sodium pyruvate (10 mL; Invitrogen, Waltham, MA, USA),
10 mmol/L 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) (10 mL; Invitrogen, Waltham,
MA, USA), 1% Minimum Essential Medium Non-Essential Amino Acids (MEM NEAA) (10 mL;
Invitrogen), 10% FBS (Japan Bio Serum, Fukuyama, Japan), β-mercaptoethanol (50 nmol/L; Invitrogen),
100 U/mL penicillin, and antibiotic-antimycotic 100× (5 mL; 100 mg/mL streptomycin, and 0.25 μg/mL
amphotericin B; Invitrogen) with GM-CSF (10 ng/mL) (Miltenyi Biotec, Bergisch Gladbach, Germany).
Medium was refreshed twice in 7 days. Non-adherent cells were collected on day 7, and cells were
purified immunomagnetically by positive selection with CD11c (N418) MicroBeads (Miltenyi Biotec).
Our previous study has reported that the purity of BMDCs was 95–97%, that was confirmed by flow
cytometric analysis [15]. Purified BMDCs were cultured with/without stimulants such as IL-4 and
IL-31, and/or Glyteer for 24 h or 48 h. Culture supernatants were collected for ELISA analysis. Cell
pellets were utilized for qRT-PCR or FACS analysis. This method of generating BMDCs and cell culture
matches that in our previous study [15].
4.3. Quantitative Reverse-Transcription (qRT)-PCR Analysis
Total RNA was extracted by using RNeasy® Mini Kit (Qiagen, Hilden, Germany), then reverse
transcription for making cDNA was conducted by using PrimeScriptTM RT reagent kit (Takara Bio,
Kusatsu, Japan). qRT-PCR was performed on CFX Connect Real-time PCR Detection System (Bio-Rad,
Hercules, CA, USA) using TB Green® Premix Ex Taq (Takara Bio, Kusatsu, Japan). Amplification
was launched as the first step at 95 ◦C for 30 s, then followed by 40 cycles of qRT-PCR at 95 ◦C for
5 s and at 61 ◦C for 20 s as the second step. mRNA expression was measured with normalization by
housekeeping gene using β-actin in triplicate, and the mRNA expressions were presented as the fold
induction relative to the control group. Each primer sequences are shown in Table 1.
Table 1. The sequences of primers.
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4.4. ELISA
Murine Ccl 17 and Ccl 22 ELISA Kit (R&D Systems, Minneapolis, MN, USA) was utilized to
measure production of Ccl 17 and Ccl 22 following the manufacturer’s protocol. Absorbance of the
wells of the ELISA plate was measured using DTX 800 Multimode Detector (Beckman Coulter).
4.5. Fluorescence-Activated Cell Sorting (FACS) Analysis
LIVE/DEAD fixable dead cell staining kit (violet and near IR; Life Technologies) was used to detect
dead cells. Then, BMDCs were incubated with anti-CD16/32 antibody (Becton Dickinson, Franklin
Lakes, NJ, USA) for 30 min on ice. Anti-murine IL-31 RA antibody (Bioss Antibodies, Boston, MA,
USA) was labeled with Zenon R-Phycoerythrin (PE) Rabbit IgG Labeling Kit (Thermo Fisher Scientific,
Waltham, MA, USA), in accordance with the manufacturer’s protocol. IL-31RA was stained with
PE-conjugated anti-murine IL-31RA antibody. Isotype-matched antibodies were used as controls.
Stained cells were analyzed on a BD Canto flow cytometer (Becton Dickinson). Stained cells were also
observed using a D-Eclipse confocal laser scanning microscope (Nikon, Tokyo, Japan).
4.6. Statistical Analysis
Two-sample Student’s t test was used for statistical evaluation of the results. A p-value of <0.05
was considered to show a statistically significant difference. All data are presented as mean ± standard
error of the mean (S.E.M.) from three independent experiments.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/20/16/
4053/s1.
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Abstract: The glycerol fermentation of probiotic Staphylococcus epidermidis (S. epidermidis) in the skin
microbiome produced butyric acid in vitro at concentrations in the millimolar range. The exposure
of dorsal skin of mice to ultraviolet B (UVB) light provoked a significant increased production of
pro-inflammatory interleukin (IL)-6 cytokine. Topical application of butyric acid alone or S. epidermidis
with glycerol remarkably ameliorated the UVB-induced IL-6 production. In vivo knockdown of
short-chain fatty acid receptor 2 (FFAR2) in mouse skin considerably blocked the probiotic effect
of S. epidermidis on suppression of UVB-induced IL-6 production. These results demonstrate that
butyric acid in the metabolites of fermenting skin probiotic bacteria mediates FFAR2 to modulate the
production of pro-inflammatory cytokines induced by UVB.
Keywords: butyric acid; microbiome; probiotic; S. epidermidis; UVB
1. Introduction
Skin is a fundamental component of the innate immune system, providing a protective barrier
against the penetration of microorganisms and preventing environmental damage to the body. Exposure
to UV is known to induce clustering of specific cell-surface receptors, resulting in the activation of
signal transduction pathways [1]. Prolonged exposure of ultraviolet B (UVB) with a wavelength
of 280–320 nm is a significant risk factor causing chronic inflammation, DNA damage, and lipid
peroxidation in the epidermis [2]. Chronic exposure to this cellular stressor commonly results in skin
pathologies such as epidermal hyperplasia, erythema, and edema [3]. Within the skin epidermis,
keratinocytes have been found to play a critical role in the response to photo-damage to UVB by
releasing key inflammatory mediators such as interleukin (IL)-1, -6, -8, -10 and tumor necrosis factor
(TNF). Among these, keratinocyte-derived IL-1 and IL-6 seem to be of particular importance [4].
Many studies have demonstrated that both human and murine keratinocytes produce these cytokines
because of UV exposure [5,6]. Continuous exposure to UV results in the generation of reactive oxygen
species (ROS), exposing a variety of biomolecules to oxidative stress. This leads to damage of biological
structures, contributes to cellular injury, and ultimately resulting in tissue destruction [7].
The skin microbiome consists of a complex community of organisms that mediates essential
physiological and pathological processes. Among these organisms, Staphylococcus epidermidis
(S. epidermidis) is the predominant commensal bacterial species that colonizes normal human skin [8].
Derangement of the bacterial milieu can alter epidermal function, and thus, disrupt the local ecology
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of the skin [9]. This interplay of microbe and host appears to be critical for establishing homeostasis.
S. epidermidis has also been shown to benefit the skin immune function by diminishing inflammation after
injury [10]. Study have shown that 6-N-hydroxyaminopurine, a metabolite from S. epidermidis could
selectively inhibit UV induced skin tumors in mice [11]. Additionally, studies have provided evidence
that peptides and other metabolites produced from S. epidermidis, might also act as antimicrobial agents
and contribute to normal defense at the epidermal interface [12,13]. In the current study, we demonstrate
that butyric acid, one of the major metabolites produced by S. epidermidis fermentation, attenuates the
UVB-induced production of inflammatory cytokines by interacting with cognate receptors expressed
by keratinocytes. This suggests that manipulation of the S. epidermidis-butyric acid-FFAR2 axis is a
potential therapeutic target to protect against skin inflammatory diseases.
2. Results
2.1. S. epidermidis Mediates Glycerol Fermentation and Acetolactate Synthase (ALS) Activity
To investigate whether S. epidermidis (ATCC 12228) can ferment glycerol, S. epidermidis (107
colony-forming unit (CFU) were incubated with and without glycerol (2%) in rich media with phenol
red for 12 h. Uninoculated rich media containing phenol red with glycerol served as controls. Phenol
red was used as an indicator to monitor bacterial fermentation. In rich media incubated with bacteria,
the color of phenol red changed from red to orange because of the bacterial replication during incubation.
However, in agreement with earlier results, the rich media containing bacteria along with glycerol,
the phenol red color changed from red to yellow indicating the use of glycerol as a carbon source for
fermentation by S. epidermidis after 12 h culture (Figure 1a) [13–15]. The color change of phenol red
was quantified by measuring the optical density at 560 nm (OD560) (Figure 1b). Furthermore, OD560nm
in rich media with S. epidermidis and glycerol was significantly lower than that in rich media with
S. epidermidis alone (Figure 1a). Next, to confirm the fermentation activity of S. epidermidis using glycerol
as a carbon source, we added furfural, a potent fermentation inhibitor [16], in rich media containing
S. epidermidis and glycerol. Media with and without S. epidermidis, glycerol and furfural were used as
controls. We did not detect any color change in the media incubated with S. epidermidis with furfural
in the presence or absence of glycerol (Figure 1a). Additionally, the OD560nm was comparable to the
control group containing media only, or media with furfural, or media with glycerol. This indicates
that the fermentation or metabolic activity of S. epidermidis might have been inhibited by furfural
(Figure 1b). Microbial enzymes are found to be the major source of bacterial fermentation by catalyzing
the hydrolysis of starch or peptides. Moreover, a recent study reported that acetolactate synthase (ALS)
is a crucial enzyme in Staphylococcus aureus (S. aureus) which converts pyruvate into α-acetolactate,
promoting the production of branched-chain amino acids (BCAA) and playing an important role in the
activation of the tricarboxylic acid (TCA) cycle [17]. It also promotes anaerobic fermentation in Bacillius
subtilis (B. subtilis) by converting two molecules of pyruvate to form acetolactate, functioning as a key
regulatory enzyme in fermentation [18]. Reports also demonstrated that furfural exerts its inhibitory
effects on microbial fermentation via interfering with the activities of enzymes in the pathways of
microbial fermentation [19]. We confirmed that the ALS enzyme activity of S. epidermidis is significantly
reduced when it is incubated with furfural (inhibitor) (Figure 1c). Taken together, we confirmed that
S. epidermidis induced glycerol fermentation, which required furfural-sensitive ALS activity.
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Figure 1. S. epidermidis mediates glycerol fermentation by ALS (acetolactate synthase) enzyme activity.
(a) S. epidermidis bacteria (B) (107 CFU/mL) were incubated in rich media (M) containing phenol red
with or without 2% glycerol (G) and in the presence and absence of fermentation inhibitor furfural (F)
for 12 h. Media with glycerol (M + G), bacteria (M + B), furfural (M + F), glycerol plus furfural (M + G
+ F), or bacteria plus furfural (M + B + F) were taken as controls. Bacterial fermentation was indicated
by the color change of phenol red to yellow (arrow). (b) A graph showing the OD560 value in all the
above groups. (c) ALS activity by furfural. The reaction mixture containing lysates of S. epidermidis
bacteria (B) (107 CFU/mL) was incubated with and without furfural (F). The activity (U/mg) of ALS in
S. epidermidis bacteria was quantified. Data shown represent the mean ± SE of experiment performed
in triplicate. *** p < 0.001 (two-tailed t-test).
2.2. Butyric Acid, a Product in Fermented Media upon Glycerol Fermentation by S. epidermidis
Previous studies have detected the presence of multiple short-chain fatty acids (SCFAs) such as
acetic acid, butyric acid, lactic acid, and succinic in fermented media of S. epidermidis from glycerol
fermentation [13]. Butyric acid from S. epidermidis was found to exert growth suppressive effects
on USA300, a community-associated methicillin-resistant S. aureus (MRSA). Moreover, it shows
potent anti-inflammatory activity in skin keratinocytes by effectively inhibiting histone deacetylase
(HDAC) [20,21]. In the current study, we have screened the supernatant following glycerol fermentation
of S. epidermidis to quantify their butyric acid producing capacity by high-performance liquid
chromatography-ultraviolet (HPLC-UV) analysis. Butyric acid was detected as a sharp specific
peak in the HPLC chromatogram and was determined to be at a concentration of 6 mM in the fermented
media by comparison to a butyric acid standard curve (Figure 2a,b).
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Figure 2. High-performance liquid chromatography-ultraviolet (HPLC-UV) analysis of the butyric
acid. The fermented media from glycerol (G) fermentation by S. epidermidis bacteria (B) analyzed
by HPLC. (a) Chromatograph of only media (M), media with glycerol (M + G), media with bacteria
(M + B), and media with bacteria plus glycerol (M + B + G). The x-axis is retention time in minutes,
and the y-axis is the milli-absorbance unit at 210 nm. (b) The concentrations of BA (butyric acid) was
quantified from the height of butyric acid standard (STD) peaks. Data shown represent the mean ± SE
of experiment performed in triplicate. *** p < 0.0001 (two-tailed t-test).
2.3. Mixture of S. epidermidis and Glycerol or Butyric Acid alone Inhibited UVB Induced Skin Inflammation
Exposure to prolonged UVB radiation is deleterious to human skin, which may lead to expression
and secretion of pro-inflammatory cytokines such as IL-6 in human keratinocytes [22]. Furthermore,
chronic UVB is responsible for epidermal hyperplasia. The dorsal skin of the Institute of Cancer
Research (ICR) mice were shaved and exposed to 12 doses of UVB (195 mJ/cm2) over 4 weeks concurrent
with 4 topical applications of a mixture of S. epidermidis (107) and glycerol (2%) in phosphate-buffered
saline (PBS) over the same time period. Mice topically applied with mixture of S. epidermidis (107)
and glycerol (2%) in PBS with no UVB exposure were included as control. The dorsal skin of mice
was photographed to measure the wound healing from 0, 16, and 30 days. Mice from all groups
were sacrificed on the 30th day and skin samples were lysed to extract total protein. In mice treated
with either PBS, S. epidermidis, or glycerol alone, variable lesions were recorded which started from
edema, redness, and ulceration of the UVB exposed area and ended with thickening of the skin.
However, in mice that received topical applications of S. epidermidis and glycerol, a comparatively
lower level of erythema and ulceration were observed on UVB-exposed skin on day 16. Further
improvement was noticed on day 30, signifying maximum recovery from UVB damage (Figure 3a,b)
compared to non-exposed groups (Figure S1a). Upregulated levels of IL-6 and noticeable epidermal
hyperplasia (as quantified by epidermal thickness) were detected in mice skin topically applied with
PBS, S. epidermidis, or glycerol alone following UVB exposure because of an increase in the number of
keratinocytes and epidermal layers. By contrast, in the S. epidermidis plus glycerol treated group, IL-6
levels were significantly reduced (Figure 3c) compared to non-exposed groups (Figure S1b) and the skin
remained almost completely intact, showing a marked attenuation of UVB-induced skin thickening
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(Figure S3a,b). This indicates that metabolites from glycerol fermentation by S. epidermidis might induce
anti-inflammatory activity against chronic UVB radiation. To further confirm the anti-inflammatory
activity of S. epidermidis fermentation, another group of mice were topically applied with a mixture of
S. epidermidis and glycerol along with fermentation inhibitor, furfural. UVB irradiation-induced skin
lesions, elevation of IL-6, and epidermal hyperplasia were not ameliorated upon topical application
of S. epidermidis plus glycerol and furfural compared to control group receiving water and furfural
alone (Figure 3d and Figure S3c–f). However, significant recovery from inflammation was detected in
mice topically applied with a mixture of S. epidermidis and glycerol. This was again accompanied by a
downregulated level of IL-6 and decreased epidermal thickness, confirming that glycerol fermentation
from S. epidermidis exerts anti-inflammatory activity. In the present study, we detected the production
of butyric acid in significant amount as a metabolite in the fermentation of glycerol by S. epidermidis.
Since butyric acid has been shown to be a potent anti-inflammatory agent in skin keratinocytes and
has been tested for the attenuation of different inflammatory disorders [23,24], we first investigated
its role against UVB induced inflammation in human keratinocytes (CCD 1106 KERTr). The human
keratinocytes were irradiated with 195 mJ/cm2 UVB and the IL-6 production was dramatically enhanced
in water control group until 12 h after irradiation. However, the addition of BA (butyric acid, 4 mM),
significantly reduced the upregulated level of IL-6 (Figure S2a). As studies mentioned, both IL-6 and
IL-8 undoubtedly play pivotal roles in immunologic regulation in human skin and are involved in
skin inflammation in response to UV radiation [25]. We have also detected the upregulated level of
IL-8 in UVB exposed keratinocytes, which further rescued upon BA treatment (Figure S2b). Further,
we detected effect of BA application upon UVB exposure in vivo. Our results show that topical
application of 4 mM butyric acid ameliorated UVB-induced wound formation, and wound healing was
mild to significant from day 16 to day 30 (Figure S3g,h). In a similar manner, IL-6 was downregulated
and epidermal hyperplasia was diminished (Figure 3e and Figure S3i,j), which was consistent with
the model that butyric acid is the active glycerol fermentation metabolite by which S. epidermidis can
inhibit UV induced inflammation in the skin.
2.4. Knocking Down Free Fatty Acid Receptor 2 (FFAR2) Inhibited Butyric Acid Mediated Attenuation of
Inflammation in Chronic UVB
Most beneficial roles of SCFAs in the gastrointestinal tract (GI) are mediated by directly activating
its cognate G protein-coupled receptor, GPR43 (also known as FFAR2). For example, the chemoattractant
and anti-inflammatory activities of butyrate in chondrocytes are completely mediated by its binding to
GPR43 [26]. The activation of FFAR2 has emerged as a potentially important mechanism by which
SCFAs could directly regulate the immune cells and the process of inflammatory diseases, thus drawing
much attention in recent years [27,28]. Considering the key function of FFAR2 in inflammatory
processes, blocking the signaling of this receptor by a selective inhibitor could be a useful approach
to evaluate the role of butyric acid in the regulation of immune function in skin during chronic
UVB exposure. In the present study, FFAR2 was inhibited by via gavage feeding of FFAR2 selective
antagonist GLPG0974 (0.1–1 mg/kg) 20 min prior to topical application of butyric acid followed by
UVB exposure. In addition, we have also blocked FFAR2 receptor via subcutaneous injection of FFAR2
siRNA (5 μM) into the dorsal skin of ICR mice 20 min prior to topical application of butyric acid
followed by UVB exposure. In both conditions of blocking FFAR2, significant wound area and redness
from UVB radiation was observed (Figure S4a,b,g,h) on mice dorsal skin, which further did not recover
even after topical application of butyric acid. Inflammation, as detected by upregulation of IL-6 and
epidermal hyperplasia, was increased in mice upon FFAR2 inhibition and further remained unchanged
even on topical application of butyric acid compared to mice applied with butyric acid alone (Figure 4a,b
and Figure S4c,d,i,j). We have also confirmed the FFAR2 inhibition or gene knockdown by measuring
the protein expression level of FFAR2 by Western blot analysis and mRNA relative expression by
RTPCR analysis (Figure S4e,f,k,l). Our overall results demonstrate an essential role of FFAR2/GPR43 in
butyrate activity in UVB-induced chronic inflammation process. Butyrate reduced pro-inflammatory
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mediators IL-6, by binding to its FFAR2 receptor, which further inhibits the epidermal hyperplasia in
chronic UVB exposure.
Figure 3. Attenuation of UVB induced inflammation by application of mixture of S. epidermidis and
glycerol and its fermentation metabolite, butyric acid. (a) Skin morphology of ICR mice, topically
applied with PBS, glycerol (G) (2%), S. epidermidis bacteria (B) (107 CFU/mL), or mixture of S. epidermidis
bacteria plus glycerol (B + G) followed by exposure with UVB (195 mJ/cm2) irradiation are shown at 0,
16, and 30 day. Skin lesions are indicated by red arrows. Scale bar = 5 mm. Graph (b) indicates percent
wound area remaining of mice skin. The level of IL-6 in skin (c) from above all groups of ICR mice
was quantified using a mouse IL-6 enzyme-linked immunosorbent assay (ELISA) kit (R&D Systems).
(d) The IL-6 level in skin of ICR mice topically applied with H2O, furfural (0.4%), S. epidermidis bacteria
(B) (107 CFU/mL), glycerol (G) (2%) plus furfural (F) (0.4%), (B + G + F) or a mixture of S. epidermidis
bacteria plus glycerol (B + G) followed by exposure with UVB (195 mJ/cm2) irradiation is shown.
(e) The IL-6 level in skin of ICR mice topically applied with H2O and butyric acid (BA) (4 mM) followed
by exposure with UVB (195 mJ/cm2) irradiation is shown. Data are the means of three individual
experiments using five mice per group. ns = non-significant. *** p < 0.001. (two-tailed t-tests).
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Figure 4. Blocking FFAR2 prevents the butyric acid mediated amelioration of inflammation. (a) The level
of IL-6 in the dorsal skin of ICR mice upon gavage feeding of FFAR2 antagonist GLPG0974 dissolved in
dimethyl sulfoxide (DMSO) in saline (0.01%) and topically applied butyric acid (BA) (4 mM) and was
measured by ELISA. Mice fed with DMSO in saline and topically applied with H2O were included as
control. (b) The level of IL-6 in the dorsal skin of ICR mice subcutaneously injected with FFAR2 siRNA
10 min prior to topical application with butyric acid (BA) (4 mM) was measured by ELISA. Mice injected
with scrambled or negative control siRNA and topically applied with H2O were included as control.
Data are the means of three separate experiments using five mice per group. ns = non-significant.
*** p < 0.001. (two-tailed t-tests).
3. Discussion
Skin and its constituent epidermal keratinocytes make-up the outer most protective covering of the
body, and as such, are the primary targets for solar UVB radiation. Exposure to chronic UVB radiation alters
the cutaneous and systemic immune systems by causing several pathological alteration in cell signaling
resulting in sunburn, erythema, inflammation, and skin carcinogenesis [29]. It primarily activates various
pro-inflammatory mediators such as tumor necrosis factor-alpha (TNF-α), cyclooxygenase-2 (COX-2),
and IL-6, leading to the activation of nuclear factor kappa-light-chain-enhancer of activated B cells
(NF-κB) [30]. The findings from the previous studies showed that S. epidermidis, a commensal bacteria
from human skin, could ferment glycerol into butyric acid, one of the four SCFAs detected in fermented
media [13,15]. Glycerol is a major component in stratum corneum (SC) hydration with varied amount
in different parts of human skin (0.7 μg/cm2 in the cheek and 0.l μg/cm2 in forearm and sole). Multiple
diseases characterized by xerosis and impaired epidermal barrier function, such as atopic dermatitis
were improved by topical application of glycerol. Although glycerol could not penetrate deeper in
SC but the SCFAs generated from glycerol fermentation by skin commensal bacteria, may modulate
physiological processes such as skin barrier homeostasis and inflammation [15,31,32]. In this study,
we evaluated the role of butyric acid, a major SCFA from the fermentation of glycerol by S. epidermidis,
on chronic UVB radiation induced inflammation on ICR mice skin. The fermentation of glycerol by
S. epidermidis was detected by change in color of phenol red from red to yellow (more acidic), which was
further validated quantitatively by a significant decrease in OD560nm. In addition to SCFAs, furfural
is another metabolite produced by bacterial fermentation, and its accumulation has been shown to
inhibit fermentation by blocking the activities of multiple enzymes involved in bacterial fermentation
pathway [19,33]. We did not detect fermentation by color change or by OD560nm quantification upon
adding furfural to media containing S. epidermidis with glycerol. Furthermore, no bacterial growth was
detected when furfural was added to media containing S. epidermidis alone, demonstrating the activity
of furfural in suppressing bacterial fermentation activity. ALS is one of the major fermentation enzymes
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catalyzing the conversion of pyruvate to α-acetolactate which is further converted to isobutyrate and
then ultimately to butyrate in subsequent pathways [34,35]. Our recent study showed, ALS activity in
S. epidermidis was inhibited by a furfural derivative 5-methyl furfural (5MF) [14]. In the current study,
we detected a significant reduction in ALS activity upon incubation of bacterial lysate with furfural.
This demonstrates that ALS plays an essential role in S. epidermidis metabolism, triggering glycerol
fermentation. We detected the production of butyric acid in fermented media by HPLC analysis on the
basis of comparing the retention time and spectra with a butyric acid standard, confirming butyric acid
as one of the most abundant metabolites produced from fermentation of 2% glycerol by S. epidermidis.
Metabolites from microbial fermentation have been under investigation as potential therapeutics
against different infectious and inflammatory diseases [36]. For example, research suggested that
ingestion of probiotic bacteria, Lactobacillus johnsonii (La1) could protect against the UVR-induced
inflammation [37]. Furthermore, several lines of evidence suggest that metabolites from the fermentation
of glycerol by S. epidermidis can inhibit the growth of pathogenic Cutibacterium acnes (C. acnes), thus,
S. epidermidis may be an excellent probiotic for the treatment of chronic sinusitis [13,15,38]. Here we
detected the probiotic effect of S. epidermidis in skin against UVB mediated chronic inflammation.
Topical application of S. epidermidis or glycerol alone on ICR mice dorsal skin exposed to UVB showed
noticeable erythema, ulceration, epidermal hyperplasia, and increased IL-6 levels. Following UVB
exposure, increased infiltration of dermal inflammatory cells may lead to epidermal proliferation of
keratinocytes and hyperplastic lesion [39,40]. A significant decrease in inflammation with attenuation
of IL-6 and a reduction of epidermal thickness was observed in skin topically applied with mixture of
S. epidermidis and glycerol, suggesting that the anti-inflammatory effect observed here is likely to be
mediated through S. epidermidis fermentation using glycerol as a carbon source. Further, we confirmed
that the anti-inflammatory activity was the result of S. epidermidis fermentation with the use of the
fermentation inhibitor, furfural. Control mice topically applied with water or furfural alone followed
by irradiation with UVB appeared to have significant ulceration, epidermal thickening, and increased
IL-6. Importantly, there was no recovery from ulceration or inflammation in skin applied with a
mixture of S. epidermidis and glycerol along with furfural. Based on these findings, we infer that a
product from the fermentation of glycerol by S. epidermidis could inhibit inflammation from chronic
UVB. Bacterial interference using live beneficial bacteria is a promising method of preventing or
treating many infections. Because of the US Food and Drug Administration (FDA) restriction in use
of live probiotic bacteria for cosmetics, the promotion of beneficial effects through the generation
of fermentation metabolites from live probiotic bacteria has become a desirable alternative [28,29].
Consistent with a previous study [13], the current work used HPLC analysis to detect a substantial
amount of butyric acid in the fermented media of S. epidermidis using glycerol as a carbon source.
Anti-microbial, anti-inflammatory, and anti-cancer activity of butyric acid and its derivatives make it
as a potential drug of choice [41,42]. It has been shown that application of both butyric acid and its
co-drug could reportedly inhibit skin tumorigenesis and psoriasis-like skin inflammation [43,44]. In the
current study, topical application of butyric acid markedly decreases skin ulceration and epidermal
thickness from UVB exposure compared to the control mice skin applied with H2O. In line with the
anti-inflammatory activity of butyric acid, a significant reduction in IL-6 level was detected both in
keratinocytes and in mice skin exposed to prolonged UVB, indicating its potential use as an agent
to prevent inflammation in chronic UVB exposed skin. Reduction in level of IL-8 upon butyric acid
treatment, provided new insight for the application of butyric acid against other upregulated cytokines
against UVB induced inflammation.
Research demonstrated that butyrate can control immune/inflammatory reactions in the skin [42].
SCFAs exert their immunomodulatory effects via binding to its cognate receptor, GPR43 [45].
Exacerbated or unresolved inflammation was observed in GPR43-deficient (Gpr43−/−) mice in models
of colitis, arthritis, and asthma, demonstrating that SCFA-GPR43 interactions are obligatory for normal
resolution of certain inflammatory responses [27]. Moreover, decreased expression of GPR43 by
keratinocytes in psoriatic skin could be rescued by topical application of sodium butyrate, indicating
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that butyrate-GPR43 interactions might exert anti-inflammatory effects in psoriasis [46]. In our study,
gavage feeding of mice with GLPG0974, an antagonist for FFAR2/GPR43 receptor, inhibited the
anti-hyperplasic, anti-inflammatory effect of butyric acid. Further, topical application of butyric acid
did not rescue the UVB induced skin damage and inflammatory level of IL-6 when FFAR2 receptor
was knocked down by subcutaneous injection of FFAR2 siRNA. Overall, these results demonstrate that
butyric acid interaction with the FFAR2 receptor is a crucial phenomenon during skin inflammation.
Moreover, butyric acid-FFAR2 interactions could represent a central mechanism to account for the
effect of probiotics on immune responses modulated by chronic UV radiation.
The skin microbiome plays an important role in preserving skin homeostasis. Thus, skin
microbiome through fermentation activity might influence the skin immune system in a similar way to
the gut under inflammatory disease conditions. A recent study demonstrated that topical application
of antioxidants against UVB were found more effective than dietary supplementation because of
the length of time needed to reach optimal concentrations in the skin [47]. In this current study,
we determined that topical application of butyric acid, as a fermentation metabolite could act as a
potent regulator of immune system during chronic UVB. Additionally, the dose of butyric acid is
non-toxic to skin cells and thus may gain broad acceptance for not only therapeutics but also as an
active ingredient in cosmetics with the ultimate aim of avoiding the strong effects from chronic UVB.
4. Materials and Methods
4.1. Ethics Statement
This research was conducted in strict accordance with an approved Institutional Animal Care and
Use Committee (IACUC) protocol of the National Central University (NCU), Taiwan (NCU-106-016,
19 December 2017). ICR mice (8–9 week-old females; National Laboratory Animal Centre, Taipei,
Taiwan) were sacrificed using dry ice in a closed box.
4.2. Chemicals
Butyric acid (Sigma), acetonitrile, H3PO4, ether anhydrous, formaldehyde, hydrochloric acid
(HCl, 37%), sodium hydroxide (NaOH), Sodium dihydrogenphosphate (NaH2PO4), and phosphoric
acid (H3PO4) were purchased from J.T.Baker, Avantor Performance Materials Taiwan Co. Ltd. DMSO
and glycerol were purchased from Sigma. PBS was purchased from Gibco (Gaithersburg, MD, USA).
GLPG0974 (FFAR2 inhibitor) was also obtained from Tocris Bioscience (Ellisville, MO, USA). Butyric
acid was obtained from Sigma (St. Louis, MO, USA).
4.3. Bacterial Culture
S. epidermidis bacteria, from ATCC 12228 was cultured on 3% tryptic soy broth (TSB) (Sigma, St.
Louis, MO, USA) agar plates overnight at 37 ◦C. A single colony was inoculated in 3% TSB medium
(Difco, Becton Dickinson UK Ltd., Oxford, UK) and cultured at 37 ◦C until the logarithmic growth
phase. Bacterial pellets were harvested by centrifugation at 5000× g for 10 min, washed with PBS,
and suspended in PBS.
4.4. Fermentation of Bacteria
S. epidermidis (107 CFU/mL) were incubated in 10 mL rich media (10 g/L yeast extract (Biokar
Diagnostics, Beauvais, France), 3 g/L TSB, 2.5 g/L K2HPO4, and 1.5 g/L KH2PO4) in the absence and
presence of glycerol (2%) under aerobic conditions at 37 ◦C with shaking at 200 rpm. The rich media
glycerol (2%) without bacteria were included as a control. The 0.002% (w/v) phenol red (Sigma) in rich
media with glycerol (2%) acted as a fermentation indicator. A color change from red-orange to yellow
indicated the occurrence of bacterial fermentation, which was detected as absorbance at 560 nm.
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4.5. Inhibition of ALS Activity by Furfural
ALS (EC: 4.1. 3.18) is responsible for the conversion of pyruvate to acetolactate which can be
eventually metabolized to diacetyl and 2,3-butanediol. The rate of reaction was monitored by the
depletion of NADH at 340 nm during the conversion of pyruvate to 2,3-butanediol. The reaction
mixture contained 70 mM sodium acetate buffer (pH 5.4), 0.17 mM thiamine pyrophosphate, and lysate
(10 mg) of heat (100 ◦C) killed S. epidermidis. The reaction was started by addition of pyruvate [48] in
the presence or absence of 0.4% furfural at 45 ◦C for 5 min. Absorbance was measured with a visible
spectrophotometer at 340 nm. Values of ALS activity were expressed in enzyme as unit per mg (U/mg),
in which one unit of ALS is defined as the amount of enzyme able to produce 0.1 absorbance unit
per min.
4.6. Ultraviolet Light Exposure
ICR mice were exposed to chronic UVB with a ramping dose using an UV lamp (Model EB-280C,
Spectronics Corp., Westbury, NY, USA). The UVB light source was set at a distance such that the dorsal
surface of each mouse received 195 mJ/cm2. Dorsal skin was exposed three times per week, followed
by topical application with S. epidermidis (107) and glycerol (2%) in PBS one time per week. Whole UVB
radiation and treatment was conducted for 4 weeks. Animals were photographed at 0, 16, and 30 day
for measurement of wound from UVB and recovery from treatment. Animals were sacrificed 3 day
following the last dose and whole skin samples, including epidermis and dermis were collected.
Tissue samples (approximately 1 cm2) were taken from similar dorso-caudal locations for histological
examination. The remaining portions of the dorsal skin were used to prepare whole skin lysate for
ELISA analyses. Hematoxylin and eosin (H&E) staining was performed by the Histopathology Shared
Resources Core at Li-Tzung Biotechnology Inc. Quantitative measurements of skin thickness from
H&E were made using ImageJ software.
4.7. Wound Measurement
To investigate the wound improvement of ICR hairless mice skin induced by UVB irradiation,
the mice were transiently anesthetized using isoflurane, and the wound were measured by ImageJ
software by calculating the percent of remaining wound area to the total area of skin exposed at 0, 16,
and 30 day of UVB irradiation. Wounds were photographed using a USB digital microscope.
4.8. Histological Analysis
Histological analysis was performed to determine the epidermal thickness. Dorsal skin samples of
the experimental groups were obtained after 4 weeks of UVB exposure, fixed with 10% formalin and
embedded in paraffin. Sections were stained with H&E to examine epidermal thickness. Epidermal
thickness was measured at 10×magnification using Olympus BX63 microscope (Olympus, Tokyo, Japan).
4.9. siRNA-Mediated Gene Silencing of GPR43/FFAR2
In order to silence GPR43 gene, we used the chemically-modified siRNA that targets GPR43
receptor and the siRNA negative control, which does not target any known sequence were obtained
from GenePharma Co. (Shanghai, China). Their oligonucleotide sequences are siFFAR2: sense
strand, 5′-CCGGUGCAGUACAAGUUAUTT-3′; anti-sense strand, 5′-AUAACUUGUACUGCACC
GGTT-3′. SiControl: sense strand, 5′-UUCUCCGAACGUGUCACGUTT; anti-sense strand,
5′-ACGUGACACGUUCGGAGAATT-3′. These chemically-modified siRNAs were delivered by
intradermal injection in dorsal skin of mice using a microneedle [49,50].
4.10. Drug Treatment
Selective FFAR2 antagonist GLPG0974 (0.1 or 1 mg/kg ig) was administered to ICR mice by gavage
feeding [51]. GLPG0974 was dissolved in DMSO (0.01% in saline) and DMSO (0.01% in saline) was
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used as the vehicle control. Butyric acid (4 mM) was topically applied on dorsal skin of mice. Butyric
acid was dissolved in double distilled water.
4.11. ELISA
Skin samples from ICR mice were collected after 4 weeks of UVB exposure and were then
lysed with T-PER™ Tissue Protein Extraction Reagent (ThermoFisher Scientific, Waltham, MA,
USA) supplemented with an ethylenediaminetetraacetic acid (EDTA)-free protease inhibitor cocktail
(Sigma-Aldrich, St Louis, MO, USA). Supernatant was collected from UVB irradiated and non-irradiated
human keratinocytes (CCD 1106 KERTr) with and without BA treatment. IL-6 concentration in mice
skin and IL-6 and IL-8 concentration in supernatant from human keratinocytes were determined by
mouse or human IL-6 and IL-8 ELISA assay kit (R&D Systems, Minneapolis, MN, USA) following
previous published protocol [52].
4.12. HPLC
Media samples were vortexed and equilibrated at room temperature for 5 min. Thereafter 100 μL of
concentrated HCl was added per mL of each sample, followed by a vortex-mixing step of 15 s. The samples
were extracted for 20 min (by gently rolling) using 5 mL of diethyl ether. After centrifugation (5 min,
3500 rpm), the supernatant was transferred to another Pyrex extraction tube and 500 μL of a 1 M solution
of NaOH was added. The samples were extracted again for 20 min, followed by a centrifugation step.
The aqueous phase was transferred to an auto sampler vial and 100 μL of concentrated HCl was added.
After vortex mixing, 10 μL was injected onto the HPLC–UV apparatus. The mobile phase consisted of
20 mM of NaH2PO4 in HPLC water (pH adjusted to 2.2 using phosphoric acid) (A) and acetonitrile (B).
The UV detector was set at a wavelength of 210 nm for detection of butyric acid in sample.
4.13. Statistical Analysis
Data analysis was performed by unpaired t-test or by one-way ANOVA using GraphPad Prism®
software. The p-values of <0.05 (*), <0.01 (**), and <0.001 (***) were considered significant. The mean
± standard error (SE) for at least three independent experiments was calculated.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/20/18/
4477/s1.
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Abstract: The serine proteases kallikrein-related peptidase (KLK) 5 and KLK7 cleave cell adhesion
molecules in the epidermis. Aberrant epidermal serine protease activity is thought to play an
important role in the pathogenesis of atopic dermatitis (AD). We collected the stratum corneum (SC)
from healthy individuals (n = 46) and AD patients (n = 63) by tape stripping and then measuring
the trypsin- and chymotrypsin-like serine protease activity. We also analyzed the p.D386N and
p.E420K of SPINK5 variants and loss-of-function mutations of FLG in the AD patients. The serine
protease activity in the SC was increased not only in AD lesions but also in non-lesions of AD patients.
We found, generally, that there was a positive correlation between the serine protease activity in
the SC and the total serum immunoglobulin E (IgE) levels, serum thymus and activation-regulated
chemokine (TARC) levels, and peripheral blood eosinophil counts. Moreover, the p.D386N or p.E420K
in SPINK5 and FLG mutations were not significantly associated with the SC’s serine protease activity.
Epidermal serine protease activity was increased even in non-lesions of AD patients. Such activity
was found to correlate with a number of biomarkers of AD. Further investigations of serine proteases
might provide new treatments and prophylaxis for AD.
Keywords: atopic dermatitis; serine proteases; kallikrein-related peptidases; epidermal barrier
dysfunction; lympho-epithelial Kazal-type-related inhibitor (LEKTI); SPINK5; filaggrin
1. Introduction
Atopic dermatitis (AD) is a chronic, pruritic inflammatory skin disease that affects up to 25% of
children and 2–3% of adults [1]. AD has a complex pathogenesis involving genetic, immunologic, and
environmental factors which lead to a dysfunctional skin barrier and dysregulation of the immune
system [1]. Aberrant epidermal serine protease activity is related to the pathogenesis of inflammatory
skin diseases such as Netherton syndrome, AD, psoriasis, and rosacea [2–8]. Kallikrein-related
peptidases (KLKs) are a family of 15 trypsin- or chymotrypsin-like serine proteases encoded by
a cluster of protease-encoded genes (KLK1-15) in the human genome [9]. KLK5, a trypsin-like
serine protease, and KLK7, a chymotrypsin-like serine protease, are major epidermal KLKs. These
Int. J. Mol. Sci. 2020, 21, 913; doi:10.3390/ijms21030913 www.mdpi.com/journal/ijms37
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proteases have roles in the desquamation of epidermis by decomposing cell adhesion molecules
such as corneodesmosin, desmoglein 1, and desmocollin 1 [10]. It has been reported that the
expression and activity of several KLKs is increased in AD lesions [5,8,11]. Research suggests that
KLK5 and KLK7 are particularly involved in the pathogenesis of AD. For instance, KLK5, but not
KLK7, directly activates proteinase-activated receptor 2 and induces nuclear factor κB-mediated
overexpression of thymic stromal lymphopoietin (TSLP) [12]. Moreover, transgenic-KLK5 mice display
cutaneous and systemic hallmarks of severe inflammation and allergy with pruritus [13]. Transgenic
mice expressing human KLK7 in epidermal keratinocytes have been found to develop pathologic
skin changes with increased epidermal thickness, hyperkeratosis, dermal inflammation, and severe
pruritus [14]. Our group demonstrated that Th2 cytokines increase the KLK7 expression and function
in epidermal keratinocytes, suggesting an association between allergic inflammation and epidermal
barrier function [15].
Serine protease activity in the skin is tightly regulated by not only KLKs but also serine protease
inhibitors such as lympho-epithelial Kazal-type-related inhibitor (LEKTI), secretory leukocyte protease
inhibitor (SLPI), and elafin [16]. LEKTI, encoded by the serine protease inhibitor Kazal-type 5 (SPINK5) gene,
is composed of 15 Kazal-type domains, all of which are capable of inhibiting serine protease activity
including KLK5 and KLK7 [17,18]. Individuals with mutations of SPINK5 develop Netherton syndrome,
characterized by ichthyosis, hair abnormality, and atopic manifestations [19]. Nonsynonymous variants
of SPINK5 such as the p.D386N (c.G1156A, in exon 13) and p.E420K (c.G1258A, in exon 14) have been
reported to be associated with the pathogenesis of AD [20–25]. The p.D386N variants disrupt the role
of domain (D) 6 of LEKTI which suppresses the induction of TSLP by KLK5 [25]. The p.E420K variant
increases the furin cleavage rate at the LEKTI linker region D6–D7 and prevents the formation of the
LEKTI fragment D6D9, known to display the strongest inhibitory activity against KLK5-mediated
desmoglein 1 degradation [20].
Profilaggrin is dephosphorylated and degraded to produce monomeric filaggrin in the SC and
then further proteolyzed to release its component amino acids [26]. Profilaggrin, filaggrin and the
amino acids each make different contributions to the epidermal structure and barrier function [26]. In
2006, loss-of-function mutations in the filaggrin gene (FLG) were identified as the cause of ichthyosis
vulgaris [27]. The same year, it was first reported that loss-of-function genetic variants in FLG are
predisposing factors in the context of AD [28]. In 2009, it was reported that 27% of Japanese AD
patients carried FLG mutations [29]. To date, ten FLG mutations have been identified in the Japanese
population [30]. Although FLG mutations are well known to affect epidermal barrier functions, the
association between the mutations and the epidermal serine protease activity has not been investigated.
Here, we performed multifaceted analyses of epidermal serine protease activity in patients with
AD. We focused particularly on the relationship between the epidermal serine protease activity and
biomarkers of AD or AD-related gene variants.
2. Results
2.1. Serine Protease Activity in the SC of AD Is Increased in Both Non-Lesions and Lesions
We examined trypsin- and chymotrypsin-like serine protease activity in SC samples from normal
healthy volunteers and AD patients. The activity of trypsin- and chymotrypsin-like serine proteases in
the SC samples from both non-lesions and lesions of the AD patients were significantly higher than
those from the healthy individuals (Figure 1A,B). The trypsin-like serine protease activity of the AD
lesions was higher than that of the non-lesions (Figure 1A). A significant positive correlation between
trypsin- and chymotrypsin-like serine protease activity was observed in both the non-lesions and
lesions of the AD patients (Figure 1C,D).
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Figure 1. Serine protease activity in the stratum corneum (SC) of atopic dermatitis (AD) patients was
increased in both non-lesions and lesions. (A,B) Trypsin- and chymotrypsin-like serine protease activity
in the SC of normal healthy volunteers (n = 46) and both non-lesions (AD-NL) and lesions (AD-L) of
AD patients (n = 63) were measured. ** p < 0.01, *** p < 0.001. (C,D) The correlations between trypsin-
and chymotrypsin-like serine protease activity in the non-lesions and lesions of AD patients were
analyzed by Spearman’s rank correlation coefficient.
2.2. The Association between Serine Protease Activity in the SC of AD and Medical Treatments
We next analysed the association between serine protease activity in the SC in lesions of AD
patients (n = 63) and various medical treatments. The treatments were as follows: topical corticosteroid
(n = 44), topical tacrolimus (n = 15), oral antihistamine (n = 36), oral corticosteroid (n = 6) and oral
cyclosporine (n = 4). The trypsin-like serine protease activity in the SC of patients with topical
corticosteroid therapy was significantly higher than those without topical corticosteroid therapy
(Figure 2A). On the other hand, the chymotrypsin-like serine protease activity in the SC was not
significantly different with or without topical corticosteroid therapy (Figure 2B). Neither trypsin- and
chymotrypsin-like serine protease activity in the SC was significantly different with or without topical
tacrolimus, oral antihistamine, oral corticosteroid or oral cyclosporine therapies (Figure 2C–J).
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Figure 2. The association between serine protease activity in the SC in lesions of AD patients and
medical treatments. Trypsin- or chymotrypsin-like serine protease activity in lesions were compared
with and without topical corticosteroid (A,B), topical tacrolimus (C,D), oral antihistamine (E,F), oral
corticosteroid (G,H) and oral cyclosporine therapies (I,J). * p < 0.05.
2.3. Serine Protease Activity in the SC of AD Correlate with Biomarkers of AD
We further examined the correlation between serine protease activity in the SC and the biomarkers
of AD. We observed that the serum total immunoglobulin E (IgE) levels were highly correlated
with the trypsin-like serine protease activity in non-lesions of the AD patients, but not with the
chymotrypsin-like serine protease activity in non-lesions or the trypsin- or chymotrypsin-like serine
protease activity in AD lesions (Figure 3A–D). The serum levels of thymus and activation-regulated
chemokine (TARC) were highly correlated with the trypsin- or chymotrypsin-like serine protease
activity in the non-lesions of the AD patients and the trypsin-like serine protease activity in AD
lesions, but not with the chymotrypsin-like serine protease activity in AD lesions (Figure 3E–H).
Our study found, further, that peripheral blood eosinophil counts were highly correlated with the
trypsin-like serine protease activity in the non-lesions and lesions of the AD patients, but not with the
chymotrypsin-like serine protease activity in the AD non-lesions or lesions (Figure 3I–L).
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Figure 3. The correlations between serine protease activity in the SC and biomarkers of AD. The
correlations between trypsin- or chymotrypsin-like serine protease activity in non-lesions (AD-NL) or
lesions (AD-L) and the serum total IgE levels (A–D), serum TARC levels (E–H) and the peripheral blood
eosinophil counts (Eo) (I–L) of the AD patients were analyzed by Spearman’s rank correlation coefficient.
2.4. p.D386N and p.E420K of SPINK5 and Loss-Of-Function Mutations in FLG Do Not Affect the Serine
Protease Activity in the SC
To clarify the association between serine protease activity in the SC and the AD-related gene
variants, we analyzed FLG mutations in the AD patients. Eighteen of the 115 patients (15.7%) had one
of the ten FLG mutations. We were able to perform protease assays with the SC samples from 61 of the
AD patients. Ten of the 61 patients (16.4%) had the FLG mutations: p.Q1701X (n = 1), p.S2554X (n = 1),
p.S2889X (n = 4), p.S3296X (n = 2) and p.K4022X (n = 2). We also analyzed p.D386N (c.G1156A) and
p.E420K (c.G1258A) of SPINK5 in the AD patients. In respect of p.D386N, the numbers of the genotypes
were as follows: GG (n = 21), GA (n = 28), and AA (n = 12). For p.E420K, the numbers of the genotypes
were as follows: GG (n = 14), GA (n = 31), and AA (n = 16). The trypsin- and chymotrypsin-like
serine protease activity in the SC was not significantly different among the subgroups of p.D386N
(Figure 4A,B) or p.E420K (Figure 4C,D). In addition, FLG mutations did not significantly affect the
trypsin- or chymotrypsin-like serine protease activity of the SC in the AD patients (Figure 4E,F).
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Figure 4. Serine protease activity in the SC of the subgroups of patients with the variants of the
SPINK5 gene and FLG gene in AD patients. Trypsin- and chymotrypsin-like serine protease activity in
non-lesions and lesions was compared among the subgroups of the p.D386N (A–B) or p.E420K (C–D)
of SPINK5 and among the subgroups with or without loss-of-function mutations of FLG (E–F).
3. Discussion
It has been reported that the expression and activity of several KLKs are increased in AD lesions
and trigger or enhance epidermal barrier dysfunction [5,8,11]. In this context, we examined the serine
protease activity in the SC of both non-lesions and lesions of AD patients. Our findings demonstrated
for the first time that serine protease activity is increased not only in lesions but also in non-lesions of
AD patients.
Our results are consistent with previous reports that the quantity and activity of serine proteases
are increased in AD lesions [5,8]. Our new finding that serine protease activity is also increased
in non-lesions suggests two possibilities: (1) Serine protease activity may be influenced by some
genetic factors; and (2) Non-lesions of AD patients have subclinical inflammation that may induce the
enhancement of serine protease activity.
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Considering the fact that Th2 cytokines such as interleukin (IL)-4 and IL-13 increase the expression
and function of KLK7 in epidermal keratinocytes [15], the upregulation of chymotrypsin-like serine
protease activity may be induced by systemic Th2 inflammation. However, the trypsin-like serine
protease activity is not affected by Th2 cytokines [15]. Our present analyses showed that trypsin-like
serine protease activity is also increased in both non-lesions and lesions of AD. Further analyses are
needed to clarify the mechanism underlying the increase in trypsin-like serine protease activity.
We next investigated the association between serine protease activity in the SC and the content of
therapy for AD. The trypsin-like serine protease activity in the SC of patients with topical corticosteroid
therapy was significantly higher than those without topical corticosteroid therapy. These results suggest
the possibility that patients with clinically severe AD needed to be treated with topical corticosteroid
and clinically mild patients were able to be treated with topical tacrolimus or moisturizer only. Thus
far, it is unknown why there is a difference between trypsin-like and chymotrypsin-like serine protease
activity even though they are positively correlated (see Figure 1). Furthermore, it was unclear whether
all the patients strictly took ointments or oral medicines. In addition, we did not prepare a wash-out
period before collecting samples. These questions will guide future investigations.
We also investigated the correlation between serine protease activity in the SC and several
biomarkers of AD. Not all serine protease activity was significantly correlated with the serum total IgE
levels, serum TARC levels, or peripheral blood eosinophil counts, but there were tendencies for these
to correlate positively. The absence of statistical significance in several of the comparisons might be
due to the insufficiency of the sample number considered for the analysis or the technical instability of
our protease assays. Serum total IgE reflects the degree of allergen sensitization [31,32]. Serum TARC
is the most sensitive clinical biomarker of AD [33]. Peripheral blood eosinophil numbers also correlate
roughly with disease severity [34]. Our results suggest that serine protease activity in the SC correlates
with the clinical severity of AD and allergen sensitization due to epidermal barrier dysfunction.
We investigated whether nonsynonymous variants of SPINK5 and loss-of-function mutations in
FLG are involved in serine protease activity in the SC. p.D386N and p.E420K polymorphisms of SPINK5
were each reported to be associated with the pathogenesis of AD [20–25]. We found, specifically, that
the p.D386N variant disrupts the role of D6 of LEKTI which suppresses the induction of TSLP by
KLK5 [25]. Moreover, the p.E420K substitution increases the furin cleavage rate at the LEKTI linker
region D6–D7 and prevents the formation of the LEKTI fragment D6D9, known to display the strongest
inhibitory activity against KLK5-mediated desmoglein 1 degradation [20]. However, our analyses
revealed that p.D386N and p.E420K do not change the trypsin- or chymotrypsin-like serine protease
activity of the SC in AD patients. Japanese AD patients might exhibit another genetic particularity
related to serine protease activity that neutralizes the effects of p.D386N and p.E420K.
The FLG mutations are well known to be strongly associated with the pathogenesis of AD [28,29],
but not all AD patients have FLG mutations. Therefore, one or more other genetic factors can be
expected to be associated with the pathogenesis. We had hypothesized that AD patients without FLG
mutations have serine proteases-related gene variants such as SPINK5 and aberrant protease activity,
but our analyses revealed that there is no significant association between these mutations and the
serine protease activity in the SC. On the contrary, there was a tendency for the AD patients with FLG
mutations to have higher serine protease activity compared to the patients without FLG mutations.
Further analyses might clarify the association between the increase in serine protease activity and
genetic factors in AD patients.
In conclusion, the results of our present analyses demonstrated for the first time that epidermal
serine protease activity is increased even in non-lesions of AD patients and this activity is associated
with biomarkers of AD. In addition, p.D386N and p.E420K of SPINK5 and FLG mutations did not
affect the serine protease activity of the SC in Japanese individuals with AD. Further investigations of
epidermal serine protease activity might enable the design of new therapeutic and prophylactic drugs
for the treatment of AD.
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4. Subjects and Methods
4.1. Human Samples
The SC samples and blood samples were collected with written informed consent from normal
healthy volunteers and patients with AD at Okayama University Hospital and its affiliated hospitals.
This study was approved by the Ethics Committee of Okayama University (approval nos. 1511-012,
1605-027 and 1809-015).
4.2. Collection of the Stratum Corneum
Samples of the SC of healthy individuals were obtained from the forearms of normal healthy
volunteers (n = 46; ages 35.0± 8.8 years). The SC of patients who had been diagnosed with AD based
on the diagnostic criteria of Hanifin and Rajka were obtained from the upper extremities (lesions and
non-lesions) (n = 63; ages 38.2± 12.8 years). Cellotape™ (Nichiban, Tokyo) was used to collect the
SC samples. The 10-cm-long tape was put on and peeled from the surface of the extremities (approx.
10–20 times) until the adhesion disappeared. The tape was then stored at −20 ◦C until the following
treatment with hexane.
The tape was soaked in 5 mL of hexane and then shaken to detach the SC from the tape’s adhesive
film. After the insoluble tape was removed, the solution was centrifuged at 3000 rpm for 15 min. A
supernatant was subtracted and 1 mL of hexane was added. A solution was transferred to a 1.5-mL
microtube and centrifuged at 15,000 rpm for 15 min. A supernatant was subtracted again and the
recovered samples were air-dried. The weight was measured. The dried SC samples were mixed with
200 μL of 10 mmol/L Tris-HCl (pH 7.8) and incubated at 37 ◦C for 1 h on a shaker and then used in the
protease assays.
4.3. Protease Assays
For the measurement of protease activity in the SC samples, 100 μL of sample solution was mixed
with 100 μL of a substrate that is specific for trypsin-like serine proteases (Boc-Phe-Ser-Arg-MCA;
Peptide Institute, Osaka, Japan) or chymotrypsin-like serine proteases (Suc-Leu-Leu-Val-Tyr-MCA;
Peptide Institute) in 10 mmol/L Tris-HCl (pH 7.8). The final concentration of each substrate was 0.4
mmol/L. The mixture was incubated at 37 ◦C for 24 h and the fluorescence (excitation/emission =
380/460 nm) was then measured by a FlexStation 3 Multi-Mode Microplate Reader (Molecular Devices,
Sunnyvale, CA) at the Central Research Laboratory, Okayama University Medical School. For the
correction of the differences in the SC sample amounts, the value of measured fluorescence (AU) was
divided by dried weight of the SC sample (mg).
4.4. Blood Examinations and Medical Treatment Histories
The patients’ laboratory data were extracted from their medical records. The serum total IgE level,
serum TARC level and peripheral blood eosinophil count that had been obtained at the time point
closest to the patient’s tape stripping were selected. We also collected the medical treatment histories
of the patients such as their use of topical corticosteroid and topical tacrolimus, oral antihistamine, oral
corticosteroid and oral cyclosporine.
4.5. Analysis of the SPINK5 Gene and the FLG Gene
Genomic DNA was extracted from whole blood using the Wizard Genomic DNA Purification
Kit (Promega, Madison, WI, USA). For exon 13 of SPINK5, the 453-bp DNA was amplified with two
specific primers (SPINK5-E13-FW: 5′-TTCCTATCTCTTGGCATATGATGT-3′ and SPINK5-E13-RV:
5′-TGTCTCCAATCAGACAGTTTCTC-3′). For exon 14 of SPINK5, the 294-bp DNA was amplified with
two specific primers (SPINK5-E14-FW: 5′-CAGGGTTAGGCACATCACATTC-3′ and SPINK5-E14-RV:
5′-TAAGGAATGCACGTGTTCCCTG-3′).
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The polymerase chain reaction (PCR) products were purified using exonuclease I and shrimp
alkaline phosphatase (USB, Cleveland, OH, USA) and sequenced using a BigDye Terminator v3.1 Cycle
Sequencing Kit (Applied Biosystems, Foster City, CA, USA) and an ABI3100 DNA sequencer (Applied
Biosystems) at the Central Research Laboratory, Okayama University Medical School.
Real-time PCR-based genotyping of FLG mutations was performed. In the present FLG mutation
screening, we investigated the 10 FLG mutations as described [30]. Briefly, real-time PCR-based
genotyping of the FLG mutations was performed with a TaqMan probe genotyping assay. Real-time
PCR-based genotyping of the FLG mutations was performed with a TaqMan probe genotyping assay
according to the manufacturer’s instructions (Roche Diagnostics, Basel, Switzerland). To detect an
allele of each mutation, a set of two TaqMan probes labeled with a fluorescent dye (FAM or CAL Fluor
Orange 560) and a quencher dye (BHQ-1), in addition to sequence-specific forward and reverse primers,
were synthesized by Biosearch Technologies (Novato, CA, USA). The sequence of assay probes/primers
was as provided [30]. The real-time PCR was performed with a LightCycler 480 system II 384 plate
(Roche Diagnostics) in a final volume of 5 μL. Genotyping was then performed using the endpoint
genotyping analysis of the LightCycler 480 software.
4.6. Statistical Analyses
All statistical analyses were conducted with GraphPad Prism 4 ver. 4.03 software (GraphPad
Software, La Jolla, CA, USA). Student’s t-test was used to determine the significance of differences
between pairs of groups. The correlation between serine protease activity and the blood examination
results was analyzed by Spearman’s rank correlation coefficient. Values of p < 0.05 were
considered significant.
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LEKTI Lympho-epithelial Kazal-type-related inhibitor
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SPINK5 Serine protease inhibitor Kazal type 5
TARC Thymus and activation-regulated chemokine
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Abstract: Adipose tissue (AT) is the largest endocrine organ, producing bioactive products called
adipocytokines, which regulate several metabolic pathways, especially in inflammatory conditions.
On the other hand, there is evidence that chronic inflammatory skin disease is closely associated
with vascular sclerotic changes, cardiomegaly, and severe systemic amyloidosis in multiple organs.
In psoriasis, a common chronic intractable inflammatory skin disease, several studies have shown
that adipokine levels are associated with disease severity. Chronic skin disease is also associated
with metabolic syndrome, including abnormal tissue remodeling; however, the mechanism is still
unclear. We addressed this problem using keratin 14-specific caspase-1 overexpressing transgenic
(KCASP1Tg) mice with severe erosive dermatitis from 8 weeks of age, followed by re-epithelization.
The whole body and gonadal white AT (GWAT) weights were decreased. Each adipocyte was large
in number, small in size and irregularly shaped; abundant inflammatory cells, including activated
CD4+ or CD8+ T cells and toll-like receptor 4/CD11b-positive activated monocytes, infiltrated into
the GWAT. We assumed that inflammatory cytokine production in skin lesions was the key factor for
this lymphocyte/monocyte activation and AT dysregulation. We tested our hypothesis that the AT in
a mouse dermatitis model shows an impaired thermogenesis ability due to systemic inflammation.
After exposure to 4 ◦C, the mRNA expression of the thermogenic gene uncoupling protein 1 in
adipocytes was elevated; however, the body temperature of the KCASP1Tg mice decreased rapidly,
revealing an impaired thermogenesis ability of the AT due to atrophy. Tumor necrosis factor (TNF)-α,
IL-1β and interferon (INF)-γ levels were significantly increased in KCASP1Tg mouse ear skin lesions.
To investigate the direct effects of these cytokines, BL/6 wild mice were administered intraperitoneal
TNF-α, IL-1β and INF-γ injections, which resulted in small adipocytes with abundant stromal cell
infiltration, suggesting those cytokines have a synergistic effect on adipocytes. The systemic dermatitis
model mice showed atrophy of AT and increased stromal cells. These findings were reproducible by
the intraperitoneal administration of inflammatory cytokines whose production was increased in
inflamed skin lesions.
Int. J. Mol. Sci. 2020, 21, 3367; doi:10.3390/ijms21093367 www.mdpi.com/journal/ijms49
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1. Introduction
Adipose tissue (AT) is the largest endocrine organ, producing bioactive products called
adipocytokines, which regulate several metabolic pathways [1]. AT inflammation induces the
dysregulation of adipocytokine production, which plays a critical role in the pathophysiology of
atherosclerosis [2]. It is well known that obesity induces AT inflammation and contributes to vascular
and AT changes, which may lead to the development of metabolic syndrome. Metabolic syndrome
induces insulin resistance that causes hyperglycemia and diabetes, and causes dyslipidemia such as
hypertriglyceridemia and low HDL cholesterol, which are risk factors for cardiovascular disorders [3].
In addition, obese AT causes increased angiogenesis, immune cell infiltration, the overproduction of
extracellular matrix, and the increased production of pro-inflammatory adipocytokines [4]. As a result,
the risks of ischemic heart disease and cerebral strokes increase.
Chronic inflammatory skin disease is also associated with metabolic syndrome [5–7]. However,
the mechanism is under discussion, and the contribution of AT is still unclear. We addressed this
problem by using keratin 14-specific human caspase-1 overexpressing transgenic (KCASP1Tg) mice,
which are accepted as a spontaneous dermatitis model [8]. Caspase-1 is a cytoplasmic cysteine protease
characterized by its ability to process the inactive pro-interleukin-1β (IL-1β) into the biologically
active IL-1β [9]. IL-1β is an inflammatory cytokine that plays a key role in inflammation and
keratinocyte activation. KCASP1Tg mice show severe erosive dermatitis from 8 weeks old, followed by
re-epithelization and the development of parakeratotic scale-crust [8]. It was previously reported that
a sustained circulating low level of IL-1α/β derived from severe dermatitis causes vascular sclerotic
changes, cardiomegaly, and severe systemic amyloidosis in multiple organs [10].
In this study, we aimed to investigate the influence of chronic dermatitis in the pathological and
functional changes in AT using a KCASP1Tg mouse model.
2. Results
2.1. GWAT Weight Is Decreased, and Inflammation Affects AT Atrophy
We measured whole-body and GWAT weights with a precision electronic balance to evaluate
the effect of dermatitis on the AT. The whole-body and GWAT weights were significantly lower in
KCASP1Tg than in wild littermate mice at 10 weeks of age (Figure 1A,B). Next, we evaluated the
phenotype of adipocytes in GWAT using hematoxylin and eosin staining (HE). In KCASP1Tg mice,
adipocytes were small in size and irregularly shaped compared to in wild type mice (Figure 1C).
Abundant mononuclear cell infiltration compared to in control mice suggests the so-called burnout or
worn out condition of the adipocytes. We performed immunohistochemical (IHC) staining to identify
the stromal cells of AT such as T cells, monocytes and neutrophils. The infiltration of inflammatory cells
such as lymphocytes, monocytes and neutrophils was slightly higher in KCASP1Tg mice compared to
that in wild type littermates (Figure 1D).
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Figure 1. KCASP1Tg mice showed low gonadal white adipose tissue (GWAT) weights and degenerated
adipose tissue (AT). (A) The whole body and (B) GWAT weights were decreased in KCASP1Tg
compared to wild littermate mice at 10 weeks of age. (C) Representative photomicrographs of the
hematoxylin and eosin (HE) (×400) staining of the GWAT of wild littermate and KCASP1Tg mice at
10 weeks of age. Histological sections were 3.5 μm thick. Adipocyte number and adipocyte area were
measured by using ImageJ and Adiposoft (three parts of each slide, n = 3 in each group). Adipocytes
were significantly smaller and larger in number in KCASP1Tg. (D) Immunohistochemical staining
(×400) was performed to characterize stromal cells. Lymphocytes, monocytes and neutrophils were
slightly higher in KCASP1Tg but not significantly so. ** p < 0.01, **** p < 0.0001 versus control.
2.2. Activated T Cells and Monocytes Infiltrated the AT
We assessed the number or proportion and characteristic composition of the stromal cells
infiltrating the GWAT by flow cytometry. The number of infiltrated stromal cells, including lymphocytes
and monocytes, was significantly increased in KCASP1Tg mice (Figure 2A). Next, we verified the
characteristics of the lymphocytes and monocytes. We measured the proportion of the CD25+ T cells
(Figure 2B). Activated T cells, both CD4+ and CD8+, were increased in KCASP1Tg mice (Figure 2C).
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Additionally, we measured the proportion of regulatory T cells by using CD127, CD4, CD25 and
Foxp3 antibodies (Figure 2D). The regulatory T cells were increased in KCASP1Tg, but there was no
significant difference (Figure 2E). Finally, we measured the number of TLR4+ CD11b+monocytes and
proportion of Ly-6C+ CD11b+monocytes TLR4+ CD11b+monocytes were significantly increased in
KCASP1Tg, and Ly-6C+ CD11b+monocytes were also increased (Figure 2F,G).
Figure 2. AT cell infiltration in KCASP1Tg mice. (A) Flow cytometric analysis of infiltrated stromal
cells in GWAT. The black and red circles correspond to the lymphocyte and monocyte populations,
respectively, in the left figure. Stromal cell infiltration, including lymphocytes and monocytes,
was significantly increased in KCASP1Tg mice. (B,C) The population of CD25+ activated lymphocytes
was measured in CD4+ or CD8+ lymphocytes. Activated T cells were significantly increased in
KCASP1Tg. (D,E) The proportion of regulatory T cells in AT was measured. There was no significant
difference between KCASP1Tg and wild mice. (F,G) The proportion of Ly-6C+ CD11b+ and number
of TLR4+ CD11b+ activated monocytes were evaluated and increased in the AT of KCASP1Tg mice.
n = 5–6 in each group. * p < 0.05, ** p < 0.01 versus control.
2.3. Expression of Inflammation-Related Cytokine Levels in AT
An adipocytokine is a physiologically active substance secreted from adipocytes, and the amount
secreted also changes depending on the environment of the adipocytes. Representative adipocytokines
such as adiponectin, TNF-α, leptin and MCP-1 were analyzed in the adipocytes of GWAT using a
specific ELISA kit (Figure 3). The TNF-α level was significantly elevated in KCASP1Tg mice compared
to in controls. Conversely, KCASP1Tg mice showed a lower leptin level.
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Figure 3. Adipokine expression in AT. We quantified adipocytokines such as adiponectin, TNF-α,
leptin and MCP-1 from the adipocytes of GWAT by using a specific ELISA kit. The TNF-α level was
elevated in KCASP1Tg mice compared to in controls; conversely, the leptin level was decreased in
KCASP1Tg (n = 5 in each group). * p < 0.05 and ** p < 0.01 versus control.
2.4. Changes in UCP1 Expression after Cold Exposure
HSP90, IL-33 and UCP-1 are deeply involved in thermogenesis in adipocytes, and their expression
is increased by cold exposure or adrenergic stimulation. We investigated the heat production upon cold
exposure challenge and the expression of these thermogenic genes. After 4 ◦C cold exposure, the mRNA
expression of HSP90, IL-33 and UCP1 in adipocytes was quantified using real time-PCR. The mRNA
expression of HSP90 and IL-33 was significantly decreased in KCASP1Tg mice (Figure 4A). Although
the mRNA expression of UCP1 was significantly increased in KCASP1Tg mice (Figure 4A), the body
temperature decreased more rapidly upon exposure to the cold environment, and the KCASP1Tg mice
could not survive for a long time (Figure 4B).
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Figure 4. mRNA expression of heat-related proteins in GWAT after cold exposure. (A) The mRNA
expression of HSP90 and IL-33 was decreased, while that of UCP1 was increased in the adipocytes
of KCASP1Tg mice after exposure to 4 ◦C (n = 5, each group). (B) The body temperature of mice
exposed to 4 ◦C was measured every 1 hour using thermal imaging camera. The body temperature
of the KCASP1Tg mice decreased more rapidly in a cold environment (n = 5, each group). * p < 0.05,
** p < 0.01 versus control.
2.5. Pro-Inflammatory Cytokines Produced in Response to Dermatitis Caused AT Atrophy and Increased
Activated Monocyte Infiltration In Vivo
We hypothesized that cytokines produced in inflamed skin affect AT and measured the mRNA
expression levels of inflammatory cytokines in the skin of KCASP1Tg and control mice. The mRNA
expression levels of TNF-α, IL-1β and IFN-γ in ear skin were measured by real-time PCR. All cytokine
levels were significantly increased in KCASP1Tg mice (Figure 5A). To clarify the direct effect of
skin-derived cytokines on GWAT, we treated wild-type mice by the intraperitoneal administration
of inflammatory cytokines including TNF-α, IL-1β and IFN-γ. The GWATs of the TNF-α-treated
wild-type mice were similar to those of KCASP1Tg mice; the adipocytes were large in number, small
and irregularly shaped; IL-1β- and IFN-γ-injected mice also showed a similar trend (Figure 5B).
The number of infiltrating stromal cells tended to increase in mice that were administered cytokines
(Figure 5C); additionally, TLR4+ CD11b+ monocytes were significantly increased in IFN-γ treated
mice (Figure 5D).
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Figure 5. Production of inflammatory cytokines in the skin and the direct effect on AT. (A) The
TNFα, IL-1β and INF-γ levels were significantly increased in KCASP1Tg mouse ear skin lesions.
(B) Eight-week-old BL/6 wild mice were treated by intraperitoneal injections of TNF-α, IL-1β, IFN-γ
(250 μg/kg body weight/each time) or PBS three times per week for two weeks. The AT of TNF-α-treated
mice showed a similar appearance to that of KCASP1Tg mice; IL-1β- and IFN-γ-administrated mice
also showed a similar trend; adipocytes were large in number, small and irregularly shaped (HE, ×400).
(C,D) The number of infiltrating cells in GWAT was counted, and the infiltrating cells were analyzed
by flowcytometry. The number of infiltrating cells in GWAT was increased in cytokine-administrated
mice, while TLR4+ CD11b+ activated monocytes were significantly increased in IFN-γ-treated mice.
n = 5 per group. * p < 0.05, ** p < 0.01 versus control.
3. Discussion
In the current study, we demonstrated that severe dermatitis induces AT atrophy accompanied
by abundant lymphocyte and activated monocyte infiltration, the dysregulation of adipocytokine
production and maladaptation to cold environments. We observed not only histopathological AT
remodeling but also a GWAT functional change when skin is inflamed. Inflammatory skin disorders
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are not only skin-related but also involve systemic organ impairment. A previous study showed
chronic skin inflammation induces the aberrant remodeling of vascular tissues, potentially resulting
in atherosclerosis [11]. Systemic amyloidosis with functional deterioration has also been seen in
inflammatory skin conditions [12]. The erupted skin of KCASP1Tg mice produces significantly higher
amounts of IL-1α and β compared to normal skin, while the supernatant from skin lesions leads to a
severe reduction in lipid particles in an adipocyte culture system [10]. Computed tomography imaging
of KCASP1Tg mice at 6 months of age revealed a dramatic decrease in visceral fat compared to in
normal controls [10]. Based on these findings, it was hypothesized that persistent dermatitis had a
negative effect on visceral AT, and we investigated the state of GWAT using dermatitis model mice.
In KCASP1Tg mice, the whole body and GWAT weights were decreased compared to in wild
littermate mice. Each adipocyte was small and irregularly shaped, and showed abundant inflammatory
cell infiltration in GWAT. Since increased inflammatory cell infiltration and atrophy of adipocytes were
observed, it was considered that AT was strongly inflamed under chronic dermatitis. The stromal cells
that infiltrate into GWAT are mainly lymphocytes and monocytes, but it was difficult to quantify them
by examination using immunohistochemical staining. We performed stromal cell classification using
flow cytometry. It was found that lymphocytes and monocytes, which infiltrated into GWAT, were
increased in KCASP1Tg mice. In the lymphocyte fraction, both CD4+ and CD8+ T cells were activated
compared to in the control. Moreover, although there was no significant difference, regulatory T
cells also tended to increase in the inflamed AT. The CD11b antigen is expressed when premature
monocytes are activated to become differentiated monocytes and represents the best molecular marker
of the macrophage lineage [13]. In monocytes, the expression of TLR4 is important in mediating
inflammatory cytokine production in AT inflammation. In humans, TNF-α suppresses the expression
of TLR4 on monocytes; however, IL-6 or IFN-γ mediates the upregulation of TLR4 expression [14].
The number of lymphocytes and TLR4+ CD11b+ activated monocytes was significantly higher in the
AT of the KCASP1Tg mice.
AT plays an essential role in metabolic homeostasis by storing and releasing lipids and secreting
bioactive proteins and peptides called adipokines, including adiponectin, leptin, MCP-1 and TNF-α in
response to environmental changes. Both leptin and adiponectin are mainly produced by adipocytes.
The main function of leptin seems to be to provide an afferent signal of nutritional and fat mass status
to the hypothalamus, thus controlling energy fat stores and regulating appetite and body weight [15].
Leptin reduces the appetite; increased adipocyte storage leads to higher leptin production, which
results in a further loss of appetite. On the other hand, adiponectin helps to repair damaged blood
vessel walls, prevent arteriosclerosis, increase insulin’s action and lower blood pressure. However,
clinically, blood adiponectin concentration is inversely correlated to visceral fat mass; the mechanism
behind this relationship has not been elucidated so far. In psoriasis, one of the most common chronic
intractable inflammatory skin diseases, several studies showed that adipokine levels are associated with
disease severity [16]. AT plays an important role in the development of psoriasis. Leptin induces IL-6,
CXCL-1, IL-8 and MCP-1 production, which is involved in the hyperproliferation of the epidermis in
psoriasis [17]. To the contrary, adiponectin is an anti-inflammatory adipocytokine, and when dermatitis
is caused in adiponectin knock out mice, the expression of IL-17A, IL-17F and IL-22 increases [18].
Moreover, an increased circulating level of IL-1 has been shown to be accompanied by the local
overexpression of TNF-α and IL-12/23 p40 [19], as was also seen in our model mice. However, although
our model mice exhibited AT atrophy, psoriasis patients are often obese. BMI is also known to be a risk
factor for developing psoriasis [20]. The lower leptin level in KCASP1Tg mice may be responsible for
the upregulation of body weight. Additionally, adiponectin production from GWAT was significantly
increased because adipocytes oversecrete adiponectin in chronic dermatitis. The effects of systemic
dermatitis on AT in our study differ from those in psoriasis and may resemble those in erythroderma,
which often results in weight loss. However, a recent report shows that psoriasis patients treated with
anti-TNF-α antibodies experience weight gain [21]. If it occurs more often in patients with severe
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psoriasis and high improvement rates for psoriasis, it is likely that dermatitis has a considerable impact
on weight loss.
We speculated that the AT in a dermatitis model shows an impaired thermogenesis ability due to
systemic inflammation. After exposure to 4 ◦C, the mRNA expression of heat-related proteins such as
HSP90, IL-33 and UCP1 in GWAT was measured. Heat shock proteins (HSPs) are primary mitigators
of cell stress HSPs expression is also induced by cold exposure in brown adipose tissue [22]. It is well
known that brown adipocytes play an important role in heat production in mice [23]. When white
adipocytes face various stimuli such as cold exposure and adrenergic stimulation, they form beige
adipocytes and induce UCP1, producing brown adipocytes [24]. This process can be induced by IL-33,
which is released from various cells in response to stress and injury in adult mice and activates type
2 innate lymphocytes (ILC2) [25]. In our study, although IL-33 levels were lower in the KCASP1Tg
mice, UCP1 expression was significantly increased after exposure to the 4 ◦C environment. Therefore,
heat production occurred correctly; however, the body temperature of the KCASP1Tg mice decreased
more rapidly in the cold environment, and these mice died earlier than the wild-type mice, meaning
survival in a cold environment may be harder due to AT atrophy.
We assumed that increased inflammatory cytokine production in the skin lesions was the key factor
for this lymphocyte/monocyte activation and AT dysregulation. In fact, TNFα, IL-1β and INF-γ levels
were significantly increased in KCASP1Tg mouse ear skin lesions (Figure 5A). To investigate the direct
effects of these cytokines, BL/6 wild mice were administrated intraperitoneal injections of TNF-α, IL-1β
and IFN-γ, revealing small adipocytes and abundant stromal cell infiltration, suggesting those cytokines
exert a synergistic effect on adipocytes (Figure 5B–D). According to our results, inflammatory cytokines
whose production is increased by the eczema lesions cause AT atrophy and increased inflammatory
cell infiltration in AT. We have reported, in previous studies, that the inhibition of IL-1 can prevent
cerebrovascular disease [26]. In this study, we did not prove the prevention of AT damage by treating
dermatitis. However, controlling dermatitis with topical corticosteroids, immunosuppressants or
anti-cytokine antibodies probably reduce damage to AT. Of course, the long-term use of topical steroids
can cause side effects such as skin atrophy, rosacea-like dermatitis and dermatomycosis [27,28], and
immunosuppressants or anti-cytokine antibodies may cause severe infections and malignant tumors.
We should realize that dermatitis causes damage to various organs and the importance of the active
treatment of dermatitis.
There are only a few studies evaluating AT pathology and function in inflammatory skin disease.
We found that skin-derived inflammatory cytokines led to the secretion of pro-inflammatory proteins
from adipocytes. As a result, activated monocytes and lymphocytes infiltrated into the AT, which lead
to AT atrophy and increased the difficulty in the metabolic adaptation to cold temperatures. Our study
suggested that inflammatory skin diseases lead to organ damage and require careful attention.
4. Materials and Methods
4.1. Mouse Study
We used 8–10-week-old spontaneous dermatitis transgenic female KCASP1Tg mice, while
female littermate C57BL/6 mice were used as controls. The experimental protocol was approved by
the Mie University Board Committee for Animal Care and Use (Protocol #22-39-2, approved date,
1 October 2014). Eight-week-old female wild mice were also administered intraperitoneal injections of
recombinant tumor necrosis factor-alpha (TNF-α), recombinant IL-1β, recombinant interferon-gamma
(IFN-γ) or phosphate-buffered saline (PBS). The cytokines were diluted in PBS and 250 μg/kg of body
weight each time were injected three times per week for two weeks. All the recombinant compounds
were purchased from Biolegend (San Diego, CA). All the mice were sacrificed the day after the sixth
injection. For the cold stimulation study, 10-week-old KCASP1Tg and littermate mice were housed,
one per cage, at a temperature of 22 ◦C. All the mice were transferred to a 4 ◦C room, and body
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temperature was measured every hour using thermal imaging camera FLIR i5 (Extech Instruments,
Waltham, MA, USA). After eight hours, all the mice were sacrificed and AT was sampled.
4.2. Tissue Sampling
Isolated adipocytes were prepared as previously reported with minor modifications [29,30].
In brief, extracted gonadal white AT (GWAT) was minced and incubated in PBS with 0.5% bovine
serum albumin (BSA, Sigma-Aldrich, St. Louis, MO, USA), 10 mM CaCl2, and 2 mg/mL of collagenase
type II (Worthington Biochemical Corporation, Lakewood, NJ, USA) at 37 ◦C for 20 min at 200 rpm.
The suspension was filtered through a 100-μm nylon filter and centrifuged at room temperature at
400 rpm for one minute; the floating cells (adipocytes) were then collected. The remaining suspension
was further centrifuged at 1500 rpm for 10 min. The supernatant was decanted and the remaining
cell pellets were resuspended with 0.5% BSA/PBS. We counted the number of viable cells based on
trypan blue exclusion and diluted the cell suspensions to final concentrations of 5–10 × 106 cells/mL as
adipose-infiltrated stromal cells.
4.3. Histological and Immunohistochemistry Analysis
Tissue was fixed in 10% formalin neutral buffer solution (Wako, Osaka, Japan), embedded in
paraffin, cut into 3.5-μm sections and stained with hematoxylin and eosin (HE). Immunohistochemistry
(IHC) was performed with primary antibodies—rabbit anti-mouse CD4 antibody (Cell Signaling
Technology, Danvers, MA, USA), rabbit anti-mouse CD8a antibody (Cell Signaling Technology), rabbit
anti-Ly6G antibody (Abcam, Cambridge, UK) and rat anti-Ly6C antibody (abcam)—and secondary
antibodies—goat anti-rabbit immunoglobulins/biotinylated (Dako, Santa Clara, CA, USA) and simple
stain MAX-PO (rat) (Nichirei Biosciences, Tokyo, Japan). The adipocytes were observed with 400× HE
and counted, and the area was measured using ImageJ and Adiposoft (NIH, Bethesda, MD, USA).
4.4. Flow Cytometry Analysis
AT-infiltrating stromal cells were stained with FITC anti-mouse CD3ε antibody, PE anti-mouse
CD4 antibody, PE/Cy7 anti-mouse CD25 antibody, APC anti-mouse CD8a antibody, FITC anti-mouse
CD127 antibody, PerCP/Cy5.5 anti-mouse CD4 antibody, APC anti-mouse CD25 antibody (these
antibodies were purchased from Biolegend, San Diego, CA, USA), PE anti-mouse/Foxp3 antibody
(Invitrogen, Carlsbad, CA, USA), PE anti-mouse CD11b antibody (Biolegend), PE/Cy7 anti-mouse
Ly-6C antibody (Biolegend, San Diego, CA, USA) and APC anti-toll-like receptor 4 (TLR4) antibody
(Invitrogen, Waltham, MA, USA), and analyzed using an Accuri C6 (Becton, Dickinson and Company,
Franklin Lakes, NJ, USA).
4.5. Real-Time Polymerase Chain Reaction (PCR)
Total RNA was extracted from ear skin and AT using TRI Reagent (Molecular Research Center,
Cincinnati, OH) according to the manufacturer’s protocol. The RNA concentration was measured
using a NanoDrop Lite spectrophotometer (Thermo Fisher Scientific, Worsham, MA, USA) and 1 μg of
total RNA was converted to cDNA using the High-Capacity RNA-to-cDNA Kit (Applied Biosystems,
Foster City, CA, USA). The TaqMan Universal PCR Master Mix II with UNG (Applied Biosystems,
Foster City, CA, USA) was used to measure the mRNA expression of TNF-α (Mm00443258_m1), IL-1β
(Mm01336189_m1), IFN-γ (Mm01168134_m), heat shock protein 90 (HSP90, Mm00658568_gH), IL-33
(Mm00505403_m1) and uncoupling protein 1 (UCP-1, Mm01244861_m1). All probes were purchased
from Applied Biosystems and glyceraldehyde-3-phosphate dehydrogenase (Mm99999915_g1) was used
as the internal control. Amplification was performed in a LightCycler 96 System (Roche Diagnostics,
Basel, Switzerland). The cycling parameters were as follows: 95 ◦C for 30 s, followed by 40 cycles of
amplification at 95 ◦C for 5 s and 60 ◦C for 30 s.
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4.6. Enzyme-Linked Immunosorbent Assay (ELISA)
The total protein content from adipocytes was extracted using a radioimmunoprecipitation assay
buffer (Nacalai tesque, Kyoto, Japan). Adiponectin, TNF-α, leptin and monocyte chemotactic protein-1
(MCP-1) levels were measured using specific ELISA kits (R&D systems Minneapolis, MN) according to
the manufacturer’s protocol, and the data were normalized to GWAT weight. The absorbance was
measured using MULTISKAN JX (Thermo Fisher Scientific, Worsham, MA, USA). The values were
analyzed using Ascent Software for Multiskan Ascent (Thermo Fisher Scientific, Worsham, MA, USA).
4.7. Statistical Analysis
Statistical analysis was performed using the PRISM software version 8 (GraphPad, San Diego,
CA, USA). The Mann–Whitney U test was used to compare variables between groups. Differences
were considered significant at p < 0.05.
5. Conclusions
The systemic dermatitis model mice showed atrophy of AT and an increased infiltration of activated
T cells and monocytes into the AT. These were reproducible by the intraperitoneal administration of
inflammatory cytokines such as TNF-α, IL-1β and IFN-g, whose production was increased in inflamed
skin lesions. The persistence of skin inflammation can potentially cause negative reactions in AT.
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Abstract: Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by T helper 2
cell (Th2)-shifted abnormal immunity, skin barrier impairment, and pruritus. The prevalence of AD
in childhood is slightly higher in boys than in girls; after puberty, the sexual difference is reversed.
The female preponderance in all generations exists in intrinsic AD with enhanced Th1 activity and
nickel allergy, lacking increased serum IgE or filaggrin mutation. AD is often deteriorated before
menstruation. We review the effects of sex hormones on immune responses and skin permeability
barrier and propose possible hypotheses for the above phenomena. After puberty, the immune
responses of patients are remarkably influenced by sex hormones. Estrogen and progesterone
enhance the activities of Th2/regulatory T cell (Treg) but suppress Th1/Th17. Androgens suppress
Th1/Th2/Th17 and induce Treg. The skin permeability barrier is fortified by estrogen but is impaired
by progesterone and androgens. Dehydroepiandrosterone suppresses Th2 but enhances Th1. The
amount of steroid sulfatase converting dehydroepiandrosterone sulfate to dehydroepiandrosterone
is higher in women than in men, and thus, women might be more susceptible to the influence of
dehydroepiandrosterone. The balance of modulatory effects of sex hormones on immune responses
and skin barrier might regulate the course of AD.
Keywords: atopic dermatitis; estrogen; progesterone; androgen; dehydroepiandrosterone; T helper 2
cell; skin barrier
1. Introduction
Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by T helper 2 cell
(Th2)-shifted abnormal immunity, skin barrier impairment, and pruritus (Figure 1) [1–3]. These three
elements are mutually related and organize the clinicopathological features of AD. AD patients mostly
show reduction of filaggrin expression partly due to mutation of this gene [1–3] and reveal decreases in
water content and of ceramide synthesis in the stratum corneum (SC) [1–3]. Moreover, tight junctions
(TJs) are dysfunctional in AD: the levels of zonula occludens 1 were decreased in the non-lesional sites
of AD, and the levels of zonula occludens 1 and claudin-1 were decreased in the lesional sites relative to
the levels in skin from healthy subjects [4]. Such impaired SC and TJ barriers allow the penetration of
allergens like house dust mite, food, or pathogens, inducing sensitization to these allergens [1–3]. The
AD lesional skin is infiltrated mainly by Th2 cells producing interleukin-4 (IL-4), IL-13, or IL-31 and by
T22 cells producing IL-22, while chronic lesion is associated with the infiltration of Th1 cells producing
interferon-γ (IFN-γ). Recently, the infiltration of Th17 cells is also noted in AD lesions [5]. Most AD
patients show increased serum IgE levels and specific IgE antibodies against a variety of environmental
allergens [1–3]. AD patients suffer from severe pruritus due to a variety of pruritogens like histamine,
cytokines like thymic stromal lymphopoietin (TSLP), IL-31, IL-4, IL-13, or neuropeptides and abnormal
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extension of sensory nerves into the epidermis due to the increased expression of nerve growth factor
or artemin or to the decreased expression of semaphorin 3A [2].
Figure 1. The three elements composing the pathogenesis of atopic dermatitis. Th2, T helper 2 cell;
IL-4, interleukin-4; NGF, nerve growth factor; TSLP, thymic stromal lymphopoietin.
The prevalence of AD in childhood is slightly higher in boys than in girls: 8.7% and 5.6% for
boys and girls, respectively, at <4 years old in the Netherlands [6]. After puberty, there is a slightly
higher prevalence of AD in females: 5.7% and 8.1% for men and women, respectively, in Japan [7] or
6.04% and 8.01% in Europe and the USA [8]. This tendency is more remarkable in asthma, another
Th2-shifted allergic disease [9]; the female:male percentage of patients was 35:65 at ages of 2 to 13
years, was inversed with 65:35 at ages of 23 to 64 years, are similar between those at ages of 14 to 22
years [10]. Adult female patients with asthma show more severe symptoms than adult male patients;
the percentage of hospitalization for symptoms is 68% versus 32% in females versus males [11].
After puberty, the secretion of sex hormones from the ovary, testis, or adrenal gland is enormously
increased. The immune responses or skin barrier in adolescents and adults might thus be more
susceptible to influence by sex hormones compared to those in childhood. The effects of sex hormones
might be related to the generation-dependent sexual difference in the prevalence of allergic diseases [12].
Interestingly, female preponderance of AD-like dermatitis possibly after puberty is detected in
KFRS4/Kyo rats [13]. Dermatitis with severe pruritus initially appeared around 4 months of age,
rapidly worsened from 6 to 8 months of age, and predominantly occurred in females: 100% of female
versus 50% of male KFRS4/Kyo rats of 8 months old that were examined. The skin lesions were
infiltrated with eosinophils, mast cells, and lymphocytes and were associated with increased plasma
IgE levels and increased Th2 and Th17 cytokine mRNA levels in the skin-draining lymph nodes.
Rats become sexually mature at about the sixth week but attain social maturity 5–6 months later [14],
corresponding to the age with worsening dermatitis in KFRS4/Kyo rats. It is thus hypothesized that
female sex hormones like estrogen or progesterone may contribute to the higher incidence of dermatitis
in female KFRS4/Kyo rats.
On the other hand, female preponderance in all generations exists in intrinsic AD with enhanced
Th1 activity and high incidence of nickel (Ni) allergy and without increased serum IgE values or
filaggrin mutation [15]. Moreover, in female patients with AD, the disease is often deteriorated before
menstruation, i.e., in the luteal phase when both estrogen and progesterone are secreted (Figure 2) [16].
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These phenomena indicate that sex hormones might modulate the course of AD in the context of
immune responses, skin barrier, or pruritus.
Figure 2. Menstrual cycle. Reprinted from https://commons.wikimedia.org/wiki/File:MenstrualCycle2.
png. This file is licensed under the Creative Commons Attribution-Share Alike 3.0 Unported
(https://creativecommons.org/licenses/by-sa/3.0/deed.en) license.
In this article, we firstly review the previous studies regarding the regulatory effects of sex
hormones on the immune responses and skin barrier. We next propose hypotheses on possible
hormonal regulation in the generation-dependent sexual difference in the prevalence of extrinsic AD,
female preponderance of intrinsic AD, and premenstrual deterioration of AD.
2. The Effects of Sex Hormones on Immune Responses
2.1. General Tendency (Table 1)
Female hormones estrogen and progesterone mostly enhance the activities of Th2 cells and
regulatory T cells (Tregs) but suppress Th1 and Th17 activities, which is favorable for the acceptance of
allogeneic fetus during pregnancy [17]. Androgens like testosterone or dihydrotestosterone (DHT)
are mostly immunosuppressive and suppress Th1, Th2, and Th17 activities but induce Treg activity.
The magnitude of stimulation or suppression by female hormones is mostly higher than that by male
hormones [18]. Generally in adolescents and adults, Th1 activities are higher in men than in women
while Th2 activities are much higher in women than in men [18]. The sexual differences in Th17 or Treg
activities are ambiguous. Dehydroepiandrosterone (DHEA) produced in the adrenal cortex enhances
Th1 responses and shifts the balance of Th1/Th2 toward Th1-dominant immunity [19]. Females have
higher amounts of steroid sulfatase converting dehydroepiandrosterone sulfate (DHEAS) to active
DHEA and, thus, might be more susceptible to influence by DHEA compared to males [20]. To date, it
has not been precisely examined how sex hormones regulate the activity of Th22 cells producing IL-22
alone without IL-17A.
Table 1. The effects of sex hormones on immune responses and skin barrier impairment.
Hormones Th1 Th2 Th17 Treg
Skin Barrier
Impairment
Androgen ↓ ↓ ↓ ↑ ↑
Estrogen ↑~ ↑~
Progesterone ↑
DHEA ↑ ↓ ? ? ?
Total activity F <M FM ? ? F <M
↑, Moderate stimulation; , strong stimulation; ↓, moderate suppression; , strong suppression; ?, ambiguous; ↑~ ,
Stimulatory or inhibitory effects dependent on the concentration, tissue, or disease context; Th1, T helper 1 cell; Treg,
regulatory T cell; DHEA, dehydroepiandrosterone; F, female; M, male.
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2.2. Female Hormones
2.2.1. Estrogens (Table 2)
Table 2. Summary of the effects of estrogen on the activities of T helper 1 cell (Th1), Th2, Th17, and




Species Th Activities References
Adaptive Immunity
T-bet↑ vivo mice Th1↑ [21] *
IFN-γ↑ vivo mice Th1↑ [21] *
IL-12↑ vivo mice Th1↑ [21] *
T-bet↓ vitro human Th1↓ [22] **
T-bet↓ vivo mice Th1↓ [23] †
IFN-γ↓ vivo mice Th1↓ [24] †
IFN-γ↓ vitro mice Th1↓ [25] §
IFN-γ↓ vitro human Th1↓ [22] **
IFN-γ↓ vivo mice Th1↓ [23] †
GATA-3↑ vivo mice Th2↑ [26]
GATA-3↑ vivo mice Th2↑ [23] †
IL-4↑ vivo mice Th2↑ [26]
IL-4↑ vivo mice Th2↑ [23] †
B cells
IgM, IgE↑ vitro mice Th2↑ [27]
RORc↓ vivo mice Th17↓ [24] †
RORc↓ vitro human Th17↓ [28]
RORc↓ vitro/vivo mice Th17↓ [25]
RORγt↓ vitro human Th17↓ [22] **
RORγt↓ vivo mice Th17↓ [23] †
IL-17A↓ vitro mice Th17↓ [25] §
IL-17A↓ vivo mice Th17↓ [24] †
IL-17A↓ vitro human Th17↓ [22] **
IL-17A↓ vivo mice Th17↓ [23] †
IL-22↓ vitro mice Th17↓ [25] §
IL-17A↑ vivo mice Th17↑ [29] ‡
IL-21↑ vivo mice Th17↑ [29] ‡
IL-22↑ vivo mice Th17↑ [21] *
RORγt↑ vivo mice Th17↑ [21] *
RORγt↑ vivo mice Th17↑ [29] ‡
Foxp3↑ vitro human Treg↑ [28]
Foxp3↑ vitro human Treg↑ [30]
Foxp3↑ vivo mice Treg↑ [23] †
Foxp3↑ vivo/vitro mice Treg↑ [31]
IL-10↑ vivo mice Treg↑ [23] †
IL10↑ vitro mice Treg↑ [12]
TGF-↑ vivo mice Treg↑ [23] †
Foxp3↓ vitro human Treg↓ [22] **
IL-10↓ vitro human Treg↓ [22] **
Innate immunity
Macrophage
IL-10↑ vitro human Th2↑ [32]
Macrophage
IL-1RA↑ vitro human Th2↑ [32]
Macrophage
CD192↑ vitro human Th2↑ [32]
Mast cell degranulation↑ vitro mice Th2↑ [33]
↑, stimulation; ↓, suppression; ROR, retinoic acid receptor-related orphan nuclear receptor; Foxp3, forkhead
box P3; GATA3, GATA binding protein 3; T-bet, T-box-containing protein expressed in T cells; STAT3, signal
transducer and activator of transcription 3; *, Estrous level of estradiol (E2) induced the effects, pregnancy-level
of E2 did not; **, Effects of polyphenolic compound delphinidin; †, Pregnancy-levels of E2; ‡, Estrogen receptor
agonist diarylpropionitrile; §, 10−10M E2 induced the effects, but 10−11E2 did not; Effects of selective estrogen
receptor modulator.
Estrogens are estrone, estradiol (E2), and estriol. E2 is produced by ovarian granulosa cells and
placenta. The immunomodulatory effects of E2 are mediated mainly by intracellular estrogen receptor
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α (ERα) and ERβ or structurally unrelated membrane G-protein-coupled estrogen receptor 1. E2
promotes Th2 activity [26,32]: E2 at pregnancy levels of concentration enhanced the expression of GATA
binding protein 3 (GATA3) and IL-4 in ovariectomized experimental autoimmune encephalomyelitis
(EAE) model mice [23]. E2 also enhanced IgE production in mouse splenocytes [27].
The effects of E2 on Th1 cells are complex and depend on the concentration, tissue, or disease
context: E2 at estrous levels of concentration in vivo enhanced the expression of T-box-containing
protein expressed in T cell (T-bet) and IFN-γ production in female ovariectomized autoimmune
thyroiditis model mice [21]. In contrast, E2 at pregnancy levels of concentration reduced the production
of IL-12 and IFN-γ in phytohemagglutinin plus lipopolysaccharide (LPS)-stimulated human whole
blood cells [34]. The high-dose estrogen treatment reduced the expression of IFN-γ and T-bet in EAE
model mice [23]. It appears that pregnancy levels of E2 shift the Th1/Th2 balance towards Th2 profiles,
inhibiting Th1 development [22,35].
Though E2 mostly suppresses Th17 activity [22,24], several studies reported the stimulatory
effects of E2 on Th17 cells: E2 at estrous levels of concentration enhanced the expression of IL-21
and retinoic acid receptor-related orphan nuclear receptor γt (RORγt) in female ovariectomized
autoimmune thyroiditis model mice [21]. Diarylpropionitrile, a specific agonist of ERβ and not
of ERα, in vivo enhanced IL-17A, IL-21, and RORγt mRNA levels in splenocytes of experimental
autoimmune thyroiditis model mice through binding of the agonist-activated ERβ to IL-17A and IL-21
gene promoters [29]. In contrast, E2 at estrous levels of concentration suppressed RORc expression
and IL-17A and IL-22 production in response to sperm or Candida albicans in female ovariectomized
mice [25]. The treatment with estrogen at pregnancy levels of concentration suppressed RORγt
expression and IL-17A and IL-6 production in EAE model mice [23]. E2 upregulated the expression of
repressor of estrogen receptor activity (REA) and recruited REA to the estrogen response elements
(EREs) on the RORγt promoter region, thus inhibiting RORγt expression [36].
E2 enhances the activity and/or proliferation of Tregs [28]: E2 enhanced the expression of forkhead
box P3 (Foxp3) by inducing binding of the E2/ERα complex to EREs on a human Foxp3 promoter [30].
Polanczyk et al. reported that E2 in vivo and in vitro increased Foxp3 expression and Treg number
in mice [31]. Tai et al. reported that E2, at physiological doses, in vitro stimulated the conversion of
CD4+CD25-T cells into CD4+CD25+T cells, which exhibited the enhanced expression of Foxp3 and
IL-10 in mice [12].
Estrogen also acts on mast cells and induces IgE-mediated degranulation [33,37], indicating the
stimulatory effects of E2 on allergic diseases. In Th2 hapten toluene diisocyanate (TDI)-sensitized
allergic airway inflammation model mice, ERα and ERβ agonists induced IL-33 production of airway
epithelial cells and eosinophil infiltration into the lung [38].
2.2.2. Progesterone (Table 3)
Progesterone is secreted by the ovarian corpus luteum and placenta and plays a major role in
the establishment and maintenance of pregnancy. The effects of progesterone are mainly mediated
by intracellular progesterone receptors while some rapid non-transcriptional actions are mediated by
structurally unrelated membrane progesterone receptors [17].
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Table 3. Summary of the effects of progesterone on the activities of T helper 1 cell (Th1), Th2, Th17, and
regulatory T cell (Treg).
Effects Vivo/Vitro Species Th Activities References
Adaptive Immunity
T-bet↓ vitro cows Th1↓ [39]
IFN-γ↓ vitro cows Th1↓ [39]
PIBF- STAT6↑ vitro human Th2↑ [40]
GATA3↑ vivo/vitro mice Th2↑ [41]
IL-4↑ ex vivo mice Th2↑ [42]
IL-4↑ vitro cows Th2↑ [39]
IL-4↑ vivo mice Th2↑ [42]
B cell
IgE↑ vivo mice Th2↑ [42]
Vaginal epithelial cell
TSLP↑ vivo/vitro mice Th2↑ [41]
STAT3 RORC CCR6 IL-23R
IL-6R AHR↓ vitro human Th17↓ [43]
RORγt↓ vivo/vitro mice Th17↓ [41]
RORC↓ vitro cows Th17↓ [39]
IL-17A↓ vitro human Th17↓ [43]
IL-17A↓ vitro cows Th17↓ [39]
IL-17F↓ vitro human Th17↓ [43]
IL-21↓ vitro human Th17↓ [43]
CD39+
regulatory Th17↑ vivo mice Th17↑※ [44]
IL-17A↑ vivo mice Th17↑※ [44]
IL-22↑ vivo mice Th17↑※ [44]
IL-23↑ vivo mice Th17↑※ [44]
IL-6↑ vivo mice Th17↑※ [44]
TGF-β↑ vivo mice Th17↑※ [44]
Foxp3↑ vitro mice Treg↑ [43]
Foxp3↑ vivo/vitro mice Treg↑ [41]
Innate Immunity
Airway epithelial cells
Amphiregulin↑ vivo mice [44]
※,CD39+ regulatory Th17 cells; ↑, stimulation; ↓, suppression; ROR, retinoic acid receptor-related orphan nuclear
receptor; Foxp3, forkhead box P3; GATA3, GATA binding protein 3; T-bet, T-box-containing protein expressed in
T cells; STAT, signal transducer and activator of transcription; AHR, aryl hydrocarbon receptor; CCR6 CC-type
chemokine receptor 6; TSLP, thymic stromal lymphopoietin; PIBF, progesterone-induced blocking factor.
Progesterone promotes Th2 activity [45]: progesterone acts on T cells and induces the secretion
of progesterone-inducible blocking factor (PIBF) which binds IL-4 receptor α(IL-4Rα)/PIBFR on the
cell surface and induces the Janus kinase 1 (Jak1)/signal transducer and activator of transcription 6
(STAT6) pathway to increase the production of Th2 cytokines like IL-4 or IL-10 [40]. Progesterone
increased TSLP expression in vaginal epithelium and GATA-3 expression and IL-4 production in
CD4+T cells in Neisseria gonorhoeae-infected vagina of mice [41]. Progesterone treatment increased IL-4
production in peripheral blood mononuclear cells (PBMCs) from pregnant cows [39]. The pro-Th2
effect of progesterone is consistent with the higher IL-4 and IL-10 production in PBMCs from pregnant
cows with high progesterone levels than those from nonpregnant cows [39]. Progesterone treatment on
ovariectomized asthma model mice increased serum IgE levels and IL-4 production in bronchoalveolar
lavage cells [42], indicating the contribution of progesterone to the elicitation of allergic diseases.
In contrast, progesterone directly suppresses Th1 development in mice [46]. Progesterone
treatment suppressed T-bet expression and IFN-γ production in PBMCs from pregnant cows [39].
The Th1-suppressive effect of progesterone is also consistent with the decreased IFN-γ production in
PBMCs from pregnant cows compared to those from nonpregnant cows [39].
Progesterone suppresses the differentiation of Th17 cells: progesterone in vitro suppressed
IL-17A, IL-17F, and IL-21 production and RORc expression in human cord blood cells under the
Th17-differentiation conditions and also suppressed their STAT3 phosphorylation in response to
IL-6 [43]. Progesterone suppressed RORγt expression and decreased IL-17A-producing CD4+T cell
numbers in Neisseria gonorhoeae-infected vagina of mice [41].
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Progesterone induces the differentiation of Tregs [44]: progesterone in vitro drove the allogeneic
activation-induced differentiation of human cord blood naive T cells into immunosuppressive Tregs,
which highly expressed FoxP3 and memory T cell marker CD45RO [43]. Progesterone increased the
percentage of CD4+CD25+Foxp3+ Tregs in Neisseria gonorhoeae-infected vagina of mice [41]. These
reports totally suggest that progesterone favors Th2/Treg activities but suppresses Th1/Th17 activities,
which might be favorable for tolerance to allogeneic fetus and for maintenance of pregnancy [17].
2.3. Androgens (Table 4)
Table 4. Summary of the effects of androgens on the activities of T helper 1 cell (Th1), Th2, Th17, and
regulatory T cell (Treg).
Effects Vivo/Vitro Species Th Activities References
Adaptive Immunity
ptpn1↑ STAT4↓ vivo/ vitro human and mice Th1↓ [47]
PPARα↑ vitro/vivo mice Th1↓ [48]
IFN-γ↓ vitro/vivo mice Th1↓ [48]
IFN-γ↓ vitro mice Th1↓ [49]
IFN-γ↓ vitro human Th1↓ [50]
IL-12↓ vitro human Th1↓ [50]
CXCL10↓ vitro human Th1↓ [50]
IL-13↓ vitro human Th2↓ [50]
IL-4↓ vitro human Th2↓ [50]
IL-5↓ vitro human Th2↓ [50]




vivo mice Th2↓ [52]
PPARγ↓ vitro/vivo mice Th17↑ [48]
IL-17A↑ vitro/vivo mice Th17↑ [48]
IL-23R↓ vivo mice Th17↓ [53]
IL-23R↓ vitro Mice Th17↓ [54]
IL-17A↓ vitro mice Th17↓ [49]
IL-17A↓ vivo mice Th17↓ [53]
IL-17A↓ vitro human Th17↓ [50]
ARE-Foxp3↑ vitro human Treg↑ [55]
IL-10↑ vitro human Treg↑ [50]
Innate Immunity
Mast cell
IL-4↓ vivo mice Th2↓ [53]
ILC2
IL-13↓ vivo mice Th2↓ [53]
Basophil
IL-4↓ vivo mice Th2↓ [53]
↑, stimulation; ↓, suppression; ROR, retinoic acid receptor-related orphan nuclear receptor; Foxp3, forkhead box P3;
STAT, signal transducer and activator of transcription; ptpn1, protein tyrosine phosphatase, non-receptor type 1;
PPAR peroxisome proliferator-activated receptor; ARE, androgen response element; ILC, innate lymphoid cell.
Androgens, such as dihydrotestosterone (DHT) or testosterone, are synthesized in the gonads
and adrenal glands. Testosterone is the most concentrated androgen in adult male serum. DHT is
present at one-tenth the concentration of testosterone though DHT is more potent than testosterone.
Testosterone can be aromatized to E2 by aromatase. Androgens mainly bind intracellular androgen
receptors (ARs) but also bind plasma membrane G-protein-coupled receptors [56].
Androgens are mostly immunosuppressive [51,57]. Androgens inhibit Th1 differentiation:
testosterone inhibited IL-12-induced phosphorylation of STAT4 in murine CD4+T cells by inducing the
expression of protein tyrosine phosphatase nonreceptor 1, which inactivates Jak2 and Tyk2 kinases [47].
DHT inhibited IFN-γ production in murine CD4+T cells by enhancing the expression of peroxisome
proliferator-activated receptor α (PPARα), which represses IFNγ transcription [48].
Androgens inhibit Th2 differentiation: DHT treatment of bone-marrow-derived dendritic cells
pulsed with Trichuris muris antigen reduced their Th2-priming activity with a complete ablation of
IL-4, IL-10, and IL-13 production by co-cultured T cells [54]. DHT treatment of prostate stromal
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cells suppressed the production of IL-4, IL-5, and IL-13 production by co-cultured CD4+ T cells [50].
Gonadectomized male mice showed increased IL-13-producing innate lymphoid cell 2 (ILC2) and
Th2 cells and increased serum IgE levels compared to sham-operated mice in response to house dust
mite antigens [53], indicating the suppressive effects of androgens on type 2 immune responses. In
male castrated phospholipase A-sensitized allergic rhinitis model mice, testosterone administration
decreased the production of phospholipase A-specific IgE [52], indicating the suppressive effects of
androgens on allergic rhinitis. Androgens also suppress B cell lymphopoiesis [51]: testosterone acted
on bone marrow stromal cells to induce the production of transforming growth factor-β, which reduced
the production of IL-7 required for B cell proliferation and differentiation [56].
Androgens suppress Th17 differentiation: male gonadectomized mice showed increased
IL-17A-producing Th17 and γδT cells compared to sham-operated mice in response to house dust mite
antigens [53]. The deficiency of AR signaling enhanced IL-17A production and IL-23R expression
in T cells under Th17-differentiation conditions [53]. These results indicate the inhibitory effects of
androgens on type 17 immune responses. Testosterone treatment of murine T cells in vitro decreased
IFN-γ or IL-17 production under the Th1- or Th17-differentiation conditions, respectively [49].
On the other hand, androgens induce Tregs: androgen-activated AR bound androgen response
elements on the Foxp3 promoter and enhanced the acetylation of histone H4 on the promoter, allowing
the binding of additional transcription factors, and thus enhanced the expression of Foxp3 in human
T cells [55]. Danazol, an attenuated androgen, increased CD4+CD25highCD127lowFoxp3+ Tregs in
patients with aplastic anemia [58].
2.4. DHEA (Table 5)
Table 5. Summary of the effects of dehydroepiandrosterone (DHEA) on the activities of T helper 1 cell
(Th1), Th2, Th17, and regulatory T cell (Treg).
Effects Vivo/Vitro Species Th Activities References
Adaptive Immunity
IFN-γ↑ vivo mice Th1↑ [59]
IFN-γ↑ ex vivo mice Th1↑ [60]
IFN-γ↑ vitro mice Th1↑ [19]
IL-12↑ vitro mice Th1↑ [10]
IFN-γ↓ vivo mice Th1↓ [61] *
IFN-γ↓ vivo mice Th1↓ [62]
IL-4↓ vivo mice Th2↓ [59]
IL-4↓ vitro mice Th2↓ [63]
IL-4↓ vitro human Th2↓ [64]
IL-4↓ vivo mice Th2↓ [61] *
IL-4↓ vivo mice Th2↓ [60]
IL-4↓ ex vivo mice Th2↓ [60]
IL-5↓ vivo mice Th2↓ [59]
IL-5↓ vivo mice Th2↓ [62]
IL-5↓ vitro human Th2↓ [64]
IL-5↓ ex vivo mice Th2↓ [60]
IL-13↓ vivo mice Th2↓ [59]
CCL11↓ vivo mice Th2↓ [59]
CCL24↓ vivo mice Th2↓ [59]
B cell
IgE ↓ vivo mice Th2↓ [65]
B cell
IgE ↓ vivo mice Th2↓ [60]
B cell
IgG1↓ vivo mice [60]
IL-13↑ vivo mice Th2↑ [62]
RORC↓ vivo mice Th17↓ [61] *
IL-17A↓ vivo mice Th17↓ [61] *
IL-17A↓ vivo mice Th17↓ [62]
TNF-α↓ vivo mice Th17↓ [60]
IL-6↓ vivo mice Th17↓ [62]
TGFβ↓ vivo mice Th17↓ [62]
TNF-α↑ vitro human Th17↑ [66] †
IL-6↑ vitro human Th17↑ [66] †
IL-1β↑ vitro human Th17↑ [66] †
Foxp3↓ vitro human Treg↓ [67]
IL-10↓ vitro mice Treg↓ [62]
IL-10↓ vitro mice Treg↓ [63]
Foxp3↑ vivo mice Treg↑ [68] **
IL-10↑ vivo mice Treg↑ [61] *
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Table 5. Cont.
Effects Vivo/Vitro Species Th Activities References
Innate Immunity
Mast cell
infiltration↓ vivo mice Th2↓ [60]
Eosinophil
infiltration↓ vivo mice Th2↓ [59]
Eosinophil
infiltration↓ vivo mice Th2↓ [60]
HaCat cells
CCL17↓ vitro human Th2↓ [60]
HaCat cells
CCL22↓ vitro human Th2↓ [60]
BEAS-2B
CCL11↓ vitro human Th2↓ [59]
BEAS-2B





*, Possible effects of DHEA metabolite, 5-androsten-3β,17β-diol (adiol), via estrogen receptor β (ERβ); **, Synthetic
DHEA analog HE3286; †, Effects via ER; ↑, stimulation; ↓, suppression; ?, ambiguous; ROR, retinoic acid
receptor-related orphan nuclear receptor; Foxp3, forkhead box P3; ICAM1, intercellular adhesion molecule 1;
VCAM1, vascular cell adhesion molecule 1.
DHEAS is the most abundant steroid in human blood serum and is secreted by the adrenal
cortex [69]. DHEAS is converted by steroid sulfatase to an active form, DHEA [69]. Steroid sulfatase is
controlled by an X-linked gene that escapes the Lyon effect of X-inactivation; as a result, women have
twice the amount of steroid sulfatase than men [70], especially in peripheral lymphoid organs [20]. The
DHEA/DHEAS ratio in circulation is usually higher in women than in men [71], and under 50 years
old, the plasma DHEA concentration of women is higher than that of men [72]. It is thus hypothesized
that women might be more susceptible to the effects of DHEA than men [20] though the effects might
be influenced by other factors such as receptor and downstream pathways. DHEA itself binds nuclear
steroid hormone receptors like AR, ERα, or ERβ with lower affinities than cognate ligands. DHEA is
metabolized to other steroid hormones, testosterone, DHT, or E2 (Figure 3), and these metabolites bind
the corresponding steroid receptors: DHEA metabolite 5-androsten-3β,17β-diol can bind ERβ [61].
Moreover, recent studies revealed that DHEA and DHEAS act as ligands of many nuclear receptors
like PPARα, pregnane X receptor, and constitutive androstanol receptor and membrane receptors like
TrkA, N-methyl-D-aspartic acid receptors, or γ-amino butyric acid receptors [73]. Thus, the biological
effects of DHEA depend on the levels of metabolizing enzymes and individual receptors and, thus,
vary with species, tissues, or cell types.
DHEA mostly enhances Th1 differentiation: DHEA treatment enhanced IL-12 and IFN-γ
production in female murine peritoneal cells in vivo and enhanced the expression of very late
antigen-4 and leukocyte function-associated antigen-1 in CD4+ T cells in vitro [19]. DHEA in vivo
increased the expression of vascular cell adhesion molecule-1 and intercellular adhesion molecule-1
in ovary granulosa cells of mice [19,74]. DHEA suppresses type 2 immune responses [65]: in female
ovalbumin-sensitized asthma model mice, DHEA administration reduced eosinophil infiltration
into the lung; serum ovalbumin-specific IgE levels; and the expression of IL-4, IL-5, and IL-13 and
type 2 chemokines CC-chemokine ligand 1 (CCL1) and CCL24 in bronchoalveolar lavage fluid but
increased IFN-γ production in ovalbumin-activated splenocytes [59]. DHEA reduced IL-4 production
but increased IL-2 production in concanavalin A-stimulated human PBMCs [64]. In LPS-induced
experimental inflammation model mice, DHEA increased the Th1/Th2 ratio in spleen T cells [63]. DHEA
significantly increased Th1 cytokine levels (IL-2 and IFN-α) and decreased Th2 cytokine levels (IL-4 and
IL-10) in primary cultured spleen T cells [63]. DHEA decreased Na+K+-ATPase activity and increased
Ca2+ ATPase activity in T cells, which might regulate the balance of cytokine secretion [63]. Thus,
DHEA enhances Th1 immune response and regulates the balance of Th1/Th2 toward Th1-dominant
immunity. In AD model mice induced by topical 2,4-dinitrochlorobenzene (DNCB), oral or topical
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DHEA attenuated the infiltration of eosinophils and mast cells into DNCB-challenged ear skin. In
those mice, oral or topical DHEA also reduced serum IL-4 and IgE levels and reduced IL-4 and
IL-5 production but increased IFN-γ production in splenocytes [60]. DHEA in vitro suppressed the
production of type 2 chemokines, CCL17 and CCL22, in tumor necrosis factor-α-stimulated HaCat
cells [60].
Figure 3. Dehydroepiandrosterone (DHEA) metabolizing pathway. DHEAS, dehydroepiandrosterone
sulfate; DHT, dihydrotestosterone; T, testosterone; E2, estradiol; AR, androgen receptor; ER, estrogen
receptor; 17β-HSD, 17β-hydroxysteroid dehydrogenase; RoDH1, retinol dehydrogenase type 1; ,
binding to the steroid receptor described.
The effects of DHEA on Th17 and Treg are ambiguous [62] and dependent on tissue or
disease context [66]: DHEA treatment increased the number of Foxp3+ Tregs in splenocytes of
female ovariectomized mice [75]. In EAE model mice and human multiple sclerosis patients,
DHEA directly inhibited the activity of Th17 cells, inducing IL-10-producing Tregs via ERβ
activation [61]. This effect may be mediated by 5-androsten-3β,17β-diol, converted from DHEA
by 17β-hydroxysteroid dehydrogenase (Figure 3). Synthetic DHEA analog HE3286 increased the
frequency of CD4+CD25+Foxp3+ Tregs in spleen in collagen-induced arthritis model mice [68] though
the receptors for this analog are unknown and not ERα, ERβ, or AR. In contrast, DHEA reduced the
expression of Foxp3 without altering Treg frequency in PBMCs from patients co-infected with HIV and
tuberculosis [67].
3. The Effects of Sex Hormones on the Skin Barrier (Table 1)
Overall, in adults, skin hydration is slightly higher in women than in men and basal transepidermal
water loss (TEWL) is significantly higher in men than in women [35,76]. The epidermal permeability
barrier is impaired by androgens and progesterone but is restored by E2 [77]. E2 paradoxically worsens
the progesterone-induced barrier impairment [78]. The skin barrier is impaired in the luteal phase
when both progesterone and estrogen are secreted [79].
The ovariectomy of female C57/BL6 mice reduced skin hydration, delayed skin permeability
recovery after tape stripping, and reduced epidermal thickness; these were restored by the
administration of E2 [80]. Ovariectomy also reduced the expression of desmoglein-1, involucrin, and
loricrin, key constituents of corneodesmosome and cornified envelope (CE) in SC; these were restored
by E2 treatment [80]. Ovariectomy of female nude mice (ICR-Foxn1nu) also reduced the expression of
filaggrin and integrin β in the skin [81]. These results support that E2 strengthens the skin permeability
barrier and integrity.
The castration of male mice (Sk:h1) or treatment with AR antagonist flutamide accelerated skin
permeability recovery after tape stripping, and testosterone administration delayed recovery in the
castrated mice [82]. Testosterone treatment of castrated mice reduced the number of lamellar bodies in
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the cytosol of stratum granulosum (SG) cells and decreased secreted lamellar contents at the interface
of SC and SG [82]. These results support that testosterone perturbs the skin permeability barrier
homeostasis. The administration of E2 in pregnant rats reduced TEWL of day-20 fetus while that
was increased by DHT [77]. The administration of E2 accelerated lipid deposition and formation
of lamellar unit structures in the SC of day-20 fetal epidermis in utero while these were delayed
by DHT [77]. In fetal skin explants from day-17 rats, estrogen increased while DHT reduced the
activity of β-glucocerebrosidase, which converts glucosylceramides to ceramides and is essential for
the formation of lamellar unit structures throughout SC interstices [83]. In the same explants, estrogen
accelerated while DHT delayed the expression of filaggrin and loricrin, key constituents of keratohyalin
granules and CE, respectively [84]. These results indicate that E2 accelerates while androgen delays SC
barrier formation.
Topical testosterone delayed skin permeability barrier recovery in male hairless mice (HR-1),
and the delay was overcome by co-application of E2 [78]. Progesterone also delayed the recovery;
however, the delay was paradoxically enhanced by E2 [78]. To date, the precise mechanism of how
progesterone delays skin permeability barrier recovery is not elucidated; however, it is indicated
that progesterone opposes the protective effect of E2 on skin permeability barrier and that the skin
permeability barrier may be impaired in females in the luteal phase when both progesterone and
estrogen are secreted. Muizzuddin et al. showed that the skin permeability barrier was the weakest
between days 22 and 26 of the menstrual cycle, the mid-luteal phase [85]. TEWL is higher at the day
of minimal estrogen/progesterone ratio (around day 26) than that at the day of maximal estrogen
secretion (around day 13) [79]. It is thus hypothesized that the skin barrier might be protected by E2,
which might be opposed by progesterone. The skin patch test reaction to Ni is higher at the luteal
phase than that at the ovulatory phase or at the follicular phase [86], which may be due to the skin
permeability barrier impairment at the luteal phase when progesterone is secreted. In the uterus of
ovariectomized mice, E2 treatment increased mRNA levels of small proline-rich protein 2 (SPRR2),
which was dampened by progesterone [87]. Since SPRRs are key constituents of CE in SC of the
skin, further studies should elucidate if such suppressive effects of progesterone might be reproduced
in the skin. In contrast, progesterone upregulated the expression of TJ proteins occludin and zona
occludens 2 in the epidermis, and this effect was canceled by E2 in ovariectomized FvB mice [88].
Progesterone upregulated the expression of occludin in human gut tissues and Caco-2 cells [89]. It is
thus hypothesized that the TJ barrier might be restored by progesterone but impaired by E2, opposite
to the SC barrier, though confirmative studies are required for its verification.
It is reported that oral DHEA in humans at > 60 years old improved skin hydration, epidermal
thickness, sebum production, and pigmentation [90]. Such antiaging effects of DHEA are mainly
generated by the enhanced collagen biosynthesis and deposition: topical DHEA increased the mRNA
levels of procollagen 1/3 and heat shock protein 47, a type 1 collagen chaperone protein in human
dermal fibroblasts [91]. In contrast, topical DHEA treatment reduced the expression of genes associated
with the terminal differentiation and cornification of keratinocytes, corneodesmosin, claudin 8, SPRR2G,
late envelope protein 7, and Jagged 1, indicating the suppression of skin barrier properties [92]. To
date, the direct effects of DHEA on skin permeability barrier have not been reported and should further
be examined. In the testis, DHEAS but not DHEA augmented the TJ connections between Sertoli cells
by promoting the expression of claudin-3 and -5 via membrane Gnα11-coupled receptors independent
of AR [93].
4. The Effects of Sex Hormones on the Pruritus
There have been no reports that sex hormones act as pruritogens. However, E2 and/or progesterone
directly or indirectly induce the secretion of Th2-related cytokines, IL-4, IL-13, IL-31, TSLP, or
IL-33; these cytokines bind the corresponding receptors on C-type sensory neurons and generate
an itch sensation [94]. In Th2 hapten TDI-sentitized allergic dermatitis model mice, oral or topical
administration of ERα agonist propylpyrazoletriol induced TSLP and IL-33 expression in keratinocytes
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and promoted scratching behavior [95]; the pruritus might be caused by TSLP and IL-33. Estrogen also
acted on mast cells and promoted the release of histamines [33,37], which also act as pruritogens.
In sensory neuron-keratinocyte coculture model, DHEA produced by keratinocytes promoted
neurite growth possibly through the activation of TrkA [96,97], indicating the relations to abnormal
neurite outgrowth into the epidermis of AD lesions. The effects of sex hormones on neurite growth
should further be examined precisely.
5. Intrinsic AD
Intrinsic AD patients occupy around 10–20% of whole AD, show normal IgE values, lack
IgE antibodies against environmental or food allergens, and lack barrier disruption and filaggrin
gene mutation [15]. Intrinsic AD patients manifest Dennie–Morgan fold but without icthyosis
vulgaris and palmar hyperlinearity and with milder severity of AD. Intrinsic AD patients show
positive on patch tests to metals, especially to Ni, at a higher percentage than extrinsic AD
patients, indicating the higher incidence of metal allergy [98]. Intrinsic AD patients show high
Ni concentrations in serum and sweat [98,99], indicating the enhanced absorption and/or transport
of Ni derived from food and sensitization with Ni in the circulation and skin. Immunologically,
intrinsic AD patients show higher Th1 activity than that of extrinsic AD patients and show Th2
activity comparable to that of extrinsic AD patients [100]. Since Ni interacts with toll-like receptor 4 in
addition to major histocompatibility/self-peptide complex and induces a mixed Th1 and Th2 cytokine
responses [98,101–103], a considerable number of intrinsic AD patients, though not all, might show
both Th1 and Th2 responses to Ni through its presentation by antigen presenting cells in the skin patch
test. Thus, metals might act as the main allergens in intrinsic AD though other agents might also work
in its pathogenesis. In both children or adults, the prevalence of intrinsic AD is higher in females than
in males [104,105]; moreover, the prevalence of Ni allergy is higher in females than in males [106,107].
6. Possible Hypotheses on the Generation-Dependent Sexual Difference in the Prevalence of
Extrinsic AD (Table 6)
It is hypothesized that prepubertal children might be mostly devoid of the influence of sex
hormones considering their very low concentrations. The effects of DHEA, shifting the Th1/Th2 balance
to Th1, might be more remarkably revealed in girls than in boys due to the higher levels of steroid
sulfatase converting DHEAS to DHEA. Thus, both atopic asthma and extrinsic AD, Th2-shifted allergic
diseases with atopic diathesis, might be more prevalent in boys than in girls. The male preponderance
in childhood asthma might also involve gender-specific factors other than hormonal regulation [108]:
boys have smaller airway diameters relative to lung volume (dysanapsis; [109]) and show a higher
percentage of positive skin prick tests or IgE antibodies against aeroallergens than girls, indicating
higher atopic diathesis in boys than in girls [110]. The higher aeroallergen sensitivities in boys may also
be related to the male predominance in childhood AD [111]. Alternatively, the higher asthma incidence
in boys may be because underdiagnosed and undertreated asthma patients exist among girls [112].
After puberty, the levels of sex hormones, estrogen, progesterone, testosterone, or DHT are greatly
increased and individuals might thus be more greatly influenced by the immunological effects of those
sex hormones than those of DHEA [18,113,114]. Women are exposed to higher levels of estrogen and
progesterone promoting Th2 activity. The prevalence and severity of atopic asthma might thus become
much higher in women than in men exposed to higher levels of androgens suppressing Th2 activity.
The female preponderance in adult asthma may also involve other gender-specific factors [108]: the
bronchial hyperresponsiveness is more frequent in women than in men; women are more likely to be
exposed to indoor aeroallergens than men.
In the case of adult extrinsic AD, patients are influenced by the effects of sex hormones both
on immune responses and skin barrier impairment. The Th2 shift is more prevalent in women than
in men; however, skin barrier impairment is more likely to occur in men exposed to high levels of
androgens perturbing skin permeability barrier. In women, skin barrier is restored by estrogen at
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the follicular and ovulatory phases but are disturbed by progesterone at the luteal phase. Totally,
female adults might be slightly more protected from skin barrier impairment compared to male adults,
considering the postmenopausal skin barrier disruption in females and its restoration by hormonal
agents, including both estrogen and progesterone [115]. Thus, female adults with higher Th2 activity
but slightly more protection from skin barrier impairment may show a slightly higher prevalence of
extrinsic AD compared to male adults, though the sexual difference is moderate compared to strict
female preponderance of adult atopic asthma. It is known that Th1 activity is enhanced in the chronic
phase of AD and that Th17 cells may also be involved in the pathogenesis of AD [5], which might
be more applicable to women than men since estrogen might promote Th1 and Th17 activities at
estrous level of concentrations [21]. Other gender-specific factors might also be related to the moderate
female preponderance of adult AD: women are more responsive to pruritogens than men, and female
mice showed higher scratching counts than male mice under the stimulus of proteinase-activated
receptor-2-activating peptide [116]. The involvement of sex hormones in hyperknesis or alloknesis
should further be investigated.
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7. Possible Hypotheses on Female Preponderance of Intrinsic AD (Table 7)
We herein propose a hypothesis on female preponderance of intrinsic AD in the context of metal
allergy, one possible agent of its pathogenesis. Patients with intrinsic AD are not associated with
atopic diathesis, filaggrin gene mutation, or congenital skin barrier impairment and are associated
with enhanced Th1 activity as well as Th2 and high incidence of Ni allergy though not in all patients.
Before puberty, there is no sexual difference in the chances of Ni exposure, though in Western countries,
girls are more frequently exposed to Ni due to the first pierce experiences. Th1 responses to Ni might
be more remarkable in girls with higher susceptibility to DHEA promoting Th1 activity than in boys.
Totally, intrinsic AD in childhood might be more prevalent in girls than in boys.
After puberty, women are more frequently exposed to Ni by wearing ornaments than men.
The immune response to Ni might be gradually shifted from Th1 to Th2 since repeated elicitation
with antigens alters the balance of cytokines released locally, with a shift toward Th2-dominated
responses [117]. Immune responses after puberty might be more susceptible to the influence of sex
hormones than of DHEA. After puberty, Th2 responses to Ni might be more remarkable in women
with higher levels of estrogen and progesterone stimulating Th2 activity than men with higher levels
of androgens suppressing Th2 activity. The intrinsic AD after puberty might thus become much more
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prevalent in women than in men. The female preponderance of intrinsic AD may also involve certain
gender-dependent factors unrelated to metal allergy, which should further be identified.
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8. Possible Hypotheses on the Premenstrual Deterioration of AD in Females
About half of female AD patients experience premenstrual deterioration of AD symptoms [118].
The deterioration might be due to the dual effects of estrogen and progesterone on Th2 activity and
skin barrier. At the luteal phase, both estrogen and progesterone are secreted and, thus, Th2-skewing
effects are higher than in the other phases; moreover, the skin permeability barrier is perturbed by
progesterone, especially, just prior to menstruation with minimal estrogen/progesterone ratio.
The deterioration of AD during pregnancy is also reported; 52% or 61% of female AD patients
who experienced pregnancy had noticed deterioration of AD during pregnancy in the UK [119] or
Korea [120], respectively. The deterioration of AD during pregnancy might also reflect the effects of
extremely high concentrations of E2 and progesterone on Th2 activity and skin barrier. Moreover, the
prevalence of deterioration during pregnancy was higher in intrinsic AD patients (100%) compared to
that in extrinsic AD patients (47.1%) in the Korean study [120]. It is thus hypothesized that intrinsic
AD patients might be more susceptible to the influence of female sex hormones compared to extrinsic
AD patients.
9. Serum Hormone Concentrations in Patients with Allergic Diseases
It is reported that serum concentrations of DHEA or testosterone are lower in male AD patients
compared to the reference group [64,121]. These indicate that DHEA- or testosterone-induced
suppressive effects on Th2 activity are reduced in male AD patients, which might aggravate the
symptoms of AD. It is also reported that serum concentrations of DHEA or DHEAS are lower in
patients with asthma or chronic spontaneous urticaria compared to the reference group, irrespective
of gender [122]. It is thus speculated that the reduction of Th2-suppressive effects by DHEA
might accelerate the Th2 shift in these patients though confirmatory studies are needed to verify
the speculation.
It is reported that prolonged physical stress with energy and sleep deprivation reduced serum
DHEA levels and increased serum DHEAS levels, indicating the decrease of steroid sulfatase activity
and/or increase of sulfotransferase activity by prolonged physical stress [123]. It is thus hypothesized
that the reduction of DHEA levels might be one possible cause of the stress-induced exacerbation of
allergic diseases.
10. Conclusions
We reviewed the effects of sex hormones related to the course of AD and focused on immune
responses and skin barrier. The balance of the effects of sex hormones might up- or downregulate the
prevalence and course of AD. Future studies should elucidate the effects of sex hormones on Th22
activity or pruritus, using AD model mice.
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Abstract: T helper-17 (Th17) cells, which mainly produce IL-17, are associated with development of
various autoimmune diseases such as rheumatoid arthritis, inflammatory bowel diseases, multiple
sclerosis, and psoriasis. IL-17 and related cytokines are therapeutic targets of these diseases. In atopic
dermatitis (AD), Th2 cytokines such as IL-4 and IL-13 are regarded to be the main player of the
disease; however, Th17 cytokines are also expressed in AD skin lesions. Expression of IL-22 rather
than IL-17 is predominant in AD skin, which is contrary to cytokine expression in psoriasis skin.
Relatively low IL-17 expression in AD skin can induce relatively low antimicrobial peptide expression,
which may be a reason why bacterial infection is frequently seen in AD patients. Failure of clinical
trials for investigating the efficacy of anti-IL-12/23 p40 in AD has suggested that IL-17 expressed in
skin lesions should not be the main player but a bystander responding to barrier dysfunction.
Keywords: IL-22; IL-26; subtypes of atopic dermatitis; ustekinumab; wound healing; antimicrobial
peptides
1. Introduction
Atopic dermatitis (AD) is a chronic skin disease characterized by relapsing eczema with pruritus
as a primary lesion. Most patients with AD have atopic diathesis such as family history of allergic
diseases or past history of asthma, rhinitis, or conjunctivitis [1]. In Japan, AD is not a rare skin disease,
whose frequency is about 10–15% until the age of forty [2]. Age-related remission is achieved in a
certain proportion of patients with AD, especially when the onset is younger or the symptoms are
milder [3,4]. Although some patients develop AD in their adulthood, onset of AD in elderly people is
very rare. Other skin diseases such as cutaneous T-cell lymphoma (CTCL), drug eruption, and bullous
diseases should be considered as a possible diagnosis. Most of all, CTCL should not be misdiagnosed
with AD because immunosuppressive drugs such as cyclosporine and anti-tumor necrosis factor
(TNF)-α antibody can exacerbate disease activity of CTCL [5–7]. When the diagnosis is not clear,
topical steroid or ultraviolet phototherapy should be applied.
AD has significant negative social and economic impacts, substantially decreasing the quality of
life of the patients and their families [8,9]. Skin conditions of AD children influence quality of life of
both children and their caregivers. Pruritus, emotional distress, and sleep disturbance are big problems
for them, which should be paid more attention to. It is important to induce long-term remission.
Remission can be achieved by conventional treatment for mild or moderate AD, while it is very difficult
for severe AD patients [3,4]. Treatment strategies consist of drug therapy with topical agents such as
steroid or tacrolimus, skin care with moisturizers for dry skin, and investigation and elimination of
exacerbating factors [1]. The pathogenesis of AD can be explained from the perspectives of the skin
barrier, allergic inflammation, and neuroendocrine dysfunction represented by severe pruritus [10].
With regards to allergic immune responses, cytokines expressed by T helper (Th) 2 cells and group 2
innate lymphoid cells such as interleukin (IL)-4, IL-5, and IL-13 have been assumed as main players
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of AD [11–13]. It was also reported that Th1 cytokines like interferon (IFN)-γ were expressed in AD
lesional skin [14,15]. In recent years, Th17 cytokines such as IL-17 and IL-22 were reported to be
expressed in AD lesional skin [16–20]. In this review, the importance of Th17-related cytokines in
pathogenesis and treatment of AD will be discussed.
2. Th17 Cells in Pathogenesis of Psoriasis
CD4+ helper T cells, upon activation, develop into different T helper cell subsets. Th17 cells, which
are different from Th1 or Th2 cells, produce IL-17, IL-17F, and IL-22 as well as IL-21 [21]. Th17 cells
are essential in clearing pathogens during host defense reactions. IL-17 and IL-22 are also important
for chronic autoinflammatory diseases such as rheumatoid arthritis, inflammatory bowel diseases
including Chron’s disease and ulcerative colitis, multiple sclerosis, and psoriasis. While transforming
growth factor-β and IL-6 are important for differentiation of the subset, IL-23 produced by dendritic
cells activated by TNF-α is essential for its maintenance and activation. It is widely accepted that a
vicious circle among TNF-α, IL-23, and IL-17 is established in psoriasis. Monoclonal antibodies against
TNF-α, IL-12/23p40 subunit, IL-23p19, and IL-17 are clinically used and very effective [22–25].
IL-17 has multiple physiological functions. It activates macrophages to express TNF-α and
IL-1β [26] and fibroblasts to produce IL-6, IL-8, and matrix metalloproteinases [27]. These cytokines
are important for inflammatory process and tissue remodeling. It also stimulates blood endothelial
cells to produce chemoattractants and express VCAM-1 and ICAM-1 in a p38 MAPK-dependent
manner, which helps immune cells evade from blood to tissues [28]. Epithelial cells stimulated by
IL-17 express IL-8 and granulocyte colony-stimulating factor, inducing migration and activation of
neutrophils [29]. In addition, IL-17 was found to synergistically enhance TNF-α-induced production
of these cytokines. IL-17 also increases production of antimicrobial peptides (AMPs), which are part
of the innate immune response and are found among all classes of life [30,31]. These peptides kill
bacteria, mycobacteria, enveloped viruses, and fungi. Skin-resident commensal microbes produce
their own AMPs, act to enhance the normal production of AMPs by keratinocytes, and are beneficial to
maintaining inflammatory homeostasis by suppressing excess cytokine release after minor epidermal
injury [32]. IL-22, which is another cytokine expressed by Th17, enhances AMP production together
with IL-17 [31]. This cytokine induces epidermal proliferation [33]. IL-26, an antimicrobial protein
that has the ability to directly kill extracellular bacteria, is also secreted by Th17 [34]. IL-26 was more
strongly expressed in lesions from the self-limited tuberculoid leprosy compared with expression in
progressive lepromatous patients. IL-26 directly bound to Mycobacterium leprae in axenic culture and
reduced bacteria viability. Thus, Th17 is important for neutrophilic infiltration, epidermal proliferation
called acanthosis, and innate immune responses including enhanced production of AMPs, which are
main histological findings characteristic to psoriasis.
3. Involvement of Th17-Related Cytokines in AD
3.1. Th17-Related Cytokine Expression in AD
Possible involvement of Th17 in the pathogenesis of AD has been reported by some
researchers [16–20]. The percentage of IL-17-poducing CD4+ T cells in peripheral blood from AD
patients was increased and associated with severity of AD [16]. There was a significant correlation
between the percentages of IL-17+ and IFN-γ+ cells, although the percentage of Th17 cells was not
closely related to Th1/Th2 balance. Immunohistochemically, IL-17+ cells infiltrated in the papillary
dermis of AD lesional skin. There was another study showing that more IL-17-producing cells
infiltrated into the site of an atopy patch test than in healthy skin [17]. IL-17 secretion was not
enhanced by IL-23, IL-1β, or IL-6, but was enhanced by the Staphylococcus aureus-derived superantigen
staphylococcal enterotoxin B. Another group, however, showed that the number of Th1 and Th17
subsets in peripheral blood from AD patients was significantly decreased, but that of the Th2 subset
was similar to that of normal controls [35]. The frequency of Th17 cells showed a significant, negative
86
Int. J. Mol. Sci. 2020, 21, 1314
correlation with serum thymus and activation-regulated chemokine (TARC) and IgE levels and the
number of eosinophils. It was recently reported that the frequency of IL-13+ cells, which was correlated
with IgE levels and SCORing AD (SCORAD) score, was associated with IL-22-producing T cells in
severe AD patients [36]. When examining skin samples from AD, psoriasis, and healthy controls,
IL-17 expression level was increased in AD skin compared to normal skin, although it was much
lower than that in psoriasis skin [18]. By contrast, Th2 cells were significantly elevated in AD. Distinct
IL-22-producing CD4+ and CD8+ T-cell populations were significantly increased in AD skin compared
with psoriasis. IL-22-producing CD8+ T-cell frequency correlated with AD disease severity. Taken
together, IL-22 rather than IL-17 is dominant in AD skin, while IL-17 is dominant in psoriasis skin.
It is a recent trend to divide various diseases into subgroups by cytokine production. Two
subgroups of asthma, intrinsic and extrinsic, have been proposed [37]. Extrinsic asthma is triggered by
allergens and is characterized by enhanced Th2 cytokine production. Intrinsic asthma is characterized
by later onset in life, female predominance, higher degree of severity, and more frequent association to
nasosinusal polyposis. This nonallergic asthma characterized by Th1 production can be objectively
distinguished from allergic asthma based on negative skin tests to usual aeroallergens. Similar
subgroups have been proposed for AD: intrinsic AD and extrinsic AD [38,39]. Extrinsic or allergic AD
shows high total serum IgE levels and the presence of specific IgE for environmental and food allergens,
whereas intrinsic or nonallergic AD exhibits normal total IgE values and the absence of specific IgE [38].
Extrinsic AD is much more common than intrinsic AD, which is approximately 20% with female
predominance. The clinical features of intrinsic AD include relative late onset, milder severity, a
higher frequency of metal allergy, and Dennie–Morgan folds, but no ichthyosis vulgaris or palmar
hyperlinearity. The skin barrier dysfunction and filaggrin gene mutations are not a feature of intrinsic
AD. The intrinsic type is characterized by the lower expression of IL-4, IL-5, and IL-13, and the higher
expression of IFN-γ. In patients with intrinsic AD, Th17-related cytokines are highly expressed [39].
Positive correlations between Th17-related molecules and SCORAD scores were only found in patients
with intrinsic AD, whereas only patients with extrinsic AD showed positive correlations between
SCORAD scores and Th2 cytokine levels and negative correlations with keratinocyte differentiation
markers such as loricrin and periplakin. Another classification of AD was proposed: Asian type and
European American type. A principal component analysis using real-time PCR data clustered the
Asian AD phenotype between the European American AD and psoriasis phenotypes [19]. Significantly
higher Th17 and lower Th1 gene induction typified AD skin in Asian patients. Moreover, AD lesional
skin in pediatric patients was reported to contain more Th17-related cytokines and AMPs than that
in adult patients [20]. Taken together, it may be safely said that IL-17 expression in lesional skin of a
certain group of AD patients is higher than that in normal skin. It is yet to be elucidated whether IL-17
plays a critical role in AD as it does in psoriasis.
With regards to serum levels of cytokines, it was reported that IL-22 in AD patients significantly
correlated with disease activity, while IL-17 did not reflect disease burden [35].
IL-26 is another cytokine produced by Th17 cells. It was recently reported that IL-26 mRNA
expression levels were elevated in AD lesional skin compared with healthy controls and that
IL-26-producing cells were increased in AD lesional skin by immunohistochemistry [40]. IL-26
may play an important role for bridging between Th17 and Th2 responses, resulting in the development
of AD.
3.2. AD Mouse Models and Th17-Related Cytokines
With regards to basic research, IL-17 was reported to regulate Th2 responses in the mouse AD
model [41]. IL-17 triggered the production of IL-4 by Th2 cells. The lack of IL-17A reduced dermatitis
and IL-4 production as well as IgE production. It is also known that IL-17 promotes the differentiation
of B cells to IgE-producing plasma cells [42]. A murine epicutaneous infection model showed that
Malassezia, which has been reported to exacerbate AD skin conditions, selectively induced IL-17-related
cytokines [43]. This process is important for preventing fungal infection through the skin. Under skin
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barrier dysfunction mimicking AD, the presence of Malassezia aggravated cutaneous inflammation,
which was dependent on IL-23 and IL-17. A CCR6+ Th17 subset of memory T cells specific to Malassezia
was more frequently detected in AD skin than in healthy skin. Thus, the Malassezia-induced Th17
response is important not only in antifungal immunity but also in worsening skin inflammatory
conditions. TNF-like weak inducer of apoptosis (TWEAK) and its receptor fibroblast growth factor
(FGF) inducible 14 are highly expressed in AD skin lesions. BALB/c mice deficient in this molecule
showed attenuated skin inflammation in an AD model, accompanied by less infiltration of inflammatory
cells and lower local levels of proinflammatory cytokines, including TWEAK, TNF-α, and IL-17 [44].
Thus, IL-17 may be an important mediator of TWEAK-induced AD-like inflammation. The numbers
of ILC3, expressing IL-17, in the skin of AD-induced mice were increased, and that neutralizing
IL-17A delayed development of AD in the mouse model [45]. ILC3 induced IL-33 production by
keratinocytes and fibroblasts. IL-26, another Th17 cytokine, promoted production of various cytokines
such as IL-8, IL-1β, CCL20, IL-33, and β-defensin 2 by keratinocytes through phosphorylation of signal
transducer and activator of transcription 1 and signal transducer and activator of transcription 3 [37].
JAK inhibitors, which are promising drugs for AD, blocked IL-26-induced cytokine production in
keratinocytes. Injection of IL-26 exacerbated an oxazolone-induced AD mouse model and upregulated
Th2 and Th17 cytokine expression in vivo. Thus, basic research findings also support the idea that
IL-17 and its related cytokines are important in AD pathogenesis.
4. Expression of Th17 Cytokines in Other Skin Diseases
Some reports have suggested importance of IL-17 in various skin diseases other than psoriasis
and AD. For example, IL-17 expression is reported to be increased in sera or lesional skin of systemic
lupus erythematosus [46]. IL-17A expression was significantly increased in the involved skin and sera
of systemic sclerosis patients, suggesting possible roles in the development of the disease [47,48]. Our
group reported that lesional skin of mycosis fungoides (MF) and Sezary syndrome (SS), representative
diseases of CTCL, contained a high amount of IL-17 and IL-22, the latter of which was dominant [49].
Serum IL-22 levels were significantly positively associated with disease activity in MF/SS. There
are many clinical similarities between MF/SS and AD. Both diseases are characterized by persistent
erythematous lesions with severe itch, sometimes developing to erythroderma. Bacterial, fungal, and
viral infections such as impetigo contagiosum, phlegmone, tinea corporis, and herpes simplex are
frequently accompanied. The number of eosinophils in peripheral blood is often increased and serum
TARC level is elevated. Dominancy of IL-22 over IL-17 is seen in both diseases, which may explain
clinical pictures of these diseases. Taken together, Th17 cytokine expression is widely seen in various
skin diseases.
5. Clinical Trial for AD Targeting Th17 Cytokines
5.1. Clinical Effect of Ustekinumab on AD
Ustekinumab is a recombinant human IgG1 monoclonal antibody against p40, which is a common
subunit of IL-12 and IL-23 [25]. This drug is used for psoriasis vulgaris and psoriatic arthritis. A
previous report about four male patients with severe AD between 23 and 29 years old, whose skin
eruption had been refractory to oral corticosteroids, phototherapy, and to at least two systemic drugs,
showed improvement of SCORAD and itch score after treatment with 45 mg of ustekinumab injection
at 0, 4 weeks, and every 12 weeks afterwards [50]. A 16-year-old woman with over a 13-year history
of severe AD was also reported to show clearance of severe itch after one injection of ustekinumab
45 mg, although it had been resistant to phototherapy and systemic agents such as cyclosporine and
azathioprine [51]. Complete remission was achieved with ustekinumab at the fourth week and every
12 weeks afterwards. There are, however, other reports denying efficacy of ustekinumab [52–54].
A 21-year-old man with a 7-year history of severe psoriasis refractory to conventional systemic
treatments and childhood AD history was treated with ustekinumab [52]. The patient was without
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major respiratory symptoms and AD lesions within a period of five years before the date of starting
the treatment. After an eight-month interval, ustekinumab was restarted and severe AD appeared on
the neck and lower limbs. Peripheral blood eosinophilia and abnormal increase in serum IgE were also
noted. The eczema lasted during 12 months of follow up after the final dose of ustekinumab, supporting
the diagnosis of AD. Another group reported two psoriatic patients with high serum IgE levels, in
whom ustekinumab completely improved psoriasis but paradoxically provoked or exacerbated AD-like
symptoms [54]. Recently, the possibility of ustekinumab for AD was tested in clinical trials all over the
world [55,56]. In the randomized, placebo-controlled, phase II study in Japan, 79 patients aged between
20 and 65 years with severe or very severe AD entered a 12-week, double-blind treatment period during
which they received (1:1:1) ustekinumab 45 mg, 90 mg, or placebo subcutaneous injections at weeks 0
and 4, with follow-up until week 24 [55]. There was no significant improvement with ustekinumab
treatment in least-squares mean change from baseline Eczema Area and Severity Index score at week 12.
In another phase II, double-blind, placebo-controlled study, 33 patients with moderate-to-severe AD
were randomly assigned to either ustekinumab (n = 16) or placebo (n = 17), with subsequent crossover
at 16 weeks and last dose at 32 weeks [56]. Background therapy with mild topical steroids was allowed.
Study endpoints included clinical and biopsy-based measures of tissue structure and inflammation,
using protein and gene expression studies. The ustekinumab group achieved higher clinical responses
at 12, 16 (the primary endpoint), and 20 weeks compared to placebo, but the difference between groups
was not significant. The AD molecular profile/transcriptome showed early robust gene modulation,
with sustained further improvements until 32 weeks in the initial ustekinumab group. It is still possible
that a certain subset of patients with AD may particularly benefit from ustekinumab. However, it may
be safely said that ustekinumab is much more effective in psoriasis than in AD.
5.2. Other Biologics and AD
There have been anecdotal case reports showing exacerbation of AD-like dermatitis after treatment
with anti-IL17 antibody for psoriasis [57–59]. A 31-year-old man with severe psoriasis treated with
ixekizumab presented with a one-month history of pruritic lesions [57]. The patient had no personal
or family history of allergy, AD, or eczema. Treatment with ixekizumab, started 14 months before
the episode, achieved an almost complete response of his skin disease. The patient developed the
palms exudative erythematous plaques on the hands, the trunk, and the medial aspects of the limbs.
Histologically, epidermal spongiosis with vesicle formation with dermal edema and lymphocytic
perivascular infiltrate with some eosinophils were seen. Ixekizumab may suppress the expression of
keratinocyte-derived AMPs, increasing the risk of bacterial and fungal infection, which can lead to
the eczematous phenotype. Another group reported a 70-year-old woman with intractable psoriasis
vulgaris treated with 300 mg of secukinumab [58]. Six months after the first dose of secukinumab
was administered, psoriasis lesions were cleared. Blepharitis, cheilitis, and dermatitis around the
nose, however, developed four days after every secukinumab injection. A common skin-resident
fungus Malassezia may account for these skin lesions, which might be more adequately named
seborrheic dermatitis-like lesions instead of AD-like eczema. Fezakinumab, an anti-IL-22 antibody, has
been recently tried for treatment of AD. A randomized, double-blind, placebo-controlled trial with
intravenous fezakinumab monotherapy every 2 weeks for 10 weeks, with follow-up assessments until
20 weeks, was performed for adult patients with moderate-to-severe AD [60]. At 12 weeks, the mean
declines in SCORAD for the entire study population were not different between the fezakinumab arm
and the placebo arm. In the severe AD patient subset, SCORAD decline was significantly stronger in
the drug-treated patients than placebo-treated patients at 12 weeks. Common adverse events were
upper respiratory tract infections. Although this drug significantly downregulated gene expression of
multiple immune pathways including Th1, Th2, and Th17, it was clinically effective only in patients
with severe AD expressing a high level of IL-22 at the baseline [61]. Taken together, biologics targeting
Th17-related cytokines are not promising for the treatment of AD, except for anti-IL-22 antibody.
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6. Th2 Cytokines Are Key Players in AD
If antibodies against Th17 cytokines are not useful for AD, what is the best therapeutic target?
Th2-type immune responses induced by allergens such as mites and pollen are associated with
worsening of AD skin conditions. Th2 immune responses including increased IL-4/IL-13 expression
induce the production of IgE and TARC [62]. Serum TARC levels are useful as a marker of the disease
activity of AD, which are more sensitive than serum IgE levels, lactate dehydrogenaselevels, and
peripheral blood eosinophil counts [63]. Recently, thymic stromal lymphopoietin (TSLP) and periostin
have been discovered to be key cytokines in Th2-dominant microenvironment [64,65]. TSLP-activated
dendritic cells primed naïve T cells to produce IL-4, IL-5, IL-13, and TNF-α, while down-regulating
IL-10 and IFN-γ [64]. TSLP was highly expressed by epithelial cells, especially keratinocytes from AD
patients. Th2 cytokines IL-4 and IL-13 stimulated fibroblasts to produce periostin, which interacted
with a functional periostin receptor on keratinocytes [65]. It induces production of proinflammatory
cytokines, which consequently accelerated Th2-type immune responses. It was recently reported that
the TSLP receptor was expressed by some T cell subsets from patients with Th2-dominant diseases and
that TSLP directly enhanced IL-4/IL-13 production by T cells [66,67]. Taken together, these Th2-related
cytokines, IL-4/IL-13, TSLP, and periostin are driving factors of a vicious circle in AD and can be good
candidates for therapeutic targets. Indeed, dupilumab, a monoclonal antibody against the IL-4 receptor,
is very effective for severe AD [68].
7. The Importance of Th17 Cytokines in the Skin
Skin is a border between the outer world and the body. It is important to block invasion of foreign
materials such as poison and parasites. Trauma and loss of skin barrier function in diseased skin, such
as in AD and psoriasis, causes a high risk of the invasion. In both conditions, mechanical stimulation
can be the cause of onset. It is called the Kobner phenomenon in psoriasis. High proliferation of
epidermal cells and rapid keratinization are seen in both skin conditions. Expression of K6 and K16 is
increased and that of K1 and K10 is decreased [69,70]. Increased expression of cathepsin D, which
modulates expression of involucrin, loricrin, and filaggrin, has been reported [71].
Cytokine expression and cellular infiltration in psoriasis lesional skin is also very similar to
what is seen in cases of trauma. IL-17A, which is expressed both in wounded skin and psoriasis
skin, plays important roles in wound healing, tissue regeneration, and carcinogenesis [72]. The
cytokine mediates activation of EGFR, which is critical for the expansion and migration of Lrig1+
stem cells, promoting wound healing [73]. FGF2 or IL-17 deficiency resulted in impaired epithelial
proliferation, increased pro-inflammatory microbiota outgrowth, and consequently worse pathology
in a mouse colitis model [74]. The dysregulated microbiota in the model induced transforming growth
factor-β1 expression, which in turn induced FGF2 expression mainly in regulatory T cells. Thus,
microbiota-driven FGF2 and IL-17 cooperate to repair the damaged intestinal epithelium. Injury of
the mucosa causes fast expansion of Th17 cells and their induction [75]. Th17 cells produce various
cytokines, such as TNF-α, IL-17, and IL-22, which can promote cell survival and proliferation, and thus
tissue regeneration, in several organs including the skin [72]. IL-17 promoted macrophage infiltration
into wounded skin and scar formation through an indirect mechanism [76]. Depletion of macrophages
with clodronate liposomes abrogated the effect of IL-17. Levels of monocyte chemotactic protein
(MCP) 1, MCP2, and MCP3 were increased by IL-17 stimulation. IL-17 induced the infiltration of a
specific subtype of macrophages to aggravate fibrosis through an MCP-dependent mechanism. On
the other hand, Th17 cells are potentially pathogenic if not tightly controlled. Failure of these control
mechanisms can result in chronic inflammatory conditions such as psoriasis.
Infiltration of neutrophils and macrophages is commonly seen, and AMP expression is increased
both in wounded skin and in psoriasis skin. Vascular formation is prominent in the dermis. Taken
together, it may be safely said that psoriasis is a hyperreaction to traumatic stimuli with the background
of genetics, circumstances, and metabolic status (Figure 1).
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Figure 1. Proliferation of epidermal cells, AMP expression, vascular formation, and infiltration
of Th17, neutrophils, and macrophages, commonly seen in wounded skin and in psoriasis skin.
We sometimes experience fungal infection in patients treated with anit-IL7A or anti-IL17 receptor
A antibody. Considering that Th17 cytokines are expressed in various skin diseases with barrier
dysfunction and that antibodies against IL-12/IL-23p40 or IL-17A are not effective for AD, IL-17 and its
related cytokine expression can be regarded as a common defense mechanism in the skin. Relatively
low AMP expression leads to a higher risk of infection seen in AD and CTCL [77,78]. Targeting the
Th17 cytokine has been successful for psoriasis, but may not be always the case in other skin diseases.
8. Ideal Biologics for Psoriasis, AD, and CTCL
Clinical effects of biologics are remarkable, and many diseases including skin diseases are currently
treated with them. The cost of developing these agents, however, is huge and it is important to predict
which molecule is promising or not. First of all, the molecule should be highly expressed in lesional
skin compared to normal skin. Second, the expression of the target should be highest in the disease
among various skin diseases. It is important not to block bystander cytokines. IL-22 is highly expressed
in psoriasis, but its expression is lower in AD. IL-17 expression in AD is not as high as that in psoriasis.
Anti-IL-22 antibody is not effective in psoriasis, and anti-IL12/23p40 or anti-IL-17A antibodies are not
promising as treatment for AD. Only the anti-IL-22 antibody may be beneficial for a certain group
of AD patients (Table 1). Blocking cytokines uniquely expressed in the disease is important to stop
a vicious circle. Third, it would be safer to block interactions between cytokines and their receptors
than targeting surface molecules. Exclusion of a certain cell type by antibody-dependent cellular
cytotoxicity induced by biologics may cause unexpected severe effects. This kind of strategy targeting
surface molecules should be adopted for the treatment of malignancy [79,80].
Table 1. Antibodies against Th17 and Th2-related cytokines for atopic dermatitis (AD).
Cytokines Clinical Response References
IL-17A Worsening of dermatitis [57–59]
IL-12/23p40 No effect in clinical trial [55,56]
IL-22 Effective for some patients [60,61]
IL-4/13 Very effective [68]
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9. Conclusions
It is true that Th17 cells infiltrate into lesional skin of AD, and Th17-related cytokines are expressed
there. These cytokines have some roles in the inflammatory process of the disease. It is, however, also
true that IL-17 in AD is not as important as it is in psoriasis. Expression of IL-17 and other Th17-related
cytokines is widely seen in many skin diseases. My current assumption is that IL-17 expression in the
skin is a defense mechanism against foreign materials invading the body.
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Abbreviations
AD atopic dermatitis
CTCL cutaneous T-cell lymphoma





TARC thymus and activation-regulated chemokine
SCORAD SCORing AD
TWEAK TNF-like weak inducer of apoptosis
FGF fibroblast growth factor
MF mycosis fungoides
SS Sezary syndrome
TSLP thymic stromal lymphopoietin
MCP monocyte chemotactic protein
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Abstract: Atopic dermatitis (AD) is a chronic relapsing inflammatory skin disease, associated with
impaired skin barrier function and an atopic background. Various complicating factors, such as
irritants, aeroallergens, food, microbial organisms, contact allergens, sweat, and scratching can induce
the development of AD symptoms. Irritants, including soap/shampoo and clothes, can cause itching
and eczematous lesions. In addition, young children with AD tend to become sensitized to eggs,
milk, or peanuts, while older children and adults more often become sensitized to environmental
allergens, such as house dust mites (HDM), animal dander, or pollen. Serum-specific IgE levels and
skin prick test reactions to food tend to show high negative predictive values and low specificity
and positive predictive values for diagnosing food allergy. On the other hand, AD adult patients
tend to have severe skin symptoms and exhibit high HDM-specific IgE levels. Microbial organisms,
e.g., Staphylococcus aureus and Malassezia furfur, might contribute to the pathogenetic mechanisms of
AD. While sweat plays a major role in maintaining skin homeostasis, it can become an aggravating
factor in patients with AD. Furthermore, scratching often exacerbates eczematous lesions. Several
patient-specific complicating factors are seen in most cases. The identification and management of
complicating factors are important for controlling AD.
Keywords: atopic dermatitis; complicating factors; aggravating factors; triggering factors; irritants;
aeroallergens; food; microbial organisms; contact allergens; sweat; scratching
1. Introduction
Atopic dermatitis (AD) is a common, chronic relapsing inflammatory, multifactorial skin disease,
which is characterized by intense pruritus [1–3]. It affects up to 20% of children and 1–3% of adults [4].
The mechanisms responsible for the onset and aggravation of AD involve skin barrier dysfunction
and an atopic background. In patients with AD, the functions of the intercellular lipids of the stratum
corneum are impaired because of abnormal reductions in ceramide levels [5,6]. The horny cell
layer, which consists of keratin and filaggrin, is structurally tough. A loss-of-function mutation in
filaggrin and filaggrin deficiency related to inflammation have been observed in patients with AD [7,8].
A reduction in skin barrier function might allow stimuli and allergens to penetrate the skin more
easily. Interleukin (IL)-33, IL-25, and thymic stromal lymphopoietin (TSLP), which are released from
epidermal keratinocytes upon exposure to proteases, allergens, infections, or tissue damage, induce
type-2 immune reactions, leading to the induction of allergen-specific IgE antibody production.
With regard to the treatment of AD, topical corticosteroids and topical calcineurin inhibitors are
the main treatments for inflammation, whereas the topical application of moisturizers is used to treat
cutaneous barrier dysfunction [1,2,9]. Systemic treatment, e.g., oral cyclosporin and UV irradiation, is
an option for severe refractory cases [1,2,10]. Several patient-specific complicating factors are seen in
most cases. It is important to identify such factors and establish strategies to combat them. This review
concisely discusses the identification and management of the complicating factors of AD.
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2. Irritants
Skin barrier function is impaired in patients with AD. Therefore, there is a tendency for itching and
eczematous lesions to develop after AD patients come into contact with irritants (Table 1). To prevent
this, AD patients should cleanse their skin gently to get rid of any dirt. Regarding the pH of the corneal
layer, a subacidic state is considered healthy. A barrier-dependent increase in pH, e.g., due to the use
of neutral-to-alkaline soaps, leads to a reduction in skin barrier function [11]. Soaps and shampoos
that contain non-irritant ingredients can be used instead. Furthermore, residual soap and shampoo
can induce irritant dermatitis. Therefore, it is important to fully wash away soap/shampoo. Synthetic
fabrics and wool also tend to produce itching and irritate the skin [1,2,12–14]. A previous study has
shown that the irritative capacity of synthetic shirts is significantly higher in patients with AD, while
cotton shirts are tolerated best [12]. Thus, AD patients should select non-irritating clothes.
Table 1. Management of irritants.
Irritants Management References
Scrubbing the body Wash the body gently without using nylon towels [1,2]
Soap and shampoo Use non-irritating soap and shampoo [1,2,7]
Irritating clothes (e.g., wool-based clothes) Choose suitable non-irritating clothes (e.g., cotton clothes) [1,2,8,9]
Hair Tie hair up [1]
Saliva (during infancy) Wash away or wipe off [1]
3. Aeroallergens
3.1. House Dust Mites (HDM)
Aeroallergens, such as HDM, animal dander, and pollen, can lead to the exacerbation of AD. HDM
is one of the main allergens blamed for household dust allergies [15]. The most frequently responsible
mites are Dermatophagoides pteronyssinus (European house dust mite) and D. farinae (American house
dust mite), which produce various allergens in their bodies and feces. Currently, there are >30 defined
mite allergens (Table 2) [16]. It is considered that the most clinically important allergens are Der p 1
and Der p 2 from D. Pteronyssinus and Der f 1 and Der f 2 from D. farinae. The HDM allergen Der p 1 is
found at concentrations of 0.05–0.2 ng/m3 in inhalable indoor air [17].
Table 2. Representative allergens derived from D. Pteronyssinus and D. farina [16].
Allergen Biochemical Name Molecular Weight (kDa)
Der p 1/Der f 1 Cysteine protease 24 and 27
Der p 2/Der f 2 NPC2 family 15
Der p 3/Der f 3 Trypsin 31 and 29
Der p 4/Der f 4 Alpha-amylase 60 and 57.9
Der p 5/Der f 5 Unknown 14 and 15.5
Der p 6/Der f 6 Chymotrypsin 25
Der p 7/Der f 7 Bactericidal permeability-increasing like protein 26, 30, and 31
Der p 8/Der f 8 Glutathione S-transferase 27 and 32
Der p 9 Collagenolytic serine protease 29
Der p 10/Der f 10 Tropomyosin 36 and 37
Patients with AD frequently exhibit high total serum IgE levels and environmental allergen-specific
IgE. In addition, skin prick testing and atopic patch testing (APT) produce positive reactions
to these allergens in AD patients [18–20]. APT has been used to test for delayed-type
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hypersensitivity/eczematous reactions. Langerhans cells from AD patients have been shown to
have an increased capacity to present HDM allergen antigens to T cells via the high affinity receptor
for IgE (FcεRI) [21,22], suggesting that IgE-mediated delayed-type hypersensitivity reactions to HDM
allergens are associated with the pathogenesis of AD [23–25]. It has been reported that AD patients
that experience delayed-type hypersensitivity reactions tend to have severe skin symptoms and exhibit
high total IgE levels and HDM-specific IgE levels [17]. In addition, the positivity rate of patch tests
performed with HDM antigens was found to be significantly higher in patients that mainly had eczema
lesions on exposed areas, such as the hands, forearms, head, and neck, than in patients who also had
eczema lesions on non-exposed areas [26].
Even when a patient’s serum levels of HDM-specific IgE are increased and strong reactions to HDM
are seen during skin tests, whether exposure to HDM is considered to be an aggravating factor in that
case should be determined based on the patient’s episodes and symptoms [1]. For example, it should
be clarified whether the patient develops symptoms of immediate-type hypersensitivity reactions, i.e.,
wheals, conjunctival or rhinitis symptoms, or asthma attacks, when they are in environments containing
large amounts of HDM. Regarding the involvement of delayed-type hypersensitivity reactions in AD,
if a patient experiences periods in which their skin symptoms improve or worsen due to changes
in their living environment, e.g., due to moving house, travelling, or hospitalization, mites should
be considered to be a potential aggravating factor, and the anti-mite measures described below are
recommended [1].
Measures that can reduce HDM levels include the use of wood flooring, floor cleaning, vacuum
cleaning bedclothes, drying bedclothes in the sun, and the removal of sofas made of cloth and stuffed
toys [1,2,14]. While AD lesions were improved by HDM avoidance based on such measures [27,28],
reductions in HDM levels had no effect on skin symptoms [29]. The effects of HDM allergen
immunotherapy on AD lesions have been investigated by several groups [30,31]. Ridolo et al. reported
that the treatment of AD with the causative aeroallergen can be used as an add-on therapy in selected
patients who are non-responsive to conventional therapy [30].
3.2. Animal Dander
In most modern cities, cats and dogs are often present in houses, and some individuals become
allergic to proteins found in cat or dog dander. Cats are the second most common source of indoor
environmental allergens after HDM. Cat allergens are found at high levels (20 ng/m3) [32]. Ten
cat allergens have been identified. The major allergen responsible for symptoms is Fel d 1, a
secretoglobin [33].
Čelakovská et al. reported that persistent AD lesions occurred more often in patients that had
become sensitized to animal dander or HDM [34]. In addition, IgE sensitization to animal dander
or HDM might increase the risk of patients developing asthma or rhinitis [34]. In patients with cat
allergies, allergen immunotherapy has been performed with cat dander extract, which was effective at
treating cat allergy symptoms, especially respiratory symptoms [35]. In addition, weaker skin test
reactions to the cat extract were seen in the treated group than in the placebo group [35].
3.3. Pollen
Pollen grains, which represent a small fraction of the viable biological particles present in the
air, are important aeroallergens in the outdoor environment. Airborne pollen can exacerbate AD
lesions [36–38]. In a previous study, pronounced eczema flare-ups occurred on exposed rather than
covered areas of skin. Epicutaneous patch testing with pollen allergen extract induced eczematous
lesions in patients with AD [36,37]. In grass pollen-exposed subjects, the serum levels of chemokine
(C-C motif) ligand 17 (CCL17), CCL22, and IL-4 were significantly increased [30]. The preventative
measures that can be used against pollen allergies include brushing pollen off clothes, washing your
face when arriving home, wearing glasses and masks, and using air conditioning with pollen filters
(Table 3) [1,2,14].
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Table 3. Evaluation and management of aeroallergens.
Allergen Evaluation Management References
HDM
Serum-specific IgE antibody levels
Skin prick testing and patch testing
Evaluating changes in skin
symptoms caused by environmental




Cleaning bedclothes with a vacuum
cleaner, drying them in the sun, and
washing sheets
Encasing mattresses and bedding to




Serum-specific IgE antibody levels
Asking the patient about experiences
involving the worsening of skin




Prohibiting pets in the bedroom
[1,2,14]
Pollen
Serum-specific IgE antibody levels
Skin prick testing and patch testing
Asking the patient about experiences
involving the worsening of skin
symptoms on exposed areas during
a period of pollen scattering
Brushing pollen off clothes and washing
face when arriving home
Using protective glasses and masks
Using air conditioning with pollen filters
[1,2,14]
4. Food
4.1. Blood and Skin Tests
Food allergens might contribute to the pathogenetic mechanisms of AD, especially during infancy.
Serum-specific IgE levels and skin prick test results exhibit high negative predictive values (95%) and
low specificity and positive predictive values (40–60%) for diagnosing food hypersensitivity [14,39–41].
These findings indicate that negative test results are helpful for ruling out food allergies; however,
positive results only signify sensitization and need to be assessed in combination with clinical findings.
Therefore, the effects of food allergens should be evaluated based on the results of oral food challenges,
which should be performed after causative food elimination in addition to obtaining a detailed medical
history and evaluating the patient’s serum-specific IgE antibody levels and skin test results [1,2,14].
4.2. Allergen-Free Diet for Pregnant/Lactating Women
A systematic review of randomized controlled studies that examined the use of allergen-free
diets in pregnant/lactating women has been reported [42]. Dietary restrictions involving allergen
elimination in pregnant and lactating women did not prevent the onset of AD in infants. Therefore,
dietary restrictions in pregnant and lactating women are not needed to prevent the onset of AD in their
children [1].
4.3. Percutaneous Sensitization in Food Allergy
Lack et al. performed an epidemiological survey of peanut allergies and detected a significant
relationship between peanut allergies and the application of skincare preparations containing peanut
oil in children [43]. Based on these findings, the dual-allergen exposure hypothesis, which suggests
that oral allergen intake induces immunotolerance, whereas allergen exposure via skin with decreased
barrier function induces sensitization, has been proposed [44]. Since the proposal of this hypothesis,
allergies caused by percutaneous sensitization, in which sensitization is established by the skin




Staphylococcus aureus is frequently detected in AD lesions. Kong et al. reported that the frequency
of Staphylococcus sequences, particularly S. aureus, increased during disease flare-ups and was correlated
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with the severity of skin symptoms in children with AD [45]. In addition, Simpson et al. demonstrated
that AD patients that had been colonized with S. aureus had higher levels of type-2 biomarkers (higher
blood eosinophil counts and serum levels of total IgE, CCL17, and periostin) and exhibited greater
allergen sensitization than both non-colonized AD patients and non-atopic, non-colonized control
individuals [46]. Huang et al. investigated the effects of suppressing S. aureus growth with sodium
hypochlorite (bleach) baths [47]. The AD patients that received bleach baths displayed significantly
greater reductions in disease severity compared with the control subjects.
5.2. Malassezia Furfur
The characteristic distribution of AD skin lesions, which often affect the head and neck, implies
that an association exists between the exacerbation of AD and cutaneous microflora, such as Malassezia
furfur. Reactivity to Malassezia allergens, which was measured based on serum-specific IgE levels,
positive skin prick tests, and positive patch tests, was found to be increased in AD patients with head
and neck dermatitis [48–50]. It has been reported that oral [51] and topical antifungal drugs [52] are
effective against AD. Taken together with the findings of previous studies into S. aureus and M. furfur,
further research is required to fully understand the relationship between the microbial organisms
found on the skin and the clinical symptoms of AD [1].
6. Contact Allergens
6.1. Contact Allergy
Allergic contact dermatitis is a delayed-type hypersensitivity reaction to small environmental
chemicals, i.e., haptens or prehaptens, that come into contact with the skin. Contact allergies can
cause refractory eczematous lesions in patients with AD. In particular, if an AD patient displays an
atypical distribution of eczematous lesions, they might be suffering from a contact allergy. According
to previous studies, the frequency of contact allergies in AD patients ranges from 26% to 54% [53]. The
most common contact allergens are metals, topical drugs, fragrance, and rubber accelerators [53–55]
(Table 4). In a previous study, the avoidance of products containing allergenic substances markedly or
partially improved eczematous lesions in two-thirds of AD patients that exhibited positive patch test
reactions [53]. With regard to nickel and cosmetics, females become sensitized to them more often than
males, probably because of their greater use of cosmetics and jewelry, especially among females with
pierced ears.
6.2. Intrinsic AD
AD can be categorized into the IgE-high, extrinsic type and the IgE-normal, intrinsic type [56].
Extrinsic AD is the classical type, which displays a high prevalence and is associated with elevated
IgE levels and skin barrier dysfunction due to decreased filaggrin expression. On the other hand, the
incidence of intrinsic AD, which predominantly affects females, is approximately 20%. It has been
shown that the percentage of interferon-γ-producing Th1 cells in the peripheral blood is significantly
higher in intrinsic AD patients than in extrinsic AD patients [57]. Interestingly, patients with intrinsic
AD displayed a higher proportion of positive patch test reactions to metals than those with extrinsic
AD, and a metal-free diet partially ameliorated skin symptoms in patients with intrinsic AD, but not
those with extrinsic AD [53,58]. Furthermore, Yamaguchi et al. reported that the concentration of
nickel in sweat was higher in intrinsic AD patients than in extrinsic AD patients and was inversely
correlated with serum IgE levels [58]. These findings suggest that metal allergies are a potential cause
of intrinsic AD.
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Table 4. Representative contact allergens in AD patients.






Fragrances Fragrance mixMyroxylon pereirae (Balsam of Peru) [53–55]













Other chemicals Lanolin [53,55]
7. Sweating
7.1. The Function and Composition of Sweat
Sweat includes natural moisturizing factors (e.g., lactate, urea, and electrolytes, free amino acids,
and pyrrolidone carboxylic acid), antimicrobial peptides (e.g., dermcidin, β-defensins, and cathelicidin),
IgA, sodium bicarbonate, pyruvic acid, proteases, and protease inhibitors, and contributes to skin
homeostasis, including temperature regulation, skin moisture regulation, and immune functions [59,60].
Several previous studies have reported that the composition of sweat was changed in patients with
AD [61–63]. Liebke et al. found that the sodium concentration of sweat was significantly higher in
children with AD than in healthy children [61]. Moreover, Sugawara et al. showed that patients with
AD had significantly reduced levels of sodium, potassium, lactate, urea, and pyrrolidone carboxylic
acid in their sweat than healthy controls [62]. These findings suggest that impaired sweating might
reduce the levels of natural moisturizing factors and cause dry skin in patients with AD. It is considered
that patients with AD are at higher risk of skin infections and S. aureus colonization. Rieg et al.
found that patients with AD displayed significantly lower levels of dermcidin-derived antimicrobial
peptides in their sweat than healthy controls [63]. Furthermore, the skin bacterial count after physical
exercise-induced sweating was lower in the AD patients than in the healthy subjects [63]. Imayama et al.
demonstrated that AD patients had lower secretory IgA levels in their sweat than healthy controls [64].
These findings suggest that decreased levels of antimicrobial peptides and IgA in sweat might lead to
increased susceptibility to skin infections in patients with AD.
7.2. Decreased Sweating in AD Patients
Patients with AD often sweat significantly less than healthy individuals [65–67]. Several possible
mechanisms have been suggested to be responsible for the decreased sweating seen in patients with
AD [59,60]. It has previously been reported that horny plugs or mucopolysaccharides were seen in the
openings of the sweat ducts in conditions involving sweat retention [68,69]. With regard to sweat-gland
functions, acetylcholine-induced sweating responses were reduced in AD patients compared with
those seen in healthy controls, and histamine suppressed acetylcholine-induced sweating via H1
receptor-mediated signaling [70,71]. Furthermore, sweat leakage into the surrounding tissues was
observed in patients with AD. The leakage of sweat, as demonstrated by sweat gland-specific dermcidin
expression in the dermis around the sweat ducts and glands, was specifically detected in the skin of AD
102
Int. J. Mol. Sci. 2020, 21, 2671
patients [72]. Interestingly, the expression of claudin-3, which acts as a component of the tight junctions
between the luminal cells throughout the sweat gland, was significantly reduced in patients with AD
compared with that observed in healthy individuals [71]. The reductions in sweating induced via these
mechanisms might cause skin dryness and increase patients’ susceptibility to infection, resulting in the
exacerbation of the symptoms of AD.
7.3. Sweat Allergies
While sweat is important for maintaining homeostasis, it is likely to induce pruritus in patients
with AD. Hide et al. reported that intradermal tests with autologous sweat induced positive reactions
in many patients with AD [73]. In addition, it has been reported that patients with AD exhibited
positive reactions to sweat antigens in a histamine release test [73]. Interestingly, Hiragun et al. found
that MGL_1304, a fungal protein derived from Malassezia globosa, is a major antigen in human sweat,
and recombinant MGL_1304 induced histamine release from basophils in most AD patients [74].
Patients with AD might develop immediate-type hypersensitivity reactions to sweat antigens, leading
to exacerbated itching and irritation in response to sweating. These findings suggest that mast cells
might react to sweat that leaks from weak sweat ducts and glands in patients with AD.
7.4. Measures for Sweating
It is not necessary to avoid sweating because sweating is important for skin homeostasis. However,
leaving excess sweat on the skin surface can induce itching in patients with AD. Several studies
have shown that taking a shower after sweating is effective at relieving symptoms [75,76]. Therefore,
if excess sweat remains on the skin surface, it can be washed away or wiped off [1].
8. Scratching Behavior
8.1. Scratching-Induced Aggravation of AD Lesions
Patients with AD often scratch their skin, resulting in further skin damage, which can lead to
the exacerbation of eczematous lesions. It has been hypothesized that IL-33, IL-25, and TSLP, which
are released from epidermal keratinocytes, act as endogenous “danger signals” or “alarmins” that
alert the immune system to tissue damage [77]. It has been shown that the serum levels of IL-33 were
higher in AD patients than in healthy individuals [78]. In addition, the patients’ serum IL-33 levels
were correlated with their excoriation scores [78]. These findings suggest that tissue injuries caused by
scratching of the skin might result in increased release of keratinocyte-derived cytokines, including
IL-33, from damaged cells in patients with AD. Moreover, several previous studies have suggested
that endogenous molecules that are released from tissues or cells by skin damage, including scratching,
stimulate immune reactions in allergic dermatitis [79–81]. Therefore, scratching contributes to the
exacerbation of eczematous lesions in AD.
8.2. Factors Influencing Scratching Behavior
Scratching can be caused by various itching-related and non-itching-related factors (Table 5).
Itching signals are transmitted from the periphery to the brain via the dorsal horn by primary sensory
neurons and spinothalamic tract neurons, and itching is induced by various mediators [77,82,83].
At the periphery, histamine acts as a pruritogen. Several type-2 cytokines, such as IL-4, IL-13, and
IL-31, also directly activate sensory neurons [77,84–87]. Targeting the IL-31 pathway has been shown
to be effective in patients with AD [84]. IL-4 and IL-13 are cytokines that are central to the pathogenesis
of atopic disease and are primarily produced by Th2 cells [77]. Dupilumab is a human monoclonal
antibody that is directed against the α-subunit of the IL-4 receptor. It blocks signaling from both IL-4
and IL-13 [85]. The administration of dupilumab resulted in significant improvements in inflammation
and pruritus in AD patients [86]. Moreover, the epithelium-derived cytokine TSLP, which is deeply
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involved in the development of inflammatory responses in AD [77], acts directly on a subset of primary
sensory neurons and induces itching [87].
Table 5. Major factors influencing scratching in AD.
Factors Details of Contents References
Inflammatory mediators
Amines (histamine, serotonin) [13,88]
Cytokines (IL-4, IL-13, IL-31, IL-33, and TSLP) [77,82,83]
Proteases (kallikreins, tryptase,
endogenous/exogenous proteases) [89,90]
Neuropeptides (substance P) [91,92]
Neurotrophic factors (nerve growth factor,
artemin) [82,93]
Neurotransmitters (acetylcholine) [94]
Environmental factors Temperature, humidity, dry environments [83]
Psychological stress [1,83]
Habitual scratching [1]
In addition to these mediators, proteases (e.g., kallikreins, tryptase, endogenous/exogenous
proteases) [89,90], neuropeptides (e.g., substance P) [91,92], and neurotrophic factors (nerve growth
factor (NGF), artemin) [82,83,93] are considered to contribute to pruritus. Moreover, it has been
reported that abnormal elongation of the sensory nerves into the epidermis occurs in the skin of AD
patients [82]. In a mouse model of dry skin-induced itching, the expression of NGF was found to be
elevated in the skin, and the number of intradermal nerve fibers increased [95]. On the other hand,
semaphorins are a class of secreted membrane proteins, which function as axonal growth cone guidance
molecules [82]. Semaphorin 3A is the first member of the semaphorin family that has been shown
to cause growth cone collapse in neurons [96]. Semaphorin 3A regulates NGF-induced sprouting of
sensory afferents in the spinal cord [97]. The abnormal elongation of the sensory nerves seen in AD
is considered to be caused by an imbalance in the levels of nerve elongation factors, such as NGF,
and nerve-repulsion factors, such as semaphorin 3A [82]. Such abnormal extension of the sensory
nerves into the epidermis might lead to mechanical itching-induced dysesthesia, in which abnormal
sensory states are induced by light cutaneous stimuli (alloknesis) [77,83]. In addition, patients with
AD can experience strong itching in response to normal itch-evoking stimuli (hyperkinesis) [77,83].
Non-itching sensations, such as heat and pain, can also be experienced as itching by patients with
AD [83].
The micro-opioid (beta-endorphin/micro-opioid receptor) and kappa-opioid (dynorphin A
(DynA)/kappa-opioid receptor) systems are involved in the regulation of pruritus in the central
nervous system. It has been reported that the micro-opioid and kappa-opioid systems are present in
the human epidermis [98], suggesting that these systems might be responsible for peripheral pruritus.
Kumagai et al. suggested that the micro-opioid system is itch-inducible, while the kappa-opioid
system is itch-suppressive [99]. Interestingly, Tominaga et al. reported that the kappa-opioid system
was downregulated in the epidermises of AD patients [100], indicating that patients with AD might
experience itching due to the downregulation of the itch-suppressive system.
Patients with AD often scratch their skin in response to factors that are not related to itching.
With regard to psychological aspects, it is known that the itching symptoms of AD patients can be
worsened by stress and can be improved by stress management and behavioral modification [1].
Moreover, a vicious cycle of itching, scratching, and damaged skin might lead to scratching mainly out
of habit instead of due to itching (habitual scratching). Thus, it is important to consider the possible
involvement of such non-itching-related factors in addition to suppressing inflammation and pruritus
in order to control the scratching behavior of AD patients.
104
Int. J. Mol. Sci. 2020, 21, 2671
9. Other Factors
9.1. Psychological Stressors
Emotional stress can increase not only itching but also the inflammation via the release of
inflammatory mediators in AD patients [101,102]. The patients with AD had higher anxiety levels than
healthy individuals, and those with a stronger trait anxiety than state anxiety showed elevated serum
IgE levels and Th2 shifting [101]. Moreover, psychological variables affect serum levels of interferon-γ
and IL-4 more in the patients with AD than healthy individuals [102]. These findings suggest that
psychological stressors might affect the immunological reactions in the patients with AD.
9.2. Circadian Rhythms
Clinical symptoms in patients with allergic diseases including AD often depend on diurnal
variations [103]. An intrinsic daily physiological rhythm called circadian rhythm is thought to affect
the immune system. Several experimental studies have demonstrated that mutation in the circadian
clock genes greatly affects immune responses [104–106]. Immune tolerance development is closely
associated with the onset of immunological disorders. It has been shown that exposure to constant
light impairs circadian rhythms, leading to the disturbance of tolerance induction [107]. Therefore,
constant light environments such as lighting conditions at home in our night-active modern society
may affect the development of AD.
10. Conclusions
Various aggravating factors, including both allergic and non-allergic factors, have been suggested
to influence the course of AD. To identify factors that are specific to individual patients, it is important
to consider whether the degree of eczematous lesions is affected by environmental changes, oral food
challenges, or the avoidance of contact with suspected causative substances. In addition, we need to
establish treatment strategies that take patients’ lifestyles into account. Furthermore, it is not necessary
for AD patients to avoid sweating because it is important for skin homeostasis. However, leaving
excess sweat on the skin can induce skin symptoms; therefore, sweat should be washed away or wiped
off. Moreover, scratching leads to further skin damage, resulting in the exacerbation of eczematous
lesions. It is important to consider clinical factors that might influencing scratching behavior (e.g.,
inflammation, stress, and habitual scratching). Future studies will contribute to the elucidation of the
pathogenetic mechanism of AD, leading to improvements in the management of complicating factors.
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Abstract: The aryl hydrocarbon receptor (AHR)/AHR-nuclear translocator (ARNT) system is
a sensitive sensor for small molecular, xenobiotic chemicals of exogenous and endogenous
origin, including dioxins, phytochemicals, microbial bioproducts, and tryptophan photoproducts.
AHR/ARNT are abundantly expressed in the skin. Once activated, the AHR/ARNT axis strengthens
skin barrier functions and accelerates epidermal terminal differentiation by upregulating filaggrin
expression. In addition, AHR activation induces oxidative stress. However, some AHR
ligands simultaneously activate the nuclear factor-erythroid 2-related factor-2 (NRF2) transcription
factor, which is a master switch of antioxidative enzymes that neutralizes oxidative stress.
The immunoregulatory system governing T-helper 17/22 (Th17/22) and T regulatory cells (Treg) is
also regulated by the AHR system. Notably, AHR agonists, such as tapinarof, are currently used as
therapeutic agents in psoriasis and atopic dermatitis. In this review, we summarize recent topics on
AHR related to atopic dermatitis and psoriasis.
Keywords: aryl hydrocarbon receptor (AHR); aryl hydrocarbon receptor-nuclear translocator (ARNT);
nuclear factor-erythroid 2-related factor-2 (NRF2); atopic dermatitis; psoriasis; tapinarof; filaggrin;
skin barrier; Th17; Th22; Treg; reactive oxygen species; antioxidants
1. Introduction
The skin is the outermost surface of the body and is vulnerable to a myriad of external
chemicals and internal substances. To maintain homeostasis, skin cells, including keratinocytes,
sebocytes, fibroblasts, dendritic cells, and other immune cells, express several chemical sensors,
such as aryl hydrocarbon receptor (AHR), pregnane X receptor, constitutive androstane receptor,
and peroxisome proliferator-activated receptors [1–4]. Among these chemical receptors, AHR has
gained special attention because it plays a crucial role in photoaging, epidermal differentiation,
and immunomodulation [2,3,5–7].
AHR, also called dioxin receptor, binds to environmental polyaromatic hydrocarbons and dioxins
with high affinity and induces oxidative stress by generating abundant reactive oxygen species
(ROS) [5–7]. Additionally, AHR is a promiscuous receptor and is activated by a plethora of exogenous
and endogenous ligands, such as photo-induced chromophores, phytochemicals, and microbial
bioproducts [8–12]. Many AHR ligands exert antioxidative activity by activating antioxidative
transcription factor nuclear factor-erythroid 2-related factor-2 (NRF2) [10,13]. Medicinal coal tar and
Int. J. Mol. Sci. 2019, 20, 5424; doi:10.3390/ijms20215424 www.mdpi.com/journal/ijms113
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soybean tar Glyteer activate both AHR and NRF2 and have been used to treat inflammatory skin
diseases, such as atopic dermatitis (AD) and psoriasis [14,15].
AD and psoriasis are common inflammatory skin diseases. An excellent therapeutic response to
biologics indicates a pivotal pathogenic role of interleukin (IL)-4/IL-13 signaling in AD [16,17] and
the tumor necrosis factor (TNF)-α/IL-23/IL-17A axis in psoriasis [18,19]. Although distinct signaling
pathways operate in developing full-blown AD and psoriasis, 81% of dysregulated genes in AD are
shared with those in psoriasis in skin lesions [20]. Notably, recent phase II, randomized dose-finding
studies have demonstrated that topical application of the natural AHR agonist tapinarof is efficacious
and well tolerated in patients with AD and psoriasis [21,22].
The purpose of this article is to summarize the diverse action of AHR signaling in balancing
skin homeostasis and to elucidate the fundamental mechanisms of therapeutic AHR potentials in the
treatment of AD and psoriasis.
2. AHR Signaling and Modulation of Oxidative and Antioxidative Balance
AHR is a ligand-activated transcription factor [7]. In the absence of ligands, AHR resides in
the cytoplasm where it forms a protein complex with heat shock protein 90 (HSP90), hepatitis B
virus X-associated protein 2 (XAP-2), and p23 [23,24]. After ligand binding, AHR dissociates
from the cytoplasmic complex and a nuclear translocation site of AHR is exposed. Then, AHR is
translocated into the nucleus where AHR dimerizes with AHR-nuclear translocator (ARNT), binds DNA
responsive elements called xenobiotic responsive elements (XREs), and upregulates the transcription
of target genes, such as phase I metabolizing enzyme cytochrome P450 (CYP) members (i.e., CYP1A1,
CYP1A2, and CYP1B1) [7,25–29].
Hazardous dioxins such as 2,3,7,8,-tetrachlorodibenzo-p-dioxin (TCDD) activate AHR and
upregulate CYP1A1, CYP1A2, and CYP1B1 expression [5,30,31]. Human keratinocytes abundantly
express CYP1A1 and to a lesser extent CYP1B1 but not CYP1A2 [32]. CYP1A1 attempts to metabolize
TCDD but the continuous efforts of CYP1A1 are unsuccessful because TCDD is structurally stable [33].
The metabolizing process by CYP1A1 generates excessive amounts of ROS and induces oxidative
damage in the cell [5,30,31] (Figure 1). To demonstrate these findings, TCDD-induced ROS production
was inhibited in AHR-silenced or CYP1A1-silenced cells [30]. As CYP1B1 silencing did not affect
TCDD-induced ROS generation, the AHR-CYP1A1 axis is likely to be crucial for generating cellular
oxidative stress by hazardous dioxins [30]. A chemical carcinogen β-naphthoflavone also activates
CYP1A1 and CYP1A2 via AHR activation in mice [34]. β-Naphthoflavone induces mitochondrial
ROS generation. However, this activation is attenuated by an AHR inhibitor or CYP1A1/1A2
silencing [34]. AHR-CYP1A1-mediated oxidative stress is responsible at least in part for the production
of proinflammatory cytokines, such as interleukin (IL)-1, IL-6, and IL-8 [35,36].
To survive during oxidative stress, antioxidative machinery is simultaneously activated after
AHR activation in the cells. Ligation of AHR also activates antioxidative transcription factor NRF2
and upregulates the expression of phase II antioxidative enzymes (i.e., glutathione S-transferases,
heme oxygenase 1 (HMOX1), NAD(P)H dehydrogenase, quinone 1 (NQO1), glutathione S-transferases,
and uridine 5’-diphospho-glucuronosyltransferases [13,14,25,26,37–40]. In contrast to proinflammatory
consequences after AHR-CYP1A1-ROS induction, the AHR-NRF2 axis is likely to be anti-inflammatory
and reduces the production of proinflammatory cytokines [13,39,41]. Many salubrious antioxidative
phytochemical extracts (i.e., artichoke (Cynara scolymus) in Mediterranean regions, Opuntia ficus-indica
in Latin America, and Houttuynia cordata in Asia) activate the AHR-NRF2 system and upregulate the
expression of antioxidative enzymes [13,37,38]. Dioxins activate the AHR-NRF2 battery [40,42,43],
however, their powerful AHR-CYP1A1 activation may induce far more oxidative stress that cannot be
extinguished by the AHR-NRF2 antioxidative system. Alternatively, salubrious phytochemical AHR
ligands stimulate the AHR-NRF2 axis more strongly than the AHR-CYP1A1-ROS pathway and exert
antioxidative action [10].
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Figure 1. Aryl hydrocarbon receptor (AHR) signal and action points of tapinarof (red words and
arrows). AHR is a promiscuous chemical sensor that is activated by various oxidative and antioxidative
ligands. Once activated, cytoplasmic AHR translocates into the nucleus where it heterodimerizes with
an AHR-nuclear translocator (ARNT) and then induces the transcription of AHR-responsive genes such
as cytochrome P450 1A1 (CYP1A1). CYP1A1 degrades AHR ligands. Some ligands such as dioxins
are chemically stable and long-lived. Therefore, CYP1A1 generates high amounts of reactive oxygen
species (ROS) after sustained efforts to degrade them. Some antioxidative AHR ligands activate nuclear
factor-erythroid 2-related factor-2 (NRF2) transcription factor, which upregulates gene expression
of various antioxidative enzymes, such as heme oxygenase 1 (HMOX1), NAD(P)H dehydrogenase,
and quinone 1 (NQO1), and these antioxidative enzymes neutralize ROS. AHR/ARNT signaling also
activates OVO-like 1 (OVOL1) transcription factor and upregulates the expression of filaggrin (FLG) and
loricrin (LOR). AHR upregulates the expression of involucrin (IVL) in an OVOL1-independent manner.
Therefore, AHR/ARNT signaling accelerates epidermal terminal differentiation and enhances the repair
of barrier disruption. Interleukin (IL)-4 and IL-13 activate signal transducer and activator of transcription
6 (STAT6) and inhibit the OVOL1/FLG, OVOL1/LOR, and AHR/IVL axes. However, suitable AHR
activation can inhibit the IL-4/IL-13-mediated STAT6 activation and restore the expression of FLG,
LOR, and IVL. Regarding immune response, AHR signaling affects T-helper (Th17) differentiation and
is essential for IL-22 production. AHR ligation (especially by high concentrations of ligands) induces
the differentiation of regulatory cell populations, Treg and Tr1 cells. Tapinarof is an antioxidative AHR
ligand and upregulates CYP1A1 expression. Topical tapinarof is efficacious in psoriasis and atopic
dermatitis. Current studies demonstrate that tapinarof activates NRF2/antioxidative signaling and
reduces oxidative stress. Tapinarof also upregulates FLG and IVL expression. Tapinarof downregulates
IL-17A production and increases IL-22 production.
3. AHR and Epidermal Terminal Differentiation
The mammalian epidermis protects the body against injuries from external and environmental
factors by providing a barrier-forming cornified layer. Epidermal terminal differentiation or
cornified envelope maturation is accomplished by sequential cross-linking of ceramides and various
terminal differentiation proteins, such as involucrin (IVL), loricrin (LOR), and filaggrin (FLG) by
transglutaminase-1; the majority of these skin barrier-forming proteins map to chromosome 1q21 [44,45].
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Notably, activation of the AHR-ARNT axis accelerates epidermal terminal differentiation by
coordinately upregulating the production of a series of skin barrier-forming proteins in vivo [46] and
in vitro [3,44,47,48]. In parallel, both Ahr-deficient and Ahr-transgenic mice reveal an abnormality
in keratinization [49,50]. Severe abnormalities in keratinization are also observed in Arnt-deficient
mice [51,52].
Both oxidative and antioxidative ligands for AHR can accelerate epidermal terminal
differentiation [3,12,44,47,48]. Slow-metabolizing dioxins induce strong and sustained AHR activation,
which results in exaggerated keratinization of keratinocytes and sebocytes and the development of
chloracne [2,53]. In contrast, mild and transient AHR activation by antioxidative phytochemical or
endogenous AHR ligands are effective in maintaining healthy barrier-intact skin [3,10,54].
Sunlight, especially UVB, generates tryptophan photoderivatives such as
formylindolo[3,2-b]carbazole (FICZ), which is a high-affinity ligand for AHR that upregulates CYP1A1
expression [8,55–57]. Compared with slow-metabolizing TCDD, FICZ is rapidly metabolized by
CYP1A1 [8,55,56]. Similar to other AHR ligands, FICZ upregulates filaggrin via AHR signaling [57–59].
Although an erythematogenic dose of UVB is harmful through a variety of mechanisms, exposure to
a suberythematous dose of UVB prior to tape-stripping results in significantly accelerated barrier
recovery rates [60]. Physiological low-dose UVB exposure may be beneficial for skin barrier protection
by FICZ-AHR/ARNT-mediated upregulation of filaggrin and other barrier-related proteins [57–59]
(Figure 1). In this context, topical application of FICZ significantly attenuated transepidermal water
loss and dermatitis score in a murine mite-induced dermatitis model [58].
Mechanisms regarding how AHR signaling accelerates keratinocyte differentiation are not fully
understood. Kennedy et al. points to an essential role of ROS production in this regulation [47]. We have
demonstrated that AHR signaling upregulates the expression of OVO-like 1 (OVOL1) transcription
factor and activates its cytoplasmic to nuclear translocation [3,59,61,62]. Both filaggrin and loricrin are
under the control of the AHR-OVOL1 pathway, whereas AHR-mediated involucrin upregulation is
independent of OVOL1 [63].
IL-4/IL-13 signaling downregulates the expression of filaggrin, loricrin, and involucrin via signal
transducer and activator of transcription 6 (STAT6) activation, impairing the epidermal terminal
differentiation and barrier dysfunction [14,15,37,44,61,64,65]. IL-4/IL-13 signaling is likely to impair
the cytoplasmic to nuclear translocation of OVOL1, which interferes with the AHR-OVOL1-filaggrin
axis [59,61]. Notably, IL-4/IL-13 signaling reciprocally enhances the protein expression of AHR and
to a lesser extent ARNT in keratinocytes (Figure 2). Similar results were observed in murine B
cells [66]. The implication of IL-4/IL-13-mediated AHR upregulation remains elusive. In addition,
IL-4/IL-13-mediated STAT6 activation stimulates keratinocyte to produce periostin, which induces
IL-24 production in keratinocytes [67]. IL-24 reduces the filaggrin expression via STAT3 activation [67].
AHR ligands, such as coal tar, Glyteer and FICZ, activate the AHR/ARNT pathway, block the
IL-4/IL-13-mediated STAT6 activation, induce the entry of OVOL1 into the nuclei, and restore barrier
dysfunction [15,59,61,68].
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Figure 2. Human epidermal keratinocytes are stimulated with 10 ng/mL of IL-4 augments the protein
expression of aryl hydrocarbon receptor (AHR) and AHR-nuclear translocator (ARNT) compared with
untreated control by Western blot analysis.
4. AHR and Immune Modulation
As a crucial chemosensor, AHR activity modulates immune function. AHR and its immunological
significance are best characterized in intestinal immunology [28,29,69,70]. Ahr-deficient mice have an
inherent weak gut barrier [71–73]. In this context, genome-wide association studies have identified
AHR as a susceptibility locus in inflammatory bowel diseases [74]. Indeed, the expression of AHR is
reduced in the lesioned intestine in inflammatory bowel diseases [75]. This finding may be strongly
related to the fact that the intestinal tract is a rich source of AHR ligands derived from dietary materials
and microbial bioproducts [69,76].
Early research on AHR-mediated immune modulation was based on toxicological approaches
using dioxins [77]. Dioxin-exposed rodents exhibit waste syndrome, dose-dependent
thymic involution, depletion of other lymphoid organs, and reduced circulating lymphocyte
counts [77]. Antibody production by B cells is also inhibited by toxic doses of dioxins [77].
However, extensive attention by immunologists has recently been focused on the physiological function
of AHR in immune regulation [29,69,70,76].
Ligation of AHR by TCDD and endogenous or natural compounds preferentially affects
differentiation and propagation of T-helper 17 (Th17) and T regulatory (Treg) cells [29,69,70].
Tryptophan is an essential amino acid and is thought to produce various candidates for endogenous
AHR ligands by different metabolic processes. These metabolic pathways include kynurenine
production by indoleamine 2,3-dioxygenase and tryptophan 2,3-dioxygenase, FICZ by UVB exposure,
and indole derivatives by bacterial degradation [29,69,70]. Dietary materials such as Brasicca contain
glucosinolate glucobrassicin, which is metabolized to produce indolo-[3,2-b]-carbazole (ICZ) [29].
The major metabolic pathway of tryptophan is the kynurenine pathway, however, the binding capacity
of kynurenine to AHR is very low compared to FICZ and ICZ [29].
In murine CD4+ cells, AHR is highly expressed in Th17 cells, not detectable in Th1 and Th2 cells,
and marginally expressed in Treg cells [78]. In addition, Lin-Sca+ and Sca− progenitor cells in bone
marrow, double negative (CD4− and CD8−) cells in the thymus, innate lymphoid cell type 3 (ILC3) cells,
dendritic cells, γδ T cells, and Langerhans cells express high levels of AHR [28,29]. In Ahr-deficient
mice, T-bet and Ifng expression in Th1, Gata3 and Il4 expression in Th2, and RORγt (Rorc) and Il17a/Il17f
expression in Th17 cells are not significantly affected. However, Il22 expression in Th17 cells is almost
completely abrogated in Ahr-deficient mice [78]. FICZ upregulates Il17a, Il17f, and Il22 expression
in Th17 cells. The expression of AHR is detected in human Th17 cells at higher levels than in Th1
cells and FICZ upregulates the IL17A, IL17F, and IL22 expression in Th17 cells [78]. Flowcytometric
analysis also revealed that FICZ enhances Th17 differentiation and IL-22 production [69]. In a murine
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Th17-mediated experimental autoimmune encephalomyelitis model, injection of FICZ accelerated
disease onset whereas it was delayed in Ahr-deficient mice. Treg cells were unaffected in this model [78].
In contrast, TCDD treatment increased the number of Treg cells, which exhibited an immunosuppressive
function in a murine graft-versus-host disease model [79]. The TCDD-induced increase in Treg number
was abrogated in Ahr-deficient mice [79]. These studies suggest that prolonged activation of AHR by
TCDD may potentiate Treg cell deviation, but transient AHR activation may shift the immune response
toward Th17 and more strongly to Th22 cell differentiation (Figure 1).
Th17 and ILC3 cells express high levels of AHR, IL-17, and IL-22 and are crucial for intestinal
protective immunity against commensal and pathogenic microbiota [80]. In contrast to the
abovementioned experimental autoimmune encephalomyelitis model in which AHR ligation enhances
IL-17 and IL-22 production, Ahr-deficiency augments Th17 cell differentiation in the intestinal tract
where large amounts of dietary- and microbiota-derived AHR ligands are present [80]. In Ahr-deficient
mice, the amount of microbiota is significantly increased, which is likely to promote Th17 differentiation.
Alternatively, Ahr-deficient mice exhibit IL-22 reduction, which is consistently found in an experimental
autoimmune encephalomyelitis model. Notably, IL-22 supplementation to Ahr-deficient mice
normalizes the expansion of the microbiota and reduces Th17 deviation, demonstrating that IL-22 is
protective against intestinal infection [80]. In addition, ILC3s produce larger amounts of IL-22 than
Th17 cells after AHR ligation [80].
In the gut, heterogenous cell populations exist in Foxp3+ Treg cells depending on the expression
of neuropilin (Nrp1) and RORγt. Nrp1 is a surface marker to distinguish thymus-derived Tregs (Nrp1
+ tTregs) versus peripherally derived Tregs (Nrp1- pTregs) [70]. In the small and large intestines,
all Nrp1 + RORγt −, Nrp1− RORγt+ and Nrp1− RORγt− Treg subpopulations express high levels of
AHR [70]. Ahr deficiency in these Treg cells induces a significant decrease of Nrp1− RORγt+ and
Nrp1- RORγt−, but not Nrp1+ RORγt−, Treg subpopulations in the intestine, whereas those in the
spleen and mesenteric lymph nodes are not affected [70]. In contrast, AHR activation by FICZ injection
preferentially enhances the Nrp1− RORγt− Treg subpopulation. High-throughput RNA sequencing
revealed that Ccr6, Gpr15, Itgae, Rgs9, and Gzma genes important for Treg homing and functions in
the gut are downregulated in Ahr-deficient Tregs while Th1-associated genes Ifng, Ccl5, and Tbx21 are
upregulated. Moreover, these AHR-expressing Treg cells inhibit T cell-induced wasting disease and
colitis [70].
As described above, AHR ligation induces the CYP1A1 production, which efficiently degrades
AHR ligands [28,29]. Therefore, constitutive overexpression of CYP1A1 in mice depletes the reservoir
of natural AHR ligands, generating a quasi Ahr-deficient state [76]. Th17 cells from Ahr-deficient
mice do not produce IL-22. In parallel, Cyp1a1-overexpressed Th17 cells show a reduced IL-22
production [76]. Both Ahr-deficient and Cyp1a1-overexpressed mice exhibit loss of ILC3 in the
small and large intestines. IL-22 derived from ILC3 and Th17 cells is essential in the defense
against Citrobacter rodentium. Thus, C. rodentium-induced colitis becomes life-threatening both in
Ahr-deficient and Cyp1a1-overexpressed mice [76]. Although AHR ligation upregulates CYP1A1,
CYP1B1, and CYP1A2 expression, CYP1B1 and CYP1A2 are not crucial for degrading AHR ligands [76].
FICZ-mediated Th17 differentiation and IL-22 production is achieved by extremely low concentrations
of FICZ in Cyp1a1-deficient CD4+ cells [69]. Furthermore, FICZ promotes IL-17A + IL-22+, but not
IL-17 + IL-22−, cell differentiation [69].
Although AHR ligation tends to affect Th17 and Treg cell differentiation, outcomes are
inconsistent in different experimental systems. The dose and the duration of AHR activation
by high-affinity AHR ligands are likely the primary factors that explain the fate of T cell
differentiation [81]. To this end, Ehrlich et al. examined the effects of low and high doses of
four high-affinity AHR ligands (TCDD, FICZ, 2-(1H-Indol-3-ylcarbonyl)-4-thiazolecarboxylic acid
(ITE), and 11-Chloro-7H-benzo[de]benzo[4,5]imidazo[2,1-a]isoquinolin-7-one (11-Cl-BBQ)) on CD4+
T cell differentiation using a parent-into-F1 alloresponse mouse model. Intraperitoneal injection of
high doses of all agents induced the production of IL-10 producing, Foxp3+ type 1 regulatory T
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cells (Tr1 cells) on day 2, and increased Foxp3+ Tregs on day 10 in conjunction with suppression
of the alloresponse. Alternatively, low doses of the ligands, even when given daily, did not induce
Tregs nor alter the alloresponse, but instead increased the percentage of CD4+ cells that produce
IL-17 [81]. In summary, accumulating evidence suggests that AHR ligation stimulates Th17 cells to
differentiate into Th17/22 cells. AHR ligands may also enhance the regulatory cell population especially
in high doses.
5. AHR and Atopic Dermatitis
AD is a common and heterogenous eczematous skin disorder characterized by Th2-deviated
skin inflammation, barrier disruption, and chronic pruritus [17,82,83]. Frequent relapse with intense
pruritus deteriorates quality of life and decreases treatment satisfaction of the afflicted patients [84–88].
The lifetime incidence of AD is as high as 20% in the general population [89]. Skin barrier dysfunction
is associated with the reduced production of terminal differentiation molecules such as filaggrin [15,51].
Abnormal skin barrier integrity also causes an increased colonization of microbes such as Staphylococcus
aureus, which further exacerbate Th2-deviated skin inflammation [90,91]. In addition, some autoimmune
diseases are comorbid with AD [92].
Investigation on AHR gene polymorphism reveals that AHR rs10249788 and rs2066853
polymorphisms are found in patients with AD, psoriasis, and healthy controls, but no significant
differences were detected in genotype or allele frequencies between the three groups [93].
However, the AHR rs2066853 (AG +AA) or rs10249788 (CT + TT) genotypes are a risk factor for severe
dry skin phenotype and the combined rs10249788 (CT + TT) and rs2066853 (AG + AA) genotypes
lead to a higher risk for severe dry skin in Chinese patients with AD [93]. rs10249788 exists in the
AHR promoter region where nuclear factor 1C (NF1C) binds and suppresses the transcription and
protein expression of AHR [94]. Notably, NF1C prefers to associate with the C allele compared to the T
allele at rs10249788. Thus, subjects with the rs10249788 (CC) allele express less AHR than those with
the rs10249788 (TT) allele [94]. In fact, AHR mRNA levels for the TT genotype are 1.7-fold higher
than those for the CC genotype [95]. No significant differences were obtained in AHR production
between the CC and CT genotypes [95]. In parallel with increased levels of AHR, cells with the TT
genotype express significantly higher levels of CYP1A1, IL-24, and IL-1β [95]. It is intriguing that IL-24
downregulates the filaggrin expression via STAT3 activation [67].
Immunohistological and real time PCR studies for AHR have been reported in AD [96,97].
Hong et al. showed an increased expression of both AHR and ARNT without CYP1A1 induction in the
lesioned skin of AD compared with normal control skin [96]. Alternatively, Kim et al. demonstrated
an increased expression of ARNT and CYP1A1 but not AHR in the lesional skin of AD [97]. As the
Th2-deviated milieu potently reduces filaggrin and other barrier-related molecules, the upregulation of
AHR/ARNT may be compensatory to attenuate the Th2-mediated filaggrin reduction. A recent study
by Yu et al. demonstrated the possibility that the Th2-deviated milieu decreases the production of
endogenous AHR ligand such as indole-3-aldehyde by commensal skin microbiota [98]. These findings
collectively suggest that most AHR likely lack physiological ligands in the Th2-prone milieu in AD.
Therefore, rapid-metabolizing AHR ligands, such as FICZ and indole-3-aldehyde, appropriately activate
the AHR/ARNT/FLG axis and may be beneficial in treating AD [58,98]. However, vigorous and
long-lasting activation of the AHR/ARNT/FLG axis by slow-metabolizing dioxins and environmental
pollutants may exacerbate barrier dysfunction and aggravate AD [96,99].
Although the pathogenic implication of AHR and its gene polymorphism in AD
remain elusive, recent clinical trials using topical AHR ligand tapinarof have reported
its efficacy for AD [100–102]. Tapinarof (5-[(E)-2-phenylethenyl]-2-[propan-2-yl] benzene-1,
3-diol, WBI-1001, GSK2894512 or bentivimod) is a naturally derived (but is now a fully synthetic)
hydroxylated stilbene produced by bacterial symbionts of entomopathogenic nematodes [100–103].
Tapinarof is a high affinity AHR ligand with antioxidative activity via NRF2 activation and
a ROS-scavenging structure [102] (Figure 1). Tapinarof has gained increased attention because its
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topical application is efficacious for patients with AD in clinical trials [21,100,104]. Tapinarof activates
the AHR/CYP1A1 axis and augments the expression of filaggrin and involucrin [102]. Even in
barrier-disrupted AD patients, systemic absorption of topical tapinarof is limited and likely decreases
during the treatment course in parallel with treatment success that restores the barrier dysfunction [104].
In general, topical tapinarof is tolerable but frequent adverse events include headaches and
folliculitis [104].
In an early clinical trial, patients with AD affecting 3–20% of their body surface area (BSA) and
with an Investigator’s Global Assessment (IGA; 0: clear, 1: almost clear, 2: mild, 3: moderate, 4: severe,
5: very severe) of 2–4 were randomized (1:1:1) to receive a placebo (n = 51), topical tapinarof 0.5%
(n = 50) or 1% (n = 47) in a cream formulation applied twice daily for six weeks [100]. There was
a decrease of 1.3 (43%; p < 0.001; 95% confidence interval (CI) −1.2 to −0.5) and 1.8 (56.3%; p < 0.001;
95% CI −1.6 to −0.9) in IGA at day 42 in the topical tapinarof 0.5% and 1% groups, respectively,
compared with a decrease of 0.5 (14.7%) in the placebo group. At day 42, improvement in Eczema
Area and Severity Index (EASI) score was 68.9% (p < 0.001) and 76.3% (p < 0.001) for tapinarof 0.5%
and 1%, respectively, compared with 23.3% for placebo. Improvement in pruritus severity score at
day 42 was 29.8% (p < 0.001) and 66.9% (p < 0.001) for tapinarof 0.5% and 1%, respectively, compared
with 9.5% for placebo [100]. Adverse events included headaches (placebo: 0%; 0.5% tapinarof: 8%; 1%
tapinarof: 14%), migraines (placebo: 0%; 0.5% tapinarof: 4%; 1% tapinarof: 3%), folliculitis (placebo:
0%; 0.5% tapinarof: 6%; 1% tapinarof: 8%), and contact dermatitis (placebo: 0%; 0.5% tapinarof: 3%:
1% tapinarof: 5%) [100].
A phase II, double-blind, vehicle-controlled, randomized, six-arm trial (1:1:1:1:1:1) in patients
aged 12 to 65 years, with BSA involvement of at least 5% to 35% and an IGA score of 3 or higher
(moderate to severe) at baseline was performed. Primary end points included an IGA score of clear
or almost clear (0 or 1) and a minimum two-grade improvement (treatment success) at week 12 [21].
The rates of treatment success with topical tapinarof cream at week 12 were 53% (1% twice daily,
n = 40), 46% (1% once daily, n = 41), 37% (0.5% twice daily, n = 43), 34% (0.5% once daily, n = 41),
24% (vehicle twice daily, n = 42), and 28% (vehicle once daily, n = 40). The rate with tapinarof
1% twice daily (53%) was statistically significantly higher than the rate with vehicle twice daily
(24%). Notably, treatment success was maintained for four weeks after the end of tapinarof treatment.
The proportion of patients achieving EASI75 (75% or greater improvement in EASI) score reduction at
week 12 was significantly higher in the groups treated with 1% tapinarof (60% and 51% for twice daily
and once daily, respectively) than with vehicle (26% and 25% in the groups receiving vehicle twice
daily and once daily, respectively) [21]. Headaches (e.g., 10% (1% twice daily), 2% (0.5% twice daily),
and 0% (0.5% twice daily)) and folliculitis (e.g., 10% (1% twice daily), 7% (0.5% twice daily), and 0%
(0.5% twice daily)) were again frequent adverse events [21].
In a murine dermatitis model, topically applied FICZ activated AHR and significantly reduced
the dermatitis score and histological inflammation with a decrease of Il22 gene expression in chronic
mite antigen-induced dermatitis [58]. In addition, topical FICZ restored the dermatitis-induced
filaggrin downregulation [58]. CCL17 and CCL22 are crucial chemokines to recruit Th2 cells [68].
IL-4/IL-13 stimulates dendritic cells to produce CCL17 and CCL22 via STAT6 activation and contributes
to the recruitment of Th2 cells in the lesional skin of AD [68]. Soybean tar Glyteer inhibits
the IL-4/IL-13-mediated STAT6 activation and subsequent production of CCL17 and CCL22 in
dendritic cells [68]. In addition, pruritogenic Th2 cytokine IL-31 synergistically upregulates the
IL-4/IL-13-mediated CCL17 and CCL22 production in dendritic cells because IL-4/IL-13 increase IL-31
receptor A (IL31RA) expression [105]. Glyteer again attenuates the IL-4/IL-13-mediated IL31RA
upregulation and subsequent CCL17 and CCL22 production by inhibiting STAT6 activation [105]. It is
known that coal tar inhibits STAT6 activation via the NRF2-antioxidative pathway [15]. Ligation of
AHR by FICZ also reduces the expression of type 1 IgE Fc receptor in Langerhans cells [106].
Although antioxidative AHR ligands are therapeutic for dermatitis, exaggerated activation of
AHR by genetic manipulation in transgenic mice or by dioxin treatment induces itchy dermatitis most
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likely due to an abnormally accelerated keratinization process, epidermal acanthosis, elongation of
nerve fibers, and production of pruritogenic artemin [47,99,107]. Therefore, extreme activation of AHR
is deleterious for skin. In parallel, ovalbumin-induced delayed hypersensitivity is enhanced by topical
benzopyrene with upregulation of IL-5, IL-13, and IL-17 expression in lymph node cells [96].
Since FICZ is an endogenous UVB photoproduct [8], the barrier-protecting effects of FICZ
may explain, at least in part, why UVB phototherapy is efficacious for the treatment of AD and
psoriasis [108,109].
6. AHR and Psoriasis
Psoriasis is an (auto)immune-mediated disease that manifests as widespread desquamative
erythema [110,111]. Males are twice as likely to be affected than females [112,113]. The cosmetic
disfigurement associated with psoriasis profoundly impairs the patients’ quality of life, treatment
satisfaction and adherence, and socioeconomic stability [114,115]. The autoimmune nature
of psoriasis is exemplified by its high comorbidity with psoriatic arthritis [110,116–118] and
other autoimmune diseases including autoimmune bullous diseases [119–124]. Psoriasis is also
comorbid with cardiovascular diseases, metabolic diseases, and renal disorders, which represent
a condition called inflammatory skin march [111,125–129]. The excellent therapeutic efficacy of
anti-TNF-α/IL-23/IL-17A biologics for psoriasis point to the central role of the TNF-α/IL-23/IL-17A axis
in its pathogenesis [18,19,130–134] Additionally, genetic and environmental factors are known to be
involved in its pathogenesis [135,136].
As AHR predominantly regulates the immune balance of Th17/22 and Treg cells [28,29,69,70],
AHR is expected to play a significant role in psoriasis [102]. In an imiquimod-induced psoriasis
model, AhR deficiency exacerbates skin inflammation with upregulated gene expression of Il22,
Il17a, and Il23 [137]. The intensity of delayed type-hypersensitivity is also enhanced in Ahr-deficient
mice [137]. However, further experiments demonstrated that Ahr-deficiency in nonhematopoietic cells,
including keratinocytes, but not in hematopoietic cells, was likely responsible for the exacerbation of
inflammation [137]. Notably, intraperitoneal injection of FICZ ameliorated the imiquimod-induced
psoriasis-like inflammation. Tapinarof and FICZ also reduced the imiquimod-induced psoriasiform skin
inflammation by inhibiting Il17a, Il17f, Il19, Il22, Il23a, and Il1b gene expression [102]. The therapeutic
action of tapinarof and FICZ was AHR-dependent because it was not observed in Ahr-deficient
mice [102]. In an ex vivo activation assay of skin-resident immunocompetent cells using normal human
skin, tapinarof inhibited the expression of IL17A message approximately 50% but increased the IL22
expression [102,138] (Figure 1). In mice, IL-22 is produced from Th17, γδT, ILC3, and CD4−CD8−TCRβ+
cells [139]. AHR was required for IL-22 production by Th17, but not by the three other cell types,
in the imiquimod-treated ears [139]. Although imiquimod-induced skin inflammation is popular as
a psoriasis model, attention should be paid because imiquimod is degraded by CYP1A1 so the efficacy
of AHR agonists may partly rely on this effect in the imiquimod model [140].
Immunohistological and real time PCR studies have demonstrated that the expression of AHR and
ARNT is upregulated in the lesional skin of psoriasis, whereas CYP1A1 expression was significantly
decreased compared to normal controls [97]. In contrast, serum levels of both AHR and CYP1A1 are
elevated in patients with psoriasis compared to normal controls [141]. Further studies are warranted
to investigate these controversial data.
In parallel with its preclinical studies, topical tapinarof is efficacious in the treatment of psoriasis.
In a randomized, double-blind, placebo-controlled phase II trial, 61 patients with 1–10% BSA covered
with plaque psoriasis and a PGA of 2–4 were randomized (2:1) to receive either 1% tapinarof cream or
placebo, applied twice daily for 12 weeks [142]. At week 12, the improvement in PGA was 62.8% for
patients treated with tapinarof compared with 13.0% for patients randomized to placebo (p < 0.0001).
The proportion of patients who achieved a PGA of clear or almost clear was significantly higher with
tapinarof treatment (67.5%) compared with placebo (4.8%, p < 0.0001) [142]. In another double-blind,
vehicle-controlled, randomized six-arm trial (1:1:1:1:1:1) in adults with psoriasis with body surface
121
Int. J. Mol. Sci. 2019, 20, 5424
involvement ≥ 1% and ≤ 15% and PGA score ≥ 2 at baseline, treatment success defined by PGA
0 or 1 and a two-grade improvement at week 12 was significantly higher in the tapinarof groups
(65% (1% twice daily), 56% (1% once daily), 46% (0.5% twice daily), and 36% (0.5% once daily))
than vehicle groups (11% (twice daily) and 5% (once daily)); this was maintained for four weeks
post-treatment [22]. The most commonly (≥5%) reported adverse events that emerged after treatment
were folliculitis (19/152, 13% tapinarof groups and 1/75, 1% vehicle groups) and contact dermatitis
(12/152, 8% only in the tapinarof groups) [22]. These preclinical and clinical studies reinforce that AHR
ligand tapinarof is efficacious in the treatment of psoriasis and atopic dermatitis. In 2019, tapinarof (1%
benvitimod cream) was officially approved by the Chinese government for medical use for psoriasis
after successful Chinese clinical trials [103]. Overall, why topical and systemic AHR ligands reduce
psoriatic inflammation by inhibiting IL-17 and IL-22 in vivo while the same ligands upregulate the
expression of IL-17 and IL-22 in vitro is still unknown.
7. Conclusions
Humans empirically utilize natural antioxidative resources to keep their skin healthy, including coal
tar, Galactomyces fermentation filtrate, Opuntia ficus-indica in Latin America, Artichoke in Mediterranean
regions, and Houttuynia cordata and Artemisia princeps in Asia [12,13,15,37,38,62]. These agents are
potent AHR ligands which activate the AHR-ARNT system and enhance the terminal differentiation
of epidermal keratinocytes [12,13,15,37,38,62]. They also exert antioxidative action via AHR-NRF2
activation [12,13,15,37,38]. The study of the signal transduction mechanisms of the AHR/ARNT system
has demonstrated that this system is also deeply involved in immune regulation especially in Th17/22
and Treg maturation [28,29]. A selective AHR agonist, tapinarof is currently being studied because this
medicinal agent improves both psoriasis and AD in which different pathomechanisms operate (the
TNF-α/IL-23/IL-17 axis in psoriasis and IL-4/IL-13 signaling in AD). Further mechanistic approaches
are warranted to develop new drugs targeting the AHR system.
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Abstract: The aim of this study was to investigate possible stress-associated disturbances in lipid
metabolism in mononuclear cells, mainly lymphocytes of patients with psoriasis vulgaris (Ps, n = 32)
or with psoriatic arthritis (PsA, n= 16) in respect to the healthy volunteers (n= 16). The results showed
disturbances in lipid metabolism of psoriatic patients reflected by different phospholipid profiles.
The levels of non-enzymatic lipid metabolites associated with oxidative stress 8-isoprostaglandin F2α
(8-isoPGF2α) and free 4-hydroxynonenal (4-HNE) were higher in PsA, although levels of 4-HNE-His
adducts were higher in Ps. In the case of the enzymatic metabolism of lipids, enhanced levels
of endocannabinoids were observed in both forms of psoriasis, while higher expression of their
receptors and activities of phospholipases were detected only in Ps. Moreover, cyclooxygenase-1
(COX-1) activity was enhanced only in Ps, but cyclooxygenase-2 (COX-2) was enhanced both in
Ps and PsA, generating higher levels of eicosanoids: prostaglandin E1 (PGE1), leukotriene B4
(LTB4), 13-hydroxyoctadecadienoic acid (13HODE), thromboxane B2 (TXB2). Surprisingly, some of
major eicosanoids 15-d-PGJ2 (15-deoxy-Δ12,14-prostaglandin J2), 15-hydroxyeicosatetraenoic acid
(15-HETE) were elevated in Ps and reduced in PsA. The results of our study revealed changes in lipid
metabolism with enhancement of immune system-modulating mediators in psoriatic mononuclear
cells. Evaluating further differential stress responses in Ps and PsA affecting lipid metabolism and
immunity might be useful to improve the prevention and therapeutic treatments of psoriasis.
Keywords: lipid mediators; psoriasis vulgaris; psoriatic arthritis; lipid peroxidation products;
endocannabinoids; eicosanoids
1. Introduction
Psoriasis is a chronic autoimmune disease, the most common form of which is psoriasis vulgaris,
characterized by pathological interactions between immune cells, especially lymphocytes, and skin
cells, especially keratinocytes. In some patients, psoriasis is characterized by a more severe clinical
course, leading to the development of psoriatic arthritis [1]. The cause of the disease remains unknown,
although some genetic or environmental factors are associated with the development of psoriasis.
Thus, it has been observed that lymphocytes and the cytokines they produce, especially interferon γ
(IFNγ) and interleukin 17 (IL-17), affect other cells, leading to chronic inflammation and characteristic
symptoms such as cutaneous plaques in psoriasis or arthrosis and loss of movement in psoriatic arthritis.
Moreover, the pro-inflammatory phenotype of lymphocytes and other immune cells is observed not
only locally in the skin or joints, but also in cells isolated from blood, which confirms that general
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inflammation is present in psoriasis [2]. However, that can only partially explain the course of the
disease, still leaving many questions open in respect to the development of psoriasis or the transition of
one form to another. Recent studies on immunological diseases have revealed that their development
is often accompanied by oxidative stress and increased metabolism of phospholipids, suggesting that
both ROS and lipid mediators play important roles in the pathophysiology of psoriasis [3]. In psoriasis,
both systemic and local, oxidative stress and increased metabolism of phospholipids have been
demonstrated. Among immune-competent, inflammatory cells of psoriatic patients were observed
especially for granulocytes, which increasingly generate lipid peroxidation products, thus modulating
their inflammatory activities [4]. Furthermore, it has been shown that activation of lymphocytes is also
accompanied by the generation of large amounts of reactive oxygen species (ROS) that are important
mediators of cytokine-mediated redox biology [5]. Biological activities of ROS are related to their
ability to react with biomolecules, such as phospholipids, in particular polyunsaturated fatty acids
(PUFA), which leads to lipid peroxidation and generation of reactive aldehydes, e.g., 4-hydroxynonenal
(4-HNE), which is denoted also as a “second messenger of free radicals” [6].
In addition to lipid peroxidation, cellular phospholipids are also metabolized by enzymes,
the activities of which are increased in various inflammatory processes. The most important
enzymes involved in the generation of lipid mediators are phospholipases, cyclooxygenases
(COXs), and lipoxygenases (LOXs) [7]. During this process phospholipases begin biosynthesis
of endocannabinoids among which the best known are 2-acyloglycerol (2-AG) and anandamide (AEA).
Enhanced levels of them are observed in inflammatory diseases like osteoarthritis or systemic lupus
erythematosus [8,9]. Endocannabinoids affect cells mostly by interactions with their receptors,
cannabinoid receptors (CB1 and CB2). It is known that activation of CB2 receptor results in
anti-inflammatory and anti-oxidative regulation, while activation of CB1 shows pro-inflammatory
and pro-oxidative activity [10]. In addition, endocannabinoids have been found to be involved in
the development of psoriatic comorbidities. Therefore, it can be assumed that disturbances of the
endocannabinoid system may also play a significant role in the course of psoriasis.
Moreover, recent studies suggest, that effect of endocannabinoids action is also dependent on the
action of their metabolites [11]. Anandamide is metabolized into arachidonic acid which together with
arachidonic acid revealed from phospholipids is further metabolized into eicosanoids by (COXs) and
LOX. Among cyclooxygenases COX-2 is believed to be the main enzyme responsible for generation of
active lipid mediators during inflammation [12], while arachidonic acid is also a substrate to synthesis
of thromboxanes, leukotrienes, and prostaglandins [13].
Since lipid mediators are commonly observed in autoimmune diseases, they are constantly gaining
increased attention among researchers focused on autoimmune diseases. Lipid mediators might
accordingly be important for studies on diseases with poorly understood pathophysiology and without
effective therapy, like psoriasis. As such, the aim of this study was to investigate oxidative lipid
modifications in mononuclear cells, mainly lymphocytes isolated from patients suffering from psoriasis
vulgaris (Ps) or psoriatic arthritis (PsA).
2. Results
Phospholipids that could distinguish patients with psoriasis vulgaris and psoriatic arthritis were
selected by use of multivariate statistics. Twenty phospholipid species with variable importance in
projection (VIP ≥ 1) were selected, which were driving the separation of examined groups. Principal
component analysis (PCA) model (Figure 1) was constructed to check classification of each group.
The complete data set with the log transformed and auto-scaled phospholipid variables was used
to carry out the analysis. The PCA model, on which each point represents an individual sample,
showed that the group of healthy subjects was clearly separated from the patients groups, while the
separation between both types of psoriasis almost did not occur. The model captured 78.1% of the total
variance. The variation in the variables is represented by two principal components of PC1 (57.7%)
versus PC2 (14.7%). It is highly probable that PC1 is associated with the age, while PC2 indicates a
132
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positive correlation with disease state. It was observed that the samples from both groups of psoriatic
patients showed positive values for PC2, whereas those from healthy subjects presented negative
values. Finally, we used partial least squares-discriminate analysis (PLS-DA) (Figure S1) and VIP for
estimation of the importance of each phospholipid species which drove the separation of the examined
groups (Table 1).
Figure 1. Principal component analysis (PCA) plot of the phospholipid species relative abundance
determined by HILIC-LC-MS in lymphocytes of patient with psoriasis vulgaris (n = 10) and psoriatic
arthritis (n = 10) as well as healthy subjects (n = 10); 95% confidential intervals are indicated by
shaded area.
Table 1 shows the details of these species that belong to lysophosphatidylcholine (LPC),
phosphatidylcholine (PC), phosphatidylinositol (PI), and sphingomyelin (SM) classes. Two
phosphatidylcholines containing eicosatrienoic (20:3) and docosadienoic (22:2) acid, namely
PC(20:0/22:2), and PC(20:3/24:0), had the highest VIP scores. In general, PC was down-regulated
in patients of both types of psoriasis while two SM species, containing tetracosadienoic (24:2) and
docosaenoic acid (22:1), respectively, were up-regulated. Other phospholipid species that were changed
in the course of both forms of psoriasis belong to the PI class. PI species were down-regulated in
both groups of patients with exception of PI(24:0/24:0), PI(24:0/24:1), and PI(18:0/22:0), which were
highly up-regulated. Important to notice is that PI species containing arachidonic and linoleic acid,
namely PI(16:0/20:4), PI(18:0/20:4), and PI(18:2/22:0) were significantly down-regulated in both groups
of psoriatic patients in comparison to healthy subjects. Moreover, most of PI species were found to be
more altered in PsA patients than those with Ps. LPC species with the score > 1, namely LPC(16:0) and
LPC(18:0), were found to be highly up-regulated in psoriasis in comparison to healthy subjects. Hence,
these two LPC species were mostly responsible for the differentiation of both types of psoriasis from
healthy subjects (Table 1).
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It is often assumed that the reduced level of PUFAs is related to their ROS-dependent and
enzyme-dependent metabolism. Consequently, the elevated levels of lipid peroxidation products
belonging to compounds generated during PUFAs’ oxidative fragmentation, such as 4-HNE, as well
as to compounds generated during PUFAs oxidative cyclisation, such as 8-iso prostaglandin F2α
(8-isoPGF2α), was observed, in particular in patients with PsA (Figure 2).
Figure 2. The level of phospholipid oxidative modifications products and of 4-HNE-protein adducts
in mononuclear cells of healthy peoples (n = 16) and patients with psoriasis vulgaris (n = 32) and
psoriatic arthritis (n = 16). 8-isoPGF2α, F2α-8-isoprostaglandin; 4-HNE, 4-hydroxynonenal. Data points
represent the mean ± SD; a, significantly different from healthy subject, p < 0.05; x, significantly different
from patients with psoriasis vulgaris, p < 0.05.
That might indeed be that case with psoriatic patients because their observed decrease of PUFAs
was associated by enhanced activities of the enzymes metabolizing lipids including phospholipases
(PLA2 and PAF-AH), as well as of cyclooxygenase 1 (COX1) and cyclooxygenase2 (COX2), especially
in Ps (Figure 3).
Figure 3. The activity of the enzymes involved in phospholipid metabolism in mononuclear cells of
patients psoriasis vulgaris (n= 32) and psoriatic arthritis (n= 16) as well as healthy subjects (n= 16). PLA2,
phosholipase A2; PAF-AF, platelet-activating factor acetylhydrolase; COX, cyclooxygenases. Data points
represent the mean ± SD; a, significantly different from healthy subject, p < 0.05; x, significantly different
from patients with psoriasis vulgaris, p < 0.05.
It is likely that increased activity of the above listed enzymes promoted generation of
endocannabinoids. The levels of anandamide and LEA increased more in mononuclear cells of patients
with PsA, while the concentration of 2-AG, 2-LG (2-linoleoylglycerol), and OEA (oleoylethanolamide)
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was higher in patients with Ps (Table 2). An elevated level of endocannabinoids was observed
despite the increased activity of enzymes degrading them (FAAH—fatty acid amide hydrolase and
MAGL—monoacylglycerol lipase), especially in mononuclear cells of patients with Ps (Table 2).
Table 2. The level of endocannabinoids and enzymes degrading them (FAAH and MAGL) in
mononuclear cells of patients with psoriasis vulgaris (n = 32) and psoriatic arthritis (n = 16)
Abbreviations: 2-AG, 2-arachidonoylglycerol; 2-LG, 2-linoleoylglycerol; AEA, anandamide; FAAH,
fatty acid amide hydrolase; LEA, dihomo-γ-linolenoylethanolamine; MAGL, monoacylglycerol lipase;
OEA, oleoylethanolamide. Data points represent the mean ± SD; a, significantly different from healthy
subject, p < 0.05; x, significantly different from patients with Ps, p < 0.05.
Analyzed Parameters Healthy Subjects Psoriasis Vulgaris Psoriatic Arthritis
AEA
(pmol/mg protein) 0.17 ± 0.02 0.19 ± 0.03a 0.23 ± 0.04ax
2-AG
(pmol/mg protein) 1.87 ± 0.18 3.24 ± 0.45a 2.78 ± 0.37ax
2-LG
(pmol/mg protein) 5.59 ± 0.87 7.92 ± 0.99a 7.41 ± 0.93a
LEA
(pmol/mg protein) 0.79 ± 0.08 0.94 ± 0.15a 1.17 ± 0.15ax
OEA
(pmol/mg protein) 0.33 ± 0.05 0.47 ± 0.07a 0.36 ± 0.05a
FAAH
(pmol/min/mg protein) 170 ± 16 219 ± 28a 242 ± 31ax
MAGL
(pmol/min/mg protein) 55 ± 6 75 ± 10a 83 ± 14ax
Increased level of endocannabinoids resulted in enhanced expression of cannabinoids receptors
(CB1 and CB2), as well as other receptors activated also by endocannabinoids (GPR55 and TRPV1) in
Ps and decreased expression of these receptors in PsA (Figure 4). Products of phospholipid metabolism
including endocannabinoids, but also fatty acids and eicosanoids, are ligands of nuclear peroxisome
proliferator-activated receptors (PPARα, PPARγ, PPARδ). A significant increase in the expression of
these receptors was observed in mononuclear cells obtained from patients with Ps, while it was only
moderately raised in mononuclear cells of patients with PsA (Figure 4).
Figure 4. The expression of receptors involved in phospholipid metabolism in mononuclear cells of
patients with psoriasis vulgaris (n = 16) and psoriatic arthritis (n = 8) and healthy peoples (n = 8).
CB1, CB2, cannabinoid receptors; GRP55, G protein-coupled receptor 55; TRPV, the transient receptor
potential cation channel subfamily V member 1; PPAR, peroxisome proliferator-activated receptor.
Data points represent the mean ± SD; a, significantly different from healthy subjects, p < 0.05; x,
significantly different from patients with psoriasis vulgaris, p < 0.05.
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Increased activity of PLA2 lead to the enhanced release of arachidonic acid, which is further
metabolized (mainly by cyclooxygenases and lipoxygenases) into another large group of active
lipid mediators, notably eicosanoids (Figure 5) Among them, pro-inflammatory factors, such as
13-hydroxyoctadecadienoic acid (13-HODE) and leukotriene B4 (LTB4) levels, were increased in both
forms of the disease. In particular LTB4 level increased dramatically in psoriasis, especially in Ps.
In addition, thromboxane B2 (TxB2), (metabolite of pro-inflammatory thromboxane A2 (TxA2) level
was increased in Ps, which might be related to the activities of cyclooxygenases. The analysis
of anti-inflammatory mediators revealed decreased levels of 15-deoxy-Δ12,14-prostaglandin J2
(15-d-PGJ2) in patients with Ps, while 15-hydroxyeicosatetraenoic acid (15-HETE) levels were slightly,
but significantly, increased in Ps, and prostaglandin E1 (PGE1) levels were increased both in Ps
(four-fold) and in PsA (two-fold).
Since psoriasis is known to be associated with inflammation, basic pro-inflammatory and
anti-inflammatory parameters were examined (Figure 6). The levels of pro-inflammatory cytokine IL-2
was increased above normal in mononuclear cells of both forms of psoriasis, while anti-inflammatory
IL-10 levels were not changed in psoriatic patients.
Figure 5. The level of the eicosanoids in mononuclear cells of patients with psoriasis (n = 32), psoriatic
arthritis (n= 16), as well as healthy subjects (n= 16). Data points represent the mean± SD; a, significantly
different from healthy subject, p < 0.05; x, significantly different from patients with psoriasis
vulgaris. Prostaglandin E1 (PGE1), leukotriene B4 (LTB4), 13-hydroxyoctadecadienoic acid (13HODE),
thromboxane B2 (TXB2). Surprisingly, some of major eicosanoids 15-deoxy-Δ12,14-prostaglandin
J2 (15-d-PGJ2), 15-hydroxyeicosatetraenoic acid (15-HETE). Data points represent the mean ± SD;
a, significantly different from healthy subject, p < 0.05; x, significantly different from patients with Ps,
p < 0.05.
Figure 6. The expression of interleukins and pro-inflammatory mediators in mononuclear cells from
patients with psoriasis vulgaris (n = 16), psoriatic arthritis (n = 8), and healthy subjects (n = 8).
IL-interleukine. Data points represent the mean ± SD; a, significantly different from healthy subjects,
p < 0.05.
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3. Discussion
Psoriasis is a complex inflammatory disease associated with increased activation of lymphocytes [14],
which leads to the generation of pro-inflammatory cytokines and to pro-oxidative processes causing
oxidative stress [3]. The results of our study confirm the onset of oxidative stress in psoriasis, which is,
in particular in PsA, manifested by changes in the metabolism of phospholipids in mononuclear cells,
mainly containing lymphocytes, thus offering better understanding of the diseases, due to differentially
expressed changes in lipid metabolism between Ps and PsA examined mononuclear cells.
The main source of ROS in cells are usually mitochondria whose respiratory chain may be disrupted
by various factors, including phospholipids’ metabolites, such as endocannabinoids, the levels of which
were, in the current study, found to be increased in the mononuclear cells of psoriatic patients. It is
known that the main endocannabinoids, AEA and 2-AG, may stimulate the function of mitochondria,
including the production of hydrogen peroxide by enhanced entry of calcium ions into the cell [15].
In addition, activation of cannabinoid receptors (CB1), caused by endocannabinoids, which was, in our
study, also found to be increased in mononuclear cells of psoriatic patients, may promote oxidative
stress by enhanced inflammation, e.g., through NOS stimulation leading to increased generation of
superoxide and nitric oxide [16]. In favor of this possibility are increased activities of cytosolic NADPH
and xanthine oxidases in granulocytes and in plasma of patients with psoriasis, in particular if obtained
from patients with PsA [4]. Such changes were accompanied by disturbances in the antioxidant system,
which was spread in a stress-response manner lowering the level/activity of cellular antioxidants.
Similarly, redox imbalance and inflammation observed in psoriatic patients were, in the current
study, associated with changes in ROS-dependent and enzyme-dependent phospholipid metabolism
of mononuclear cells affecting especially PUFAs, which are lipid species the most sensitive to the ROS
attack causing lipid peroxidation. Different phospholipid species, including phosphatidylcholines
and phosphatidylinositols containing linoleic, arachidonic, eicosatetraenoic and docosadienoic acids,
in particular, were down-regulated in mononuclear cells of psoriatic patients. Arachidonic acid and
linoleic acid are the major PUFAs, which are oxidized in a ROS-dependent manner to biologically-active
lipid mediators, including products of oxidative fragmentation (mainly α,β-unsaturated electrophilic
aldehydes, with 4-HNE as the most important one) and products of oxidative cyclisation (mainly
prostaglandin derivatives, such as 8-isoPGF2α) that further propagate oxidative damages altering
functional activities of the immune-competent cells [17]. The mechanism of 8-isoPGF2α action is based
on TNFα activation [18]. So far, increased levels of 8-isoPGF2α have been found in psoriatic patients’
serum [19] as well as in the skin cells [20] being accompanied by elevated TNFα expression [21].
However, 4-HNE is a more potent biomarker of lipid peroxidation, which is involved in complex
regulation of inflammatory and immunological responses [6]. The increased levels of the free 4-HNE
were observed in our study especially in the mononuclear cells of PsA patients. Opposite to that,
the levels of histidine-bound protein adducts of 4-HNE were higher in examined cells of patients
with Ps indicating differential metabolic and scavenging pathways for this “second messenger of
free radicals” in Ps and in PsA patients. It is known that unsaturated aldehydes, such as 4-HNE,
have a strong affinity for covalently linking with nucleophilic amino and thiol groups of biomolecules,
including proteins and glutathione (GSH) [17]. Since the thiol groups of protein cysteine residues act
as redox switches controlling cell signaling and metabolism [22], versatile interactions of cysteine with
signaling molecules, such as 4-HNE, can selectively modulate protein functions [23]. Complementary
to that, modifications of protein residues, not only cysteine but also histidine or lysine, may lead to
disturbances of biological functions of modified proteins and their translocation to the cell membrane
and activation of protein G [24–26]. Our findings suggest that such protein adducts may participate
in enhanced expression of protein G-coupled receptors (including cannabinoid receptors), as was
observed in this study in mononuclear cells of psoriatic patients.
The cellular metabolism of phospholipids, independent of ROS, also includes enzymatic reactions
leading to the generation of endocannabinoids dependent on the activity of phospholipases [27].
Despite the increased activity of endocannabinoid-metabolizing enzymes (FAAH and MAGL),
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endocannabinoid levels were elevated in our patients. The main endocannabinoids, anandamide and
2-arachidonoylglycerol (2-AG), participate in the modulation of inflammation and redox balance mainly
through the activation of cannabinoid receptors [28]. Crosstalk between ROS and endocannabinoids
has been proven in various diseases [27], but so far not in patients with psoriasis, as was done for the
first time in the present study.
In addition, inflammation is associated with increased expression of lymphocyte receptors: GPR55
and TRPV1 [29,30]. According to in vitro studies endocannabinoids themselves may also act as
anti-inflammatory agents by promoting the Th2 cell phenotype and further inhibit the production
of pro-inflammatory cytokines by lymphocytes [31]. This may suggest that endocannabinoids are
generated, among others, to alleviate the inflammatory aspects of psoriasis. In fact, in the case of Ps
we observed a higher expression of endocannabinoid receptors but, surprisingly, in the case of PsA,
the expression of these receptors has been reduced, suggesting no cellular response to the regulatory
role of endocannabinoids. It is possible that the receptors or membrane protein G have been modified
by 4-HNE, which can explain also less pronounced increase of the soluble 4-HNE-protein adducts in
patients with PsA, who have otherwise higher levels of the free aldehyde than patients with Ps. In any
case, the disrupted immunosuppressive effect of endocannabinoids in PsA may be an important factor
differentiating the pathophysiology of both forms of psoriasis and may promote exacerbation of Ps
into the form of PsA.
Enzymatic degradation of endocannabinoids, with COXs participation in particular, plays a
critical role in the onset of the inflammatory cascade with the generation of different biologically-active
compounds, including eicosanoids [32]. Among them are various bioactive agents, such as
prostaglandins, thromboxanes, and leukotrienes, which can participate in the pathophysiology
of psoriasis. Eicosanoids may have opposite inflammatory effects and, thus, modulate skin disorders.
The results of this study revealed a significant increase in mononuclear cells of patients with psoriasis
TxB2, a stable metabolite of TxA2, which plays a pro-inflammatory role in imiquimod-induced psoriatic
dermatitis [33]. Additionally, elevated LTB4 levels may promote skin inflammation [34]. Inflammation
may also be modified by 15d-PGJ2, which is elevated in Ps, and which inhibits NFκB mediated
metabolic pathways by inhibiting IκB kinase (IKK) activity [35].
Another mechanism of interactions redox biology-lipid metabolism in the mononuclear cells
of psoriatic patients may be associated with the expression of nuclear receptors like peroxisome
proliferator-activated receptors—PPARs [36], whose forms: PPARα, PPARγ, and PPARδ were enhanced
in mononuclear cells of patients with psoriasis, particularly with Ps. Moreover, PUFAs, eicosanoids,
and endocannabinoids may be ligands of PPARs, which in B and T lymphocytes serve as important
regulators of the immune system as potential anti-inflammatory targets for PPAR ligands [37,38].
PPARα and PPARδ show antioxidant properties by suppressing enzymes involved in
ROS/RNS generation [39], while enhanced activation of PPARα may also prevent NFκB–dependent
inflammation [40]. The results obtained by the murine translation study indicated that PPARα
activation may be one of the protective mechanisms against progression of skin inflammation [41].
Additionally, the PPARδ promotes synthesis of antioxidants, such as thioredoxin, superoxide dismutase,
or heme oxygenase [42]. Thus, PPARδ enhanced expression seems to be an important antioxidative
mechanism in patients with Ps. The significant decrease in their expression observed in PsA confirms
that the lack of anti-stress protection against ROS leads to an increase the severity of this disease.
In addition, increased PPARγ expression, as discovered in this study, may be involved in reduction of
TNFα level, particularly in PsA [43].
4. Materials and Methods
4.1. Materials
Blood samples were collected from 32 patients with psoriasis vulgaris (Ps) (16 females, 16 men;
mean age 38) and 16 patients with psoriatic arthritis (seven females, nine men; mean age 35).
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Only patients with psoriasis vulgaris for at least six months and characterized by at least 10% of the
total body surface affected by the disease were included in the study (the median of their psoriasis
surface index and severity index (PASI) was 21, with a range of 15–25). Patients with psoriatic arthritis
(PsA) were diagnosed on the basis of a questionnaire CASPAR (ClASsification criteria for Psoriatic
Arthritis). All participants gave their informed consent for inclusion in the research. The research
was carried out in accordance with the Helsinki Declaration, and the protocol was approved by the
Local Bioethics Commission at the Medical University of Białystok (Poland), no. R-I-002/289/2017
(2017.09.28). People receiving topical or oral medications during the four weeks before the study and
comorbidities/smoking or alcohol abuse were excluded from examinations.
Blood was collected into tubes with ethylenediaminetetraacetic acid as an anti-coagulant and
butylhydroxytoluene as an antioxidant. Density gradient centrifugation (Gradisol L, 300 g, 25 min) was
used to obtain mononuclear cells mainly containing lymphocytes fraction from blood. This fraction was
washed in phosphate-buffered saline (PBS), then resuspended in PBS containing proteases inhibitors
mix. Purity of the cells has been examined microscopically (Nikon Eclipse Ti, Nikon Instruments
Inc., Melville, NY, USA). Isolated fractions were lysed by sonification on ice and stored at −80 ◦C
before further analysis. All obtained parameters are expressed per mg of protein (protein levels were
examined using Bradford method [44]).
4.2. Methods
4.2.1. Phospholipid Profile Estimation
Mononuclear cells from ten patients with Ps, ten patients with PsA (5f + 5m) and ten healthy
subjects (5f + 5m) were used to estimate phospholipid profile of each group. Total lipids from all
samples were extracted by the modified Bligh and Dyer method [45]. The total amount of phospholipids
(PL) was calculated by using a phosphorus assay, performed according to Bartlett and Lewis [46].
Hydrophilic interaction chromatography liquid chromatography-mass spectrometry (HILIC-LC)-MS,
performed on an Agilent 1290 ultra-performance liquid chromatography (UPLC) system coupled to an
Agilent 6540 quadrupole time of flight mass spectrometer (Agilent Technologies, Palo Alto, CA, USA)
was applied to obtain the phospholipid profile. An Ascentis Si HPLC Pore column (15 cm × 1.0 mm,
3 μm; Sigma Aldrich, St. Louis, MO, USA) was used for chromatographic separation in gradient mode.
The method was described in details previously [47]. Internal standards PC 14:0/14:0, PI 16:0/16:0,
and PE 14:0/14:0 (Avanti Polar Lipids, Alabaster, AL, USA) were used to confirm the ion variations
observed in the MS spectra. Identification of each phospholipid species was performed according
to the typical fragmentation pathways [48]. The area of each extracted ion chromatogram peak was
normalized to the area of an internal standard to calculate relative abundance of each ion. Detailed
description of the lipidomic methodology is provided in supplementary materials.
4.2.2. Determination of the Activity of Lipid Metabolizing Enzymes
Spectrophotometric method was used to assay phospholipase A2 (PLA2-EC.3.1.1.4) activity using
PLA2 Assay Kit (no. 765021, Cayman Chemical Company, Ann Arbor, MI, USA) according to the kit
instructions [49].
PAF acetylhydrolase (PAF-AH-EC.3.1.1.47) activity was measured spectrophotometrically using
the Cayman’s PAF Acetylhydrolase Assay Kit (no. 760901, Cayman Chemical Company, Ann Arbor,
MI, USA) according to kit instructions [50].
Cyclooxygenase 1 and 2 (COX1/2-EC.1.14.99.1) activities were measured spectrophotometrically
using a commercial assay kit (Cayman Chemical Company, Ann Arbor, MI, USA) [51]. For distinguishing
COX1 activity from COX2 activity the specific COX1 inhibitor SC-560 was used [52].
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4.2.3. 4-HNE Determination
Gas chromatography-mass spectrometry (GC/MS) using the selected ion monitoring (SIM) mode,
as the O-PFB-oxime-TMS derivatives, using minor modifications of the method of Luo [53] was used to
measure product of phospholipid fragmentation—4-HNE. Transitions of the precursor to the product
ion were as follows: m/z 333.0 and 181.0 for 4-HNE-PFB-TMS and m/z 307 for IS (benzaldehyde-D6+)
derivative. (7890A GC-7000 quadrupole MS/MS, Agilent Technologies, Palo Alto, CA, USA).
4.2.4. 4-HNE-Protein Adducts Determination
The 4-HNE-protein adducts level was measured using ELISA method using anti-4-HNE-His
murine monoclonal antibody (genuine anti-4-HNE-Hismurine monoclonal antibody, clone 4-HNE 1g4)
and goat anti-mouse antibody (Dako, Carpinteria, CA, USA) as primary and secondary antibodies [54].
Results were shown as a percentage of the expression determined in control cells.
4.2.5. 8-isoPGF2α Determination
LC-MS/MS method of Coolen [55] was used to determination of phospholipid oxidative cyclisation
product, 8-isoPGF2α, which was analyzed in negative-ion mode using MRM mode: m/z 353.2→193.1
(for 8-isoPGF2α) and 357.2→197.1 (for 8-isoPGF2α-d4 used as an internal standard) (LCMS 8060,
Shimadzu, Kyoto, Japan).
4.2.6. Determination of Endocannabinoids and Enzymes Them Degradation
The LC-MS/MS method was used for the quantification of the endocannabinoids level [56].
Endocannabinoids were analyzed in positive-ion mode using MRM mode. Transitions of the
precursors to the product ions were as follows: m/z 348.0→62.15 for AEA, m/z 379.0→269.35
for 2-AG, m/z 356.0→63.05 for AEA-d8, m/z 387.0→294.0 m/z for 2-AG-d8, m/z 430.0→66.0 for
OEA-d4, m/z 324.0→62.0 for LEA, m/z 355.0→263.0 for 2-LG, 326.0→62.0 for OEA. (LCMS 8060,
Shimadzu, Kyoto, Japan). Results were expressed as amount of cannabinoids per mg of protein.
The Siegmund procedure [57] was used to determine FAAH (EC.3.5.1.99) activity, following the releasing
of m-nitroaniline (m-NA) from decanoyl m-nitroaniline at 410 nm. Enzyme activity was expressed as
the amount of enzyme metabolizing 1 pmol of substrat per minute per mg of protein. Releasing of
5’-thio-2-nitrobenzoic acid from arachidonoyl-1-thio-glycerol was used to spectrophotometric [340 nm]
determination of MAGL (EC.3.1.1.23) activity [58]. Enzyme activity was expressed as the amount of
enzyme metabolizing 1 pmol of substrate per minute per mg of protein.
4.2.7. Lipid Mediators Determination
Lipid mediators levels: TXB2, PGE1, 15d-PGJ2, 13-HODE, LTB4, and 15-HETE were estimated
using ultra-performing liquid chromatography tandem mass spectrometry (LCMS 8060, Shimadzu,
Kyoto, Japan) [59]. 15-HETE-d8, LTB4-d4, PGF2α-d4 and PGD2-d4 were used as internal standards for
quantification. Lipid mediators were extracted using SPE and analyzed in negative-ion mode (MRM).
The precursor to the product ion transition was as follows: m/z 369.3→169.1 for TXB2, m/z 353.3→317.2
for PGE1, 315.2→271.2 for 15-d-PGJ2, m/z 295→277 for 13-HODE, and m/z 319→301.2 for 15-HETE.
4.2.8. Proteins Examination
Western blot analysis of protein expression was performed according to Eissa and Seada [60].
Samples were electrophoretically separated on 10% gels, transferred to 0.2 μm pore-sized nitrocellulose,
and incubated overnight with primary antibodies against: GPR55, PPARα (host: rabbit) β-actin (host:
mouse) that were purchased from Sigma-Aldrich, (St. Louis, MO, USA). Primary antibodies against:
Il-10 (host mouse), CB1, CB2, TRPV1 (host rabbit) were purchased from Santa Cruz Biotechnology
(Santa Cruz, CA, USA). Primary antibodies against PPARγ (host: rat) were purchased from Abcam
(Cambridge, UK). Primary antibodies against PPARδ were purchased from Invitrogen (Carlsbad,
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CA, USA). Primary antibodies against IL-2 (host: rat) were purchased from Thermo Fisher Scientific
(Thermo Fisher Scientific, Waltham, MA, USA). Next membranes were incubated for 2 h with alkaline
phosphatase secondary IgG antibody against corresponding primary antibody (Sigma-Aldrich, St. Louis,
MO, USA). Protein bands were visualized using the BCIP/NBT Liquid substrate system (Sigma-Aldrich,
St. Louis, MO, USA). To compare the proteins expression between samples, each band intensity was
estimated using VersaDoc System and Quantity One software (Bio-Rad Laboratories Inc., Hercules,
CA, USA). The results are expressed as a percentage of the expression determined in the control cells.
4.3. Statistical analysis
All data were expressed as mean ± SD. For data analysis program Statistica (Statistica 13.3, StatSoft
Polska, Cracow, Poland) were used. These data were analyzed using one-way analysis of variance
followed by a post hoc Tukey test. Values of p < 0.05 were considered significant.
5. Conclusions
In conclusion, the results of our research suggest that the development of both forms of psoriasis
is strongly associated with oxidative stress resulting in altered lipid metabolism and cytokine
production, leading to the development of pro-inflammatory preconditioning of the immune cells.
In such a vicious circle, mononuclear cells additionally activate pro-inflammatory states and enhance
pro-oxidative, stressful conditions. Thus, ROS and enzyme-dependent changes in mononuclear cell
phospholipids can be considered as important processes associated with the pathophysiology of
psoriasis. Moreover, the reduced expression of endocannabinoid receptors in PsA suggests the failure
of the anti-inflammatory mechanism and may be an important factor leading to the transformation of
Ps into a more severe form of PsA. Finally, we assume that monitoring the level of 4-HNE adducts can
help predict the progression of Ps into PsA if done complementary to the other parameters of lipid
metabolism and the levels of respective cytokines that should be analyzed in further studies.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/20/17/
4249/s1
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EDTA Ethylenediaminetetraacetic acid
ELISA Enzyme-linked immunosorbent assay
ERK5 Extracellular-signal-regulated kinase 5
FAAH Fatty acid amide hydrolase
GC Gas chromatography
GPR55 G protein-coupled receptor 55
HILIC Hydrophilic interaction chromatography
















PAF-AH Platelet-activating factor acetylhydrolase
PBS Phosphate-buffered saline
PC Phosphatidylcholine




PLS-DA partial least squares-discriminate analysis
PPAR Peroxisome proliferator-activated receptor
Ps Psoriasis vulgaris
PsA Psoriatic arthritis
PUFAs Polyunsaturated fatty acids
ROS Reactive oxygen species
RT Retention time
SIM Selected ion monitoring
SLE Systemic lupus erythematosus
SM Sphingomyelin
Th T helper lymphocytes
TNFα Tumor necrosis factor α
TNFR Tumor necrosis factor receptor
TRPV1 The transient receptor potential cation channel subfamily V member 1
TxA2 Thromboxane A2
TxB2 Thromboxane B2
UPLC Ultra-performance liquid chromatography
VIP variable importance in projection
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receptor 55 (GPR55) expresses differently in patients with Crohn’s disease and ulcerative colitis. Scand. J.
Gastroenterol. 2017, 52, 711–715. [CrossRef] [PubMed]
30. Gouin, O.; L’Herondelle, K.; Lebonvallet, N.; Le Gall-Ianotto, C.; Sakka, M.; Buhé, V.; Plée-Gautier, E.;
Carré, J.-L.; Lefeuvre, L.; Misery, L.; et al. TRPV1 and TRPA1 in cutaneous neurogenic and chronic
inflammation: Pro-inflammatory response induced by their activation and their sensitization. Protein Cell
2017, 8, 644–661. [CrossRef] [PubMed]
31. Klein, T.W.; Newton, C.; Larsen, K.; Chou, J.; Perkins, I.; Lu, L.; Nong, L.; Friedman, H. Cannabinoid receptors
and T helper cells. J. Neuroimmunol. 2004, 147, 91–94. [CrossRef] [PubMed]
32. Camara-Lemarroy, C.R.; Gonzalez-Moreno, E.I.; Guzman-de la Garza, F.J.; Fernandez-Garza, N.E. Arachidonic
Acid Derivatives and Their Role in Peripheral Nerve Degeneration and Regeneration. Sci. World J. 2012,
2012, 7. [CrossRef] [PubMed]
33. Tanada-Ueharaguchi, Y.; Honda, T.; Murata, T.; Arita, M.; Miyachi, Y.; Kabashima, K. Thromboxane A2
promotes the development of imiquimod-induced mouse psoriasis model via TP receptor. J. Dermatol. Sci.
2016, 84, e5. [CrossRef]
34. Del Prete, A.; Shao, W.-H.; Mitola, S.; Santoro, G.; Sozzani, S.; Haribabu, B. Regulation of dendritic cell
migration and adaptive immune response by leukotriene B4 receptors: A role for LTB4 in up-regulation of
CCR7 expression and function. Blood 2007, 109, 626–631. [CrossRef] [PubMed]
35. Paul, S.; Traver, M.K.; Kashyap, A.K.; Washington, M.A.; Latoche, J.R.; Schaefer, B.C. T cell receptor signals to
NF-κB are transmitted by a cytosolic p62-Bcl10-Malt1-IKK signalosome. Sci. Signal. 2014, 7, ra45. [CrossRef]
[PubMed]
36. Ament, Z.; Masoodi, M.; Griffin, J.L. Applications of metabolomics for understanding the action of peroxisome
proliferator-activated receptors (PPARs) in diabetes, obesity and cancer. Genome Med. 2012, 4, 32. [CrossRef]
[PubMed]
37. O’Sullivan, S.E. Cannabinoids go nuclear: Evidence for activation of peroxisome proliferator-activated
receptors. Br. J. Pharm. 2007, 152, 576–582. [CrossRef] [PubMed]
38. Xu, Z.; Wang, G.; Zhu, Y.; Liu, R.; Song, J.; Ni, Y.; Sun, H.; Yang, B.; Hou, M.; Chen, L.; et al. PPAR-γ agonist
ameliorates liver pathology accompanied by increasing regulatory B and T cells in high-fat-diet mice. Obesity
2017, 25, 581–590. [CrossRef]
39. Aleshin, S.; Reiser, G. Role of the peroxisome proliferator-activated receptors (PPAR)-α, β/δ and γ triad in
regulation of reactive oxygen species signaling in brain. Biol. Chem. 2013, 394, 1553–1570. [CrossRef]
40. Contreras, A.V.; Torres, N.; Tovar, A.R. PPAR-α as a Key Nutritional and Environmental Sensor for Metabolic
Adaptation. Adv. Nutr. 2013, 4, 439–452. [CrossRef]
145
Int. J. Mol. Sci. 2019, 20, 4249
41. Kim, M.-S.; Pyun, H.-B.; Hwang, J.-K. Panduratin A, an activator of PPAR-α/δ, suppresses the development
of oxazolone-induced atopic dermatitis-like symptoms in hairless mice. Life Sci. 2014, 100, 45–54. [CrossRef]
[PubMed]
42. Kim, H.J.; Ham, S.A.; Paek, K.S.; Hwang, J.S.; Jung, S.Y.; Kim, M.Y.; Jin, H.; Kang, E.S.; Woo, I.S.; Kim, H.J.;
et al. Transcriptional up-regulation of antioxidant genes by PPARδ inhibits angiotensin II-induced premature
senescence in vascular smooth muscle cells. Biochem. Biophys. Res. Commun. 2011, 406, 564–569. [CrossRef]
[PubMed]
43. Marx, N.; Kehrle, B.; Kohlhammer, K.; Grüb, M.; Koenig, W.; Hombach, V.; Libby, P.; Plutzky, J. PPAR
Activators as Antiinflammatory Mediators in Human T Lymphocytes. Circ. Res. 2002, 90, 703–710. [CrossRef]
[PubMed]
44. Bradford, M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing
the principle of protein-dye binding. Anal. Biochem. 1976, 72, 248–254. [CrossRef]
45. Bligh, E.G.; Dyer, W.J. A Rapid Method of Total Lipid Extraction and Purification. Can. J. Biochem. Physiol.
1959, 37, 911–917. [CrossRef] [PubMed]
46. Bartlett, E.M.; Lewis, D.H. Spectrophotometric determination of phosphate esters in the presence and absence
of orthophosphate. Anal. Biochem. 1970, 36, 159–167. [CrossRef]
47. Łuczaj, W.; Domingues, P.; Domingues, M.R.; Pancewicz, S.; Skrzydlewska, E. Phospholipidomic Analysis
Reveals Changes in Sphingomyelin and Lysophosphatidylcholine Profiles in Plasma from Patients with
Neuroborreliosis. Lipids 2017, 52, 93–98. [CrossRef] [PubMed]
48. Pulfer, M.; Murphy, R.C. Electrospray mass spectrometry of phospholipids. Mass Spectrom. Rev. 2003, 22,
332–364. [CrossRef] [PubMed]
49. Reynolds, L.J.; Hughes, L.L.; Yu, L.; Dennis, E.A. 1-Hexadecyl-2-arachidonoylthio-2-deoxy-sn-glycero-3-phosphorylcholine
as a substrate for the microtiterplate assay of human cytosolic phospholipase A2. Anal. Biochem. 1994, 217,
25–32. [CrossRef] [PubMed]
50. Aarsman, A.J.; Neys, F.W.; Van den Bosch, H. Catabolism of platelet-activating factor and its acyl
analog. Differentiation of the activities of lysophospholipase and platelet-activating-factor acetylhydrolase.
Eur. J. Biochem. 1991, 200, 187–193. [CrossRef]
51. Kulmacz, R.J.; Lands, W.E. Requirements for hydroperoxide by the cyclooxygenase and peroxidase activities
of prostaglandin H synthase. Prostaglandins 1983, 25, 531–540. [CrossRef]
52. Smith, C.J.; Zhang, Y.; Koboldt, C.M.; Muhammad, J.; Zweifel, B.S.; Shaffer, A.; Talley, J.J.; Masferrer, J.L.;
Seibert, K.; Isakson, P.C. Pharmacological analysis of cyclooxygenase-1 in inflammation. PNAS 1998, 95,
13313–13318. [CrossRef] [PubMed]
53. Luo, X.P.; Yazdanpanah, M.; Bhooi, N.; Lehotay, D.C. Determination of aldehydes and other lipid peroxidation
products in biological samples by gas chromatography-mass spectrometry. Anal. Biochem. 1995, 228, 294–298.
[CrossRef]
54. Weber, D.; Milkovic, L.; Bennett, S.J.; Griffiths, H.R.; Zarkovic, N.; Grune, T. Measurement of HNE-protein
adducts in human plasma and serum by ELISA—Comparison of two primary antibodies. Redox Biol. 2013, 1,
226–233. [CrossRef] [PubMed]
55. Coolen, S.A.J.; van Buuren, B.; Duchateau, G.; Upritchard, J.; Verhagen, H. Kinetics of biomarkers: Biological
and technical validity of isoprostanes in plasma. Amino Acids 2005, 29, 429–436. [CrossRef] [PubMed]
56. Gouveia-Figueira, S.; Nording, M.L. Development and validation of a sensitive UPLC-ESI-MS/MS method for
the simultaneous quantification of 15 endocannabinoids and related compounds in milk and other biofluids.
Anal. Chem. 2014, 86, 1186–1195. [CrossRef] [PubMed]
57. Siegmund, S.V.; Seki, E.; Osawa, Y.; Uchinami, H.; Cravatt, B.F.; Schwabe, R.F. Fatty acid amide hydrolase
determines anandamide-induced cell death in the liver. J. Biol. Chem. 2006, 281, 10431–10438. [CrossRef]
58. Ulloa, N.M.; Deutsch, D.G. Assessment of a Spectrophotometric Assay for Monoacylglycerol Lipase Activity.
AAPS J. 2010, 12, 197–201. [CrossRef]
146
Int. J. Mol. Sci. 2019, 20, 4249
59. Watkins, B.A.; Kim, J.; Kenny, A.; Pedersen, T.L.; Pappan, K.L.; Newman, J.W. Circulating levels of
endocannabinoids and oxylipins altered by dietary lipids in older women are likely associated with
previously identified gene targets. Biochim. et Biophys. Acta (BBA)-Mol. Cell Biol. Lipids 2016, 1861, 1693–1704.
[CrossRef]
60. Eissa, S.; Seada, L.S. Quantitation of bcl-2 protein in bladder cancer tissue by enzyme immunoassay:
Comparison with Western blot and immunohistochemistry. Clin. Chem. 1998, 44, 1423–1429.
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
147

 International Journal of 
Molecular Sciences
Review
Risk Factors for the Development of Psoriasis
Koji Kamiya *, Megumi Kishimoto, Junichi Sugai, Mayumi Komine and Mamitaro Ohtsuki
Department of Dermatology, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke, Tochigi 329-0498, Japan
* Correspondence: m01023kk@jichi.ac.jp; Tel.: +81-285-58-7360
Received: 24 July 2019; Accepted: 3 September 2019; Published: 5 September 2019
Abstract: Psoriasis is an immune-mediated genetic skin disease. The underlying pathomechanisms
involve complex interaction between the innate and adaptive immune system. T cells interact with
dendritic cells, macrophages, and keratinocytes, which can be mediated by their secreted cytokines.
In the past decade, biologics targeting tumor necrosis factor-α, interleukin (IL)-23, and IL-17 have been
developed and approved for the treatment of psoriasis. These biologics have dramatically changed the
treatment and management of psoriasis. In contrast, various triggering factors can elicit the disease
in genetically predisposed individuals. Recent studies suggest that the exacerbation of psoriasis
can lead to systemic inflammation and cardiovascular comorbidity. In addition, psoriasis may be
associated with other auto-inflammatory and auto-immune diseases. In this review, we summarize
the risk factors, which can be divided into two groups (namely, extrinsic and intrinsic risk factors),
responsible for the onset and exacerbation of psoriasis in order to facilitate its prevention.
Keywords: psoriasis; risk factor; extrinsic risk factor; intrinsic risk factor; onset; exacerbation
1. Introduction
Psoriasis is a chronic inflammatory skin disease characterized by sharply demarcated erythematous
plaques with whitish scale [1,2]. Psoriasis is one of the most frequent chronic inflammatory skin
diseases. The prevalence of psoriasis varies with the country, and psoriasis can appear at any age [3,4],
suggesting that ethnicity, genetic background, and environmental factors affect the onset of psoriasis.
Genetic factors play a significant role in the pathogenesis of psoriasis. Psoriasis susceptibility 1
(PSORS1), which lies within an approximately 220 kb segment of the major histocompatibility complex
on chromosome 6p21, is a major susceptibility locus for psoriasis [5–7]. HLA-Cw6 is the susceptibility
allele within PSORS1 [8]; it is associated with early onset and severe and unstable disease [8,9].
In genetically predisposed individuals, various triggering factors can elicit the disease. In past surveys
from 1982 to 2012, the exacerbating factors for the Japanese population were observed to be stress
(6.4% to 16.6%), seasonal factors (9.7% to 13.3%), infection (3.5% to 8.3%), sun exposure (1.3% to 3.5%),
and β-blockers (0.9% to 2.3%) [10–12]. The comorbidities included hypertension (1.1% to 27.8%),
diabetes mellitus (DM) (7.0% to 13.9%), cardiovascular diseases (4.2% to 8.1%), and tonsillitis (3.5% to
5.4%) [10–12]. The risk factors for psoriasis can be divided into two groups, namely, extrinsic and
intrinsic risk factors (Figure 1). In this review, we focus on each component of these groups and discuss
their effects on the development of psoriasis.
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Figure 1. Risk factors for the onset and exacerbation of psoriasis. As shown in this figure, extrinsic and
intrinsic factors are associated with the onset and exacerbation of psoriasis.
2. Extrinsic Risk Factors
2.1. Mechanical Stress
In patients with psoriasis, skin lesions appear in uninvolved areas after various injuries [13–16]; this
is known as the Koebner phenomenon. Radiotherapy, ultraviolet (UV) B, and even a slight skin irritation
have been reported to trigger new lesions of psoriasis [17–19]. However, psoriatic lesions are not always
observed in the uninvolved skin after injuries [20,21]. Type, site, depth, and degree of trauma may
affect the pathogenesis of the Koebner phenomenon [20]. Under appropriate conditions, the Koebner
phenomenon may occur, especially when there is dermal trauma with epidermal involvement. It is
speculated that increased papillary dermis blood flow helps bring mediators that play a part in the
pathogenesis of psoriasis [20]. However, the mechanisms underlying the Koebner phenomenon remain
to be completely elucidated [20,21]. Nerve growth factor (NGF) is a neurotrophic factor that is expressed
in both the nervous system and peripheral organs. NGF is thought to be associated with the Koebner
phenomenon [22]. After a cutaneous trauma, in a developing psoriasis lesion, keratinocyte proliferation
and up-regulation of NGF in basal keratinocytes are early events and precede epidermotropism of
T lymphocytes [22]. In addition, NGF secreted by the psoriatic keratinocytes is functionally active.
Notably, the keratinocytes of patients with psoriasis produce higher levels of NGF. This study suggests
that NGF plays a critical role in the pathogenesis of psoriasis and that the regulatory role of NGF and
its receptor system is functionally active in the early stage of developing lesions of psoriasis. Resident
memory T cells (TRM) have been described as a non-circulating memory T cell subset that persists
long-term in peripheral tissues; psoriasis is one of the TRM-mediated autoimmune inflammatory
skin diseases [23]. Interestingly, psoriasis lesions could be triggered and sustained by skin-resident
pathogenic T cells in the non-lesioned skin of psoriasis patients [24,25]. Activation of resident T cells
is necessary and sufficient for the development of lesions in psoriasis [24]. A subpopulation of T
cells infiltrating the epidermis during active disease turn into TRM cells, and TRM cells are retained
in resolved psoriasis [26]. These cells establish a site-specific disease memory and are capable of
producing cytokines that play a critical role in the pathogenesis of psoriasis [26]. These observations
suggest that TRM cells are key players not only in the recurrent lesions of psoriasis but also in the
lesions of the Koebner phenomenon. Type 1 interferons (IFNs), such as IFN-α and IFN-β, have been
suggested to play an indispensable role in initiating psoriasis during skin injury [27]. Skin injury
rapidly induces IFN-β from keratinocytes and IFN-α from dermal plasmacytoid dendritic cells through
distinct mechanisms [27]. Host antimicrobial peptide LL37 potentiates double-stranded RNA immune
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pathways and single-stranded RNA or DNA pathways in plasmacytoid dendritic cells. Production of
type 1 IFNs induced by skin injury may explain the Koebner phenomenon.
2.2. Air Pollutants and Sun Exposure
The increase in air pollution over the years has had major effects on the human skin, and various air
pollutants such as polycyclic aromatic hydrocarbons, volatile organic compounds, oxides, particulate
matter, ozone, heavy metals, and UV damage the skin by inducing oxidative stress [28]. Cadmium
is one of the air pollutants which affect the pathogenesis of psoriasis. Patients with severe psoriasis
had higher blood cadmium when compared with the general population [29]. This study suggests
that environmental exposure to cadmium may compromise immunity, and microenvironmental
perturbation can predispose one to the worsening of psoriasis. The UV radiation that reaches the
Earth’s surface is divided into two subtypes: more than 95% UVA (315–400 nm) and 1%–5% UVB
(280–315 nm). In the past several decades, phototherapy has been widely used to treat psoriasis [30].
Both narrowband UVB (311 nm) and excimer laser (308 nm) are currently used as the first-line therapy
for psoriasis, and psoralen UVA (PUVA) is also used as the second-line therapy with preference to
refractory psoriatic plaques [30]. There is a subset of patients with severely photosensitive psoriasis
in whom the condition is predominantly photodistributed and is severe in the summer months [31].
In this study, patients with photosensitive psoriasis showed striking female predominance, very low
mean age of psoriasis onset, family history of psoriasis, a strong HLA-Cw*0602 association, and a
rapid abnormal clinical response to broadband UVA, comprising erythema and/or scaling plaques [31].
A phenotypically distinct subset of psoriasis was characterized by histopathological analysis. In a
certain group, psoriasis can develop after UV exposure.
2.3. Drugs
Drug-related psoriasis is recognized as the onset and exacerbation of psoriasis which is associated
with certain drugs. It is often difficult to identify drug-related causes of psoriasis in clinical situations.
This is because the latency period between the start of the medication and the onset of psoriatic skin
lesions can vary considerably between drugs [32]. In some cases, the psoriasis flare can persist even after
the suspected drug has been discontinued. Moreover, there may be little difference between psoriasis and
drug-related psoriasis in terms of the clinical and histopathological findings [32]. Drug-related psoriasis
would manifest as plaque psoriasis, palmoplantar psoriasis, nail psoriasis, scalp psoriasis, pustular
psoriasis, and erythrodermic psoriasis [33]. In most cases, histopathological findings of drug-related
psoriasis are virtually indistinguishable from those of conventional psoriasis [32]. Histopathological
findings of eosinophilic infiltrates in the dermis and lichenoid reaction might help in the diagnosis of
drug-related psoriasis [34]. While in psoriasis plaques unrelated to drugs, the capillaries in the upper
dermis are convoluted and tortuous, that alteration is sometimes missing in drug-related psoriasis [34].
Moreover, there might also be differences regarding the formation of micro-abscesses of neutrophils in
the upper layer of the epidermis [34]. However, these are just a few and not the most important clues
that might orientate to a drug-related cause of psoriasis. Drug ingestion may result in the exacerbation
of pre-existing psoriasis, induction of psoriatic lesions on clinically uninvolved skin in patients with
psoriasis, or precipitation of the disease in patients without family history of psoriasis as well as in
predisposed individuals [35]. The most widely accepted drugs are β-blockers, lithium, anti-malarial
drugs, interferons, imiquimod, angiotensin-converting enzyme inhibitors, terbinafine, tetracycline,
nonsteroidal anti-inflammatory drugs, and fibrate drugs [32,33,36,37]. The mechanisms of drug-related
psoriasis still remain to be fully elucidated and the molecular mechanisms are complicated. However,
some drugs have been known to affect keratinocyte hyperproliferation and the IL-23/IL-17 axis. Cyclic
adenosine monophosphate (cAMP) is an intracellular messenger that is responsible for the stimulation
of proteins for cellular differentiation and inhibition of proliferation, and β-blockers lead to a decrease
in intraepidermal cAMP, causing keratinocyte hyperproliferation [32,33,38]. Imiquimod-induced skin
inflammation is the most widely accepted psoriasis animal model [39]. Imiquimod, which activates
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the toll-like receptor-7/8, can induce and exacerbate psoriasis, critically dependent on the IL-23/IL-17
axis [39]. Recently, immune check point inhibitors and molecular inhibitors have been used for the
treatment of malignancies and autoimmune diseases, and these drugs may affect the immune system,
leading to the development of psoriasis [40–42]. The symptoms of psoriasis are rarely exacerbated
during biologic therapy. However, psoriasis can also be triggered by biologics [43,44], and this is
recognized as paradoxical reactions. Although most of the paradoxical reactions reported have been
associated with the use of tumor necrosis factor (TNF)-α inhibitors, other biologics targeting interleukin
(IL)-23 and IL-17 are increasingly common [45]. Biologics targeting TNF-α, IL-23, and IL-17 block
immune signaling pathways, which can lead to cytokine imbalances [45]. Paradoxical reactions are
thought to be due to an imbalance in cytokine production with an overproduction of IFN-α and altered
lymphocyte recruitment and migration [45,46]. Suspected drugs should be discontinued and switched
to an alternative drug in patients with drug-related psoriasis.
2.4. Vaccination
Patients with psoriasis are at increased risk of infection, mostly because of treatment with
immunomodulatory or immunosuppressive drugs [47]. Thus, vaccination is recommended to prevent
specific infections [47–49]. However, vaccination can often trigger and exacerbate psoriasis. Several
studies support the association between influenza vaccination and the exacerbation of psoriasis [50,51].
Influenza vaccination may also trigger the onset of psoriasis [52]. Bacillus Calmette–Guerin (BCG)
vaccine, which is a live attenuated strain of Mycobacterium bovis, is primarily used for the prevention of
tuberculosis [53]. Psoriasis can be triggered post BCG vaccination [54,55]. BCG has also been used as
local immunotherapy for bladder cancer, and a case of erythrodermic pustular psoriasis induced by
BCG immunotherapy has been reported [56]. In a retrospective study, psoriasis was found to more
frequently occur after adenovirus vaccination [57]. Psoriasis may also be triggered by other vaccines
such as tetanus–diphtheria vaccination and pneumococcal polysaccharide vaccination [58,59]. These
vaccinations are thought to generate T helper 1 (Th1) and Th17 immune responses which lead to the
onset and exacerbation of psoriasis, although the precise pathomechanisms of psoriasis induced by
vaccination remain to be elucidated. The incidence of psoriasis induced by vaccination is very low;
rather, vaccination is therapeutically effective in patients with psoriasis.
2.5. Infection
The association between psoriasis and streptococcal infection is well established [60]. Psoriasis
occurs after streptococcal infection, and the most common type is guttate psoriasis. Although the
symptoms are self-limited, they can recur with the recurrence of streptococcal infection. Thus,
tonsillectomy may be a potential treatment option for patients with recalcitrant psoriasis associated
with episodes of tonsillitis [61]. Although prior infection with Streptococcus pyogenes is associated with
guttate psoriasis, the ability to trigger guttate psoriasis is not serotype specific [60]. Staphylococcus
(S.) aureus is also associated with the development of psoriasis [38]. Dysregulated skin microbiomes
have been found to be associated with psoriasis [62]. Colonization of S. aureus in the lesions has
been demonstrated in approximately 60% of patients with psoriasis, compared with 5% to 30% of
normal healthy skin [38]. Moreover, the severity of psoriasis significantly correlates with enterotoxin
production by the isolated S. aureus strains [63]. Candida species are a part of the normal human
microbiota, and they were highly detected in either the skin or the mucosal membranes of patients
with psoriasis [64]. A statistically significantly higher Candida species detection rate was also observed
for mucosal membranes [64]. The detection rates of Candida species are significantly higher in patients
with psoriasis as compared with those in healthy controls, especially in the oral mucosa milieux [64].
However, patients with psoriasis and healthy controls do not significantly differ in the rate of Candida
species isolated from the skin [64]. Candida albicans is the most common disease-causing Candida species
and its colonization promotes antifungal immunity, which may be associated with the pathogenesis of
psoriasis [65]. Malassezia is a lipophilic yeast found on skin and body surfaces; it may contribute to
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the exacerbation of psoriasis [38]. It still remains to be established whether the species of Malassezia
can initiate the development of psoriasis lesions. Human immunodeficiency virus (HIV) is also a
well-known risk factor associated with psoriasis [66]. It is paradoxical that, while drugs that target
T lymphocytes are effective in psoriasis, the condition should be exacerbated by HIV infection [66].
Although HIV infection causes the onset and exacerbation of psoriasis, the precise pathomechanisms still
remain to be fully elucidated. Other viruses such as papilloma viruses, retroviruses, and endogenous
retroviruses have also been implicated in psoriasis [67].
2.6. Lifestyle
Smoking and alcohol consumption have been associated with psoriasis. A systematic review and
meta-analysis revealed that patients with psoriasis are more likely to be current or former smokers [68].
Smoking is associated with an increased risk of developing psoriasis [69]. In addition, smoking is
strongly associated with pustular lesions of psoriasis [70]. A trend was found toward an increased
risk of psoriasis with increasing pack-years or duration of smoking. Another study also showed that
there was a positive correlation between the amount and/or duration of smoking and the occurrence
of psoriasis [71]. Alcohol consumption appears to be a risk factor for psoriasis. However, a past
systematic review concluded that there was not enough evidence to establish whether the alcohol
consumption was indeed a risk factor [72]. Nonetheless, alcohol consumption was observed to be
greater in patients with psoriasis than in the general population. Although the relationship between
psoriasis and alcohol consumption is complex and multifactorial, alcohol abuse positively correlates
with psoriasis severity and reduced treatment efficacy [73]. In addition, alcohol abuse is associated with
significantly increased mortality rates [74]. Qualitative changes to the diet may play a significant role in
maintaining the intestinal microbiome, and diet-induced dysbiosis may induce the cytokine imbalances
associated with the pathogenesis of psoriasis [75–77]. Dietary modifications such as supplementation
with polyunsaturated fatty acids, folic acid, vitamin D, and antioxidants can also be considered as
adjuncts in the management of psoriasis [73]. To date, randomized controlled trials have produced
conflicting results. Diet is a complex combination of foods from various groups; nutrients and the rich
diversity of such foods may contribute to its protective effects against psoriasis [78].
3. Intrinsic Risk Factors
3.1. Obesity
Metabolic syndrome is common in patients with psoriasis [79–83] and obesity is strongly associated
with the onset and exacerbation of psoriasis [78,84,85]. Patients with psoriasis have a significantly
higher prevalence of obesity [70,86–88] as well as a higher risk of obesity [89–91]. In a previous
meta-analysis, obesity was associated with severe psoriasis [92]. A large prospective cohort study also
showed a positive association between body mass index (BMI) and psoriasis [93]. However, BMI has
high specificity but low sensitivity to identify adiposity, as it fails to identify half of the people with
excess body fat [94,95]. In contrast, waist circumference is more reliable measure of body fat, and many
studies have shown a strong association between waist circumference and psoriasis [93,96,97]. Obesity
can be defined as the expansion of white adipose tissue [85], and various mediators secreted by adipose
tissue lead to a low-grade inflammatory state, contributing to the pathogenesis of psoriasis [98–101].
Pro-inflammatory adipokines such as TNF-α, IL-6, leptin, and adiponectin are produced in adipose
tissue [98]. Blocking the TNF-α signaling pathway improves the inflammatory cycle of psoriasis,
while it does not improve insulin sensitivity in patients with type 2 DM [102]. Leptin is an adipose
tissue hormone that functions as an afferent signal in a negative feedback loop that maintains
homeostatic control of adipose tissue mass [103]. Leptin is an important regulator of metabolic status
and influences inflammatory and immune responses [104]. Leptin can enhance immune functions,
including inflammatory cytokine production in macrophages, granulocyte chemotaxis, and increased
Th17 proliferation [105,106]. The presence of elevated leptin inhibits the differentiation of regulatory
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T cells, which maintain tolerance and prevent psoriasis, in adipose tissue [106]. In fact, serum or
plasma levels of leptin are higher in patients with psoriasis as compared to the healthy controls [107].
In addition, tissue levels of leptin are increased in the skin of patients with psoriasis [108]. Adiponectin
is an adipocyte-specific factor which contributes to a beneficial metabolic action in whole-body
energy homeostasis [109]. In contrast to leptin, adiponectin protects cells from apoptosis and reduces
inflammation in various cell types [109]. Although adiponectin may act as an anti-inflammatory
adipokine in patients with psoriasis, the association still remains unclear [110]. Weight loss itself
appears to improve psoriasis symptoms [111,112] and is likely to improve decreased response to oral
systemic therapies and biologics [113–117]. Moreover, weight loss may decrease the risk of drug
toxicity of systemic therapies [118–121].
3.2. Diabetes Mellitus
The prevalence of DM is generally influenced by ethnic origin and lifestyle factors. However,
the prevalence of DM might be similar among diverse patient populations, ethnic backgrounds,
and baseline therapy [122]. A meta-analysis revealed that psoriasis was associated with DM [122].
Other meta-analyses have also demonstrated the association between psoriasis and the risk of
DM [81,123]. DM is divided into two groups, namely, type 2 and type 1 DM. Patients with psoriasis
have a significantly higher risk of type 2 DM. However, the prevalence of type 2 DM does not correlate
with patient age or severity of psoriasis [124]. Psoriasis is a marker for increased risk of type 2 DM
independent of its severity. It is unclear which disease comes first, psoriasis or type 2 DM [124].
As mentioned above, obesity is a risk factor for psoriasis. Obesity contributes to the onset and
exacerbation of type 2 DM directly. Thus, obesity is associated with psoriasis as well as type 2 DM,
and type 2 DM may not contribute to the pathogenesis of psoriasis directly. In contrast to type 2 DM,
type 1 DM is a chronic disease characterized by insulin deficiency due to autoimmune destruction
of insulin-producing pancreatic β-cells, leading to hyperglycemia [125]. Proinflammatory cytokines,
including TNF-α, are involved in the pathogenesis of type 1 DM [126,127]. Interestingly, both Th1
and Th17 cells may contribute to the onset of type 1 DM [128,129]. Although type 1 DM may not
contribute to the pathogenesis of psoriasis directly, the TNF-α/IL-23/IL-17 axis plays a crucial role in
the pathogenesis of psoriasis and type 1 DM.
3.3. Dyslipidemia
Psoriasis is associated with obesity [70,86–88], and excess adipose tissue may contribute to
dyslipidemia. Patients with psoriasis have a higher prevalence of dyslipidemia, which is likely
to increase with the severity of psoriasis [130–133]. A past study including 70 patients with
psoriasis revealed that dyslipidemia was observed in 62.85% of the patients [133]. Most often it
was hypertriglyceridemia (39%) and hypertriglyceridemia with a lowered value of high-density
lipoprotein (HDL). Dyslipidemia can also appear during oral systemic therapies for psoriasis [134].
Retinoids have the most potent activity leading to dyslipidemia, such as increased levels of triglycerides,
total cholesterol, low-density lipoprotein cholesterol, and very-low-density lipoprotein cholesterol
and simultaneously decreased levels of HDL cholesterol [135–137]. Cyclosporin can also lead to
dyslipidemia [138]. It is possible that cyclosporine unmasks a latent tendency for mild to moderate
hypertriglyceridemia [138], and this study concluded that fasting triglyceride levels should be monitored
during cyclosporine therapy, especially after 1 to 2 months of use, and in patients with preexisting
increased triglycerides and/or a history of etretinate use. Although dyslipidemia is associated with
immunological abnormalities [134], it still remains unknown whether dyslipidemia affects the onset
and exacerbation of psoriasis.
3.4. Hypertension
In a meta-analysis, patients with psoriasis showed greater prevalence and incidence of
hypertension [139]. This meta-analysis also revealed that severe psoriasis was associated with
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greater incidence of hypertension [139]. Patients with psoriasis appear to have more severe
hypertension [140,141]. A multicenter noninterventional observational study including 2210 patients
with psoriasis revealed that 26% of patients with psoriasis had hypertension, and the incidence of
hypertension was higher when compared with the general population [142]. Conversely, hypertension
may be associated with the incidence of psoriasis [143]. Although psoriasis and hypertension have
shared risk factors such as obesity and smoking, most studies have shown an independent association
of psoriasis with hypertension after adjusting for these risk factors [139]. The mechanisms underlying
this association remain unknown.
3.5. Mental Stress
Mental stress is a feeling of strain and pressure caused by internal perceptions which lead to
anxiety or other negative emotions. Mental stress occurs when individuals think the demands exceed
their ability to cope. Mental stress is commonly regarded as a well-established trigger of psoriasis
and many patients with psoriasis and physicians believe that mental stress exacerbates psoriasis.
Although psoriasis leads to higher degree of distress as proved by measurements on Dermatology
Life Quality Index scales, the relation between mental stress and psoriasis is complex. In a past
systematic review including 39 studies (32,537 patients), 46% of patients believed their disease was
stress reactive and 54% recalled preceding stressful events [144]. However, there was no high-quality
evidence to support the notion that the preceding stress was strongly associated with the onset and
exacerbation of psoriasis. The association was based primarily on retrospective studies with many
limitations. It seems unclear whether mental stress affects the clinical course of psoriasis. In contrast, a
prospective study concluded that cognitive and behavioral patterns of worrying and scratching were
both independently related to an increase four weeks later in disease severity and itch, at moments
when patients experienced a high level of daily stressors [145]. At these moments, stressors also
interacted with vulnerability factors, suggesting that patients with more daily stress and high worrying
and scratching had particularly worsened disease severity and itch. Scratching in response to itch
subsequently leads to an itch–scratch–itch cycle causing the exacerbation of psoriasis. Further studies
are necessary to elucidate the association between mental stress and psoriasis.
4. Conclusions
In this review, both extrinsic and intrinsic risk factors for the development of psoriasis were
discussed in detail. Biologics have dramatically changed the treatment of psoriasis. In contrast,
elimination of the risk factors is also important for controlling the disease. From the clinicians’
perspective, the exacerbation of psoriasis induced by the Koebner phenomenon and drugs can be
avoided by proper knowledge. From the patients’ perspective, lifestyle could be modified by proper
education, although the extent varies among patients. However, various factors interact with each
other and can affect the pathogenesis of psoriasis directly and/or indirectly. For example, obesity,
dyslipidemia, and hypertension are associated with the course of psoriasis and are also dependent
on the patient’s age, lifestyle, and concomitant diseases. Moreover, the impacts of the patient’s age,
lifestyle, and concomitant diseases vary among individuals. The risk factors of psoriasis are not fully
understood, and future studies need to successfully establish preventive approaches for psoriasis.
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DM Diabetes mellitus
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PUVA Psoralen ultraviolet A
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Abstract: (1) Background: In literature it is reported that 20–30% of psoriatic patients evolve to
psoriatic arthritis over time. Currently, no specific biochemical markers can either predict progression
to psoriatic arthritis or response to therapies. This study aimed to identify osteoimmunological
markers applicable to clinical practice, giving a quantitative tool for evaluating pathological status
and, eventually, to provide prognostic support in diagnosis. (2) Methods: Soluble (serum) bone
and cartilage markers were quantified in 50 patients with only psoriasis, 50 psoriatic patients
with psoriatic arthritis, and 20 healthy controls by means of multiplex and enzyme-linked
immunoassays. (3) Results: Differences in the concentrations of matrix metalloproteases (MMPs),
tissue inhibitors of metalloproteinases (TIMPs), receptor activator of nuclear factor kappa-B- ligand
(RANK-L), procollagen type I N propeptide (PINP), C-terminal telopeptide of type I collagen
(CTx-I), dickkopf-related protein 1 (DKK1), and sclerostin (SOST) distinguished healthy controls
from psoriasis and psoriatic arthritis patients. We found that MMP2, MMP12, MMP13, TIMP2, and
TIMP4 distinguished psoriasis from psoriatic arthritis patients undergoing a systemic treatment, with
a good diagnostic accuracy (Area under the ROC Curve (AUC) > 0.7). Then, chitinase-3-like protein
1 (CHI3L1) and MMP10 distinguished psoriasis from psoriatic arthritis not undergoing systemic
therapy and, in the presence of onychopathy, MMP8 levels were higher in psoriasis than in psoriatic
arthritis. However, in these latter cases, the diagnostic accuracy of the identified biomarkers was
low (0.5 < AUC < 0.7). (4) Conclusions. By highlighting never exploited differences, the wide
osteoimmunological biomarkers panel provides a novel clue to the development of diagnostic paths
in psoriasis and psoriasis-associated arthropathic disease.
Keywords: psoriasis; psoriatic arthritis; osteoimmunological markers; bone resorption
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1. Introduction
Adult psoriatic disease depicts a continuum encompassing disease progression from psoriasis (Ps)
to psoriatic arthritis (PsA) [1]. In contrast to children, in adults, PsA manifests mainly after Ps and its
musculoskeletal damages may be prevented with an early diagnosis and treatment [1,2]. Remarkably,
20–30% of Ps patients develop PsA but the non-clinically oriented instrumental screening of psoriatic
patients is neither routinely adopted nor recommended due to the connected costs [1]. Thus, both
clinical signs, such as psoriatic onychopathy and non-specific inflammatory parameters, are considered
to identify Ps patients with a putative higher risk of developing PsA [3]. This is also accompanied
by other proposed tools, such as the psoriasis epidemiology screening tool (PEST) questionnaire,
evaluating the risk of developing PsA [4]. However, epidemiological studies based on clinical health
records comparing Ps and PsA cohorts displayed contrasting results about the possible risk factors
implicated in the evolution from Ps to PsA [5].
A biochemical marker that clearly predicts PsA in a cohort of Ps patients is still elusive. A biomarker
is defined as a measurable characteristic indicating a biological or pathophysiological process and can
be used to identify the risk to develop a certain disease [6]. Several studies investigated the association
of different biomarkers with PsA. This condition has been associated with higher levels of cartilage
oligomeric matrix protein (COMP), osteoprotegerin (OPG), matrix metalloproteinase 3 (MMP3), and
the ratio between C-propeptide of type II collagen (CIIP) and collagen fragment neoepitope Col2–3/4
(C2C) [7]. Other studies found higher levels of CXCL10 in PsA patients compared to Ps patients [8],
interleukin (IL)-6 [9], Dikkopf-1 (DKK-1), and macrophage-colony stimulating factor (M-CSF) [10].
However, the clinical significance of these studies is somehow limited due to the restricted panel of
biomarkers considered and, more importantly, the lack of consideration of the therapeutic regimens
and comorbidities/clinical signs (e.g., nail involvement).
Based on this background, this study aimed to investigate the possible association between a wide
panel of osteoimmunological biomarkers with Ps and PsA, and in the relative sub-cohorts in order to
identify a possible laboratory tool that could support PsA diagnosis and early prediction.
2. Results
2.1. Clinical Features of the Study Cohorts
Table 1 summarizes the study population demographics and clinical features.
Table 1. Clinical features of patients at the time of recruitment.
Variables Total Cases (n = 100) Ps Group (n = 50) PsA Group (n = 50) CTRL Group (n = 20)
Age median (IQR), years 49 (19–82) 48 (19–82) 48 (28–79) 48 (29–67)
Female, n (%) 28 (28) 17 (34) 11 (22) 10 (50)
Male, n (%) 72 (72) 33 (66) 39 (78) 10 (50)
BMI median (IQR), kg/m2 25 (23–28) 25 (23–29) 26 (23–28) 24 (22–25)
Ps duration median (IQR),
months 195 (83–319) 200 (67–347) 195 (110–317) -
Eruptive/stable Ps, (n) - 39/11 -
PsA duration median (IQR),
months - - 25 (4–110) -
PASI median (IQR) 5 (2–8) 6 (5–12) 4 (1–7) -
Onychopathy (n) 43 19 24 -
Non systemic therapy (n) 64 31 33 -
Systemic therapy (n) 36 19 17 -
Acitretin (n) (dose) 1 (20 mg/die) 1 (20 mg/die) 0 -
CsA (n) (dose) 6 (237.5 (221.3–257.5)mg/die)
5 (250 (220–260)
mg/die) 1 (225 mg/die) -





Systemic prednisone (n) (dose) 1 (10 mg/die) - 1 (10 mg/die) -
BMI: Body mass index, CsA: Cyclosporin, CTRL: Controls, IQR: Interquartile range, MTX: Methotrexate, n: number,
Ps: Psoriasis, PsA: Psoriatic arthritis.
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In both Ps and PsA groups, a prevalence of male subjects, 66% and 78%, respectively, was observed
despite no gender prevalence being reported. Median ages were 48 (19–82) years in Ps, 51(28–79) years
in PsA, and 48 (29–67) years in controls. The body mass index (BMI), in the three groups, was 25
(23–29), 26 (23–28), and 24 (22–25) kg/m2, respectively.
The Psoriasis Area Severity Score (PASI) was higher in Ps (6 (5–12)) than in PsA (4 (1–7)).
Onychopathic signs were present in 38% of Ps subjects and 48% of PsA subjects, according to the
literature [11,12], PsA occurred after the diagnosis of Ps in 88% of patients. At recruitment, patients
undergoing systemic therapy (ST) were 38% Ps and 34% PsA patients, respectively. Among these,
28 patients were treated with methotrexate (MTX, 13 Ps and 15 PsA), 6 with cyclosporine (CsA, 5 Ps
and 1 PsA), 1 with acitretin (Ps), and 1 with cortisone (PsA).
2.2. Biochemical Characterization of the Study Cohorts
When considered in their entirety, without any subgrouping for treatment status, no significant
differences were observed for any of the tested markers between Ps and PsA. Conversely, compared
to the control group (CTRL), both Ps and PsA groups differed for most of the analyzed molecules,
except for MMP3, MMP7, MMP12, tissue inhibitors of metalloproteinase (TIMP)-1, TIMP-2, OPG,
C-telopeptide of type II collagen (CTx-II), and chitinase-3-like protein 1 (CHI3L1) (Table 2).
















(35.00–1266.00) p < 0.001 ⇑ p = 0.001 ⇑
MMP2 (ng/mL) 91.70(74.58–102.26) 21.18 (7.8–76.60) 16.52 (4.75–78.11) p < 0.001 ⇓ p < 0.001 ⇓
MMP3 (ng/mL) 6.27 (3.10–11.67) 2.39 (1.14–4.93) 2.29 (0.74–4.44) n.s n.s
MMP7 (ng/mL) 0.86 (0.47–1.16) 0.42 (0.22–1.08) 0.38 (0.19–1.31) n.s n.s
MMP8 (ng/mL) 0.61 (0.51–0.71) 1.35 (0.83–3.01) 1.32 (0.71–3.15) p = 0.001 ⇑ p = 0.009 ⇑
MMP9 (ng/mL) 0.83 (0.61–1.25) 8.22 (3.31–11.72) 6.59 (3.35–11.63) p < 0.001 ⇑ p < 0.001 ⇑
MMP10 (pg/mL) 1.60 (1.60–1.60) 317 (1.60–824.30) 257.47(1.60–541.60) p < 0.001 ⇑ p < 0.001 ⇑
MMP12 (pg/mL) 1.00 (1.00–444.20) 86.63(11.76–165.40)
76.99
(7.65–144.10) n.s n.s








(10.09–83.73) 59.83 (8.91–76.81) p = 0.011 ⇓ p < 0.001 ⇓
TIMP3 (ng/mL) 0.09 (0.09–1.66) 8.79 (0.76–10.73) 6.98 (0.61–9.17) p < 0.001 ⇑ p < 0.001 ⇑
TIMP4 (pg/mL) 1072.75(701.90–1934.00)
27.11
(1.70–320.90) 1.70 (1.70–175.20) p < 0.001 ⇓ p < 0.001 ⇓





(86.79–235.20) p < 0.001 ⇓ p < 0.001 ⇓
PINP (ng/mL) 46.17(33.55–62.88) 5.94 (5.01–7.40) 7.08 (4.87–8.22) p < 0.001 ⇓ p < 0.001 ⇓
CTx-I (ng/mL) 1.70 (1.38–2.14) 0.55 (0.44–0.61) 0.51 (0.40–0.62) p < 0.001 ⇓ p < 0.001 ⇓
CTx-II (ng/mL) 0.25 (0.19–0.29) 0.26 (0.20–0.31) 0.26 (0.20–0.30) n.s n.s











Measures are expressed as median (IQR). CHI3L1: chitinase-3-like protein 1, CTRL: controls, CTx-I: C-terminal
cross-linked telopetide of type I collagen, CTx-II: C-terminal cross-linked telopeptides of type II collagen, DKK1:
Dickkopf-related protein 1, IQR: Interquartile range, MMP: Matrix metalloproteinases, n.s.: Not significant, PINP:
procollagen type I N-terminal propeptide, Ps: Psoriasis, PsA: Psoriatic arthritis, RANKL: receptor activator of NF-κB
ligand, TIMP: tissue inhibitor of metalloproteinases, SOST: sclerostin.
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Furthermore, statistically significant correlations were found between markers’ concentration
and duration of both Ps and PsA: MMP2, MMP12, MMP13, TIMP1, TIMP2, TIMP3, sclerostin (SOST),
and CHI3L1 in Ps (positive correlation) and with MMP10 and TIMP2 in PsA (negative correlation).
Moreover, in Ps group, MMP8, MMP10, and CTx-I positively correlated with PASI score, while TIMP4
was negatively correlated (Table 3).
Table 3. Correlation analysis between osteoimmunological biomarker concentrations and duration of
disease or PASI score. Correlations reaching statistical significance are given in bold.
Markers
Ps Duration PsA Duration Ps PASI PsA PASI
p r p r p r p r
MMP1 0.486 −0.10 0.790 −0.04 0.216 0.18 0.647 0.07
MMP2 0.001 0.46 0.929 0.01 0.322 −0.14 0.205 −0.18
MMP3 0.549 0.09 0.458 0.11 0.459 −0.11 0.829 −0.03
MMP7 0.651 0.07 0.120 −0.23 0.316 0.14 0.746 −0.05
MMP8 0.177 0.19 0.098 −0.24 0.040 0.29 0.054 0.27
MMP9 0.630 0.07 0.306 −0.15 0.257 0.16 0.226 0.17
MMP10 0.876 0.02 0.025 −0.32 0.004 0.40 0.057 0.27
MMP12 0.001 0.45 0.418 −0.12 0.372 −0.13 0.313 −0.15
MMP13 0.010 0.36 0.392 −0.13 0.667 −0.06 0.781 −0.04
TIMP1 0.016 0.34 0.049 −0.29 0.935 0.01 0.361 −0.13
TIMP2 0.037 0.30 0.203 −0.19 0.871 0.02 0.372 −0.13
TIMP3 0.042 0.29 0.087 −0.25 0.946 0.01 0.709 −0.05
TIMP4 0.065 0.26 0.052 0.28 0.041 −0.29 0.497 −0.10
OPG 0.341 0.14 0.176 0.20 0.067 −0.26 0.448 −0.11
RANKL 0.335 −0.14 0.616 −0.07 0.450 −0.11 0.680 0.06
PINP 0.571 −0.08 0.638 −0.07 0.999 0.00 0.480 0.10
CTX-I 0.215 −0.18 0.341 0.14 0.048 0.28 0.440 0.11
CTX-II 0.398 0.12 0.956 −0.01 0.124 −0.22 0.161 −0.20
DKK1 0.233 0.17 0.684 −0.06 0.474 −0.10 0.985 0.00
SOST 0.015 0.34 0.343 −0.14 0.286 −0.15 0.421 −0.12
CHI3L1 0.010 0.36 0.384 0.13 0.284 −0.15 0.596 0.08
CHI3L1: Chitinase-3-like protein 1, CTx-I: C-terminal cross-linked telopetide of type I collagen, CTx-II: C-terminal
cross-linked telopeptides of type II collagen, DKK1: Dickkopf-related protein 1, MMP: Matrix metalloproteinases,
PASI: Psoriasis area severity index, p: p value, PINP: Procollagen type I N-terminal propeptide, Ps: Psoriasis, PsA:
Psoriatic arthritis, RANKL: Receptor activator of NF-κB ligand, r: Pearson coefficient, TIMP: Tissue inhibitor of
metalloproteinases, SOST: Sclerostin.
2.3. Effect of Systemic Treatments
The Ps and PsA cohorts were further divided based on the therapy regimen (subjects undergone
to systemic treatments (ST) and not systemically treated (NST)).
When Ps and PsA subjects ST (n = 19 and n = 17, respectively) were compared, MMP2 (57.47 vs.
11.50 ng/mL, p = 0.006), MMP12 (124.10 vs. 76.43 pg/mL, p = 0.013), MMP13 (62.48 vs. 4.90 pg/mL,
p = 0.029), TIMP2 (80.00 vs. 50.34 ng/mL, p = 0.001), and TIMP4 (177.7 vs. 1.7 pg/mL, p = 0.012) were
higher in Ps to PsA (Figure 1A). As expected, PASI score was higher in Ps than in PsA patients (5.5 vs.
1.8, p = 0.004).
The Relative Operating Characteristic (ROC) analysis shows that the area under the ROC curve
(AUC) for both the single markers (MMP2: 0.768, MMP12: 0.743, TIMP2: 0.811, TIMP4: 0.724) and
their combination (0.755 to 0.845) display a moderately accurate diagnostic potential in discriminating
Ps from PsA ST patients. Noteworthy, the combination of all these markers gave the highest diagnostic
accuracy (AUC = 0.845) (Figure S1).
By focusing on the NST group, Ps NST (n = 31) and PsA NST (n = 33) significantly differed for
MMP10 (340.9 vs. 224.9 pg/mL, p = 0.031), and CHI3L1 (65.21 vs. 91.54 pg/mL, p = 0.042) (Figure 1B),
with the PASI score being always higher in Ps than in PsA (7 vs. 4, p = 0.002).
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Figure 1. (a) Changes in PASI and serum profile of osteoimmunological markers in Ps ST group (hashed
box) and PsA ST group (gray box). (b) Changes in PASI and serum profile of osteoimmunological
markers in Ps NST group (hashed box) and PsA NST group (gray box). The box and whiskers plot
identify, respectively, the value of the median (intermediate line), the 25th and 75th percentile (box),
and the minimum and maximum value (whiskers). Asterisks indicate significant intergroup differences
(* p < 0.05, ** p < 0.01). CHI3L1: Chitinase-3-like protein 1, MMP: Matrix metalloproteinases, NST:
not systemically treated, PASI: Psoriasis area severity index, Ps: Psoriasis, PsA: Psoriatic arthritis, ST:
systemically treated, TIMP: Tissue inhibitor of metalloproteinases.
In Ps NST, MMP10 positively correlated with CHI3L1 (r = 0.446, p = 0.011), and negatively with
PsA duration (r = −0.32, p = 0.024).
From the ROC analysis emerges the AUC for these markers and their combinations are below
0.700 (Figure S2). Compared to Ps NST (n = 31), Ps ST (n = 19) had significantly increased serum levels
of MMP2 (57.47 vs. 10.37 ng/mL, p = 0.007), MMP3 (3.52 vs. 1.65 ng/mL, p = 0.026), MMP12 (124.1
vs. 31.84 pg/mL, p = 0.002), MMP13 (62.48 vs. 12.21 pg/mL, p = 0.013), TIMP2 (80.00 vs. 14.34 ng/mL,
p = 0.003), TIMP3 (9.83 vs. 1.33 ng/mL, p = 0.022), and CTx-I (265.2 vs. 246.8 pg/mL, p = 0.01) (Figure 2).
Interestingly, no osteoimmunological biomarkers were statistically different in the comparison
PsA ST (n = 17) vs. PsA NST (n = 33).
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Figure 2. Changes in the serum profile of osteoimmunological markers in Ps ST group (hashed box)
and Ps NST group (grey box). The box and whiskers plot identifies, respectively, the value of the
median (intermediate line), the 25th and 75th percentile (box), and the minimum and maximum
value (whiskers). Asterisks indicate significant intergroup differences (* p < 0.05, ** p < 0.01). CTx-I:
C-terminal cross-linked telopetide of type I collagen, MMP: Matrix metalloproteinases, NST: not
systemically treated, Ps: Psoriasis, PsA: Psoriatic arthritis, ST: systemically treated, TIMP: Tissue
inhibitor of metalloproteinases.
2.4. Onychopathy Biochemical Signature
Ps patients with onychopathy (Ps O) had higher PASI (6.5 vs. 3.7 p = 0.009) and higher circulating
MMP8 (1.96 vs. 1.26 ng/mL, p = 0.028) compared to onychopathic PsA patients (PsA O) (Figure 3).
ROC analysis gave an AUC below 0.700, for MMP8 (Figure S3).
Non-onychopathic Ps compared to PsA counterparts achieved significance only for PASI (6.6 vs.
1.7 p = 0.002).
Figure 3. Changes in PASI and serum profile of MMP8 in Ps O group (hashed box) and PsA O group
(dotted box). The box and whiskers plot identifies, respectively, the value of the median (intermediate
line), the 25th and 75th percentile (box), and the minimum and maximum value (whiskers). Asterisks
indicate significant intergroup differences (* p < 0.05, ** p < 0.01). MMP: Matrix metalloproteinasis, PASI:
Psoriasis area severity index, Ps O: Psoriatic onychopathy, PsA O: Psoriatic arthritis with onychopathy.
3. Discussion
The present study investigated two different possible sets of osteoimmunological biomarkers to
screen for PsA among Ps. This is of particular interest because Ps patients, especially those with a mild
cutaneous involvement, having a subclinical PsA are hardly identifiable using standard measures.
The consequent delayed diagnosis of PsA results in a more severe impact on the joint status. Imaging
techniques have a high diagnostic potential, but they are intrinsically limited in terms of predictability.
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Contrarily, since biochemical markers expression anticipates the micro/macro-structural changes, they
have a predictive potential. However, markers discriminating between Ps and PsA have not been
identified, although advances have been gained in the biochemical differential characterization between
RA and seronegative arthropathies [13].
Previous findings gave controversy results, eventually due to the high within-cohort heterogeneity.
Indeed, in our study, when the entire cohorts are considered, the main differences were between Ps
and PsA and healthy controls. Similarly, previous studies failed in determining any difference between
Ps and PsA in sRANKL, COMP, and OPG concentrations. A possible explanation of differences
found comparing Ps and PsA patients with their healthy counterparts is that, actually, some Ps
patients that are asymptomatic for PsA are, instead, suffering from subclinical cartilage and bone
changing [14]. In particular, the pathological changes in cartilage and bone can be associated with
enthesitis, dactylitis, nail dystrophy, and new bone apposition. Importantly, aberrant bone formation
characterizes and clearly differentiates PsA from rheumatoid arthritis (RA) and other inflammatory
arthritis where resorptive phenomena prevail [15,16]. On the other hand, the inclusion of patients
under different treatment regimens and/or with different clinical features within the same cohorts
makes the comparison less fine.
A first set of biomarkers, composed matrix metalloproteinases, and their tissue inhibitors comprises
of MMP2, MMP12, MMP13, TIMP2, and TIMP4 whose circulating levels are higher in Ps undergoing
systemic therapy compared to the parallel PsA cohort. Moreover, the ROC analysis of both single and
differently combined markers (even more, the combination of all five) gave a good diagnostic accuracy.
Consequently, this panel is particularly promising because of the wide use of MTX in both Ps and PsA.
The effects of systemic treatments on the osteoimmune function is clearly depicted, in our study, by the
decrease in the circulating levels of most of the markers here considered.
A second set of biomarkers seems to be useful in differentiating between Ps and PsA that have
never undergone systemic treatments (NST). Given their naïve condition, the comparison of Ps NST and
PsA NST patients could be considered as the most useful. This set comprises of MMP10 and CHI3L1
whose levels are, moreover, reciprocally correlated. CHI3L1 is an inactive chitinase due to the lack of
the catalytic domain whose physiological functions have not been fully clarified, although it may play
a role in inflammation [17–19]. Biological activities of CHI3L1 include regulation of cell proliferation,
adhesion, migration, and activation. Furthermore, CHI3L1 is produced by a variety of inflammatory
cells, including neutrophils, monocytes/macrophages, and osteoclasts [20], and its induction has been
reported in patients suffering from many diseases, including several autoimmune disorders [21]. In
addition, elevated plasma levels of CHI3L1 have also been found in RA [22]. According to previous
findings, Ps patients experience higher CHI3L1 circulating levels than healthy subjects [23]. Our result
seems to indicate that this protein could be a new inflammatory biomarker associated with PsA.
Nail psoriasis is, among others, a risk factor for the development of PsA, especially within the distal
interphalangeal joints, as suggested by McGonagle and colleagues [24,25]. Remarkably, the enthesistis
of the extensor tendon of the finger in the distal interphalangeal joint of the hand may clinically manifest
with psoriatic onychopathy [26]. Although it is reported in literature that psoriatic onychopathy
appears in 50% of Ps and in 93% of PsA patients [27], PsA is diagnosed after Ps development in 88% of
adult patients. Several epidemiological studies associated psoriatic onychopathy with Ps duration, Ps
early onset, high PASI, and concurrent PsA [28]. Systemic therapies, both biologics and non-biological,
are regarded as effective and as a possible secondary treatment step in case of lack/loss of response
to topical therapies in patients with high PASI or high DLQI (the dermatology life quality index) or
PsA [29]. MTX and CsA can improve the nail lesions, with MTX being more effective in treating nail
matrix changes, while CsA is more effective in improving nail bed scores [30].
In those subjects presenting onychopathy signs, MMP8 concentrations were higher in Ps than in
PsA. Being a collagenase, MMP8 preferentially cleaves the interstitial type I collagen and is the first
collagenase that appears during dermal wound-healing [31,32]. MMP8 is expressed by keratinocytes,
fibroblasts, and granulocytes, at the level of the cutaneous lesions, and by synovial cells. In this latter
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case it was hypothesized that MMP8 solves a function in osteo-articular remodeling [33]. It is known
that MMP-expressing cells are found in high amounts in the flogotic joint [34]. Therefore, it could be
hypothesized that the circulating levels of MMP8 in PsA patients with onychopathy, compared to their
Ps counterparts, were low because of its release into the close joint structures rather than into the blood
stream. In fact, in PsA patients, as in those with RA, the levels of MMPs are elevated within the joint,
which is a closed environment [35]. On the contrary, in Ps subjects without any joint involvement,
MMP8 is released directly into the bloodstream, since expressed at the skin level which is, instead,
an open system. Although possible, this speculation needs to be demonstrated.
The cross-sectional nature of this study and the somehow limited sample size (pilot study)
represent the main limitations, although this is compensated by the great homogeneity of the selected
cohorts that limits the number of variables potentially affecting the circulating levels of the analyzed
biomarkers. Remarkably, due to the exiguity of the sample, it was not possible to evaluate the
influences of drugs and severity on the biomarker’s levels. Future studies are mandatory to assess
the osteoimmunological biomarker specificity for PsA and further compare the present findings with
other autoimmune diseases involving joints, such as RA or gout.
4. Methods
4.1. Ethical Committee
The clinical trial was approved by the ethical committee (BioArp, Ospedale San Raffaele, Milano,
Italia), and registered at clinicaltrials.gov (NCT03455166). The study was carried out following the rules
of the Declaration of Helsinki of 1975, revised in 2008 (https://www.wma.net/what-we-do/medical-
ethics/declaration-of-helsinki/).
A written consent to the use of clinical data was obtained from all patients after being informed
about the study procedures, their benefits, and eventual risks.
4.2. Patients Selection and Study Design
Patients with a diagnosis of plaque psoriasis (Ps, n = 50) and patients with Ps and PsA (PsA, n = 50)
were enrolled at the department of dermatology and venereology of the IRCCS Istituto Ortopedico
Galeazzi (Milan, Italy), starting from June 2015 until April 2017, during routine clinical activities.
Inclusion criteria for Ps patients were plaque psoriasis (no erythrodermic, inverse, or guttate forms)
for more than six months, neither current nor previous treatment with biological drugs, and no
joint involvement.
Inclusion criteria for PsA patients fulfilling classification for psoriatic arthritis (CASPAR)
criteria [36] were active peripheral (disease activity index for psoriatic arthritis (DAPSA) [37] ≥5 points)
and axial arthropathy (Bath ankylosing spondylitis disease activity index (BASDAI) [38] ≥4 points),
as well as enthesitis (Leeds enthesitis index (LEI) [39] >0 points), and dactylitis (dactylitis severity score
(DSS) [40] >2 points) with cutaneous involvement (PASI >3), neither current treatment with biological
drugs nor biological treatment. For PsA, we included a new diagnosis of PsA in order, but also of
patients without an experience with biologics or patients unresponsive to biological treatments willing
to start a new systemic treatment, or, if they experienced biologics, they stopped them in favor of a
systemic conventional treatment for a minimum of 4 months before entering in this study. Remarkably,
patients should have suspended topical therapy for at least 4 weeks.
Psoriatic onychopathy was included only if nail psoriasis severity index (NAPSI) [41] ≥ 3 points.
Exclusion criteria, common to the two groups, included pregnancy, current or previous
malignancies, other acute or chronic inflammatory diseases, infectious diseases (human
immunodeficiency virus (HIV), hepatitis B and C [42], tuberculosis), other rheumatologic diseases,
primary bone metabolic diseases, recent bone fractures (within 6 months), anxiety, psychosis,
or depressive disorders, supplementations, or particular diets (included fasting) [43–45].
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4.3. Dermatology and Rheumatology Assessment of Patients
During the outpatient visit, Ps history, disease onset and evolution were evaluated. The most
prevalent type of Ps was determined, along with the body sites involved and the presence of the
onychopathic trait. A psoriasis area and severity index (PASI) score was assigned by two independent
board-certified dermatologists.
PsA diagnosis was formulated by two independent board certified rheumatologists prior to the
dermatological examination, based on anamnestic and clinical evaluations of the patient’s inflammatory
and imaging indexes. In particular, based on CASPAR criteria [36] and ultrasound (US) or nuclear
magnetic resonance imaging (NMRI), the specialist evaluated the presence of Ps, signs and symptoms
of joint inflammation (i.e., dactylitis, enthesitis), and reduced joint mobility.
Finally, laboratory analyses completed the diagnostic path by investigating markers useful in the
differential diagnosis with other forms of inflammatory arthritis (e.g., rheumatoid factor, anti-CCP,
inflammatory indices).
4.4. Blood Sampling and Biochemical Determinations
Blood samples were collected by standard venipuncture of the antecubital vein in SST II Advance
Vacutainer® (Becton, Dickinson and Co., Franklin Lakes, NJ, USA). Blood was immediately centrifuged
at 1300× g (10 min, 15 ◦C) and serum was aliquoted and stored at −80 ◦C until assayed. Serum samples
from 20 healthy Caucasian age- and sex-matched subjects (10 males and 10 females, Cliniscience,
Nanterre, FR, EU) were used as a control (CTRL).
Serum matrix metalloproteinases (MMP1, MMP2, MMP3, MMP7, MMP8, MMP9, MMP10,
MMP12, MMP13) and their tissue inhibitors (TIMP1, TIMP2, TIMP3, TIMP4) were quantified using a
multiplex assay on a Bio-Plex® Multiplex System (Bio-Rad Laboratories Inc., Hercules, CA, USA).
Osteoimmune markers, OPG, and RANKL, concentrations were measured in serum using
monoclonal antibody-based immunoassays (ELISA) (BioVendor-Laboratorni Medicina A.S., Brno, CZ,
EU). A marker of bone resorption, CTx-I, and a marker of bone formation, PINP, were measured
in serum by monoclonal antibody-based immunoassays (Cloud-Clone Corp©, Houston, TX, USA).
Serum markers of cartilage degradation and inflammation, CTx-II and CHI3L1, also known as YKL-40,
were measured by a competitive enzyme immunoassay (Cloud-Clone Corp©) and a sandwich enzyme
immunoassay (BioVendor-Laboratorni Medicina A.S.), respectively. Inhibitors of the Wnt signaling
pathway, DKK1, and SOST, were assayed in serum by a solid-phase ELISA (Quantikine® R&D Systems
Inc., Minneapolis, MN, USA).
The lower limits of detection (LOD) were 0.03 pmol/L for OPG, 0.4 pmol/L for RANKL, 44.3 pg/mL
for CTx-I, 12.4 pg/mL for PINP, 52.3 pg/mL for CTx-II, 5.0 pg/mL for CHI3L1, 4.20 pg/mL for DKK1,
and 1.78 pg/mL for SOST. Intra-assay (CVw) and inter-assay (CVb) variations were: 2.5–4.9% and
1.7–9.0% for OPG, 7.25–11.51% and 11.21–12.77% for RANKL, <10% and <12% for CTx-I, PINP, CTx-II,
CHI3L1, 4.2% and 7.6% for DKK1, 2.1% and 10.8% for SOST.
Strict warnings were applied during the pre-analytical phase (i.e., collection, handling, and
storage) in order to limit variability in the final analytical output [12,13].
4.5. Statistical Analysis
Shapiro–Wilk’s normality test was performed on data from the entire cohort. Since the
non-parametrical distribution of the values, quantitative parameters are expressed as the median and
the interquartile range in the descriptive analysis. The within-group comparisons were performed
using Mann–Whitney U-test. Kruskall–Wallis test was used for multiple comparison. Spearman’s rank
correlation test was applied to evaluate correlations that were considered significant when r ≥ 0.25.
Diagnostic accuracy of those markers displaying a statistically significant difference in the
subgroup’s comparison was determined by the ROC (receiver operating characteristic) curves analysis.
The AUC (area under curve)-based accuracy was classified according to Swets JA [14].
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The significance was set at p < 0.05. Analyses were performed using SPSS software (IBM, Armonk,
NY, USA).
5. Conclusions
This study, comparing a large panel of osteoimmunological biomarkers, highlighted profound
differences between Ps, PsA, and healthy controls. These phenotypic differences, which are attenuated
in the comparison between Ps and PsA, reinforces the thesis according to which these two diseases
belong to the same pathological spectrum. However, we also identified important differences in the
expression of specific tissue-remodeling associated enzymatic activities in selected sub-cohorts of Ps
and PsA subjects that seem to be dependent upon the treatment (systemic vs. topic) and the presence
nail involvement (onychopathy).
Supplementary Materials: Supplementary Materials can be found at http://www.mdpi.com/1422-0067/20/22/
5617/s1.
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Abstract: Epidermal keratinocytes represent a rich source of C-C motif chemokine 20 (CCL20)
and recruit CCR6+ interleukin (IL)-17A–producing T cells that are known to be pathogenic for
psoriasis. A previous study revealed that scratch injury on keratinocytes upregulates CCL20
production, which is implicated in the Koebner phenomenon characteristically seen in psoriasis
patients. However, the molecular mechanisms leading to scratch-induced CCL20 production remain
elusive. In this study, we demonstrate that scratch injury upregulates the phosphorylation of
epidermal growth factor receptor (EGFR) and that the specific EGFR inhibitor PD153035 attenuates
scratch-induced CCL20 upregulation in an extracellular signal-related kinase (ERK)-dependent,
and to a lesser extent, a c-Jun N-terminal kinase (JNK)-dependent but p38 mitogen-activated protein
kinase (MAPK)–independent manner. Immunoreactive CCL20 was visualized in the keratinocytes
that lined the scratched wound. IL-17A also induced the phosphorylation of EGFR and further
augmented scratch-induced CCL20 upregulation. The EGFR-ERK/JNK-CCL20 pathway in scratched
keratinocytes may explain why Koebnerization is frequently seen in psoriasis patients.
Keywords: CCL20; IL-17A; psoriasis; scratch injury; epidermal growth factor receptor; Koebner
phenomenon; ERK; JNK; p38 MAPK; keratinocyte
1. Introduction
Psoriasis is an immune-mediated skin disease characterized by epidermal hyperproliferation
and dermal inflammatory cell infiltrates such as dendritic cells and T cells [1]. Psoriasis has
shown a diverse prevalence across populations worldwide: 2.5% in Europeans, 0.05–3% in
Africans, and 0.1–0.5% in Asians [1,2]. Psoriasis markedly diminishes the quality of life, treatment
adherence/satisfaction, and socioeconomic stability of afflicted patients [3,4]. Skin injury triggers or
exacerbates psoriatic lesions in a condition named the Koebner phenomenon [5,6]. Although the
Koebner phenomenon is observed in other skin diseases such as lichen planus and vitiligo, it is
particularly associated with psoriasis [5,6]. However, the pathogenetic mechanism of Koebnerization
is not clear [5,6].
Int. J. Mol. Sci. 2020, 21, 434; doi:10.3390/ijms21020434 www.mdpi.com/journal/ijms175
Int. J. Mol. Sci. 2020, 21, 434
A number of biologic therapies are currently approved for the management of moderate to
severe psoriasis. These biologics target specific molecules in the immune system, and they have
a favorable safety and efficacy profiles than the traditional systemic agents such as methotrexate and
cyclosporine [7]. Therapeutic success by specific biologics points to the pathogenic role of the tumor
necrosis factor-α (TNF-α) axis and the interleukin (IL)-23/IL-17A axis in psoriasis [8–13]. The gene
expression of TNF, IL23, and IL17A is upregulated in the skin lesions of psoriasis patients [13–15].
Infiltration of IL-17A–producing T helper (Th17) cells is detected in the lesional skin of psoriatic
patients, and certain Th17 cells are reactive to selective autoantigens [16–18].
The recruitment of Th17 cells into the lesion is governed by CCL20-CCR6 engagement [19,20].
The expression of CCR6 has been confirmed in other IL-17A–producing cytotoxic T cells (Tc17) [21,22],
innate lymphoid cell group3 (ILC3) [23,24], and γδT cells [25,26]. CCL20 is a potent chemoattractant
for CCR6+ T cells as well as dendritic cells [20,27–29]. Psoriatic lesions are associated with
abundant epidermal CCL20 expression and dermal skin–homing CCR6+ Th17 cells [17,30,31].
Epidermal keratinocytes represent a rich source of CCL20 secretion [32]. In addition, mechanical
suctioning or scratching upregulates the mRNA and protein expression of CCL20 [27,32], and
keratinocytes release large amounts of CCL20 in a time- and scratch line number-dependent
manner [32]. In a murine psoriasis model generated by intradermal IL-23 injection, treatment
with an anti–CCL20 antibody significantly reduced the recruitment of CCR6+ cells and attenuated
IL-23–induced psoriasiform dermatitis [33]. Getschman et al. designed a CCL20 variant, CCL20S64C,
that acts as a partial agonist of CCR6 [34]. After administration, CCL20S64C competes with CCL20
and significantly attenuates IL-23–induced psoriasiform inflammation in mice [34]. These preclinical
studies reinforce the crucial role of the CCL20-CCR6 axis in the pathogenesis of psoriasis.
We have previously demonstrated an upregulated production of CCL20 following scratch
injury in keratinocytes and proposed a potential link to the Koebner phenomenon in psoriasis [32].
However, the subcellular mechanisms of scratch-induced CCL20 production in keratinocytes remain
elusive. One of the prominent biological alterations following scratch wounding is the activation
of epidermal growth factor receptor (EGFR) in epithelial cells, including keratinocytes and corneal
cells [35,36]. Therefore, we hypothesized that EGFR activation induces upstream signal transduction
for CCL20 production. In this study, we demonstrated that scratch-induced CCL20 production was
mediated by EGFR-extracellular signal-related kinase (ERK), and to a lesser extent, by the EGFR–c-Jun
N-terminal kinase (JNK) pathway in keratinocytes. IL-17A also upregulated CCL20 production via
EGFR activation and further potentiated scratch-induced CCL20 production, suggesting that epidermal
CCL20 production is an integral part in the pathogenesis of psoriasis and Koebnerization.
2. Results
2.1. Scratch-Induced CCL20 Expression Is Ameliorated by EGFR Inhibition
Consistent with our previous report [32], scratch injury augmented the protein production of
CCL20 compared with non-scratched control human keratinocytes (Figure 1). Significant amounts
of CCL20 were released from scratched keratinocytes as early as 3 h after scratch injury (Figure 1).
Notably, the EGFR inhibitor PD153035 significantly inhibited scratch-induced CCL20 upregulation
(Figure 2A). Moreover, PD153035 significantly decreased the baseline production of CCL20 even in
non-scratched controls (Figure 2A). We next examined whether or not scratch injury phosphorylates
EGFR. In accordance with previous reports [35,36], scratch injury upregulated the phosphorylation of
EGFR (P-EGFR) compared with non-scratched controls, and scratch-induced P-EGFR upregulation
was attenuated in the presence of PD153035 (Figure 2B). These results suggest a pivotal regulatory role
of EGFR signaling in scratch-induced CCL20 production in keratinocytes.
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Figure 1. Scratch injury–induced CCL20 production. The production of CCL20 was measured at 3,
6, and 24 h after the initiation of culture in non-scratched control and scratched keratinocyte cultures.
Representative data of three independent experiments are shown. ** p < 0.01. *** p < 0.001.
Figure 2. Scratch injury-induced CCL20 production depends on activation of epidermal growth factor
receptor (EGFR). (A) Scratch injury-induced CCL20 production was measured in the presence or
absence of PD153035 (EGFR inhibitor, 300 or 600 nM) at 24 h after scratching. (B) The phosphorylation
of EGFR (P-EGFR) was measured by western blot analysis at 1 h after scratching. Representative
enzyme-linked immunosorbent assay (ELISA) data and Western blot images of three independent
experiments are shown. ** p < 0.01. *** p < 0.001.
2.2. Spatial Distribution of CCL20 Expression in Keratinocytes
Subsequently, we attempted to visualize the CCL20 expression using an immunofluorescence
technique. Compared with IgG staining in negative controls (Figure 3A), the immunoreactive CCL20
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was positively but faintly and diffusely stained in the non-scratched control keratinocytes (Figure 3B).
Compared with staining in negative controls (Figure 3C), CCL20 expression was clearly enhanced in
the keratinocytes residing along the scratch-edge area (Figure 3D, arrows). These findings strongly
suggest that the scratch injury triggers CCL20 production in keratinocytes adjacent to the wound.
Figure 3. Immunofluorescent visualization of CCL20 at 6 h after scratching. (A) Non-scratched control
keratinocytes stained with control IgG. (B) Non-scratched control keratinocytes stained with anti–CCL20
antibody. (C) Scratched keratinocytes stained with control IgG. (D) Scratched keratinocytes stained
with anti–CCL20 antibody. Original magnification 100×. Representative data of three independent
experiments are shown.
2.3. Scratch-Induced CCL20 Production Depends on ERK and, to a Lesser Extent, JNK, but Not the p38
Mitogen-Activated Protein Kinase (MAPK) Pathway
The variable involvement of MAPKs (ERK, JNK, and p38 MAPK) in CCL20 expression has been
reported in stimuli-specific and cell type–specific manners [37–41]. Therefore, we examined whether
scratch injury activates MAPKs in our system. As shown in Figure 4, scratch injury phosphorylated
ERK, JNK, and p38 MAPK molecules compared with nonscratched controls. We then investigated
whether scratch-induced CCL20 expression is affected by the ERK inhibitor U0126, the JNK inhibitor
SP600125, and the p38 MAPK inhibitor SB203580 (Figure 5). Of note, the scratch-induced CCL20
expression was strongly and significantly inhibited by U0126 and partially by SP600125 (Figure 5).
U0126 and SP600125 also inhibited the baseline production of CCL20 in nonscratched keratinocytes
(Figure 5). SB203580 did not inhibit baseline and scratch-induced CCL20 production (Figure 5).
These results indicate that scratch-induced CCL20 expression is regulated by ERK and partially by
JNK activation in keratinocytes.
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Figure 4. Scratch injury induces phosphorylation of ERK1/2, JNK, and p38 MAPK at 1 h after scratching.
Phosphorylation of ERK1/2, JNK, and p38 MAPK was examined by western blotting in non-scratched
control and scratched keratinocytes. Representative blot images of three independent experiments
(A) and the relative expressions of phosphorylated proteins (B) are shown. * p < 0.05. ** p < 0.01.
*** p < 0.001.
Figure 5. Scratch-induced CCL20 (24 h after scratching) upregulation depends on ERK1/2 and JNK
activation. The CCL20 production was measured in nonscratched control and scratched keratinocytes
in the presence or absence of U0126 (ERK1/2 inhibitor, 10 μM), SB203580 (p38 MAPK inhibitor, 10 μM),
and SP600125 (JNK inhibitor, 10 μM). Representative data of three independent experiments are shown.
* p < 0.05. ** p < 0.01. *** p < 0.001.
2.4. IL-17A Synergistically Enhances Scratch-Induced CCL20 Production
Because IL-17A feasibly upregulates CCL20 production in keratinocytes [42], we next checked
whether IL-17A augments scratch-induced CCL20 expression. IL-17A alone upregulated CCL20
production in non-scratched control keratinocytes in a dose-dependent fashion (Figure 6A).
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When combined with scratch injury, IL-17A additively or synergistically enhanced scratch-induced
CCL20 production (Figure 6A). Interestingly, the IL-17A–induced CCL20 production was also
attenuated by the EGFR inhibitor PD153035 (Figure 6B). In accordance with this result, IL-17A alone
induced the phosphorylation of EGFR and was attenuated by PD153035 in non-scratched control
keratinocytes (Figure 7). IL-17A induced similar levels of EGFR activation as did scratch injury.
Significant enhancement of phosphorylated EGFR (P-EGFR) was not observed in combined treatment
with scratch and IL-17A compared with IL-17A monotreatment (Figure 7). These results stress the
crucial role of EGFR activation in IL-17A–induced, as well as in scratch-induced CCL20 production.
Figure 6. IL-17A augments scratch-induced CCL20 upregulation at 3 h after scratching. (A) CCL20
production was measured in non-scratched control and scratched keratinocytes in the presence or
absence of IL-17A (0.1 or 1 ng/mL). (B) Non-scratched keratinocytes were stimulated with IL-17A
(0.1 or 1 ng/mL) with or without PD153035 (EGFR inhibitor, 300 nM). Representative data of three
independent experiments are shown. * p < 0.05. ** p < 0.01. *** p < 0.001.
Figure 7. IL-17A upregulates the phosphorylation of EGFR at 3 h after scratching.
The phosphorylation of EGFR was measured by western blot in non-scratched control keratinocytes
and scratched-keratinocytes in the presence or absence of IL-17A (1 ng/mL) or PD153035 (EGFR inhibitor,
300 nM). Representative blot images of three independent experiments and the relative expressions of
phosphorylated proteins are shown. * p < 0.05. ** p < 0.01. *** p < 0.001.
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3. Discussion
CCR6 is a representative surface marker for IL-17A–producing immune cells [19–21,23,28,43].
CCL20 and CCR6 engagement is critical for the recruitment of CCR6+ Th17 cells [27,29,44].
Although immune cells can feasibly produce CCL20 [45–48], the expression of CCL20 seems to
be confined to peripheral tissues, including skin [32,42,44]. Epidermal keratinocytes constitutively
produce CCL20 in culture conditions [32,42]. The lesional epidermal keratinocytes express abundant
CCL20 in patients with psoriasis [30,31]. Following stimulation with IL-17A, keratinocyte production
of CCL20 is markedly enhanced [42].
We have previously shown that mechanical scratching also upregulates CCL20 production
in keratinocytes [32]. However, the underlying mechanisms remain elusive. In this study,
we demonstrated that scratch-induced CCL20 expression is mediated by the EGFR-ERK (and, to a lesser
extent, by the EGFR-JNK) pathway. The scratch injury induced the phosphorylation of EGFR in
keratinocytes. The scratch-induced activation of EGFR is consistent with previous reports [35,36].
The production of CCL20 was detected as early as 3 h after scratch injury, and the blockade of EGFR
activation by its specific inhibitor, PD153035, significantly reduced scratch-induced CCL20 upregulation.
PD153035 also significantly decreased the baseline production of CCL20 in non-scratched control
keratinocytes. These results indicate that CCL20 production is highly dependent on EGFR signaling.
Notably, the immunofluorescence study revealed that CCL20 expression was markedly augmented in
keratinocytes lining the scratched edge, suggesting a clear relationship between scratch injury and
CCL20 upregulation.
Scratch injury activated and induced the phosphorylation of ERK1/2, JNK, and p38 MAPK in
keratinocytes. However, in the present study, scratch-induced CCL20 protein upregulation was
strongly blocked by an ERK inhibitor and partially by a JNK inhibitor but not by a p38 MAPK
inhibitor. In hepatocellular carcinoma cells and murine colonic epithelial cells, CCL20 expression is
known to depend on the ERK pathway [37,38]. TNF-α–induced CCL20 upregulation depends on
ERK and p38 MAPK in bronchial epithelial cells [39]. Prolactin upregulated CCL20 expression in
keratinocytes and was dependent on ERK and JNK [40]. Evidence from our own and previous studies
suggests that the ERK (partially JNK) pathway plays a pivotal role in scratch/EGFR-mediated CCL20
production. Although p38 MAPK is not directly involved in scratch-induced CCL20 production,
a recent study suggests that p38 MAPK may regulate the recycling of EGFR by accelerating the latter’s
endocytosis [49].
Positive therapeutic responses to biologics and lesional transcriptomic analysis have highlighted
the critical pathogenic role of IL-17A in psoriasis [15,32,50]. Scratch injury triggers the development of
psoriatic lesions (Koebner phenomenon) in patients with psoriasis [6]. Therefore, we next examined
the effects of IL-17A on scratch-induced CCL20 production. IL-17A dose-dependently increased
CCL20 production in non-scratched control keratinocytes, as reported previously [42]. When they
were combined with the scratch injury, we observed an additive or synergistic augmentation of CCL20
production by scratch and IL-17A. In line with a previous study that elucidated EGFR activation by
IL-17A [51,52], we also demonstrated that IL-17A upregulated the phosphorylation of EGFR and
that the EGFR inhibitor PD153035 attenuated IL-17A–mediated CCL20 production. These results
suggest that, in patients with psoriasis, the scratch injury stimulates keratinocytes to produce CCL20,
which attracts circulating Th17 cells into the scratched skin. IL-17A produced from recruited Th17 cells
may further accelerate CCL20 production from the scratched epidermis and further recruit circulating
Th17 cells to the injured skin, leading to a feed-forward positive loop that develops into the Koebnerized
psoriatic eruption. Both scratch-induced and IL-17A–induced CCL20 expression depend on EGFR
activation. Consistent with the present results, it has been demonstrated that the inhibition of EGFR by
erlotinib or cetuximab successfully improves severe psoriasis [53–56].
A first-in-human study using a humanized anti–CCL20 antibody, GSK3050002, has already been
reported for the treatment of psoriasis [27]. Intravenous GSK305002 inhibits the infiltration of Th17 cells,
but not Th1 or Th2 cells, into the suction blisters (rich in CCL20) in treated individuals, suggesting the
181
Int. J. Mol. Sci. 2020, 21, 434
active and selective involvement of the CCL20/CCR6 axis in Th17 cell homing into the skin [27].
In addition, preclinical studies reveal that a humanized anti–CCR6 antibody or a small-molecule CCR6
antagonist efficiently inhibits the infiltration of immune cells and inflammatory symptoms in a murine
psoriatic model [29,43]. These studies stress the significance of CCL20 as a potential therapeutic target
for psoriasis. In parallel, the increased expression of CCL20 and CCR6 has been demonstrated in lichen
planus which also manifests Koebnerization [57]. There are several limitations in this study. We only
examined the effects of scratch injury on the monolayer keratinocyte culture system. Further studies
are warranted using three-dimensional skin equivalent, ex vivo human skin, or in vivo mouse models.
Fibroblasts may affect the scratch-induced, keratinocyte-derived CCL20 expression in coculture models.
More extensive studies may be necessary to draw a concrete conclusion.
In conclusion, scratch-induced CCL20 production depends on the EGFR-ERK (and partially on the
JNK) pathway. As has been proposed previously [58], EGFR signaling may be a significant and integral
component in the pathogenesis of Koebnerization and psoriasis. Our study underscores the potential
role of new therapies such as anti-CCL20 antibody and EGFR/ERK inhibitors in the management
of psoriasis.
4. Materials and Methods
4.1. Reagents and Antibodies
Dimethyl sulfoxide (DMSO) was purchased from Sigma-Aldrich (St. Louis, MO, USA).
CaCl2 (Fujifilm Wako Pure Chemical Corporation, Osaka, Japan) was dissolved in UltraPure distilled
water (Invitrogen, Carlsbad, CA, USA) and added to culture medium at a final concentration of 1.6
mM. In the same way, recombinant human IL-17A (PeproTech, Rocky Hill, NJ, USA) was used at
final concentrations of 0.1 and 1.0 ng/mL. An EGFR–tyrosine kinase inhibitor, PD153035 (ChemScene
LLC, Monmouth Junction, NJ, USA), was dissolved in DMSO and added to culture medium at final
concentrations of 300 and 600 nM. Control cultures contained comparable amounts of DMSO (0.01%)
and UltraPure distilled water (1.6%). Signal-transduction inhibitors U0126 (ERK1/2 inhibitor) and
SB203580 (p38 inhibitor) were purchased from Tocris Bioscience (Bristol, UK), and SP600125 (JNK
inhibitor) was obtained from Abcam (Cambridge, UK). The antibodies used for immunofluorescence
staining were as follows: rabbit anti–human macrophage inflammatory protein 3 alpha (MIP-3α,
CCL20) polyclonal antibody, and normal rabbit polyclonal IgG (all from Abcam); and goat anti–rabbit
IgG (H + L) cross-adsorbed secondary antibody with Alexa Fluor 488 dye (Thermo Fisher Scientific,
Waltham, MA, USA). The antibodies (catalog numbers) used for western blotting were as follows: rabbit
anti–human ERK1/2 (9102S), JNK (9252S), p38 MAPK (8690S), phospho-ERK1/2 (4370S, Thr202/Tyr204),
phospho-JNK (4668S, Thr183/Tyr185), phospho-p38 MAPK (4511S, Thr180/Tyr182), EGFR (4267S),
phosphor-EGFR (3777S, Tyr1068), and β-actin (4970S) monoclonal antibodies (all from Cell Signaling
Technology, Danvers, MA, USA) as primary antibodies, and goat anti-rabbit IgG HRP-linked antibody
(7074S) (Cell Signaling Technology) as a secondary antibody.
4.2. Cell Culture
Normal human epidermal keratinocytes (NHEKs) from neonatal foreskin were cultured in
KBM-GOLD Keratinocyte Basal Medium supplemented with KGM-GOLD SingleQuots (all from
Lonza, Basel, Switzerland) containing bovine pituitary extract, recombinant epidermal growth
factor, insulin, hydrocortisone, transferrin, gentamicin sulfate–amphotericin (GA-1000) (Lonza),
and epinephrine and were maintained at 37 ◦C in 5% CO2. The culture medium was replaced
every day, and the cells were serially passaged at 70–80% confluence. In all experiments, cells were
used at the third passage. Cells (3.5 × 105 cells/well) were seeded in 6-well culture plates (Corning Inc.,
Corning, NY, USA), and the culture medium was replaced every day. At 100% confluence, cells were
treated with a high level of CaCl2 (1.6 mM, high-Ca2+ conditions), which converted the cells from the
proliferative state to the differentiating state.
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4.3. CCL20 Secretion in an In Vitro Scratched Keratinocyte Model
The in vitro scratched keratinocyte model was performed as previously described [32].
Briefly, NHEKs at 100% confluence were incubated for 24 h under high-Ca2+ conditions at 37 ◦C
in 5% CO2. Then, the cell sheets were scratched (10 lines) with a 250-μL Long Tip (Watson Bio Lab,
Tokyo, Japan). In several assays, the scratched cell sheets were also treated with IL-17A (0.1 or 1.0
ng/mL) [42,59], PD153035 (300 or 600 nM) [60], U0126 (10 μM), SB203580 (10 μM), or SP600125 (10 μM).
4.4. Enzyme-Linked Immunosorbent Assay (ELISA)
Culture supernatants were collected, and the concentrations of CCL20 were measured using
Quantikine Human CCL20 ELISA Kits (R&D Systems, Minneapolis, MN, USA) in accordance with the
manufacturer’s instructions. Absorbance at 450 nM was measured with an iMark microplate reader
(Bio-Rad Laboratories Inc., Hercules, CA, USA), and the concentrations of CCL20 were determined in
each sample by comparison with a standard curve.
4.5. Western Blotting
Protein lysates of NHEKs were isolated from cells with 100 μL/well of lysis buffer (25 mM
HEPES, 10 mM Na4P2O7/10 H2O, 100 mM NaF, 5 mM EDTA, 2 mM Na3VO4, and 1% Triton X-100),
supplemented with 10 μL/well of proteinase inhibitor cocktail (Sigma-Aldrich). The lysates were
then centrifuged at 14,000 rpm for 20 min, and the supernatants were used for analysis. The protein
concentration of each lysate was measured with a BCA protein assay kit (Thermo Fisher Scientific).
Equal amounts of protein (30 μg for EGFR, phosphor-EGFR; 20 μg for the other proteins) were mixed
with 2× sample buffer (Nacalai Tesque, Inc., Kyoto, Japan), boiled at 95 ◦C for 5 min, loaded onto
Bolt 4–12% Bis-Tris Plus Gels (Invitrogen), and electrophoresed at 200 V and 160 mA for 22 min.
The proteins were then transferred to a polyvinylidene fluoride (PVDF) membrane (Invitrogen) using
the Power Blotter XL System (Invitrogen). Membranes were blocked with 2% bovine serum albumin
(BSA; Sigma-Aldrich) in 0.1% tris buffered saline with tween (TBS-T). Membranes were probed with
primary antibodies overnight at 4 ◦C. After incubation with anti–rabbit IgG HRP-linked secondary
antibody at room temperature for 1 h, protein bands were visualized with SuperSignal West Pico
Chemiluminescent Substrate (Thermo Fisher Scientific) using the ChemiDoc Touch Imaging System
(Bio-Rad Laboratories Inc.).
4.6. Immunofluorescence Analysis
Immunofluorescence analysis was performed as reported previously [61]. The cells were cultured
in 4-well slide chambers (1.5 × 105 cells/well) (Lab-Tek, Rochester, NY, USA) in accordance with
the culture methods described herein. Then, the cell sheets were scratched and incubated for 6 h
at 37 ◦C in 5% CO2. The cell sheets were washed with PBS 3 times for 5 min each and fixed in
cold acetone for 10 min at room temperature. The cell sheets were blocked with 10% BSA (Roche
Diagnostics, Basel, Switzerland) and incubated with rabbit anti-human CCL20 polyclonal antibody
or control normal rabbit polyclonal IgG. Goat anti-rabbit IgG (H + L) cross-adsorbed secondary
antibody with Alexa Fluor 488 dye was used as the secondary antibody. The nucleus was stained with
4′,6-diamino-2-phenylindole (DAPI). Slides were then mounted with Ultra Cruz mounting medium
(Santa Cruz Biotechnology, Dallas, TX, USA) and were observed using a D-Eclipse confocal laser
scanning microscope (Nikon, Tokyo, Japan).
4.7. Statistical Analysis
All data are presented as mean ± standard deviation (SD). The significance of differences
between groups was assessed using unpaired 2-tailed student’s t-test (2 groups) or 1-way analysis of
variance (ANOVA), followed by Tukey’s multiple comparison test (multiple groups) using GraphPad
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PRISM 7.0 software (GraphPad Software, La Jolla, CA, USA). A p-value of < 0.05 was considered
statistically significant.
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Marta Kasprowicz-Furmańczyk 1 and Waldemar Placek 1
1 Department of Dermatology, Sexually Transmitted Diseases and Clinical Immunology, The University of
Warmia and Mazury, Al. Wojska Polskiego 30, 10-229 Olsztyn, Poland; martak03@wp.pl (M.K.-F.);
w.placek@wp.pl (W.P.)
2 Department of Rheumatology, Municipal Hospital in Olsztyn, 10-229 Olsztyn, Poland; magdalenakw@op.pl
3 Department of Internal Medicine, School of Medicine, Collegium Medicum, University of Warmia and
Mazury, 10-900 Olsztyn, Poland
* Correspondence: aganek@wp.pl; Tel.: +48-89-678-6670; Fax: +48-89-678-6675
Received: 16 December 2019; Accepted: 15 January 2020; Published: 17 January 2020
Abstract: The natural course of psoriasis is the appearance of new lesions in the place of previous
ones, which disappeared after a successful therapy. Recent studies of psoriasis etiopathogenesis
showed that after psoriatic plaques have disappeared, in healthy skin we can still find a trace of
inflammation in the form of tissue resident memory cells (TRM). They are originally responsible for
protection against viral and bacterial infections in non-lymphatic tissues. In psoriatic inflammation,
they are characterized by heterogeneity depending on their origin. CD8+ T cells TRM are abundantly
present in psoriatic epidermis, while CD4+ TRM preferentially populate the dermis. In psoriasis,
epidermal CD8+ TRM cells express CLA, CCR6, CD103 and IL-23R antigen and produce IL-17A
during ex vivo stimulation. However, CD4+ CD103+ TRM can also colonize the epidermis and
produce IL-22 during stimulation. Besides T cells, Th22 and epidermal DCs proved that epidermal
cells in healed skin were still present and functioning after several years of disease remission. It
explains the clinical phenomenon of the tendency of psoriatic lesions to relapse in the same location
and it allows to develop new therapeutic strategies in the future.
Keywords: psoriasis; tissue resident memory cells; IL-17
1. Introduction
The natural course of psoriasis is the long-term persistence of lesions in the same anatomical
regions and the appearance of new ones in places where they have resolved after successful therapy.
The appearance of new lesions in the place of previous ones, which disappeared after a successful
therapy, evokes feelings of depression, hopelessness and depression in patients and induces conviction
in the lack of effective therapies. Recent studies of psoriasis etiopathogenesis showed that after
psoriatic plaques have disappeared, in healthy skin we can still find a trace of inflammation in the
form of tissue resident memory cells (TRM). They are able to initiate an inflammatory cascade and
cause a relapse in the same location. In psoriasis, even during remission, they become a source of
important inflammatory cytokines IL-17A and IL-22 [1–4]. T cell-associated gene (LCK and TRCB1)
and inflammatory gene (IL17, IL22 and IFN-γ) activity remains increased in the skin after psoriasis
lesions, at least three months after the onset of the treatment with TNF-α inhibitors [5,6]. However, not
only TRMs are responsible for clinical relapses at the same location (Figure 1) (Table 1). This article is a
review of current knowledge about the “immune memory” of psoriatic lesions.
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Figure 1. The relapse of psoriatic lesions in the same localization despite efficient treatment.
Table 1. The Cells Responsible for the “memory” of Psoriatic Lesions.
Type of Cells Psoriasis Lesions Resolved Psoriasis Skin
TRM
CD4+
A few in dermis CD103- and a low
number in epidermis CD103+ A few
CD8+
A lot of in epidermis CD103+:
CD8+CD49a+ producing perforin, IFN-γ
CD8+CD49a- producing IL-17 IL-22,
IFN-γ, a few in dermis CD103- and a low
number CD103+









producing of IL-1β, IL-23, TNFα Absent
2. Tissue Resident Memory Cells (TRM)
TRM cells are transcriptionally, phenotypically and functionally different from traditional central
memory cells (TCM) and effector memory T cells (TEM). They recirculate among blood, T cell zones
of secondary lymphoid organs, lymph and non-lymphoid tissues, such as the skin, where they act
as alarm sensors or cytotoxic killers. They are characterized by heterogeneity depending on their
origin [5,7–11].
They are originally responsible for protection against viral and bacterial infections in non-lymphatic
tissues. The protective activity of TRM has been confirmed in HSV infection, vaccinia pox, lymphocytic
choriomeningitis virus (LCMV), influenza, listeriosis, malaria, as well as in some types of cancer. The
vaccination task is, among others, the education of TRM to react very quickly against an infection [9].
TRM cells are locally found in many tissues providing a rapid in situ response to infectious agents
more effectively than T cells of effector memory. They also secrete granzyme B, which helps to reduce
the spread of pathogens at the site of infection. They can activate the innate and adaptive mechanisms
of the immune response [2,10,12–15]. TRM acts as a bridge between the adaptive and innate immune
systems. Because many viruses have tissue tropism, TRM also provides protective immune responses
for tissue that it has previously encountered. Since, HSV-specific TRMs have been found in the skin,
rotavirus-specific TRMs in the intestines and flu-specific TRMs in the lungs [16,17]. However, in
addition to their protective functions, there is more and more evidence of their involvement in the
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pathogenesis of autoimmune disorders such as psoriasis, vitiligo, autoimmune hepatitis, rheumatoid
arthritis and lymphomas [11].
The main surface markers of human TRM cells are CD49a, CD69 and CD103. The CD103
marker (integrin αE subunit) is only expressed on CD8+ TRM cells, not CD4+ TRM. Its expression
is most prominent on epidermal CD4+ and CD8+ TRM cells because it enables TRM binding to
E-cadherin, which is widely expressed by epithelial cells [8,13,18]. The CD69 marker plays a key role
in distinguishing T cells in tissues from those in circulation and it is responsible for the colonization of
these cells in tissues, preventing them from recirculating. CD69 binds and inhibits the expression of
the cell surface of sphingosine-1-phosphate receptor (S1PR1). The transcription factor KLF2 promotes
the expression of S1PR1, thereby CD69 and may allow recirculation of TRM in unusual situations [19].
S1PR1 reacts to the S1P ligand, which is released by endothelial cells in the blood and lymph, allowing
TRM cells to leave the tissues for circulation. This situation is observed, among others, after exposure
to an allergen resulting in formation of secondary TRM cells [19]. However, the latest findings indicate
that the importance of CD69 for TRM residence may depend on the tissue in which they are located
(essential for TRM in the kidneys, no relevance in the gut) [18]. However, expression levels may vary
between T cells in different tissues. Another marker that can be used to differentiate two subsets of
TRM cells is CD49a—the α-subunit of the α1β1 integrin receptor (also known as very late antigen
VLA-1). It determines a subset of CD8+ TRM cells that are localized in the epidermis. These cells
produce IFN-γ and acquire high cytotoxic capacity upon IL-15 stimulation [20]. CD8+ CD49a+ TRM
cells produce perforin and IFN-γ, which is a key cytokine in fighting viral infections. CD8+ CD49-TRM
cells produce IL-17 [20,21]. TRM also expresses the Program Cell Death Protein-1 (PD-1) and T-cell
immunoglobulin mucin receptor 3 (TIM3), which are the surface proteins that suppress T cell activity.
Their expression occurs in inflamed tissues. In such situations, TRMs have an anti-inflammatory effect,
which indicates the ambiguous nature of these cells [22,23].
In healthy individuals, CD8+CD103+CD49a−TRM cells were present in both dermis
and epidermis, whereas CD8+CD103+CD49a+TRM cells were localized in the epidermis.
Epidermal CD8+CD103+CD49a−TRM cells were predominant IL-17 producers, whereas
CD8+CD103+CD49a+TRM cells excelled at IFN-γ production and rapidly gained a cytotoxic capacity
following IL-15 stimulation [21].
TRM cells develop from circulating effector T cell precursors in response to an antigen. CD103
plays a major role in their formation, and the expression of this integrin depends on the TGF-β cytokine.
CD8+ T effector cells, which do not produce TGF-β, have no expression of CD103 and they do not
differentiate into TRM cells. The homeostatic IL-15 cytokine, pro-inflammatory cytokines (IL-12 and
IL-18) and barrier cytokines, such as IL-33, which support TRM cell formation and survival, play an
important role in the development of TRM cells [7,8].
The second type of TRM are CD4+ cells, which are less-known ones, and are located near the
vessels in the dermis; they do not express CD103 and have a high proliferative capacity. They are
responsible for defense against Leishmania and Candida albicans in the gut, lungs and reproductive
system [24].
3. Tissue Resident Memory Cells in Psoriasis
CD4+ T cells with the Th1 and Th17 phenotype have long been considered the main pathogenic
subpopulations of T cells. LL37 (antimicrobial peptide derived from keratinocytes) and ADAMTSL5
(protein produced by melanocytes) in the pathogenesis of the disease has been more appreciated.
The abovementioned proteins are considered as autoantigens in psoriasis. Similarly, CD4 T-cells
recognize LL37 as an autoantigen and they correlate with PASI [25,26]. CD8+ T cells with resident
memory tissue phenotype (TRM) are abundantly present in psoriatic epidermis, while CD4+ TRM
preferentially populate the dermis. The differences in colonization result from the expression of CD69,
which blocks the sphingosine-1-phosphate receptor (S1P1), a receptor normally allowing lymph entry.
In addition, a significant proportion of skin TRM expresses CD103, the αEβ7 integrin chain, which
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interacts with E-cadherin expressed by keratinocytes (Figure 2). The signal required for their residence
is TGF-β via TGF-βRII [9]. Hair follicles through IL-15 and IL-7 production are also important in
their recruitment [27]. In addition to cytokines, lipids available in the skin are essential to maintain
TRM [10,17]
 
Figure 2. The receptors and secretory activity of tissue resident memory (TRM) CD8+ [5,22]
TRMs have been described in unchanged, healed skin in places of recurrent psoriasis, which
indicates their role in the disease’s local memory [28]. Recirculation of memory T cells between the
skin and circulation is a newly recognized immunological mechanism that plays an important role in
the initiation of psoriasiform response [3,29,30] (Figure 3). Their particular pathogenicity is determined
by the fact that they have the ability to produce IL-17 and IL-22, pro-inflammatory, key cytokines
involved in this process [23,29].
 
Figure 3. The role of TRM in psoriatic inflammation.
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The first study that highlighted the role of resident skin T cells in psoriasis was the experiment
of Boyman et al. [31]. They implanted unchanged human psoriatic skin to immunodeficient mice
(AGR129 mice, deficient in type I and II interferon receptors and the recombination activating gene
2). The reproduction of resident human T cells and the formation of psoriatic lesions were observed
within eight weeks. They showed the CD8+ phenotype with TNF-α susceptibility and were located
mainly in the epidermis and the dermal–epidermal junction [31].
Diani et al. [1] analyzed the phenotype of circulating T cells in patients with psoriasis with the
assessment of gene expression in psoriatic skin. It was found that circulating CCR6+ CD4+ TEM
(effector memory cells) and T effector cells significantly correlated with the severity of skin lesions
and inflammation (CRP) while the percentage of CXCR3+ CD4+ TEM cells correlated negatively. In
addition, CLA+ CD4+ TCM cells expressing CCR6+ or CCR4+ CXCR3+ negatively correlated with
the severity of psoriasis. CLA expression is associated with the recruitment of CD4+ T cells into the
skin, mainly when expressed on TCM cells, in particular on CD4+ TCM with the CCR4+ and CCR6+
phenotype [1,26]. In an earlier study, Bose et al. [32] proved that inhibition of the CCR7/CCL19 axis was
critical for remission of psoriasis induced by TNF inhibitors [3]. In psoriasis, circulating CCR4 + CD4+
T cells significantly correlate with disease severity (PASI), and a strong negative correlation has been
found for CCR5+ CD4+ T cells [32]. A subset of T effector CCR4+ CD8+ CD103+ cells also positively
correlates with both systemic inflammation (CRP) and the severity of skin lesions [4,33]. It was also
found that the fraction of IL-17 secreting CD4+ T-lymphocytes and probably γδ T-lymphocytes may
play a role in the formation of a self-sustaining inflammatory loop [1].
Lymphocytes CD4+ Th producing pro-inflammatory cytokines, such as IL-17A, IL-22 and IFN-γ,
are considered to be the main pathogenic T cell subpopulation, whereas CD8+, present in healthy skin
as memory T cells, have a similar pro-inflammatory cytokine profile. They are in large quantities in
the psoriatic epidermis and can recognize peptide antigens presented on MHC class I molecules like
HLA-Cw6 [29]. Blockade of β1-integrin hinders entry of T cells into the epidermis, which prevents
the development of disease eruptions on the murine AGR model of psoriasis [34]. Di Meglio et
al. [29] showed that the accumulation of epidermal CD8+ cells induces both hyperproliferation of
keratinocytes and papillomatosis (increase in CD8 + a parallel to the intensity of Ki67 staining in
keratinocytes) [29]. CD8+ T cells isolated from psoriasis patients produce psoriasis-related cytokines.
After treatment they remain in the skin as TRM and LL-37-specific CD8 + T cells, expressing integrin
α1β1 [29].
In the study of Kurihara et al. [13], biopsies from psoriatic lesions were examined. The number of
CD8+CD103+ TRM cells in the epidermis correlated with the thickness of the epidermis (p = 0.016),
suggesting their role in the formation of psoriatic lesions [13]. They were mostly CD8+ CD69+ T
cells, expressing skin colonization antigens, and the count of CD4+ CD103+ TRM was low. Some
CD8+ CD103+ T cells produced IFN-γ, IL-17A or IL-22. In addition, CD8+ CD103+ TRM cells more
frequently produced IL-17A than CD8+ CD103- and effector cells CD8+ CD103 or CD4+ CD103+.
Interestingly, the number of CD8+ CD103+ IL-17A + TRM cells in patients treated with biological
or systemic therapy was higher [13]. In contrast, in the dermis of the psoriatic plaques, TRM cells
show lower expression of CD103, as demonstrated by Cheuk et al. [5]. In the first stage of psoriatic
inflammation, in the skin without lesions yet, epidermal TRM cells expressing CCR6 cooperate with
CCL20 expressing keratinocytes [35,36].
In turn, Vo et al. [36] evaluated the phenotypic features of TRM in non-lesional, lesional psoriasis
and healthy skin. Immunofluorescence study showed that CD103+ CD8 TRM, both in non-lesional
and lesional were dominant in the epidermis compared to the skin of healthy volunteers. In addition,
IL-17A production was higher in patients with longer disease duration [36].
The optimal treatment time needed to completely silence TRM, which could ensure that there
is no recurrence of lesions at the location is unknown [37]. Therefore, psoriatic lesions preferentially
recur in previously affected areas of the skin, and pathogenic TRM cells exposed to IL-17A and IL-22
accumulate in resolved lesions [5,35]. In the study of Gallais Serezal et al. [38], tissue responses after T
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cell stimulation in healthy and psoriatic lesions were analyzed. An increase in the number of epidermal
IL-17 and IL-22—producing skin-resident T CCR6 + cells—may be a genetically predisposed reaction
to microbial stimulation in never-lesional skin in patients with psoriasis. The consequence is an
increase in IFN-g production and stimulation of keratinocytes that release INF-a, which stimulates
psoriatic inflammation.
At the same time psoriasis plaques showed IL-17-induced response patterns, indicating a relapse.
The proportional amount of induced IFN-γ, IL-10e and IL-17A correlated with relapse time in patients
after discontinuation of the treatment [38].
For the complete remission of the disease, full TRM suppression is required. Unfortunately,
TRM cells are long-lived, and resistant to damaging factors and apoptosis. This explains the frequent
relapses at the same location for psoriasis. Even after the clinical lesions have resolved, they are
capable of producing IL-17A, and effective therapy only suppresses their activity [3,37]. Furthermore,
CD8+ TRM cells accumulate in untreated psoriasis localizations, probably in correlation with disease
duration [4,11]. An interesting issue is the explanation of the longevity of memory cells. One of the
reasons is its resistance to apoptosis. The heterodimeric marker molecule CD8+ (αEβ7) consists of
CD103 and β7 subunits and plays a key role in the stability of CD8+ TRM cells by increasing the level of
the Bcl-2 molecule with anti-apoptotic activity [8,13]. In contrast, TRM can produce granzyme B (serine
protease), which can induce cellular apoptosis [23]. Moreover, IL-15 probably plays an important role
in TRM cell survival [24].
What is surprising, the effector T cells use glycolysis energy, which is less efficient in generating
ATP, but faster. TCM, on the other hand, use endogenously synthesized fatty acids, glucose catabolism
and oxidative phosphorylation to support their long-term survival and function [17,39]. TCMs use
extracellular glucose from the blood to synthesize fatty acids in the endoplasmic reticulum, using
lysosomal acid lipase, which is important in the hydrolysis of cholesteryl esters and triglycerides
in LDL molecules to cholesterol and free fatty acids (FFA). Thanks to such mechanisms, they can
be long-lived and able to react quickly to antigen [17]. Cui et al. additionally showed that IL-7, a
cytokine critical for TCM differentiation and survival, induced glycerol transport and triacylglycerol
synthesis via enhanced gene expression of glycerol channel aquaporin 9, thus providing substrates for
mitochondria via fatty acid oxidation (FAO) [17,40].
Unfortunately, there is currently no detailed data on the metabolic properties of TRM. However,
it is known that CD8+ TRM develop a transcriptional program with overexpression of FABP4
(adipocyte-FABP), FABP5 (epidermal-FABP), CD36 (a lipid scavenger receptor) and lipoprotein lipase
(cleaves triglycerides to yield FFA and diacylglycerol). Such activity of genes responsible for the
activity of these molecules is not found in naive T cells, TCM or effector memory cells [17].
The study by Pan et al. [17] showed that mouse CD8 + TRM cells generated by skin viral infection
show different expression level of genes of proteins mediating the intracellular uptake and transport of
lipids, including fatty acid-binding protein—FABP4 (adipocyte-FABP) and FABP5 (epidermal-FABP).
These are molecules facilitating exogenous FFAs acquisition and metabolism [17]. CD8 + TRM
upregulated the gene expression of FABP4/FABP5 in a peroxisome proliferator-activated receptor
gamma (PPAR-γ)—dependent manner [17,41]. T-specific deficiency of these molecules has been shown
to impair the uptake of exogenous FFA by CD8+ TRM cells, which significantly reduces their long-term
survival in vivo, but does not affect the survival of TCM in lymph nodes. In addition, CD8+ TRM skin
cells lacking FABP4/FABP5 were less effective in protecting mice against cutaneous viral infection [41].
It is interesting whether in patients with psoriasis the described situation will be similar to the one in
healthy individuals. No studies have been published on this subject yet.
In vitro, CD8+ TRM cells showed increased oxidative metabolism of mitochondria in the presence
of exogenous FFA in normal and psoriatic skin. These results suggest that FABP4 and FABP5 play a
key role in the maintenance, longevity and function of CD8+ TRM cells, and suggest that CD8+ TRM
cells use exogenous FFA and their oxidative metabolism to survive in tissue. It has been shown that
the lack of FABP4 and FABP5 does not affect CD8+ T cell proliferation or skin recruitment, but they are
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necessary for their long-term survival in the skin [41]. Perhaps the blockade of PPAR-γ functions will
allow the development of strategies for the treatment of psoriatic lesions.
Oxidative stress plays an important role in psoriatic inflammation. In the study of Esmaeili et
al. [42], the redox status of TRM CD4+ and its correlation with IL-17 response were assessed. The
increased intracellular ROS production in memory CD4+ T cells in psoriasis patients decreased catalase
gene expression compared to healthy ones, but no differences in intracellular glutathione levels and
plasma total antioxidant capacity were revealed. However, the above disorders did not affect the IL-17
response in memory T cells [42].
4. Tissue Resident Memory Cells in Psoriatic Arthritis (PsA)
Recently, data has shown that TRM cells are responsible for the development of synovitis in PsA.
However, they were not observed in rheumatoid arthritis [23].
The latest study on psoriatic arthritis (PsA) and other spondyloarthritides (SpA) assessed the
molecular profile, phenotype and function of synovial Tc17 cells (IL-17A + CD8 + T cells) to clarify their
role in pathogenesis. It turned out that, as in psoriasis, they were mainly TCRαβ +, and their number
was increased in synovial fluid vs. peripheral blood in patients with PsA or other SpA. In addition,
synovial TA17 PsA cells had the characteristics of Th17 (RORC/IL23R/CCR6/CD161) and Tc1 cells (A/B
granzyme). The synovial marker Tc17 was CXCR6, and elevated levels of CXCR6 CXCL16 ligand in
PsA were found in synovial fluid, which could contribute to their retention in the joints [43]. However,
there are many doubts if TRMs are responsible for the initiation of inflammation and whether it is the
same phenotype that persists after the treatment [23].
A new theory has emerged that TRMs involved in synovitis migrate from the skin and gut.
Although TRMs do not circulate in the blood, they can sometimes be activated so that they travel within
the lymphatic system [23,44,45]. A study by Guggino et al. [45], assessing TRM cells in peripheral
blood, gut and synovium in patients with SpA, showed that the expression of α4β7 may support the
recirculation of these cells from the gut and peripheral blood to foci of inflammation in the joints.
Although this study applies to the entire group of patients with ankylosing spondylitis, probably
patients with PSA were also included. Unfortunately, PSA patients were not analyzed separately and
there is no research on these patients.
5. The Role of Memory γδ T Cells
Matos et al. found that TRM in psoriasis patients had specific properties that TRM did not have in
healthy skin. These pathogenic clones preferentially had Vβ and Vα in the TCR region. Researchers
identified 15 TCRβ and 4 TCRα antigen receptor sequences in patients with psoriasis that were
not seen in the skin of healthy patients or atopic dermatitis patients. In addition, they observed a
reduced amount of γδ T cells in psoriasis compared to αβ T cells. It has been proven that IL-17- and
IL-22-producing T-cell clones with IL-17- and IL-22-specific antigen receptors still exist in the skin after
the active psoriatic lesions have resolved. Therefore, for full disease remission, suppression of these
resident T lymphocyte populations is required [3].
However, in psoriasis a reduced amount of γδ T cells was observed compared to αβ T cells [3]. In
contrast, γδ T lymphocytes, considered innate immune cells that can also give rise to TRM populations,
are far less known. Recently it has been shown in a mouse model that they can produce IL-17A and
IL-17F in the skin in response to imiquimod. Each subsequent test with imiquimod resulted in an ever
stronger proliferation of γδ T cells compared to the skin of mice after the first provocation [46].
6. Th22 and Tc17 Lymphocytes
In active psoriasis, we observe increased expression of IL17A, IL22 and IFN-γ in the effector T
CD4+ and CD8+ cells of the epidermis in the immediate vicinity of keratinocytes, whereas cutaneous
T cells show less activity of these genes. Cheuk et al. [5] proved that Th22 epidermal cells in healed
skin were still present and functioning after several years of disease remission. After their stimulation,
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an increase in local IL-22, IL-17A and IFN-γ production by CD4+ T cells was observed. The percentage
of IL-22-producing CD4+ epidermal cells did not correlate with the number of years of treatment,
which indicates a preserved effector function even after 6 years of the treatment [5]. It has been
shown that CD4+ epidermal T cells produced mainly IL-22, which activates keratinocytes leading to
acanthosis. In contrast, epidermal CD8+ T cells mainly produced IL-17A, which drives the production
of pro-inflammatory cytokines and chemokines by keratinocytes and is involved in the recruitment of
neutrophils [5].
Studies have also shown that there are T-cells producing both IL-22 and IL-17 in the epidermis,
which are present in lesions and healed skin in patients receiving nb-UVB therapy, and are practically
absent in patients treated with biological drugs. Perhaps this type of T cell is more pathogenic [5]. It is
known that effective nb-UVB therapy induces T cell apoptosis in the skin, but highly active effector
lymphocytes can be constantly recruited from circulation [5].
Of note, active effector T cells involved in the inflammatory process may develop into long-lived
epidermal TRM cells as the disease subsides [5,7,8].
7. Epidermal Langerhans Cells (LCs)
Psoriatic lesions’ “memory” may also be affected by Langerhans cells dysfunction. In normal skin,
epidermal Langerhans cells (eLC) are located in the epidermis and separated from dendritic skin cells
(DC) by the basal membrane. Compared with cutaneous DC, LCs express fewer Toll-like receptors
(TLRs), indicating an impaired ability to respond to TLR signaling, probably to maintain a state of
tolerance to commensal [47]. In active psoriasis, under the influence of IL-23 and IL-17, inflammatory
DCs penetrate both to the epidermis and dermis. In inflammatory DC epidermal expression of CCR2+
(eDC) occurs only in psoriasis and is phenotypically different from normal DCs’. Their number is
higher than eLC and they show high expression of genes involved in the recruitment of neutrophils,
keratinocytes and T lymphocytes. On the other hand, colonization of epidermis by eLC, under the
influence of TLR-4 and TLR-7/8 activation, produce large amounts of IL-23, and eDCs secrete IL-1β
together with IL-23 and TNF-α. After the psoriasis eruption, eDCs are absent in unchanged skin, while
eLC retain high IL-23A expression and continue to respond to TLR stimulation, producing IL-23 [47,48].
Although eDCs are 3–10 times more numerous than eLC and drive the psoriatic condition, they also
have the ability to produce anti-inflammatory IL-10 [48].
In individuals with early type of psoriasis (under 40 years of age) LCs do not show the ability
to migrate under the influence of stimuli (chemical allergens, IL-1b and TNF-α). It is probably a
phenomenon caused by the influence of the psoriatic environment rather than their defect [49,50]. Their
ability to migrate is restored under the influence of treatment (among others anti-TNF, anti-IL-12/23,
fumaric acid esters and UVB), except for therapies directed mainly towards T cells (ciclosporin A,
MTX) [50–52]. Therefore, the observed rapid relapses after discontinuation of ciclosporin A may be
explained by the role of LC in the rapid initiation of the inflammation in the same location (effect on
TRM expressing IL-23R), which thus affects the memory of psoriatic eruptions [48].
8. Clinical Significance of the Memory of Psoriasis Lesions
Psoriatic lesions are characterized by the presence of massive inflammatory infiltrates (lymphocytes,
neutrophils), proliferation and disturbance of epidermal differentiation (parakeratosis) as well as
the formation of new blood vessels. Despite being such large structures, their resolution leaves no
scars. This is quite unusual, especially comparing to other conditions in which neutrophils (pyoderma
gangrenosum) are involved, where scars are present [12]. However, after discontinuation of treatment,
a rapid recurrence of lesions is usually observed (90% in the same location) [24]. The understanding of
the psoriasis context and the role of TRM can explain the key issues associated with this disease:
- the role in resistance to treatment and reactivation of changes in the same location [24];
- the role in the Koebner isomorphic symptom [24];
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- the decision about adequate treatment time to limit lesions relapse and withdraw and reduce the
amount of TRM.
The clinical characteristics of recurrence of psoriatic lesions mirrors the biology of TRMs. Since
TRM does not work, inflammatory lesions induced by TRM are usually well demarcated with clear
margins. The relapse of lesions can be fast because they occur in TRM skin and cooperate with local
dendritic cells [12,52]. In understanding the abovementioned mechanisms, one stands a chance to
provide more effective treatment and thus long-lasting remissions in psoriasis patients.
9. Conclusions
The discovery of TRM cells in psoriasis allows a better understanding of the complicated
relationships between mediators and cells of the innate and adaptive immune system, keratinocytes
and endothelial cells. It explains the clinical phenomenon of the tendency of psoriatic lesions to relapse
in the same location and it allows to develop new therapeutic strategies in the future.
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Abstract: The association between psoriasis and cardiovascular disease risk has been supported
by recent epidemiological data. Patients with psoriasis have an increased adjusted relative risk
for myocardial infarction. As such, the cardiovascular risk conferred by severe psoriasis may be
comparable to what is seen with other well-established risk factors, such as diabetes mellitus. Previous
studies demonstrated that low-density lipoprotein (LDL) plays critical roles during atherogenesis.
It may be caused by the accumulation of macrophages and lipoprotein in the vessel wall. Oxidized
LDL (ox-LDL) stimulates the expression of adhesion molecules, such as ICAM-1 and VCAM-1,
on endothelial cells and increases the attachment of mononuclear cells and the endothelium.
Even though previous evidence demonstrated that psoriasis patients have tortuous and dilated
blood vessels in the dermis, which results in the leakage of ox-LDL, the leaked ox-LDL may increase
the expression of adhesion molecules and cytokines, and disturb the static balance of osmosis.
Therefore, exploration of the relationship between hyperlipidemia and psoriasis may be another
novel treatment option for psoriasis and may represent the most promising strategy.
Keywords: lipid; psoriasis; inflammation
1. Introduction
Psoriasis is a chronic inflammatory disease related to many diseases, especially cardiovascular
disease. Among these diseases, atherosclerosis plays the most important role [1]. Atherosclerosis
is caused by inflammation and an imbalance of the lipid metabolism. Psoriasis and atherosclerosis
not only share the same cytokines involved in the immunological mechanism, such as interleukin
(IL)-17, but also have common angiogenic factors and oxidative pathways [2]. In addition, both of them
have similar lipid profiles, including decreased high-density lipoprotein (HDL) levels and/or increased
low-density lipoprotein (LDL) levels [3]. In the pathological process of atherosclerosis, the accumulation
of cholesterol triggers the production of pro-inflammatory cytokines, such as tumor necrosis factor
alpha (TNFα), and also leads to the aggregation of monocytes and differentiation into foam cells [4].
TNFα eventually induces an inflammatory cascade in blood vessels [5]. In chronic inflammation,
TNFα may also influence the lipid profile, such as LDL-C levels, via a decreased concentration of
apolipoproteins. Moreover, TNFα lowers the quality of lipoprotein by inducing the production of
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LDL and oxLDL and reducing the level of HDL-C at the same time [6]. Oxidized LDL (oxLDL)
not only exacerbates inflammation but also promotes cholesterol accumulation in lysosomes, which
eventually leads to cell death [7]. On the other hand, HDL has a reverse cholesterol transport (RCT)
function, anti-oxidative capacity, and anti-inflammatory properties by regulating dendritic cells’ (DCs)
differentiation [8], and reducing T cell activation and IL-12 production [9]. However, these properties
are reduced during chronic inflammation, such as psoriasis [10]. Previous studies have clarified
the immunological pathway of psoriasis; however, the mechanism between psoriasis and an abnormal
lipid profile remains unknown. Thus, identification of the relationship between hyperlipidemia and
psoriasis is of paramount importance to develop a new therapeutic prospect for psoriasis.
2. Psoriasis
2.1. The Etiology of Psoriasis
Psoriasis is a chronic inflammatory skin disease related to immune inheritance. However,
to date, the true cause of the disease remains unclear. According to epidemiological statistics,
approximately 1%–3% of people worldwide develop psoriasis every year [11]. Psoriasis has long
been considered a skin disease. However, according to recent research findings, psoriasis is actually
a multisystem disease. It may be related to the occurrence and course of other diseases, including
rheumatological (psoriatic arthritis (PsA)), cardiovascular and psychiatric complications [12,13], as well
as cardiometabolic diseases, such as obesity, hypertension, and dyslipidemia [14]. At present, comorbid
cardiovascular diseases are the main cause of death in patients with psoriasis [15]. The risk of
suffering myocardial infarction in patients with severe psoriasis is seven times that in individuals
with corresponding age, sex, body mass index (BMI), and cardiovascular risk factors, and the risk of
cardiovascular mortality increases by 57% in patients with severe psoriasis [16]. In addition, patients
with psoriasis are at a higher risk for cardiovascular diseases. Psoriasis is also related to accelerated
atherosclerosis. It has been found that all T cells involved in the pathogenesis of psoriasis are also
involved in atherosclerosis [17]. Clinically, psoriasis is divided into many categories, and psoriasis
vulgaris (PV) accounts for approximately 90%. Psoriasis often causes symptoms, such as desquamation,
skin redness, and itching. In addition to affecting appearance, psoriasis causes great psychological
pressure and social distress to patients, thus reducing quality of life [18].
2.2. The Molecular Mechanism of Psoriasis
Previous studies have shown that CD4+ helper T cells may differentiate into regulatory T cells
and effector T cells (including T-helper cell type 1 (Th1) cells, T-helper cell type 2 (Th2) cells, T-helper
cell type 17 (Th17) cells, follicular helper T (Tfh) cells, and regulatory T cells (Tregs)), which are
subsequently activated. Before the discovery of other cell lineages, Th1 and Th2 cells were considered
to be the only T cells that differentiated from progenitor CD4+ helper T cells [19]. However, a new CD4+
helper T cell subset was discovered, named Th17 cells [20]. Th17 cells produce interleukin 17 (IL-17).
Among all Th cell subsets, IL-17-producing T cells play an important role in autoimmune diseases,
including multiple sclerosis, psoriasis, inflammatory bowel diseases, and steroid-resistant asthma [21].
At present, psoriasis is generally considered to be derived from the chronic activation of the IL-23/Th17
cell signaling axis, in which dominant T cell subsets are Th1 and Th17 cells. The cytokines released by
Th1 and Th17 cells facilitate immune cell aggregation, promote keratinocyte proliferation, and increase
the inflammatory response [22]. More precisely, CD4+ and CD8+ T cells with an IL-17-secretory
phenotype are most important because they produce pro-inflammatory cytokines IL-17, IL-22, and tumor
necrosis factor alpha (TNFα) [23]. The pathogenic mechanism of psoriasis is divided into the primary
initiation phase and the chronic inflammatory phase. In the primary initiation phase, the pathogenic
inflammatory response is initiated. The subsequent chronic inflammatory phase is continued by
feedback loops and amplification signals. During the development of psoriasis, T cell predominance
shifts from Th1 predominance in the initiation phase to Th17 predominance in the chronic inflammatory
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phase [24]. External stimuli, such as trauma, infection, or drug administration, cause the release of
self-nucleotides. Self-nucleotides then bind to antimicrobial peptides (AMPs) released by keratinocytes,
forming complexes [19]. AMPs are positively charged proteins and members of the innate immune
system and include cathelicidin antimicrobial peptide (CAMP), pro-inflammatory cytokines and
chemokines (for example, TNF, IL-17, IL-22, and CC-chemokine ligand 20 (CCL20), among numerous
others), and angiogenic factors [24]. Among the AMPs, CAMP is not produced when keratinocytes
are healthy. However, CAMP is upregulated when epidermal cells are destroyed. In psoriasis
lesions, the increase in CAMP production initiates pathogenic interferon (IFN) signaling cascades
and the activation of DCs, resulting in uncontrolled inflammatory reactions [25]. The complexes of
self-nucleotides and AMPs then bind to the receptors on antigen-presenting cells, such as toll-like
receptor 7 (TLR7) and TLR9 on the surface of plasmacytoid dendritic cells (pDCs). pDCs are a member
of the innate immune system circulating in the blood. After antigen presentation, pDCs promote
the activation and clonal expansion of antigen-specific CD8+ T cells, and such processes occur
in the dermis (activation of memory resident T cells) and local lymph nodes (activation of naive
T cells). In addition, in the initiation phase of psoriasis, pDCs release the inflammatory mediators
IFNα and IFNβ, thereby stimulating the secretion of pro-inflammatory mediators (such as IL-12,
IL-23, and TNF) by myeloid DCs. Subsequently, the activated CD8+ T cells migrate to the epidermal
layer and encounter class I major histocompatibility complex (MHC) receptors on the surface of
keratinocytes (or melanocytes), triggering the local release of soluble factors, including cytokines,
chemokines, and innate immune mediators, to increase local inflammation and stimulate keratinocyte
proliferation [24]. In addition to being a skin barrier, keratinocytes release inflammatory cytokines,
such as TNF; express IL-17 receptors; and participate in the initiation and amplification of psoriasis [26].
The IL-17 family consists of 6 members, IL-17A to IL-17F, among which IL-17A is the most studied
member while IL-17E (also known as IL-25) is an inhibitor of IL-17 [27]. In addition to IL-17A, Th17
cells also release various inflammatory cytokines, including IL-17F, IL-21, IL-22, and granulocyte
macrophage colony-stimulating factor (GM-CSF). Therefore, targeting the Th17 cell subset is more
therapeutically effective than targeting a single cytokine [21]. Innate immunity mediators stimulate
the activation of T cell populations, such as Th1, Th17, and Th22 cells, and then release additional
cytokines and chemokines. In particular, IL-1 allows Th17 cells to respond to IL-23 [24]. Th17 cells then
release IL-17, IL-22, TNF-α, and other cytokines [28], and participate in the macrophage-dependent and
-independent stimulation of DCs, thereby enhancing the immune response [29]. They may participate
in the production of angiogenic inflammatory mediators, including monocyte chemoattractant protein
(MCP-1), nitric oxide, and vascular endothelial growth factor [30]. The expression of vascular
endothelial growth factor receptors on epidermal cells induces cardiovascular endothelial hyperplasia
and the expression of adhesion molecules in the vascular endothelium, thereby aggregating immune
cells. Angiogenic factors induce tortuous characteristics in papillary dermal vessels at the sites
of psoriasis lesions, manifesting as the Auspitz sign. In addition, IL-17 acts on the IL-17 receptor
on keratinocytes to stimulate the production of TNF and CCL20 (a chemotactic for T cells and
DCs208) by keratinocytes [24]. IL-17 and TNF and/or other pro-inflammatory cytokines stimulate
the activation of defensins and chemokines to promote host defense and the accumulation of other
immune cells [31]. IL-22 is related to the pathological characteristics of psoriasis, including epidermal
hyperplasia, acanthosis, and parakeratosis. Important transcription factors in psoriasis include
cyclic AMP, the Janus kinase (JAK) signal transducer and activator of transcription (STAT) family,
and nuclear factor-κB (NF-κB). Activation of these transcription factors results in the production of
other factors, such as TNF and IL-17, as well as downstream amplification loops. Notably, although
IL-17 is a signature cytokine of TH17 cells, other innate and acquired immune cells also produce IL-17,
including CD8+ T cells, γδ T cells, innate lymphoid cells, and natural killer (NK) T cells [32]. Compared
with a healthy control group, patients with psoriasis display higher serum concentrations of IL-17.
However, the paradigm of Th17 cells as the main cellular source of IL-17 is no longer fully valid [33].
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Recent studies have noted that the innate immune system, including neutrophils, mast cells, γδ T cells,
and innate lymphoid cells, is the most important source of IL-17 in patients with psoriasis [34].
3. The Relationships among Psoriasis, Cardiovascular Diseases, and Dyslipidemia
3.1. Normal Function of Fat and Cholesterol in Skin Cells
The stratum corneum is the outermost layer of the epidermis, and is a barrier protecting humans
from the external environment. In addition to protecting humans against external harm, the stratum
corneum prevents water loss from the body [35]. The structure of the stratum corneum is often
described as bricks and mortar [36]. The bricks are fully differentiated keratinocytes, mostly consisting
of keratin filaments and filaggrin [37]. The mortar refers to intracellular lipids, which consist of
ceramides (CERs), free fatty acids (FFAs), and cholesterol. These lipids are arranged into a lamellar
structure, and CERs account for 50%. CERs are the main polar lipids in the stratum corneum,
and their basic composition is a sphingoid base connected to fatty acids by amide bonds. However,
the composition of CERs varies appreciably in the human body. CERs are divided into 12 categories
according to the head group composition or fatty acid esterification [38]. CERs play an important
role in skin barriers, cell adhesion, and epidermal differentiation. In addition, CERs act as second
messengers in stress-induced apoptosis [39]. CERs induce the apoptosis of tumor cells and reduce
the resistance of tumor cells to chemotherapy drugs [40]. In psoriasis, the barrier function of the skin
and water loss by the epidermis are mainly related to an abnormal composition ratio of CERs [41].
However, the total amount of CERs does not differ significantly between patients with psoriasis and
healthy individuals [42]. Studies have shown that prosaposin, a precursor of saposin, and its mRNA
were decreased in patients with psoriasis [43]. Saposins are a class of nonenzymatic proteins
involved in the hydrolysis of sphingolipids, including the postsecretory glucosyl-CERs in the stratum
corneum [44]. Sphingomyelinase is also significantly downregulated in the stratum corneum of patients
with psoriasis. The reduction in the enzymes involved in CER production and metabolism may lead
to decreases in ceramide 1 and other CERs at the sites of psoriasis lesions [41] as well as decreases
in long-chain CERs containing ester-linked fatty acids and CERs containing phytosphingosine, thereby
altering CER composition and increasing transepidermal water loss. In addition, the proportion of
the three major intracellular lipids varies in the stratum corneum. At the sites of psoriasis lesions,
the FFA content is significantly reduced while the cholesterol content is slightly increased [42].
Cholesterol constitutes approximately 25% of animal cell membranes and maintains cell integrity and
fluidity. Moreover, the dynamic arrangement of cholesterol enhances the coating ability of the cell
membrane, allowing the cell membrane to increase fluidity at low temperatures and increase stability
at high temperatures [45]. For circulating low-density lipoprotein (LDL), cholesterol is transported
via LDL receptor (LDL-R)-mediated endocytosis of holo-particles. Cholesteryl esters (CEs) delivered
by the endocytosed LDL are hydrolyzed by lysosomal acid lipase in the lysosomes. The released
unesterified (free) cholesterol is transported to the endoplasmic reticulum (ER), in which the cholesterol
is re-esterified to form CEs. The CEs are stored in cytoplasmic lipid droplets (LDs) or are transported to
the cell membrane or mitochondria. HDL binds to scavenger receptor class B type 1 (SR-B1) on the cell
surface, and CEs are selectively transported into the cells without the internalization of the whole
lipoprotein molecule. Subsequently, the CEs are hydrolyzed into free cholesterol by hormone-sensitive
lipase (HSL). This mechanism is used by steroidogenic cells that rely on cholesterol as a precursor.
Large amounts of CE-rich LDs are found in steroidogenic cells, in which the CEs are hydrolyzed into
cholesterol by HSL to supply the steroidogenic cells [46]. Each has a unique receptor specificity and
mechanism of transporting cholesterol. SR-B1 is a lipoprotein receptor [47] and plays an important role
in cholesterol efflux and steroid hormone production [48]. In addition, SR-B1 has an RCT function and
determines HDL-C levels through selectively transporting HDL-CEs to the liver, where the HDL-CEs
are converted to bile acids, or through biliary cholesterol secretion [49]. Various mouse model studies
have shown that SR-B1-null mice exhibit an increase in the amount and size of HDL-CE, which
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is accompanied by a reduced level of cholesterol in secreted bile and accelerated atherosclerosis.
In contrast, SR-B1-overexpressing mice exhibit decreased levels of HDL-CE, a reduced degree of
atherosclerosis, and a reduced extent of atherosclerosis in the liver [49]. Binding of HDL to SR-B1
increases anti-inflammatory cytokines, such as IL-10 and transforming growth factor-beta (TGF-β),
by initiating Akt and reducing NF-κB activation, thereby regulating the inflammatory response of
macrophages. SR-B1 in macrophages also regulates efferocytosis or the removal of apoptotic cells
through the Src/phosphoinositide 3-kinase (PI3K)/Akt/Rac1 signaling pathway, thereby enhancing
survival and the anti-inflammatory response of phagocytes. In endothelial cells, SR-B1 participates
in the translocation of HDL from the apical to basolateral side, which further promotes the removal of
cholesterol from intimal macrophages and lymphatic vessels [50].
3.2. The Correlation Between Psoriasis and Atherosclerosis
Patients with psoriasis are at a high risk for the incidence of cardiovascular disease and myocardial
infarction [51]. Compared with the general population, the risk factors for cardiovascular diseases in patients
with psoriasis have a high incidence, such as diabetes, hypertension, obesity, and hyperlipidemia [51].
Psoriasis is highly correlated with cardiovascular diseases, and hyperlipidemia-induced atherosclerosis
is the predominant disease [1]. A large amount of evidence indicates that psoriasis is related to severe
atherosclerosis and cardiovascular diseases while inflammation plays an important role in psoriasis and
atherosclerosis [1]. Atherosclerosis and psoriasis have very similar immune response profiles. In addition,
atherosclerosis and psoriasis share the same immunological pathways (including DCs, Th1 cells, Th17
cells, and Tregs) as well as angiogenic factors and oxidative mechanisms [2]. A number of studies show
that patients with psoriasis exhibit decreased HDL levels and/or increased low-density lipoprotein (LDL),
very-low-density lipoprotein (VLDL), and triglyceride (TG) levels [3].
3.3. The Relationship Between Psoriasis and Blood Lipids
Obesity is related to many immune diseases, including cardiovascular diseases, arteriosclerosis,
and psoriasis [52]. However, in mouse models, both obese and lean mice develop severe psoriasiform
skin inflammation after being fed a high-fat diet (HFD). Such a phenomenon is related to FFAs but
is not related to the fat mass extension, blood glucose levels, and adipose tissue-derived mediators.
The increase in FFAs leads to an immune response and insulin resistance, which alters the homeostasis
and function of immune cells. HFD also increases the level of saturated fatty acids (SFAs). SFAs stimulate
myeloid cells to produce TLR-like stimuli, which induce a pro-immune response, thus resulting
in keratinocyte activation. Therefore, decreasing the SFA content in food reduces psoriasiform
inflammation. HFD-induced obesity does not directly alter the proinflammatory status of skin and
immune cells. However, it renders the skin and immune cells more susceptible to proinflammatory
stimuli, such as imiquimod (IMQ), thereby enhancing the immune response [53]. Certain studies
failed to establish a correlation between psoriasis and lipid serum levels [54], including a large
population-based cross-sectional study conducted in the UK [55].
3.4. The Relationships among Oxidized LDL (oxLDL), the Inflammatory Response, and Psoriasis
The accumulation of excessive cholesterol in blood vessel walls could promote the dysfunction
and activation of epidermal cells, which induces an inflammatory response and eventually leads to
the production of pro-inflammatory cytokines and reactive oxygen species, the overexpression of
adhesion molecules and chemokines, and a reduction in nitric oxide levels [4]. The above processes lead
to the aggregation and invasion of monocytes and the differentiation of monocytes into macrophages.
After receiving modified LDL via scavenger receptors, macrophages are converted to foam cells.
In addition, TNFα triggers endothelial dysfunction and induces an inflammatory cascade in the blood
vessel wall, ultimately resulting in vascular sclerosis [5]. Although elevated TNFα exerts a protective
effect during acute immunity, the maintenance of a high concentration of TNFα during chronic
inflammation may alter lipid and carbohydrate metabolism. In fact, TNFα decreases the concentration
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of LDL-C through diminishing the secretion of apolipoproteins and reducing cholesterol catabolism and
excretion, thereby interfering with cholesterol metabolism. In addition, TNFα promotes the production
of pro-atherogenic small dense LDL and oxLDL to alter the quality of lipoproteins. TNFα also reduces
HDL-C levels and changes HDL composition [6]. Patients with chronic inflammatory responses
experience qualitative and quantitative changes in lipid and lipoprotein profiles, including decreases
in cholesterol, HDL-C, and apolipoprotein A-1, and increases in small dense LDL, lipoprotein(a) [Lp(a)],
and TG. In addition to TNFα, IL-6 and IL-1ß also alter lipid metabolism, including increasing VLDL
and reducing TG-rich lipoprotein clearance. An increase in serum TG levels enhances the expression
of cholesteryl ester transfer protein (CETP), which transfers TG from VLDL/LDL to LDL/HDL.
These TG-enriched particles become the substrate for hepatic lipase and lipoprotein lipase, resulting
in the production of small dense LDL and HDL as the final products. Small dense LDL more readily
enters into the arteries [9] and is more susceptible to oxidation. As a result, the antioxidant and
anti-inflammatory activities of small dense HDL become limited [56]. LDL levels and composition are
also altered due to inflammation. First, the increase in LDLR expression reduces LDL-C levels and
thus promotes the intracellular accumulation of cholesterol. Second, circulating LDL is more prone to
oxidation. Therefore, patients with chronic inflammatory diseases have high plasma levels of oxLDL.
oxLDL is more atherogenic and can enhance the inflammatory response. Moreover, oxLDL promotes
the accumulation of cholesterol and the formation of cholesterol crystals in lysosomes, which causes
lysosomal disruption and leads to increased cellular toxicity [7].
3.5. The Relationships among HDL, the Inflammatory Response, and Psoriasis
HDL has RCT, anti-inflammatory, and antioxidant functions, which are related to the prevention
of cardiovascular diseases [57]. In addition, HDL has anti-apoptotic and anti-thrombotic activities.
The protective effect of HDL is mostly due to its role in RCT. RCT refers to the process of cholesterol
transport from the peripheral tissues to the liver, where the cholesterol is secreted, converted into bile
acid, or synthesized into sterol hormones [58]. The first step in RCT is the removal of excess cholesterol
from macrophage foam cells at sclerotic sites via HDL or macrophage-derived apolipoproteins [59].
Cholesterol efflux can be achieved through a number of ways, including (a) unidirectional efflux
to lipid-free apolipoproteins, particularly apoA-1, mediated by ATP-binding cassette A1 (ABCA1);
(b) unidirectional efflux to mature HDL particles mediated by ABCG1; and (c) efflux to mature HDL
particles via passive diffusion facilitated by SR-B1 [60]. Once cholesterol is transferred to the cytoplasm,
SR-B1 delivers the macrophage-derived (HDL) cholesterol to the liver for bile acid production. The next
step is biliary secretion or transport to steroidogenic tissues, especially the adrenal gland and ovary, for
steroid production and storage. HDL terminates lipid peroxidation chain reactions via apolipoproteins
(such as apoA) and enzymes (paraoxonase (PON1), lecithin-cholesterol acyltransferase (LCAT),
and platelet activating factor-acetyl hydrolase), thereby exhibiting an antioxidant function [61]. HDL not
only inhibits monocyte transmigration and the expression of adhesion molecules in endothelial cells but
also plays an immunomodulating role in the innate and acquired immune systems. HDL regulates DCs,
monocytes, macrophages, T cells, and B cells mainly through modification of the cholesterol content
of lipid rafts [62]. The anti-inflammatory properties of HDL are achieved through apoA-1, a major
HDL-associated protein. apoA-1 stimulates the production of IL-10 and prostaglandin E2 (PGE2),
thereby inhibiting the differentiation and functions of DCs [63], and reducing T cell activation and IL-12
production [8]. During a chronic inflammatory response, the antioxidative and anti-inflammatory
properties of HDL are reduced. In addition, RCT and the ability to resist LDL oxidation are affected.
The decrease in the antioxidative property is due to proteome alterations, including decreased activity
of HDL-associated enzymes and the accumulation of complement (C3), ceruloplasmin, and serum
amyloid A (SAA) [58]. The reduced anti-inflammatory property may be related to decreased apoA-1
and apoM levels. In addition, enhancement of the pro-inflammatory mechanism is due to the impaired
cellular efflux of lipids to HDL, which initiates intracellular STAT3 signaling and induces vascular
inflammation. In addition to low plasma levels of HDL [9], HDL proteomic and lipid composition
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are altered in psoriasis [15,16], which leads to a decrease in the cholesterol efflux capacity [12,15] and
a reduction in the anti-inflammatory and antioxidant capacities of HDL. Moreover, other properties
of HDL are also altered, such as the anti-LDL oxidation capability, inhibition of TNF-α-induced
monocyte adhesion to epidermal cells, prevention of the ox-LDL-induced monocyte migration,
and protection of epidermal cells from TNF-α-induced apoptosis [14]. Patients with psoriasis exhibit
low PON-1 activity, which is negatively correlated with psoriasis area and severity index (PASI)
scores [58]. Conversely, anti-psoriatic therapy restores the composition and function of HDL [64].
HDL-associated proteins also undergo changes, among which apoA-1 and apoM are significantly
reduced. In contrast, the levels of acute-phase proteins, such as SAA, prothrombin, α-1-antitrypsin,
and α-1-acid glycoprotein 1, are significantly increased. The cholesterol efflux capacity is related to
decreased apoA-1, phosphatidylcholine, and sphingomyelin in HDL. Under chronic inflammatory
conditions, such as psoriasis, the changes in protein structure and the appearance of neo-epitopes
may lead to autoantibody production and HDL dysfunction and are even related to cardiovascular
diseases [10]. Therefore, these antibodies may serve as new biomarkers for autoimmune diseases
in cardiovascular diseases. High titers of autoantibodies against HDL (aHDL) and apoA-I are present
in chronic inflammatory diseases, which is related to high cardiovascular risk. aHDL and aapoA-I are
also found in patients with psoriasis. These antibodies are correlated with the severity of diseases and
may be related to the development of vascular sclerosis.
4. Conclusions
Psoriasis affects at least 125 million people across the world. Additional development and evaluation
of the relationship between the lipid profile and psoriasis to explore treatment efficacy is required.
In chronic inflammation, TNFα may influence the lipid profile, such as LDL-C levels, via decreased
concentrations of apolipoproteins. Moreover, TNFα lowers the quality of lipoprotein by inducing
the production of LDL and oxLDL but reducing the level of HDL-C at the same time. Oxidized LDL
(oxLDL) not only exacerbates inflammation but also promotes cholesterol accumulation in lysosomes,
which eventually leads to cell death. On the other hand, HDL has a reverse cholesterol transport (RCT)
function, anti-oxidative capacity, and anti-inflammatory properties by regulating dendritic cells’ (DCs)
differentiation and reducing T cell activation and cytokine production. However, these properties are
reduced during chronic inflammation, such as psoriasis. Thus, identification of the relationship between
hyperlipidemia and psoriasis is of paramount importance to develop a new therapeutic prospect for
psoriasis (Figure 1).
Figure 1. Immune cells and lipoprotein-associated cytokines implicated in psoriasis pathogenesis.
Characteristic markers and cytokines related to the interleukin (IL)-17/IL-23 immune signature of T cells,
lipoprotein, dendritic cells (DCs), and associated immune cells in psoriatic skin inflammation.
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Abstract: Psoriasis is a chronic inflammatory cutaneous disease, characterized by activated
plasmacytoid dendritic cells, myeloid dendritic cells, Th17 cells, and hyperproliferating keratinocytes.
Recent studies revealed skin-resident cells have pivotal roles in developing psoriatic skin lesions.
The balance in effector T cells and regulatory T cells is disturbed, leading Foxp3-positive regulatory
T cells to produce proinflammatory IL-17. Not only acquired but also innate immunity is important
in psoriasis pathogenesis, especially in triggering the disease. Group 3 innate lymphoid cell are
considered one of IL-17-producing cells in psoriasis. Short chain fatty acids produced by gut
microbiota stabilize expression of Foxp3 in regulatory T cells, thereby stabilizing their function.
The composition of gut microbiota influences the systemic inflammatory status, and associations been
shown with diabetes mellitus, cardiovascular diseases, psychomotor diseases, and other systemic
inflammatory disorders. Psoriasis has been shown to frequently comorbid with diabetes mellitus,
cardiovascular diseases, psychomotor disease and obesity, and recent report suggested the similar
abnormality in gut microbiota as the above comorbid diseases. However, the precise mechanism and
relation between psoriasis pathogenesis and gut microbiota needs further investigation. This review
introduces the recent advances in psoriasis research and tries to provide clues to solve the mysterious
relation of psoriasis and gut microbiota.
Keywords: psoriasis; tissue resident cells; innate lymphoid cells; regulatory T cells; Foxp3;
gut microbiome; systemic inflammation
1. Introduction
Psoriasis is a chronic inflammatory skin disease, with diverse disease severity and clinical
phenotypes. Currently, no curative treatment exists, however, recent advances in therapeutics have
made it possible to suppress the disease almost to disappearance. Progress in immunology and
molecular biology has dramatically changed understanding of psoriasis pathogenesis, enabling
development of novel treatment modalities.
In this review, several recent findings in psoriasis research are reviewed, to support
further investigation.
2. Present Understanding of Psoriasis Pathogenesis
Plaque psoriasis is clinically defined as a cutaneous disease with multiple plaques of scaly
erythematous lesions. The diagnosis is usually simple with macroscopic findings, but sometimes
difficult to differentiate from eczematous, lichenoid, or other conditions. Microscopic investigation
is sometimes helpful, but macroscopically difficult cases are also usually difficult to diagnose
microscopically. The reason may be that there are heterogeneous clinical groups of psoriasis patients,
suggesting that there are heterogenous pathogenetic groups in psoriasis patients. This is supported
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by the fact certain biologic drugs are efficient in some psoriasis patients but not in others. It has also
been postulated that there is mixed pathogenesis of autoimmune and autoinflammatory conditions in
psoriasis [1], and the balance of these conditions may differ among patients.
Krueger and Guttman [2] proposed a novel concept which positioned psoriasis and atopic
dermatitis at the both ends of the same inflammatory disease spectrum: Psoriasis is located at pure
Th17 inflammation, and atopic dermatitis is a combination of Th17, Th2, and Th1 inflammation.
Recent development of biologics for psoriasis treatment produced a novel skin condition, named
“paradoxical psoriasis-like eruption” [3]. Paradoxical reactions have been noted for the first time in
rheumatoid arthritis patients treated with anti-tumor necrosis factor (TNF) antibodies who developed
psoriasis-like skin eruptions. Recently other immunological conditions provoked by targeted biological
agents are included in paradoxical reactions, considered “class-effect of targeted biological agents”.
The interaction between genetically predisposed conditions and targeted biological agents may result
in the development of paradoxical reaction development. This itself is of scientific interest, in the
context of understanding mechanisms of inflammatory diseases.
The present understanding of psoriasis pathogenesis is summarized in Figure 1. Dendritic cells,
T lymphocytes, and keratinocytes are the three major cellular players. Genetic background predisposes
patients susceptible to psoriasis: epithelial cells exposed to various stimuli such as bacteria, virus,
ultraviolet light, or mechanical stress, leads to apoptosis or necrosis of these cells resulting in exposure
of self nucleic acids to tissues [4]. Self DNA bound to LL-37, a part of antimicrobial peptide cathelicidine
produced by keratinocytes (KC), stimulating plasmacytoid dendritic cells (pDC) to produce large
amount of type I interferons. Simultaneously, self RNA bound to LL-37 stimulate myeloid dendritic
cells (mDC) produce tumor necrosis factor alpha (TNFα) and inducible nitric oxide synthase (iNOS).
These cytokines produced by DCs stimulate immature T cells to develop into inflammatory T cells,
especially Th17 cells, producing interleukin (IL)-17 and IL-22, which develop psoriatic phenotype in
KC. KCs produce antimicrobial peptides such as cathelicidine, beta defensine (BD), psoriasin and S100
proteins, chemokines e.g., CXCL1, 2, 8, 10, 11, and CCL20 which attract neutrophils and Th17 cells;
and proinflammatory cytokines, such as TNFα, IL-1, and IL-17. These inflammatory reactions cause an
inflammatory loop sustaining chronic psoriasis [4].
Recent findings also imply psoriasis inflammation’s systemic nature. Obesity’s genetic background
is distinct from that of psoriasis, however, psoriasis is highly associated with obesity. One explanation
is adipose tissue in obese persons produce inflammatory adipocytokines, such as leptin, resistin, and
TNFα, leading genetically predisposed patients to develop psoriasis. Increased amount of inflammatory
adipocytokines and decreased regulatory adipocytokines have been reported in psoriasis patients,
which also correlate with disease severity. This adipocytokine imbalance accelerates insulin resistance
and endothelial dysfunction, leading to atherosclerosis and cardiovascular events [5].
3. Tissue Resident Cells
Tissue resident cells have been identified and have focused attention on the possibility of disclosing
one of the unsolved mysteries: why systemic inflammation of psoriasis chooses skin and articular as
the most involved inflammatory sites.
Clark R. et al. [6] proposed resident memory T cells as pathogenic cells of fixed and recurrent skin
lesions of psoriasis. Resident memory T cells are a recently identified T cell subset residing in epithelial
barrier tissues such as skin, gut, lung, and reproductive tracts. They are highly protective against
pathogens frequently encountered in each tissue. Boyman O et al. [7] in 2004 disclosed that normal
appearing, uninvolved skin of psoriasis patients transplanted on immune deficient mice developed
psoriatic lesions, indicating that there existed pathogenic skin resident immune cells in non-lesional
skin of psoriasis patients. Subsequent studies revealed almost 20 billion T cells reside in healthy
human skin, twice as many T cells in the entire blood volume. These skin resident T cells express
CD45RO, CLA, and CCR4, and strong effector functions with various T cell receptor (TCR) repertoires.
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Large numbers of antigenically active tissue resident T cells have subsequently been disclosed in the
gastrointestinal tract, lung, reproductive tract, peritoneum, and bone marrow [8–13].
Clinical trials of anti-E-selectin which completely block the migration of circulating T cells from
blood to skin on psoriasis patients revealed its ineffectiveness, suggesting the clue to Tissue resident
cell involvement in psoriasis [14]. Another study demonstrating transplanted normal-appearing
uninvolved skin of psoriasis patients on immunodeficient mice developed psoriasis lesions suggested
psoriasis patients’ normal-appearing skin contains pathogenic cells which can develop psoriasis lesions
without the circulating blood cells [7]. Subsequent studies revealed CD4-positive T cells with IL-22
and CD8-positive T cells producing IL-17 remained resident in previously involved psoriasis lesions
after complete clinical resolution from a variety of treatments [15,16].
Gallais serezal I et al. [17] proposed a skewed pool of resident T cells in psoriasis patients
trigger non-lesional skin of psoriasis patients to develop psoriasis lesion. They collected never
lesional psoriasis (NLP) skin from mild psoriasis patients instead of from severe psoriasis, because
in severe psoriasis, patients’ uninvolved skin shows psoriatic gene expression profiles. These NLP
with normal gene expression profiles exhibited IL-17- and IFN-γ-producing T cell accumulation after
stimulation, which triggers keratinocytes to produce IFNα introducing an alternative source of Type I
interferons in initiation of psoriasis. Their analysis revealed skewed T cell population in NLP with
CD8-positive CD49a-negative T cells, and CCR6-positive T cells producing IL-22, IL-17, and IFNγ.
NLP keratinocytes produce increased amounts of CCL20 upon stimulation with Candida albicans or
mannan suggesting the role of KC, weakly stimulated by resident fungi, in accumulation of IL-17 and
IL-22 producing CCR6-positive resident T cells in NLP skin of psoriasis patients. Resident T cells are
insufficient to develop psoriasis lesions, but upon stimulation with various stimuli, such as mechanical
stress, viral infection, and bacterial infection, these skewed population of resident memory T cells
produce inflammatory cytokines, such as IL-17, IL-22, and IFNγ, which initiate psoriasis inflammation
(Figure 2). Their study also demonstrated for the first time the role of KC in production of IFNα in
psoriasis pathogenesis.
4. Innate Lymphoid Cells
Innate lymphoid cells (ILCs) are recently identified innate immune cells. They were found among
lineage-negative cell populations not expressing any mature cell markers, such as Mac-1 for myeloid
cells, CD4 and CD8 for T cells, CD19 for B cells, or Ter-119 for erythrocytes. They have a high potency
for cytokine production without specific antigen stimulation [18]. Psoriasis has been considered an
“autoimmune” disease; however, no specific antigens have been identified so far. The innate immune
system is a relatively primitive immune system, directly activated by components of virus, bacteria,
fungi, or self-DNAs and RNAs, without specific antigens. Many cell types were included in innate
immune cells, such as neutrophils, mast cells, and natural killer cells as well as innate lymphoid cells.
It is not surprising that these innate immune cells take part in psoriasis pathogenesis.
ILCs have been subdivided into three groups: ILC1, ILC2, and ILC3. ILC1 (group 1 ILC)
characteristically produces IFN gamma, perforin, and granzyme, while ILC2 (group 2 ILC) produces
IL-5, IL-13, and IL-4, with nuclear expression of GATA3. ILC3 (group 3 ILC) expresses IL-7Rα,
matures with IL-7 and IL-23, and produces IL-17, IL-22, and lymphotoxin with nuclear expression
of RORγt [18,19]. ILC3 in humans is further divided into three subsets on the basis of expression of
natural cytotoxicity receptors: NKp44, NKp46, and NKp30. NKp44-positive ILC3 produces IL-22 and
is dependent on aryl hydrocarbon receptor (AhR). NKp44-negative ILC3 produces IL-17A following
stimulation, but NKp44-negative ILC3s have plasticity, and they are able to develop into NKp44-positive
ILC3s or into ILC1s with IFNγ production [20]. In inflammatory bowel diseases, ILC3s have been
shown to produce IL-17 in the gut [21]. Therefore, the world of ILCs looks as if it were the parallel
world of helper T cells (Figure 3).
Soare A et al. [22] reported increased numbers of ILC3 exist in the circulating blood of psoriatic
arthritis patients, and ILC3/ILC2 ratios correlated well with disease severity. ILC3 also increased in
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the lesional and non-lesional skin of psoriasis patients. Keren A et al. [23] revealed that injection of
NKp44-positive ILC3 without T cells was able to develop psoriatic skin eruption in SCID mice with
implantation of healthy human skin.
These results indicate that ILC3 may have a pathogenic role in psoriasis, which compensates the
absence of specific self-antigen.
5. Regulatory T Cells
Regulatory T cells (Treg) have immune suppressive function to suppress excess immunity
against a diverse range of antigens, such as self-antigens, commensal bacteria-derived antigens,
and environmental allergens. Many autoimmune and inflammatory diseases, such as systemic
erythematosus, inflammatory bowel diseases, and rheumatoid arthritis, show decreased Treg numbers
and function. Foxp3 (Forkhead box P3) is a transcription factor playing a crucial role in development,
maintenance and function of Tregs. Deficiency of Foxp3 results in lack of Tregs, and causes severe
systemic inflammatory diseases characterized by autoimmunity, colitis, and allergies.
Tregs usually develop in the thymus from CD4−, CD8−, double negative thymocytes, called
thymus-derived regulatory T cells (tTregs) or natural occurring Tregs (nTregs). Expression of Foxp3
are strongly induced through T cell receptor (TCR) signals after the recognition of self-antigen-MHC
complex present on antigen presenting cells (APCs). tTregs are believed to comprise most of the systemic
Treg population. A second subset of Tregs is induced in the peripheral tissues from CD4-positive naïve
T cells by stimulation with cytokine combination, such as TGFβ and IL-2. This type of Tregs is called
induced Tregs (iTregs) or peripherally induced Tregs (pTregs). iTregs usually represent Tregs induced
in vitro, while pTregs indicates Tregs developed from naïve T cells in vivo.
tTregs matured in thymus have constitutive and stable expression of Foxp3, supported by the
binding of several transcription factors to its corresponding promoter and enhancer regions. Several
enhancer regions are identified, designated as conserved non-coding sequences (CNS) 1, 2, and 3, and
CNS0 has recently been identified upstream of CNS1 [24].
Promoter region and each CNS binds specific transcription factors, which regulate the expression
of Foxp3.
The most fundamental transcription factor for Foxp3 expression may be the recently identified
Satb1, which binds to CNS0 inducing both transcriptional and epigenetic regulation. Satb1 binds
to CNS0 at the beginning of Treg commitment and serves as a pioneering element involved in
the transcriptional regulation sequence in Treg development. Nr4a is a transcription factor which
binds to CNS2 and the promoter region of Foxp3, necessary for both pTerg and tTreg development.
TCR activation induces Nr4a expression, which is essential for pTreg and tTreg development and
maintenance after TCR activation. IL-2 and TGFβ are well-known inducers of Tregs, and IL-2 is
essential in inducing both tTregs and pTregs, while TGFβ is needed in pTreg development. STAT5 is
activated downstream of IL-2R, and STAT5 response elements exist in CNS2 and Foxp3 promoter region.
CNS1 contains binding sites for Smads, NFAT, AP-1, and retinoic acid receptor (RAR). Smad2 and
Smad3 are redundantly essential for development of iTregs/pTregs in the downstream of TGFβ. CNS2
region contains biding sites for multiple transcription factors, such as STAT5, NFAT, Runx1/Cbfβ, CREB,
and Foxp3. This enhancer is very important in maintaining its own expression under inflammatory
circumstances where Tregs are subjected to inflammatory cytokines and stronger TCR stimulation.
CNS2 locus has multiple CpG sites making this region susceptible for methylation/demethylation
status. In tTregs, CNS2 is fully demethylated: full sets of transcription factors bind to this locus
enabling stable expression of Foxp3, and stable phenotype of tTregs. In pTregs, CNS2 locus is also
demethylated, but with a slightly lower stability compared to tTregs. In iTregs, CNS2 locus is rarely
demethylated, which makes this subset very unstable. This CNS2 locus is the major Treg-specific
demethylated resion (TSDR) whose demethylated status confers the stability of Foxp3 expression, and
the function of Tregs [25] (Figure 4).
The inducers and stabilizers of Foxp3 expression are summarized in Table 1.
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Table 1. Factors which induce or stabilize Foxp3 expression.
Factors Mechanism
Retinoic acids Binding to Foxp3 enhancer CNS1 through RAR
Progesterone Suppression of mTOR
Vitamine D3 Binding to Foxp3 enhancer CNS1 through VDR
Short chain fatty acids Activation of GPR43
Butyrates Inhibition of HDAC
Vitamine C Activation of TET enzymes
Hydrogen sulfide Induction of TET1 and TET2
Rapamycin Inhibition of mTOR
JAK1 inhibitor Suppression of Th17
AhR ligands Suppression of Th17
Modified from Kanamori M. et al. Trends in Immunol 2016 [24].
Retinoic acids and vitamin D3 are ligands for their specific nuclear receptors, retinoic acid receptor
(RAR), retinoid X receptor (RXR), and vitamin D receptor (VDR). Retinoids binds to RARs and/or
RXRs, which make homo or heterodimers to bind to their binding sequences in regulatory region in
the target genes. Butyrate induces retinoic acid production in gut dendritic cells, resulting in induction
and stabilization of Foxp3 expression in regulatory T cells.
Active form of vitamin D3, generated through the enzymes produced in skin or in liver and kidney,
binds to VDR, which makes heterodimers with RXR and binds to response element usually resides
in distal area of target genes and exert its functions. Ultraviolet (UV) B and antimicrobial peptides,
such as cathelicidin and S100 proteins, are inducers of active vitamin D3 production in epidermis.
Active vitamin D3 systemically distribute through blood flow binding to vitamin D binding protein
(DBP), enter target cells through binding to heat shock protein (HSP) 70 in cytoplasm, and finally
transported to the nucleus binding to VDR [26]. VDR binds to its binding site in enhancer regions
of Foxp3 gene, resulting in induction and stabilization of Foxp3 expression. Alternative receptors
other than VDR have been reported, such as retinoid orphan receptor (ROR)α, RORγ [27], and aryl
hydrocarbon receptor (AhR) [28]. By binding to these alternative receptors, vitamin D3 derivatives
have been reported to suppress inflammatory reactions, such as Th17-type inflammation, through
suppressing the transactivation function of these nuclear receptors [27].
pTregs are induced by CD103-positive dendritic cells (DCs) in mesenteric lymph nodes dependent
on TGFβ and retinoic acid. Cutaneous CD103-positive DCs have also been reported to induce
pTregs [29]. Recent report indicated that DCs in cervical lymph nodes induce Tregs, but are not
CD103-positive DCs [30,31].
Recently, Gagliani et al. [32] reported intestinal Th17 can lose the ability to produce IL-17 and behave
like regulatory T cells resembling CD4+Foxp3- Type 1 Tregs (Tr1). This functional reprogramming is
irreversible, and these transdifferentiated Tr1 cells show anti-inflammatory properties and suppress
Th17-mediated colitis.
Psoriasis patients have a decreased number of regulatory T cells with disturbed function.
Several reports indicated that successful treatment of psoriasis restored the function and number of
Tregs in peripheral blood [33,34]. Bovenschen [35] reported that Foxp3-positive regulatory T cells
are easily converted into Foxp3-low, IL-17 producing, and RORγt-expressing cells. The plasticity of
Treg/Th17 cells makes pathophysiology of the disease more complex (Figure 5).
6. Microbiome
Advancement in computer science and next generation sequencing (NGS) technique has enabled
analysis of huge amounts of genetic data at once, revealing composition of microorganisms without
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culture. High throughput 16S rRNA sequencing of gut microbial populations or total genome
sequencing and mass-spectrometry-based metabolomic analysis can characterize gut microbiome
and metabolites. Gut microbiota is a dense and diverse microbial community composed of more
than 100 trillion cells and 5 million genes over 3-fold and 100-fold more than host cells and genes.
Gut microbiota is composed of thousands of species. However, the majority belong to six bacterial
phyla: Actinobacteria, Bacteroides, Firmicutes, Fusobacteria, Proteobacteria, and Verrucomicrobia. Fungi,
Archaea, protozoa, and viruses are also included in gut microbiota. The composition of microbiota
is highly influenced by environmental factors such as food, drug, and hygiene conditions, and also
dependent on age and genetic background. Microbiota functions as natural digestive organs, as they
digest plant polysaccharides indigestible by the host, can biosynthesize essential amino acids and
vitamins, and also detoxicate hazardous materials. Recent studies revealed they also have important
roles in immune system development and resistance to pathogens. Biotransformation of drugs can
occur through gut microbiota altering the effects of drugs expected in vitro studies or catalyzing them
to cause undesirable effects. Human genome analysis has revealed genetic susceptibility to certain
diseases, and analysis of microbiota as a “second genome” would reveal more important information
for disease susceptibility and drug metabolism. Further studies on gut microbiota are needed to
understand the precise mechanisms in disease susceptibility variance and drug effects and side effects
profiles between individuals. Such research could enhance development of precision medicine [36].
Recent studies linked cardiac disease, insulin resistance, and metabolic syndrome to gut
microbiota [37,38]. Several reports supported the contribution of gut microbiota in the production
of TMA (trimethylamine), the precursor of TMAO (trimethylamine N-oxide), which is a known
proatherogenic molecule independent of traditional cardiovascular disease (CVD) risk factors. TMAO
is involved in host cholesterol metabolism and activates macrophages leading to increased risk of
CVD, myocardial infarction, and stroke. Higher TMAO producers had more Firmicutes than Bacteroides
within the stool. TMAO has also been suggested to be a candidate molecule of developing type 2
diabetes mellitus (DM). Dietary supplementation with TMAO in mice resulted in impaired glucose
tolerance and adipose tissue inflammation promotion. Crasiun and Balskus reported that cutC
gene expression by bacteria such as Disulfovibrio can cause increased conversion of choline to TMA.
Compared to healthy controls, phyla Bacteroides and Proteobacteria were reduced and phyla Firmicutes
and Fusobacteria were increased in coronary artery diseases (CAD) patients [39]. Similar results
were reported revealing decrease in phylum Bacteroides and increase in phylum Firmicutes in CAD
patients [40]. Sanchez-Alcoholado et al. [36] compared CAD patients with type 2 DM to CAD patients
without type 2 DM and revealed these two groups had different composition of gut microbiota.
CAD patients with type 2 DM had decreased phylum Bacteroides and increased phyla Firmicutes
and Proteobacteria. They also revealed plasma TMAO levels were significantly higher in CAD with
DM patients compared to CAD without DM patients, which correlated with the increase in phyla
Enterobacteriaceae and Desulfovibrio and a decrease in phylum Faecalibacterium.
Obesity is related to gut dysbiosis and increased gut permeability, resulting in abnormal
translocation of bacteria and bacterial component in blood circulation. The increase in gut barrier
permeability caused increase in blood lipopolysaccharide (LPS) levels, resulting in systemic low-grade
inflammation and metabolic disease including type 2 diabetes [41]. Glucagon-like protein (GLP) 2 is
produced by L cells in the gut, which is regulated by the host nutritional status, and increases nutrient
absorption. It induces gut epithelial cell proliferation and expression of tight junction proteins. It also
regulates production of antimicrobial peptides by Paneth cells. Gut microbiota in lean individuals
have been reported to induce endogenous GLP2 production, resulting in improvement in gut barrier
function, while that of obese patients suppresses GLP2 production leading to gut barrier impairment
and bacterial translocation in blood [42].
Zonulin is a protein modulating permeability of tight junctions in the digestive tract. It was
originally discovered in patients with Celiac disease and type 1 diabetes. Zonulin binds to its receptor
and activates the pathway of tight junction openings resulting in increased gut permeability. Increased
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permeability in gut epithelial tissues leads to increased passage of antigens, and triggers autoimmunity in
susceptible individuals. Recent study reported gliadin binds to CXCR3 triggering the release of zonulin.
Zonulin activates PKC and PLC resulting in actin poymelization and rearrangement of cytoskeleton
inducing loosening of tight junctions in a reversible manner. Increased serum level and increased
excretion in the feces of zonulin have been reported in patients with gut barrier disruption, such as
patients with Celiac disease, as well as type-1 diabetes, obesity, and non-alcoholic fatty liver disease [43].
Activated effector cells are anabolic, consuming glucose as their carbon source, and utilizing
glycolysis to obtain ATP. Memory and regulatory cells are catabolic, utilizing fatty acids, amino acids, as
well as glucose for their energy source, and utilize oxidative phosphorylation to obtain ATP. Key molecules
promoting the glycolytic and lipogenic pathway are mammalian target of Rapamycin (mTOR) and
adenosine monophosphate-activated kinase (AMPK). AMPK and mTOR are energy sensors regulated
by nutrients availability. Th17 cells depend on glycolytic-lipogenic pathway and fatty acid synthesis
for their development, while Tregs depend on oxidative phosphorylation and consume exogenous
fatty acids. HIF1α is the transcription factor which upregulates glycolytic pathway in Th17 cells
binding to RORγt promoter and enhancing its expression, while also suppressing Foxp3 expression.
It promotes differentiation of naïve T cells towards Th17 cells and inhibits differentiation into Treg
cells under normoxic and hypoxic conditions. Inflammation sites are usually in hypoxic condition
and show increased extracellular ATP concentration, which induces HIF1αactivation required for Th17
cell development, and AhR inactivation needed in Tr1 metabolism. Thus, metabolic factors have
immune-modifying ability by skewing Th17/Treg balance resulting in skewed balance in inflammation or
immune tolerance [44].
Gut microbiota profoundly affect T cell differentiation and response to immune stimuli. Segmented
filamentous bacteria (SFB), a Clostridia-related species found mainly in rodents, specifically induces
Th17 cells in the small intestine and other sites in autoimmune condition. SFB colonization is usually
beneficial because it attenuates bacteria-induced colitis, while it also induces colitis in genetically
susceptible mice strains. The abundance of SFB and the gut barrier function is regulated by IL-23R/IL-22
pathway. The disruption of gut barrier resulting in systemic distribution of bacteria or their components
induces IL-23 pathway, initiating barrier repair, and Th17 responses in order to neutralize invading
microbes. IL-23 induced by SFB stimulates production of IL-22 from ILC3 causing serum amyloid A
production by epithelial cells [45] (Figure 6).
Psoriasis is considered a systemic and chronic inflammatory disease, involving skin, as well as
the cardiovascular system, insulin homeostasis, psychomotor systems, and lipid metabolism. A recent
study has detected bacterial DNA in blood in active psoriasis patients (bacterial translocation; BT), and
those with bacterial DNA-positive psoriasis patients showed higher serum inflammatory cytokine levels,
longer duration of disease and younger onset of disease. They suggested that psoriasis eruption may be
related to bacterial DNA in blood originating in the gut [46]. Codoner et al. revealed phylum Bacteroides
decreased and phylum Faecalibacterium increased in psoriasis patients. They compared the microbiome
between BT-positive patients and BT-negative patients and did not find specific phyla of microbiome.
They speculated that dysbiosis in psoriasis patient guts caused insufficient gut barrier permeability
resulting in bacterial translocation into the blood stream [47]. Hidalgo-Cantabrana et al. reported recently
the increase in Bacteroides and decrease in Firmicutes in psoriasis patients compared to healthy controls [48].
Bacteroides can produce short chain fatty acids (SCFA) such as propionates and butyrates.
These SCFA bind to the G-protein-coupled receptor, GPR41 and GPR43, and induce GLP-1 and GLP-2
production in L cells, which influence the energy metabolism and improve gut barrier function [49].
Akkermansia muciniphila has also been suggested to produce SCFA to improve energy metabolism,
which are decreased in obese patients compared to healthy controls. SCFA are also involved in the
stabilization of Foxp3 expression as discussed above, resulting in improvement of regulatory T cell
function. GPR41 and GPR43, the receptors for SCFA, are expressed on the surface of regulatory T cells
distributed in the gut. The number of Tregs increased in mice supplemented with SCFA. Experimentally
induced autoimmune encephalomyelitis was suppressed in mice supplemented with SCFA [49].
219
Int. J. Mol. Sci. 2020, 21, 2582
Scher et al. [50] reported gut microbiota composition was different in psoriatic arthritis patients
and psoriasis without arthritis patients. They found that phylum Actinobacteria was significantly
decreased in psoriatic arthritis patients. Actinobacteria phylum includes Bifidobacterium species, of
which supplementation lowered the serum levels of CRP and TNFαa in psoriasis patients.
Another approach altering the gut microbial effect is to influence the pathway the microbiome
uses. Farnesoid X receptor (FXR) is the essential nuclear receptor whose antagonist can inhibit
high-fat diet-induced obesity in mice. FXR is involved in the metabolism of bile acid, lipid, and
glucose. Intestine-specific FXR knockout mice were resistant to high-fat diet-induced obesity. However,
contradictory results have been reported: FXR-null mice showed increased glucose intolerance on a
chow diet, and FXR-agonist was effective in improving insulin sensitivity in genetically obese mice.
Other studies presented that FXR-null mice showed increased glucose tolerance and FXR-agonist
exacerbated insulin resistance and lipid metabolism in obese mice models. Li et al. speculated this
discrepancy is due to differences in gut microbiota composition and the distinct roles of liver FXR and
intestine FXR. Their study provided evidence that FXR inhibition in the intestine by antioxidant “tempol”
or by genetic ablation of FXR is effective in suppressing diet-induced obesity and insulin resistance [51,52].
Other molecules in the context of microbiome signaling are peroxisome proliferator activated receptor
(PPAR)s. Gut microbiota influence the expression of PPARs, and PPARs transduce signals to induce or
suppress many molecules involved in inflammation, obesity, and insulin resistance [53].
7. Discussion and Conclusions
Many novel findings revealed the importance of innate immunity in psoriasis pathogenesis.
The roles of skin resident cells and Tregs have been drawing attention in psoriasis pathogenesis.
Epidemiological study revealed the relation between psoriasis and comorbid diseases such as
cardiovascular diseases, diabetes mellitus and obesity, and the gut dysbiosis in psoriasis patients
has recently been demonstrated. However, the underling mechanism and pathogenic roles of gut
microbiome has to be clarified further. This review tried to hunt the findings in basic science and in
metabolic diseases, and to combine them to be applied to future psoriasis research.
It is not clear whether dysbiosis in gut microbiota in psoriasis patients has the pathogenic roles or
just the result of systemic inflammation in psoriasis. However, the recent study on gut microbiota and
the immune regulatory mechanism suggests that dysbiosis in gut microbiota by inducing disfunction of
Tregs and activation of Th17 and ILC3 could lead genetically susceptible individuals to develop psoriasis.
It may also cause obesity, diabetes mellitus, and cardiovascular diseases, among individuals with
distinct genetic backgrounds. The increase in number of psoriasis patients in Japan with westernization
of life could be explained by the change of diet, resulting in a change in microbiota. Decrease of dietary
fibers may reduce SCFA-producing phyla in gut microbiota, resulting in activation of gut dendritic
cells to produce IL-23, which in turn may stimulate unstable Foxp3-positive Tregs to differentiate
into IL-17-producing cells. Psoriasis has been recognized as a multifactorial genetic disease, not only
depending on genetic background, but also on environmental factors including lifestyle habits, which
could also be well-explained.
Skewed balance of skin resident cells may be generated by activation of epidermal keratinocytes
producing slightly higher amount of CCL20 by commensal microbe stimulation in genetically
susceptible individuals, which could be enhanced under the environment of disturbed Treg function
and increased Th17 cytokines in individuals with dysbiosis.
In this review, the gut–skin axis is the main target of discussion, thus skin-specific cells, such as
epidermal keratinocytes and dermal fibroblasts, are not discussed. The nuclear receptors such as RARs,
VDR, and RORs are expressed not only in immune cells, but also in epidermal keratinocytes [26],
making the epidermal keratinocytes another target of immune regulation. Skin has its own microbiome,
through influencing the homeostasis of epidermis, it regulates the immune status of the whole body.
The discussion on these issues have been left at another opportunity.
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Systemic inflammation in psoriasis patients has led researchers to investigate the relation of
psoriasis to metabolic diseases and has significantly deepened recent psoriasis investigation. A systemic
approach to treat psoriasis has long been attempted with etretinate and cyclosporine, and recent
biologics have shown remarkable therapeutic effects. Knowledge in skin resident cells are preferential
to topical treatment, however, accumulating evidence in the gut–skin axis [54] would favor a nutritional
approach or signal inhibition to change microbiome composition. Therefore, increasing therapeutic
options may be available for future psoriasis treatment.
8. Figures, Tables, and Schemes
Figure 1. Pathogenesis of psoriasis. Modified from Lowes M.A. et al. Trends in Immunol 2016 [4].
External immune triggers, LL37 bound to self-DNA or RNA activate plasmacytoid and myeloid
dendritic cells (pDC and mDC). Activated plasmacytoid cells produce type 1 interferons, and myeloid
dendritic cells produce TNFα, iNOS, and IL-23, which activate Th17 cells to produce IL-17 and IL-22.
IL-17 and IL-22 induce proliferation, production of cytokines, chemokines and antimicrobial peptides
from epidermal keratinocytes, thus resulting in psoriatic phenotype.
Figure 2. Skewed balance of tissue resident immune cells induces psoriasis in never-lesional skin of
psoriasis patients. Modified from Gallais Sérézal I et al. J Allergy Clin Immunol 2018 [17].
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Weak stimulation by commensal bacteria and fungi causes sparse production of CCL20 from the
epidermal keratinocytes, resulting in skewed distribution of CCR6-positive, IL-17-producing cells in
the never-lesional skin of psoriasis patients (NLP) over IFNγ-producing cells, which prepare conditions
for psoriasis eruption when appropriate insults, such as bacterial or viral infection, or trauma occurs.
Figure 3. Three groups of innate lymphoid cells parallel three types of T helper cells. Modified from
Walker JA et al. Nat Rev Immunol 2013 [18].
Innate lymphoid cells are divided into three groups; group 1, 2, and 3. Function and essential
nuclear factors seem similar to those of corresponding T helper cells.
Figure 4. Expression of FOXP3 in pTreg is unstable. Modified from Kanamori M et al. Trends in
Immunol 2016, and Iizuka-Koga et al. J Autoimmun 2017 [24,25].
Promoter lesion of FOXP3 gene contains major Treg-specific demethylated resion (TSDR), which
binds transcription factors, such as FOXP3, CREB, Ets1, and STAT5 constitutively in tTregs, but just
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transiently in pTregs. TSDR in pTregs are partially methylated, which makes it difficult to bind
transcription factors needed for the stable expression of FOXP3.
Figure 5. Foxp3-positive Tregs, but with unstable expression, would easily lose FOXP3 expression and
become inflammatory. Modified from Iizuka-Koga M et al. J Autoimmun 2017 [25].
tTregs differentiated in thymus stably express FOXP3 and are involved in immune tolerance.
Peripherally induced Tregs and Tregs with unstable FOXP3 expression can lose FOXP3 expression and
become inflammatory cells, which may contribute to autoimmunity.
Figure 6. Gut microbiota regulates the balance of Th17 vs. Tregs. Modified from Omenetti S and
Pizzaro TT. Frontiers Immuno 2015 [43].
Segmented filamentous bacteria (SFB) colonization allow them to closely contact to intestinal
epithelium, which induce cytokines, such as serum amyloid A (SAA), and activate Th17. SAA also
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induces IL-23 production from dendritic cells, which indirectly activate Th17 and ILC3 to produce
pro-inflammatory IL-17, and IL-22. IL-22 stimulate intestinal epithelial cells to produce SAA.
Clostridia is one of the commensal bacteria in the gut, which ferment dietary fibers and produce
short chain fatty acids; butyrates. SCFA suppresses dendritic cell production of inflammatory cytokines,
such as IL-6, and also induces retinoic acid (RA) production from dendritic cells, which induces and
stabilizes FOXP3 expression in naïve Tcells. SCFA also directly act on naïve T cells to express FOXP3.
There are different strains of Bacteroides fragilis, one of which produces polysaccharide A (PSA)
and induce IL-10 production from Treg cells, thereby inducing immune suppression. The other strain
produces B. fragilis toxin (BFA), which causes impairment of tight junctions and disruption of intestinal
barrier function. Recognition of microbial products from disseminated bacteria by microbe associated
molecular patterns stimulates IL-23 production from monocytes and stimulates Th17 cells to produce
IL-17 and exacerbates inflammation.
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Abstract: The excellent clinical efficacy of anti-interleukin 17A (IL-17A) biologics on psoriasis
indicates a crucial pathogenic role of IL-17A in this autoinflammatory skin disease. IL-17A accelerates
the proliferation of epidermal keratinocytes. Keratinocytes produce a myriad of antimicrobial
peptides and chemokines, such as CXCL1, CXCL2, CXCL8, and CCL20. Antimicrobial peptides
enhance skin inflammation. IL-17A is capable of upregulating the production of these chemokines
and antimicrobial peptides in keratinocytes. CXCL1, CXCL2, and CXCL8 recruit neutrophils and
CCL20 chemoattracts IL-17A-producing CCR6+ immune cells, which further contributes to forming
an IL-17A-rich milieu. This feed-forward pathogenic process results in characteristic histopathological
features, such as epidermal hyperproliferation, intraepidermal neutrophilic microabscess, and dermal
CCR6+ cell infiltration. In this review, we focus on IL-17A and keratinocyte interaction regarding
psoriasis pathogenesis.
Keywords: psoriasis; keratinocytes; interleukin-17A; Th17; ILC3; CCL20; CXCL1; CXCL8; Koebner
phenomenon; antimicrobial peptides
1. Introduction
Psoriasis is an immune-mediated chronic skin disease characterized by epidermal hyperproliferation,
an intraepidermal accumulation of neutrophils, and dermal inflammatory cell infiltrates that are composed
of dendritic cells and T cells [1]. It has an estimated global prevalence of 2–4% [1,2]. Males are twice as likely
as females to be affected [3,4]. As desquamative erythema can affect any skin site, psoriasis profoundly
impairs the patients’ quality of life, treatment satisfaction and adherence, and socioeconomic stability [5–7].
The skin lesion usually appears on the sites with frequent trauma such as elbows and knees [8,9].
This injury-induced development of psoriasis is called Koebner phenomenon [8,9]. Environmental factors,
such as smoking, also trigger or exacerbate psoriatic lesions [10,11]. Genetic factors are critically involved
in the development of psoriasis [12,13]. In addition to skin eruption, approximately 30% of patients with
psoriasis manifest psoriatic arthritis [14–19]. Psoriasis is also significantly comorbid with other autoimmune
diseases, such as bullous pemphigoid [20–24]. Psoriasis is frequently associated with cardiovascular
diseases, metabolic diseases, and renal disorders [25–36]. Cancer risk is slightly higher in patients with
psoriasis [37]. The topical application of steroids and vitamin D3 analogues inhibits psoriatic inflammation
and normalizes epidermal differentiation [38,39]. Systemic treatments, such as methotrexate, cyclosporine,
phototherapy, and the phosphodiesterase 4 inhibitor apremilast, are useful for patients with extensive
lesions [40–45].
That the tumor necrosis factor-α (TNF-α) and IL-23/IL-17A axes appear to be major drivers in the
pathogenesis of psoriasis is underscored by the excellent response of psoriasis to biologics targeting
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TNF-α, IL-23, and IL-17A, although a difference exists in their efficacy [46–61]. Anti-TNF-α/IL-23/IL-17A
biologics successfully improve psoriatic arthritis [18,56,62–64]. Reductions in comorbid cardiovascular
events and systemic inflammation have been reported in patients with psoriasis treated with
anti-TNF/IL23/IL17 biologics [65,66].
As the clinical response to anti-IL-23/IL-17A biologics seems better than that to anti-TNF-α
biologics in psoriasis, the IL-23/IL-17A axis likely plays a more crucial role than the TNF-α axis in the
development of psoriasis [67–71]. Under the regulation of IL-23p19, IL-17A-producing CD4+ helper T
(Th17) cells create a self-amplifying, feed-forward inflammatory response that is markedly augmented
in the presence of TNF-α [68,72,73]. In addition, Th17 cells produce high amounts of TNF-α [74,75].
Therefore, IL-17A inhibition by the anti-IL-17A biologic results in early clinical, histopathologic,
and molecular resolution of psoriasis [69].
In addition, various murine psoriasis models stress a pivotal role of the IL-23/IL-17A axis
in experimental psoriasis [76–80]. Multiple animal studies have indicated that the interaction
between IL-17A and keratinocyte is the key issue in the development of psoriasis [76–79]. In parallel,
the importance of IL-17A and keratinocyte interaction is reinforced in patients with psoriasis who are
successfully treated with the anti-IL-17A biologic [69]. In this review, we will focus on the multifaceted
biological response in keratinocytes stimulated by IL-17A with regard to psoriatic pathogenesis.
2. IL-17A Signaling System
The IL-17 family plays a critical role in the immune response in infectious, inflammatory,
autoimmune, and neoplastic disorders [81,82]. The IL-17 family and its receptors are evolutionally
ancient, and they are present in species as early as lamprey and sea urchins [83,84]. IL-17 family
members comprise IL-17A, IL-17B, IL-17C, IL-17D, IL-17E, IL-17F, and IL-17AF [81,82]. IL-17AF
is a hybrid heterodimer of IL-17A and IL-17F. IL-17E is also called IL-25 and is related to the type
2 immune response and allergies [81,82,85]. Among IL-17 family members, IL-17A has been the
most strongly implicated in human health and disease. IL-17A is produced from hematopoietic cells,
including Th17, CD8+ cytotoxic T cell (Tc17), γδ T cell, natural killer cell, group 3 innate lymphoid cell
(ILC3), and “natural” Th17 cell [86–89], but IL-17B, IL-17C, and IL-25 are preferentially produced from
nonhematopoietic cells, including keratinocytes [81,82,90]. Both hematopoietic cells and keratinocytes
produce IL-17F [81,82,90]. Keratinocyte-derived IL-17C is capable of stimulating Th17 cells to secrete
more IL-17A [91].
The IL-17 receptor (IL-17R) is composed of five members: IL-17RA, IL-17RB, IL-17RC, IL-17RD,
and IL-17RE [81,82,90]. IL-17A, IL-17F, and IL-17AF all share the same IL-17R comprising IL-17RA and
IL-17RC heterodimers [81,82,90]. IL-17C binds to IL-17RA and IL-17RE heterodimers [92]. IL-25 ligates
IL-17RA and IL-17RB [81,82,90]. A recent study showed that IL-17A also activates IL-17RA and
IL-17RD heterodimers [93] (Figure 1). IL-17B binds IL-17RB, but another heterodimeric IL-17R member
remains unidentified [82]. Keratinocytes express both IL-17RA/IL-17RC and IL-17RA/IL-17RD, and the
binding of IL-17A induces the transcription of differential gene sets [93]. Initial subcellular events
in the ligation of IL-17RA/RC by IL-17A are the recruitment and activation of ACT1 encoded by
the TRAF3IP2 gene, TRAF6 and CARMA2 complexes, and the downstream activation of nuclear
factor kappa-light-chain-enhancer of activated B cells (NF-κB) and MAPKs [93–97]. The ligation of
IL-17RA/IL-17RC by IL-17A induces the activation of NF-κB, ERK, p38 MAPK, and JNK, while that
of IL-17RA/IL-17-RD mainly activates p38 MAPK and JNK and barely affects NF-κB and ERK [93].
In addition, IL-17RA physically and functionally interacts with and transactivates epidermal growth
factor (EGFR) [98]. IL-17RD potentially interacts with and transactivates fibroblast growth factor
2 receptor [82,99].
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Figure 1. Simplified effects of anti-interleukin 17A (IL-17A) on keratinocyte (KC) with regard to
psoriasis pathogenesis. IL-17A homodimers bind to IL-17 receptor A (IL-17RA) and IL-17RC or
IL-17RA and IL-17RD heterodimers. The ligation of IL-17RA/IL-17RC activates epidermal growth factor
receptor (EGFR) directly or by transforming growth factor-α (TGF-α) and heparin-binding EGF-like
growth factor (HB-EGF) and promotes keratinocyte proliferation. The ligation of IL-17RA/IL-17RC
activates various signal transduction molecules, including ERK, p38 MAPK, JNK, nuclear factor
kappa-light-chain-enhancer of activated B cells (NFκB), IκBζ, C/CAAT-enhancer-binding protein β
(C/EBPβ), and C/EBPδ. In contrast, the ligation of IL-17RA/IL-17RD preferentially activates JNK and
p38 MAPK pathways. IL-17RA/IL-17RD is estimated to transactivate fibroblast growth factor receptor
(FGFR); however, this is not conclusive. IL-17RA/IL-17RC signaling stimulates KCs to produce IL-19,
which induces the production of keratinocyte growth factor (KGF) from fibroblasts. KGF also enhances
the proliferation of KCs. IL-17A also induces the production of antimicrobial peptides, including
S100A7, S100A8, S100A9, LL-37, and defensin β 4A (DEFB4A). These antimicrobial peptides amplify
the local inflammatory process. Chemokines, such as CCL20, CXCL1, and CXCL8, are also produced
from keratinocytes by IL-17RA/IL-17RC ligation. CCL20 is a key chemokine for the recruitment of
CCR6+ Th17 cells and group 3 innate lymphoid cells (ILC3). These CCR6+ cells produce large amounts
of IL-17A. DEFB4A also exhibits a chemotactic activity by binding to CCR6. CXCL1 and CXCL2 are
potent chemoattractants for CXCR2+ neutrophils. Therefore, IL-17A is associated with all of the
histopathologic features of psoriasis.
In addition to the above-mentioned signaling cascades, IL-17A activates various other signal
molecules including signal transducer and activator of transcription 3 (STAT3) in keratinocytes [100].
STAT3 is a very crucial signaling molecule in the development of psoriasis because transgenic
mice with keratinocytes expressing a constitutively active Stat3 (K5.Stat3C mice) develop a skin
phenotype either spontaneously, or in response to wounding, that closely resembles psoriasis [101].
Moreover, a STAT3 inhibitor STA-21 inhibits the generation of skin lesion in these psoriatic
mice [102]. IL-17A is known to activate STAT3 via receptor-interacting protein 4 (RIP4) activation and
upregulates the CCL20 expression [103]. IL-17A also upregulates keratin 17 expression via STAT1 and
STAT3 activation [104]. IL-6 and IL-22 also play a synergistic role in development of psoriasis with
IL-17A [68]. Notably, both IL-6 and IL-22 are potent STAT3 activators [105]. In accordance, biological or
natural molecules such as indirubin and its derivatives useful for inactivating STAT3 exhibit therapeutic
potential for psoriasis [106] (Figure 2). It reveals that IL-17 and IL-22 promote keratinocyte stemness
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and potentiate its regeneration [107]. IL-6 is produced from keratinocytes in response to IL-17A [108].
IL-22 is produced from Th17/22 cells, Th22 cells, and other immune cells [109,110].
Figure 2. Pivotal role of signal transducer and activator of transcription 3 (STAT3) in psoriasis.
The activation of STAT3 promotes keratinocyte (KC) proliferation and inflammatory response. IL-17A
and IL-22 induce the STAT3 activation. IL-6 produced from KC also induces STAT3 activation.
In humans, impairment of the IL-17 signal causes infectious diseases, especially by Candida albicans,
which is a ubiquitous fungus and commensal yeast of the intestines and skin [96]. Notably, deficiency
of the IL17RA, IL17RC, IL17F, or TRAF3IP2 genes is implicated in chronic mucocutaneous candidiasis
disease (CMCD), which is characterized by recurrent or persistent infection affecting the nails, skin,
and oral and genital mucosae caused by the Candida species, often C. albicans [96,111–113]. Impairment of
the IL-17 signal is evident in other immunocompromised inborn errors, including autosomal-dominant
hyper IgE syndrome, autosomal dominant STAT1 gain-of-function, autosomal-recessive autoimmune
polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), autosomal-recessive CARD9
deficiency, IL12RB1 deficiency, IL12B deficiency, and RORC deficiency [96]. However, these inborn
errors seem to exhibit more complicated immune defects beyond IL-17 dysfunction and manifest
CMCD together with other types of infection, including Mycobacterium, Staphylococcus, and viral
disorders [96]. Of note, mice lacking Traf3ip2 (Act1) or Il17ra manifest similar clinical phenotype as
human CMCD patients lacking IL17RA or IL17RC [114–117]. A recent murine study by Sparber et al.
also indicates that Malassezia infection selectively triggers the IL-17A-induced immune response [118].
These findings indicate a crucial role of IL-17A in anti-fungal immunity in humans and mice.
Mice overexpressing IL-17A in keratinocytes (K14-IL-17Aind/+ mice) exhibit severe psoriasiform
skin inflammation and vascular dysfunction in conjunction with infiltration of the vasculature
by inflammatory myeloid cells [108]. The K14-IL-17Aind/+ mice acquire the highest local and
systemic IL-17A levels and exhibit a particularly severe psoriasis-like skin phenotype [108].
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Homozygous CD11c-IL-17Aind/ind mice and heterozygous CD11c-IL-17A ind/+ mice show a delayed
onset of moderate to severe psoriasis-like skin disease associated with reduced amounts of cutaneous
IL-17A compared with K14-IL-17Aind/+ mice. In agreement with elevated skin and a stepwise increase
in systemic IL-17A [119], homozygous CD11c-IL-17A ind/ind mice develop earlier and more severe
skin lesions, as well as more pronounced vascular inflammation and dysfunction than heterozygous
CD11c-IL-17A ind/+mice [76,119]. These experimental models indicate that IL-17A induces psoriasis-like
lesions in a dose-dependent manner, irrespective of its cellular source [76,119].
3. IL-17A and Psoriasis
In the early 2000s, IL-23 was found to induce the production of IL-17A by activated CD4+
T cells, which were later named Th17 cells [74,120]. These cells express RORγt (RORC) as the
master transcription factor [121] and promoted the anti-infectious defense in the mucosa and skin [96],
whereas excessive exposure to IL-23 induces their transformation into autoimmune or autoinflammatory
immune cells [122,123]. Accordingly, the intradermal injection of IL-23 induces murine psoriasis-like
dermatitis with epidermal acanthosis, neutrophil recruitment, and the infiltration of IL-17-producing T
cells [78,79,124].
Psoriasis is one of the most typical IL-23/IL-17A-driven human diseases [68,72,73]. Th17 cells,
Tc17 cells, IL-17-producing γδ T cells, and ILC3 can all be found in psoriatic skin [89,125,126].
IL-23 is composed of IL-23p40 and IL-23p19 subunits, and the expression of both is upregulated
in the lesional skin compared to the nonlesional skin in psoriasis [127]. Dermal dendritic cells and
monocytes are major sources of IL-23 production [128]. However, immunohistological staining also
proves that IL23p40 and IL23p19 are expressed in normal and psoriatic keratinocytes [127–129].
Moreover, the epidermal expression of IL-23p40 and IL-23p19 is stronger in psoriasis lesions than in
healthy controls [127–129]. Murine keratinocytes also produce biologically active IL-23 [130]. IL-23 can
promote keratinocyte growth and histological acanthosis via the JAK2/AKT/STAT3/LMO4 signaling
pathway [131]. LIM-domain only protein 4 (LMO4) is a LIM-domain protein that regulates
keratinocyte proliferation and differentiation during embryogenesis [131]. In addition, TNF-α is
an active stimulator of IL-23 production from keratinocytes in mice and possibly in humans [131].
In parallel, the anti-IL-23p40 antibody (Ustekinumab) [132,133] and anti-IL-23p19 antibodies
(guselkumab, risankizumab, and tildrakizumab) [133–135] exhibit a high efficacy to psoriasis with a
superiority of risankizumab over ustekinumab [133], and guselkumab over the anti-TNF-α antibody
adalimumab [134].
The expression of IL17A, IL17F, and IL17C is upregulated in psoriatic lesional skin [136–138].
The intradermal injection of IL17C induces epidermal thickening and neutrophil infiltration [139].
As significant efficacy of the anti-IL17C antibody has recently been noted in murine psoriasis and atopic
dermatitis [140], its human use has been suggested [141]. However, IL-17A is believed to be the most
pathogenic IL-17 family member in psoriasis [68,69,72,73,142]. The lesional skin of psoriasis harbors
IL-17A-producing immune cells [89,143], and transcriptomic analysis indicates a clear predominance
of IL-17A signals [69,142]. Subsets of IL-17A-producing T cells are reactive to autoantigens, such
as LL-37 (cathelicidin), a disintegrin and metalloprotease domain containing thrombospondin type
1 motif-like 5 (ADAMTSL5), keratin 17, and neolipid antigens generated by phospholipase A2 group
IV D (PLA2G4D) [20,125,126,144–147]. IL-17A-dominant immune activation is also detected in the
nonlesional skin of psoriasis [148].
There are three commercially available anti-IL17A biologics: secukinumab (fully human IgG1κ
anti-IL17A antibody), ixekizumab (fully human IgG4 anti-IL17A antibody), and brodalumab (fully
human IgG2 anti-IL17RA antibody). The severity of psoriatic skin lesions is generally evaluated by
the Psoriasis Area and Severity Index (PASI) [149]. The efficacy of a therapeutic agent is assessed by
the rate of responders who achieve 75%, 90%, and 100% reduction of PASI, namely, PASI75, PASI90,
and PASI100, respectively. All three anti-IL-17A biologics exbibit remarkable therapeutic efficacy for
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psoriasis. The PASI90 scores of secukinumab, ixekizumab, and brodalumab are reported to be as high
as 60% to 70% at 12 weeks post treatment [150–152].
Regarding histology, the psoriatic epidermis is acanthotic and the proliferating capacity of
keratinocyte is increased as determined by Ki67 positivity and cytokeratin 16 expression [68,153,154].
In accordance with the accumulation of neutrophils in psoriasis, the gene expression of neutrophilic
cytochemokines CXCL1, CXCL2, CXCL8, and IL-36 is upregulated in the lesional skin of
psoriasis [68,155–157]. Psoriatic keratinocytes produce a large amount of CCL20 [158,159], which is a
potent chemoattractant for CCR6+ IL-17A-producing Th17 [89,143,160], ILC3 [161,162], Tc17 [163,164],
and γδ T cells [78,165]. Interestingly, IL-17A actively upregulates the production of these key
cytochemokines as well as proliferative capacity in keratinocytes.
4. IL-17A and Keratinocyte Proliferation/Differentiation
Psoriatic keratinocytes simultaneously exhibit increased proliferation (Ki67+ or cytokeratin 16+
cell number) and differentiation [involucrin (IVL)+ cell number] [69,166–168]. Accordingly, IL17A is
an active promoter of keratinocyte proliferation and differentiation [168–171]. In psoriasis patients,
the neutralization of IL-17A by ixekizumab [168] or secukinumab [69] significantly decreases histological
acanthosis, the number of Ki-67+-proliferating keratinocytes, and epidermal cytokeratin 16 expression.
In the murine imiquimod-induced psoriasis model, topical imiquimod induces epidermal thickening
that is significantly alleviated in Traf3ip2 (Act1)-deficient mice in which IL-17 signaling is blocked [170].
The molecular mechanisms of the IL-17A-mediated acceleration of keratinocyte proliferation and
differentiation are not yet fully understood.
IL-17A alone is likely to be insufficient to evoke a significant inflammatory response and may
cooperatively or synergistically accelerate the proinflammatory cascade in combination with other
cytokines, such as TNF-α, IL-23, IL-1β, IL-6, IL-22 and transforming growth factor-β (TGF-β) [68,172].
Transcriptomic analysis reveals a clear additive or synergistic gene regulation by IL-17A and TNF-α
in human keratinocytes [173]. This gene regulation is likely attributable to two sets of transcription
factors: NF-κB and the C/CAAT-enhancer-binding proteins (C/EBP), C/EBPβ, or C/EBPδ [169,173,174].
TNF-α is a strong inducer of active NF-κB, while IL-17A activates C/EBPβ or C/EBPδ and to a lesser
extent NF-κB [169,173,174]. Therefore, the IL-17A blockade reduces the expression of these responsive
genes to a greater extent than TNF-α inhibition [168].
The C/EBP family members are highly expressed transcription factors in epidermal keratinocytes
and sebocytes in mice and humans and accelerate their differentiation [175]. The expression of
C/EBPβ protein is located in the upper spinous layer and is strongly upregulated in the lesional
skin of psoriasis [169]. Together with the elevated gene expression of CEBPB, the expression of
keratinocyte-terminal differentiation genes, such as IVL, FLG2, and TGM1, is upregulated in the lesional
skin of psoriasis [169]. In the promoter region of the IVL gene, there is a binding site for C/EBP,
and the C/EBP transcription factor is necessary for the appropriate and continuous production of IVL
protein [176]. These results suggest that IL-17A accelerates keratinocyte differentiation by increasing
C/EBPβ protein in keratinocytes [168,169,173].
Regarding keratinocyte proliferation, IL-17A stimulates keratinocytes to produce IL-19 [173,177].
The combination of IL-17 and TNF-α results in the synergistic expression of IL-19 in keratinocytes.
IL-17 alone promotes IL-19 expression by approximately 1.79-fold, and TNF-α alone slightly reduces
IL-19 expression, whereas a combination of IL-17 and TNF-α promotes expression by 54.6-fold [173,177].
IL-19 itself promotes keratinocyte migration but not proliferation [178]. However, it activates
fibroblasts to produce keratinocyte growth factor, which upregulates keratinocyte proliferation [178].
Additionally, the upregulation of cell cycle-related genes, such as CCNE1, CDCA5, and CDCA25A,
suggests a direct contribution of IL-17 to epidermal KC proliferation [169]. The expression of cytokeratin
16 is upregulated in the lesional epidermis of psoriasis patients and in keratinocytes incubated with
IL-17A [69,168,179]. The expression of cytokeratin 16 increases the proliferative capacity of keratinocytes
via EGFR phosphorylation [180].
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Other studies also underpin a possibility that IL-17A activates EGFR [98,181,182]. Chen et al.
have demonstrated that IL-17A transactivates EGFR in keratinocyte stem cells [98]. IL-17A accelerates
the enzymatic cleavage of amphiregulin, which activates EGFR in airway epithelial cells [181].
In the lesional skin of psoriasis, the expression of EGFR ligands, such as heparin-binding EGF,
transforming growth factor-α, and amphiregulin, is overexpressed [183]. Consistent with these notions,
the inhibition of EGFR by erlotinib or cetuximab successfully improves severe psoriasis [184–187].
These studies suggest that EGFR activation may partly explain the IL-17A-mediated upregulation of
keratinocyte proliferation.
5. IL-17A and Cyto/Chemokines in Keratinocytes
In keratinocytes, IL-17A upregulates the expression of various psoriasis-related cyto/chemokines
and antimicrobial peptides, such as CXCL1, CXCL8, IL-36G, CCL20, IL-19, IL-17C, S100A7, S100A8,
S100A9, LL-37, and defensin β 4A (DEFB4A) [157,169,173,188–190]. The expression of these molecules
is upregulated in the lesional skin of psoriasis and is downregulated to normal levels by biologics
targeting TNF-α [128] or IL-17A [69,168]. Some are upregulated even in the nonlesional skin of patients
with psoriasis [148]. The IL-17A-induced upregulation of these molecules is further amplified in the
presence of TNF-α and IL-19 [173,177].
CXCL1 and CXCL8 are potent chemoattractants for neutrophils [191–193]. IL-36G induces
CXCL1 and CXCL8 expression in an autocrine fashion in keratinocytes and recruits neutrophils [194].
Full-length IL-36G is cleaved by cathepsin G released from infiltrated neutrophils, and the
cleaved IL-36G exhibits a more potent functional activity than the full-length one [192,195,196].
Moreover, IL-17A upregulates IL-36G production more potently in human psoriasis-derived
keratinocytes than in healthy keratinocytes [197]. Therefore, the IL-17A, IL-36G, CXCL1/CXCL8,
and neutrophils form a feed-forward vicious cycle, and an intraepidermal neutrophilic microabscess
(Munro’s microabscess or Kogoj’s spongiform pustule) may develop [156,198,199]. The pathogenic
significance of IL-36 is stressed more in pustular rather than plaque psoriasis [156,198,199]. In parallel,
inhibition of the IL-36 pathway is efficacious for the treatment of pustular psoriasis [200].
While most chemokines redundantly bind to multiple receptors, CCL20 has only one known
receptor, CCR6 [191]. CCR6 is expressed on dendritic cells [159] and IL-17-producing immune
cells, including Th17 [89,143,201], ILC3 [161,162], Tc17 [163,164], and γδ T cells [78,165]. CCR6 is
now considered a representative marker for Th17 cells [202,203]. The human psoriatic epidermis
expresses abundant CCL20 with the dermal infiltration of CCR6+ dendritic cells and skin-homing
T cells [143,158,159]. Although dermal dendritic cells and T cells express CCL20 in the psoriatic
dermis [159], the expression of CCL20 is largely confined to the psoriatic epidermis, suggesting
that epidermal keratinocytes are the major source of CCL20 production in psoriatic lesions [158,159].
CCL20 is constitutively expressed in cultured keratinocytes [201,204], and its production is upregulated
by TNF-α and IL-17A [182,204]. Scratch injury upregulates the gene expression of CCL20, CXCL8,
and IL36G, which may be related to the scratch-induced Koebner phenomenon frequently observed in
patients with psoriasis [201]. Preclinical studies have revealed that the humanized anti-CCR6 antibody
efficiently inhibits the cutaneous infiltration of CCR6+ T cells in human and murine models [205,206].
The development of small molecule inhibitors against CCR6 is also ongoing [207,208]. Targeting the
CCL20/CCR6 axis may be a potential therapeutic strategy for the treatment of psoriasis.
6. IL-17A and Anti-Microbial Peptides in Keratinocytes
S100A7, S100A8, S100A9, LL-37, and DEFB4A are anti-microbial peptides, and their expression
is upregulated by IL-17A in keratinocytes [189,209,210]. S100A7 (psoriasin) has a multifaceted
role in keratinocyte pathophysiology, including wound healing, keratinocyte differentiation,
nucleocytoplasmic transport, and chemotaxis for CD4+ T cells, neutrophils, and monocytes [211].
The production of S100A7 is augmented in the presence of IL-19 [212], IL-36G [188], and TNF-α [213].
S100A8, S100A9, and S100A12 are alternatively known as calgranulin A, B, and C, respectively,
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and exhibit antimicrobial activity [214]. All are elevated in psoriatic plaque and decreased
by treatment with anti-IL-17A antibody secukinumab [69,168,215]. The S100 family members
primarily form homodimers or higher-order oligomers, but S100A8 and S100A9 uniquely form
heterodimeric complexes, which are known as calprotectin [214]. The chelation of Zn2+ and Mn2+
by extracellular S100A8/A9 is a proposed mechanism of antimicrobial activity [214]. S100A12 also
has a chemotactic activity for mast cells and monocytes [216]. Pure human S100A8/A9 has broad
spectrum antimicrobial activities against microorganisms, including Capnocytophaga sputigena, C.
albicans, Escherichia coli, Staphylococcus aureus, S. epidermis, Borrelia burgdorferi, and Listeria monocytogenes,
in vitro, and S100A12 has antimicrobial activity against filarial parasites [214]. The receptor for
advanced glycation end-products (RAGE) may serve as a common receptor for S100 proteins, including
S100A7, S100A8, S100A9, and S100A12 [214]. S100A8/S100A9 augments the production of CXCL1,
CXCL2, CXCL3, CXCL8, CCL20, IL-6, and TNF-α in keratinocytes [217], and it enhances keratinocyte
proliferation [217]. The transcriptional co-activator IκBζ, encoded by the NFKBIZ gene, plays a critical
role in IL-17A-, IL-17F-, and IL-17A/F-mediated signaling, such as the gene expression of S100A7 and
CCL20 [218–220].
LL-37 is an antimicrobial peptide of human cathelicidin that is produced when keratinocytes are
injured by a broad range of bacteria, viruses, and fungi [221,222]. In addition to antimicrobial peptide
activity, LL-37 exhibits “alarmin” function, affects adenosine triphosphate-receptor P2X7 and Toll-like
receptor (TLR) signaling, and EGFR transactivation or intracellular Ca2+ mobilization [223–225].
The released LL-37 binds to the infiltrated neutrophils [221]. Neutrophils are a rich source of extracellular
DNA due to their neutrophil extracellular traps [226]. Upon stimulation with complexes of host DNA
and LL-37, plasmacytoid dendritic cells produce large amounts of IFN-α [227]. Notably, LL-37 induced
the proliferation of circulating CD3+ T cells in 24 out of 52 patients with psoriasis (46%) [144]; therefore,
LL-37 is effective for autoantigens. In total, 50 LL-37-reactive CD3+ T cells, including both CD4+ and
CD8+ T cells, express the skin-homing receptor cutaneous lymphocyte antigen [144]. LL-37 peptides
bind to HLA-DR in dendritic cells and are presented to CD4+ T cells, while LL-37 peptides and the
HLA-C*0602 complex activate CD8+ T cells [144,228]. The majority of LL-37-reactive CD3+ T cells
produce IL-17, and the capacity of their IL-17 production is associated with disease severity [144].
Interestingly, the LL-37-specific IL-17-producing T cells are exclusively CD4+, whereas the LL-37-specific
CD8+ T cells do not produce IL-17 [144]. A recent study by Takahashi et al. revealed that LL-37 can
bind to self-RNA and stimulate macrophages to produce IL-6 via a scavenger receptor [229].
DEFB4A is highly expressed in psoriasis plaques and is the most psoriasis-specific antimicrobial
peptide [230,231]. In contrast, DEFB4A is expressed at negligible or low levels in normal skin and skin
lesions of eczema [230–232]. The expression of DEFB4A is upregulated by IL-17A and synergistically
by IL-17A and TNF-α [215,220]. The serum levels of DEFB4A are highly specific biomarkers for
disease activity in patients with psoriasis [215]. The number of neutrophil extracellular traps increase
in psoriasis and upregulate the expression of DEFB4A [226]. Notably, DEFB4A is a functional
(non-chemokine) ligand for CCR6 and feasibly attracts Th17 cells [233,234].
Although the biological implications of increased antimicrobial peptides in psoriasis remain
obscure, they are intimately associated with IL-17A-rich milieu. Therefore, the upregulated expression
of these antimicrobial peptides is rapidly normalized by the neutralization of IL-17A by ixekizumab [168]
or secukinumab [69].
7. Conclusions
IL-17A is a multifunctional cytokine produced from adaptive and innate immune cells, such as
Th17 and ILC3s. It orchestrates and promotes the peripheral tissue defense system against microbial
insult, especially fungal infection. Psoriasis is a major inflammatory skin disease in which the
interaction between IL-17A and epidermal keratinocytes plays a critical pathogenic role. IL-17A
stimulates the proliferation of keratinocytes. Keratinocytes also produce a variety of antimicrobial
peptides and cytochemokines in response to IL-17A. The antimicrobial peptides further exacerbate
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skin inflammation. CCL20 produced from IL-17A-stimulated keratinocytes recruits IL-17A-producing
Th17 cells and ILC3s and accelerates the feed-forward vicious cycle, which causes fully developed
psoriasis. This pathogenetic scheme has been verified with a high clinical efficacy of anti-IL-17A
biologics. Therefore, psoriasis is considered an excellent human model of how IL-17A works with
target peripheral tissues, and it provides in-depth insight into human autoinflammatory diseases.
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Abstract: Psoriasis is a chronic inflammatory skin disease characterized by scaly indurated erythema.
It impairs patients’ quality of life enormously. It has been recognized not only as a skin disease
but as a systemic disease, since it also causes arthritis (psoriatic arthritis) and mental disorders.
Furthermore, an association with cardiovascular events is indicated. With the advent of biologics,
treatment of psoriasis dramatically changed due to its high efficacy and tolerable safety. A variety
of biologic agents are available for the treatment of psoriasis nowadays. However, characteristics
such as rapidity of onset, long-term efficacy, safety profile, and effects on comorbidities are different.
Better understanding of those characteristic leads to the right choice for individual patients, resulting
in higher persistence, longer drug survival, higher patient satisfaction, and minimizing the disease
impact of psoriasis. In this paper, we focus on the efficacy and safety profile of biologics in psoriasis
patients, including plaque psoriasis and psoriatic arthritis. In addition, we discuss the impact of
biologics on comorbidities caused by psoriasis.
Keywords: biologics; psoriasis; psoriatic arthritis; tumor necrosis factor-α; inteleukin-23; interluekin-17
1. Introduction
Psoriasis is a chronic inflammatory skin disease characterized by scaly indurated erythema.
The prevalence of psoriasis in children ranges from 0% (Taiwan) to 2.1% (Italy), and in adults it varies
from 0.91% (United States) to 8.5% (Norway) [1]. It impairs patients’ quality of life enormously. It has
been recognized not only as a skin disease but as a systemic disease, since it also causes arthritis
(psoriatic arthritis; PsA) and mental disorders. Furthermore, an association with cardiovascular events
is indicated [2]. With the advent of biologics, treatment of psoriasis dramatically changed due to its
high efficacy and tolerable safety. In addition, the efficacy of biologics helps us to understand the
pathogenesis of psoriasis. Whereas biologics have shown dramatically excellent efficacy, their safety
has been a concern. To date, data on their efficacy and safety have been accumulated. In this paper,
we focus on the efficacy and safety profile of biologics in psoriasis patients, including plaque psoriasis
and PsA. In addition, we discuss the impact of biologics on comorbidities caused by psoriasis.
2. Efficacy and Safety of Biologics
Although approved biologic agents differ by countries, biologic agents commonly used for the
treatment of psoriasis are categorized into three groups, tumor necrosis factor (TNF)-α inhibitors,
interleukin (IL)-23 inhibitors, and IL-17 inhibitors, as shown in Table 1. Infliximab, adalimumab,
etanercept, certolizumab-pegol, and golimumab are TNF-α inhibitors. Golimumab is used only
for PsA. Ustekinumab is an anti-IL-12/23p40 antibody. Guselkumab, risankizumab, tildrakizumab,
and mirikizumab are anti-IL-23p19 antibodies. Secukinumab, and ixekizumab are anti-IL-17A
Int. J. Mol. Sci. 2020, 21, 1690; doi:10.3390/ijms21051690 www.mdpi.com/journal/ijms251
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antibodies. Brodalumab is an anti-IL-17RA antibody. Bimekizumab is an anti-IL-17A/F antibody,
which blocks both IL-17A and IL-17F. Many randomized controlled trials (RCTs) were conducted,
and they demonstrated that the drugs are efficacious for moderate-to-severe plaque psoriasis. Recently,
network meta-analyses enabled indirect comparison among those agents.
Table 1. Target of biologics.











Tildrakizumab (not approved yet)





Bimekizumab (not approved yet)
CTLA4-Ig Abatacept (for psoriatic arthritis)
2.1. Plaque Psoriasis
Since previous review articles have illustrated the pathogenesis of psoriasis, we do not refer to
the details [3,4]. Briefly, various triggers activate plasmacytoid dendritic cells, which are important in
early-phase psoriasis. Meanwhile, TNF-α/iNOS-producing dendritic cells (TIP-DCs) play a pivotal
role in maintaining psoriasis. TIP-DC activated by TNF-α secrete TNF-α, which activate themselves
in an autocrine way. TIP-DCs also produce IL-23, which maintains and proliferates Th-17 cells.
IL-23-stimulated Th17 cells are pathogenic and produce excessive IL-17A, F, and IL-22. Those cytokines
drive keratinocytes to abnormal differentiation and proliferation, which forms psoriasis plaque.
Activated keratinocytes also work as immune cells. They produce anti-microbial peptides and TNF-α,
which activate dendritic cells including TIP-DC. This vicious inflammatory cycle makes the plaque
remain and deteriorate. Activated keratinocytes secrete IL-17C, which activates keratinocytes in
an autocrine way. Recently, the contribution of resident memory T cells [5–8], epidermal dendritic
cells [9] in the epidermis, and type 3 innate lymphoid cells [8,10] to the development of psoriasis and
recurrent plaque has attracted attention.
New biologic agents such as risankizumab [11], guselkumab [12–16], ixekizumab [17–23],
and brodalumab [24,25] demonstrated high efficacy for patients with moderate-to-severe psoriasis.
The percentage of patients who achieved more than a 90% reduction in the Psoriasis Area Severity
Index (PASI) score at 16 weeks after initiating each treatment (PASI 90) was about 70%–80%, and that
at 52 weeks was about 80%–90% in respective clinical trials. PASI 100 was about 50%–60% at 52 weeks.
Those biologic agents showed high efficacy.
Ellis et al. appraised two network-meta analyses that assessed systemic therapies for moderate-to-
severe psoriasis [26]. They concluded that newer biologics targeting theIL-12/23 and IL-17 axes appear
to be more effective than older biologics and oral agents.
Sawyer et al. analyzed 17 studies reporting outcomes at 40-64 weeks in order to evaluate long-term
efficacy [27]. Four 52-week RCTs revealed that brodalumab was significantly more efficacious than
secukinumab, ustekinumab, and etanercept. Secukinumab was also more efficacious than ustekinumab,
and both outperformed etanercept. Evidence from 13 additional studies and four further therapies
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(adalimumab, apremilast, infliximab and ixekizumab) revealed that brodalumab was most effective,
followed by ixekizumab and secukinumab, then ustekinumab, infliximab and adalimumab. Etanercept
had the lowest expected long-term efficacy. They concluded that brodalumab is associated with a higher
likelihood of sustained PASI response, including complete clearance, at week 52 than comparators.
Sawyer et al. performed a network meta-analysis including 77 trials (34,816 patients) [28].
They revealed the superiority of brodalumab, ixekizumab, secukinumab, guselkumab and risankizumab
to tildrakizumab, ustekinumab, all TNF-α inhibitors, and non-biologic systemic treatments in efficacy
for plaque psoriasis. Furthermore, brodalumab, ixekizumab, and risankizumab showed higher efficacy
than secukinumab, but did not significantly compared with guselkumab. In terms of PASI 90 and
PASI 100 response, brodalumab, ixekizumab, guselkumab, and risankizumab demonstrated the
greatest benefits.
According to the meta-analysis of 140 studies reported by Shidian et al. [29], in terms of the
percentage of patients who attained PASI 90, infliximab, ixekizumab, secukinumab, bimekizumab,
brodalumab, risankizumab, and guselkumab showed higher efficacy than ustekinumab, adalimumab,
certolizumab, and etanercept. Moreover, adalimumab and ustekinumab were more efficacious than
certolizumab and etanercept. No significant difference was observed between any of the interventions
and the placebo for the risk of severe adverse events.
Generally, we can expect a rapid onset of efficacy on IL-17 inhibitors, especially brodalumab [30,31]
and ixekizumab [32–34]. IL-17 inhibitors and IL-23 inhibitors, especially brodalumab, ixekizumab,
and risankizumab showed high efficacy in the long-term [28,29].
2.2. Psoriatic Arthritis
A systematic review revealed 14.0%–22.7% of psoriasis patients having arthritis PsA in psoriasis
patients [35]. PsA is characterized by enthesitis and arthritis in peripheral and axial involvement with
bone proliferation and erosion [36,37]. PsA patients show distal interphalangeal joint involvement,
which is usually asymmetric. In the pathogenesis of PsA, it is advocated that inflammation occurs
in entheses in the early phase, and that the progression of enthesitis results in accompaniment
with synovitis. In the initiation phase of enthesitis, innate immune cells are thought to play a key
role. Thereafter, once certain entheseal cells are stimulated with IL-23, they secrete inflammatory
cytokines such as IL-17A, IL-22 and TNF-α, consequently augmenting inflammation [36]. Focusing on
enthesitis which is characteristic of PsA, Araujo et al. reported that ustekinumab, an anti-IL-12/IL-23p40
antibody, was superior to TNF-α inhibitors in the clearance of enthesitis [38], which underscores the
importance of IL-23 in enthesitis. With regard to the contributions of TNF-α to the development of
PsA [39,40], TNF-α increases the number of osteoclast precursor cells. TNF-α promotes differentiation
into osteoclasts through RANKL-dependent pathways and promotes bone resorption. TNF-α inhibits
Wnt signaling and induces apoptosis of osteoblasts, thereby reducing bone repair capacity. Recently,
IL-23-independent IL-17-producing cells have drawn attention, especially in the pathogenesis of axial
involvement of PsA. PsA and ankylosing spondylitis (AS) are recognized as one of spondyloarthritis
(SpA) characterized by enthesitis, peripheral and axial arthritis, and negative laboratory results of
rheumatoid factor and anti-cyclic citrullinated peptide antibody [41]. It indicates that the responsiveness
of a certain drug for AS reflects its responsiveness for axial involvement of PsA. Anti-IL-17
antibodies, secukinumab [42] and ixekizumab [43], demonstrated efficacy for AS, but anti-IL-23
antibody, risankizumab [44], did not. Those results of clinical trials suggest the importance of
IL-23-independent IL-17-producing cells in the axial involvement of PsA. iNKT and γδ-T cells are
candidates of IL-23-independent IL-17-producing cells in SpA joints. Venken et al. reported that
iNKT and γδ-T cells were a major source of T-cell-derived IL-17 in SpA joints and that those cells
produced abundant IL-17 with anti-CD3 antibody/anti-CD28 antibody stimulation even in the absence
of IL-23 [45]. Those data suggest that PsA patients with axial involvement would be better to be treated
with IL-17 inhibitors such as ixekizumab and secukinumab, or TNF-α inhibitors, instead of anti-IL-23
antibodies such as risankizumab. Although the prevalence of having axial involvement in PsA patients
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differs by diagnosis criteria, it is reported to be from 23.6% to 55.4% [46,47]. In treating PsA patients,
we should consider the considerable percentage of PsA patients having axial involvement and choose
the right biologic agent. Mease et al. found the clinical characteristics of 192 PsA patients with axial
involvement by comparing them with 1338 PsA patients without it [48]. Axial involvement was
defined as physician-reported presence of spinal involvement at enrollment, and/or radiograph or MRI
showing sacroiliitis. Patients with axial involvement showed a higher likelihood of moderate-to-severe
psoriasis(body surface area ≥ 3%, 42.5% vs. 31.5%), lower prevalence of minimal disease activity
(30.1% vs. 46.2%), higher nail psoriasis scores (visual analog scale; VAS 11.4 vs. 6.5), enthesitis counts
(5.1 vs. 3.4), serum C-reactive protein levels (4.1 vs. 2.4 mg/L), and scores for physical function (Health
Assessment Questionnaire, 0.9 vs. 0.6), pain (VAS, 47.7 vs. 36.2), and fatigue (VAS, 50.2 vs. 38.6)
than patients without axial involvement. The American College of Rheumatology (ACR) and the
National Psoriasis Foundation (NPF) published guidelines for PsA in 2019 [49], although nearly all
recommendations were conditional since the quality of evidence was most often low or very low,
and occasionally moderate.
Kawalec et al. conducted the network meta-analysis with eight eligible RCTs for efficacy (ACR
20 and ACR 50, PASI 75) and safety outcomes [50]. RCTs for abatacept, apremilast, secukinumab,
or ustekinumab in adults with moderate-to-severe PsA were included. There were significant differences
in the ACR20 response rate between secukinumab 150 mg and apremilast 20 mg, and between
secukinumab 300 mg and apremilast 20 or 30 mg. Any adverse events occurred more often in
apremilast 20 and 30 mg compared with the placebo and compared with secukinumab 150 mg.
No significant differences were revealed for severe adverse events among biologics and between
biologics and the placebo. In the overall population, as well as in the anti-TNF-α-naive subpopulation,
secukinumab at a dose of 300 and 150 mg was ranked the highest for the ACR20 endpoint, while in
the anti-TNF-α-experienced subpopulation, secukinumab 300 mg and apremilast 30 mg revealed the
highest rank. For severe adverse events, the safest was ustekinumab 90 mg.
Dressler et al. also conducted a systematic review of approved systemic treatments for PsA [51].
Data were extracted from 20 trials for ACR 20, ACR 50, and adverse events after 16–24 weeks. Results
for ACR 20 were infliximab +methotrexate vs. methotrexate: relative risk (RR) 1.40 (95% CI 1.07–1.84),
very low-quality evidence; ixekizumab Q2W vs. adalimumab Q2W: RR 1.08 (95% CI 0.86–1.36), very low
quality. In three placebo-controlled comparisons, leflunomide, methotrexate (MTX), and sulfasalazine
failed to show statistical superiority for ACR. Besides the established treatment of anti-TNF antibodies
and ustekinumab for psoriatic arthritis, the newer treatment options of anti-IL-17 antibodies and
apremilast are also effective for the treatment of PsA. Based on just one comparative trial and one drug
each, the new class of anti-IL 17 antibodies appears to be equally effective compared to the group of
anti-TNF antibodies; for apremilast, this is yet unclear.
Lu et al., RCTs evaluated the efficacy and safety of targeted synthetic disease modifying
anti-rheumatic drugs (DMARDs: tofacitinib, apremilast), as well as biological DMARDs (guselkumab,
ustekinumab, secukinumab, ixekizumab, brodalumab, abatacept, adalimumab, etanercept, infliximab,
certolizumab, and golimumab) for active PsA by a systemic literature review of 29 RCTs, including
10,204 participants and 17 treatments [52]. All treatments showed efficacy in ACR 20 and PASI 75
at 12–16 weeks in comparison with a placebo. As for safety, tofacitinib, apremilast, and ixekizumab
80 mg every 2 weeks demonstrated a higher rate of adverse events; however, in severe adverse events
no significant difference was observed among all treatments. Network meta-analysis revealed that
infliximab, golimumab, etanercept, adalimumab, guselkumab, and secukinumab 300 mg showed
superiority to other drugs in both ACR 20 and PASI 75. Focusing on biologic-naïve patients, the results
were similar to those above. Among biologic-experienced/failed patients, ustekinumab, secukinumab
(300 mg and 150 mg), ixekizumab, abatacept, certolizumab pegol, tofacitinib, and apremilast still
demonstrated higher ACR 20 then placebo, whereas only ustekinumab, secukinumab (300 mg),
ixekizumab and tofacitinib were still associated with higher PASI 75.
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In interpreting these systematic reviews, we should be aware that most clinical trials only assessed
peripheral arthritis and did not assess enthesitis, dactylitis, or even axial involvement. As written
above, it would be better to treat PsA with axial involvement with TNF-α inhibitors or IL-17 inhibitors
instead of IL-23 inhibitors. When deciding on a treatment for PsA, we should not focus only on
efficacy for arthritis, but also take skin manifestation into consideration. The safety profile should be
also considered.
2.3. Safety Concerns of Biologics
As written above, biologic agents demonstrated tolerable safety profiles in the clinical trials.
However, accumulating evidence revealed drug-specific concerns. We have already discussed the
safety concerns of biologics in the previous literature [53]. Therefore, we refer to this issue in brief.
It has been reported that TNF-α inhibitors are associated with serious infection (slightly increased risk),
tuberculosis, paradoxical reaction, lupus, and infusion reaction (only infliximab). IL-17 inhibitors are
associated with candidiasis, neutropenia, and inflammatory bowel disease. As of now, there have never
been IL-23 inhibitor-specific adverse events reported. Safety concerns common in biologics include
hepatitis B virus reactivation and interstitial pneumonia. Those concerns were raised during use of
TNF-α inhibitors. Evidence of newer drugs such as IL-17 inhibitors and IL-23 inhibitors are insufficient.
Accumulation of evidence is needed. Regarding immunogenicity, generally, predispositions of higher
immunogenicity are observed in humanized monoclonal antibodies rather than in human monoclonal
antibodies. The effect of immunogenicity on efficacy and safety seems limited in new biologic agents.
However, since psoriasis is a chronic disease and some patients need to receive biologics for a long
period of time, it might affect effectiveness and safety in the long-term. Longer observation is necessary
to clarify this. With respect to malignancy, its rates are higher in psoriasis patients than the adult
general population, but these treatments do not appear to increase malignancy risk.
Kaushik and Lebwohl focus on pregnant and pediatric patients with moderate-to-severe psoriasis,
and those with chronic infections, such as hepatitis, HIV, and latent tuberculosis, and describe
appropriate systematic treatment for them [54].
3. Impact of Biologics on Comorbidities
Psoriasis imposes a psychological burden on patients. The prevalence of having depression or
anxiety is higher in psoriasis patients than in controls [55–57]. A systematic review and meta-analysis
investigating 18 studies including a total of 1,767,583 participants, of whom 330,207 had psoriasis,
reported that patients with psoriasis had a significantly higher likelihood of suicidal ideation, suicide
attempts, and completed suicides [58]. Strober et al. evaluated the effect of biologic therapy
(ustekinumab, infliximab, etanercept, and adalimumab) on depression in psoriasis patients utilizing
Psoriasis Longitudinal Assessment and Registry (PSOLAR). The incidence rates of depressive symptoms
were 3.01 (95% CI, 2.73–3.32), 5.85 (95% CI, 4.29–7.97), and 5.70 (95% CI, 4.58–7.10) per 100 patient-years
for biologics, phototherapy, and conventional therapy, respectively. Compared with conventional
therapy, biologics reduced the risk for depressive symptoms (hazard ratio, 0.76; 95% CI, 0.59–0.98),
whereas phototherapy did not (hazard ratio, 1.05; 95% CI, 0.71–1.54) [59].
Cohen et al. investigated 12,502 psoriasis patients aged 20 years and above and 24,287 age- and
sex-matched controls utilizing Clalit Health Services, the largest healthcare provider organization in
Israel, and revealed that psoriasis was associated with Crohn′s disease (CD; odds ratio, 2.49; 95%
CI, 1.71–3.62) as well as ulcerative colitis (UC; odds ratio, 1.64; 95% CI, 1.15–2.33) [60]. Focusing
on the effect of biologics, randomized control trials for CD with secukinumab and brodalumab
resulted in a disproportionate number of cases of worsening and no evidence of efficacy [61,62].
In addition, exacerbations of inflammatory disease have been reported in psoriasis patients receiving
IL-17 inhibitors [22,25,60]. Lee et al. found that IL-17A-dependent regulation of the tight junction
protein occludin in the intestinal mucosa during epithelial injury limits excessive permeability and
maintains barrier integrity, and revealed that IL-23-independent IL-17 production by γδ T cells
255
Int. J. Mol. Sci. 2020, 21, 1690
was important for the maintenance and protection of epithelial barriers in the intestinal mucosa.
Whereas IL-17 inhibition exacerbates inflammatory bowel disease, TNF-α inhibitors are approved for
the treatment of CD and UC, and IL-23 inhibitors demonstrated clinical improvement [63,64].
Recently, “psoriatic march”, the concept of a causal link between psoriasis and cardiovascular
disease, has been widely recognized. Systemic inflammation may cause insulin resistance, which in
turn triggers endothelial cell dysfunction, leading to atherosclerosis and finally myocardial infarction
or stroke [65,66]. Systematic review and meta-analysis analyzing 14 papers, including a total of 25,042
patients with psoriasis, revealed the association of psoriasis with metabolic syndrome. They reported
that metabolic syndrome was present in 31.4% of patients with psoriasis (odds ratio, 1.42; 95%
CI, 1.28–1.65) [67]. Other articles indicated that obesity is associated with the onset, exacerbation,
and intractability of psoriasis [68–72]. As for hyperglycemia, Ikumi et al. revealed that hyperglycemia
is highly associated with psoriasis, mainly through IL-17. In patients, the severity of psoriasis
correlated with high blood glucose levels, and anti-IL-17A monoclonal antibody therapy reduced
HbA1c levels significantly in these patients. In imiquimod-induced psoriasiform dermatitis, treatment
with anti-IL-17A monoclonal antibody decreased fasting blood glucose levels [73]. Concerning
endothelial cell dysfunction, flow-mediated dilation (FMD) is a marker that reflects endothelial cell
dysfunction. Avgerinou et al. investigated FMD in 14 psoriasis patients before and 12 weeks after
treatment with adalimumab, and reported that it improved after treatment with adalimumab [74].
von Stebut et al. conducted a 52-week, randomized, double-blind, placebo-controlled, exploratory
trial in patients with moderate-to-severe plaque psoriasis without clinical cardiovascular disease,
named Evaluation of Cardiovascular Risk Markers in Psoriasis Patients Treated with Secukinumab
(CARIMA) [75]. Although a statistical difference was not observed in the baseline-adjusted mean
FMD between patients receiving secukinumab and those receiving placebo at week 12, FMD was
significantly higher than baseline in patients receiving the label dose of 300 mg secukinumab for
52 weeks. Regarding atherosclerosis, Hjuler et al. examined calcified coronary plaque, utilizing
cardiac computed tomography angiography in severe psoriasis patients, severe atopic dermatitis
patients, and retrospectively matched controls [76]. They demonstrated that psoriasis patients showed
an increased prevalence of severe coronary stenosis (stenosis >70%) (psoriasis 14.6%, controls 0%;
p = 0.02) and 3-vessel coronary affection or left main artery disease (psoriasis 20%, controls 3%;
p = 0.02), whereas AD patients showed an increased prevalence of mild single-vessel affection (AD
40.7%, controls 9.1%; p = 0.005). Elnabawi et al. conducted a prospective, observational study in order
to investigate the effect of biologic therapy on coronary artery plaque [77]. Analysis of 121 participants
who were biologics-naïve at baseline and received biologic therapy for one year revealed that biologic
therapy was associated with a 6% reduction in non-calcified plaque burden (p = 0.005) reduction in
necrotic core (p = 0.03), with no effect on fibrous burden (p = 0.71), indicating that biologic therapy in
severe psoriasis was associated with favorable modulation of coronary plaque indices. After one-year
of biologic therapy, non-calcified plaque burden decreased by 5% in patients treated with TNF-α
inhibitors (p = 0.06), by 2% in patients treated with anti-IL12/23 antibody (p = 0.36), and by 12% in
patients treated with IL-17 inhibitors (p < 0.001). Patients treated with IL-17 inhibitors demonstrated
a significantly greater reduction in non-calcified coronary plaque burden compared with those treated
with anti-IL12/23 antibody and those with no biologic treatment. Patients treated with TNF-α inhibitors
showed a significantly greater reduction in non-calcified coronary plaque burden only compared
those with non-biologic treatment (p< 0.01). Regarding cardiovascular events, a systemic review and
meta-analysis demonstrated that mild and severe psoriasis are associated with an increased risk of
myocardial infarction and stroke, and that severe psoriasis is also associated with an increased risk of
cardiovascular mortality [78]. Yang et al. conducted a meta-analysis on the effect of TNF-α inhibitors
on cardiovascular events in psoriasis and psoriatic arthritis, analyzing five studies (49,795 patients).
Compared with topical/photo treatment, TNF-α inhibitors were associated with a significant lower risk
of cardiovascular events (RR, 0.58; 95% confidence interval; CI, 0.43 to 0.77; p < 0.001). Additionally,
compared with MTX treatment, risk of cardiovascular events was also markedly decreased in the
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TNF-α inhibitor group (RR, 0.67; 95% CI, 0.52 to 0.88; p = 0.003). Wu et al. also examined patients
receiving TNF-α inhibitors (n = 9148) and patients receiving MTX (n = 8581). Psoriasis patients
receiving TNF-α inhibitors had a lower major cardiovascular event risk compared to those receiving
MTX (Kaplan–Meier rates: 1.45% vs. 4.09%: p < 0.01. Hazard ratio = 0.55; p < 0.01) [79]. The direct
effect of IL-17 inhibitors or IL-23 inhibitors on cardiovascular events has not been reported yet.
Kaushik and Lebwohl also described specific comorbidities and insights to choose the appropriate
systemic treatment in patients with moderate-to-severe psoriasis [80]. The choice of appropriate
biologic therapy for a patient is often determined by the presence of comorbidities.
4. Conclusions
Evidence of new drugs on long-term efficacy, safety, and impacts on comorbidities is relatively low.
Further accumulation is needed to clarify them. Currently, a variety of biologic agents are available for
the treatment of psoriasis. However, characteristics such as rapidity of onset, long-term efficacy, safety
profile, and effects on comorbidities are different. Better understanding those characteristics leads to
the right choice for individual patients, resulting in higher persistence, longer drug survival, higher
patient satisfaction, and minimizing the disease impact of psoriasis.
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